<SEC-DOCUMENT>0001558370-17-001198.txt : 20170301
<SEC-HEADER>0001558370-17-001198.hdr.sgml : 20170301
<ACCEPTANCE-DATETIME>20170301093117
ACCESSION NUMBER:		0001558370-17-001198
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170301
DATE AS OF CHANGE:		20170301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		17651699

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>glyc-20161231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/1/2017 8:16:37 AM-->
<html>
	<head>
		<title>
			glyc_Current_Folio_10K
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000 ;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 4pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 4pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 16pt;">
			<font style="display:inline;font-weight:bold;font-size:16pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 16pt;">
			<font style="display:inline;font-weight:bold;font-size:16pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">WASHINGTON, D.C. 20549</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 16pt;">
			<font style="display:inline;font-weight:bold;font-size:16pt;">FORM 10-K</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;font-size:11pt;">OF THE SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">For the fiscal year ended December&nbsp;31, 2016</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Commission file number 001-36177</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 22pt;">
			<font style="display:inline;font-weight:bold;font-size:22pt;">GlycoMimetics, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">(Exact name of Registrant as specified in its charter)</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 2pt;">
			<font style="display:inline;font-size:2pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:50.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:49.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.08%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Delaware</font></p>
				</td>
				<td valign="top" style="width:49.92%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">06-1686563</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.08%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">(State or other jurisdiction of</font></p>
					<p style="margin:0pt 0pt 1pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">incorporation or organization)</font></p>
				</td>
				<td valign="top" style="width:49.92%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">(IRS Employer</font></p>
					<p style="margin:0pt 0pt 1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 2pt;">
			<font style="display:inline;font-size:2pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:49.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">9708 Medical Center Drive</font></p>
					<p style="margin:0pt 0pt 1pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Rockville, Maryland</font></p>
				</td>
				<td valign="bottom" style="width:49.60%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">20850</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">(Address of principal executive offices)</font></p>
				</td>
				<td valign="top" style="width:49.60%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">(Zip Code)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Registrant&#x2019;s telephone number, including area code: (240)&nbsp;243-1201</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Securities registered pursuant to Section&nbsp;12(b) of the Act:</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 2pt;">
			<font style="display:inline;font-size:2pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:49.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:50.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.96%;padding:0pt 7.2pt 0pt 0pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Title of Each Class:</font></p>
				</td>
				<td valign="bottom" style="width:50.04%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Name of Each Exchange on which Registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:49.96%;padding:0pt 7.2pt 0pt 0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Common Stock, $0.001 par value</font></p>
				</td>
				<td valign="top" style="width:50.04%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">The NASDAQ Stock Market</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Securities registered pursuant to Section&nbsp;12(g) of the Act: None</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="center"></hr></div>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#x25FB;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#x2612;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#x25FB;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#x2612;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&#x2612;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#x25FB;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&#x2612;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#x25FB;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained to the best of registrant&#x2019;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&#x2612;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer&#x201D; and &#x201C;smaller reporting company&#x201D; in Rule 12b-2 of the Exchange Act.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 2pt;">
			<font style="display:inline;font-size:2pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:95.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:309.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:118.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:95.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Large&nbsp;accelerated&nbsp;filer</font></p>
				</td>
				<td valign="bottom" style="width:309.60pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x25FB;</font></p>
				</td>
				<td valign="bottom" style="width:118.10pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Accelerated&nbsp;filer</font></p>
				</td>
				<td valign="bottom" style="width:16.90pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2612;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:95.40pt;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:309.60pt;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:118.10pt;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.90pt;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:95.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> Non-accelerated filer</font></p>
				</td>
				<td valign="bottom" style="width:309.60pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x25FB;&nbsp;&nbsp;(Do not check if a smaller reporting company)</font></p>
				</td>
				<td valign="bottom" style="width:118.10pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Smaller&nbsp;reporting&nbsp;company</font></p>
				</td>
				<td valign="bottom" style="width:16.90pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x25FB;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;Yes&nbsp;&#x25FB;&nbsp;&nbsp;&nbsp;No&nbsp;&#x2612;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">As of June&nbsp;30, 2016, the last business day of the registrant&#x2019;s last completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $100.4 million based on the closing price of the registrant&#x2019;s Common Stock, as reported by the NASDAQ Global Market, on such date.</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">At February&nbsp;27, 2017, 23,329,900 shares of GlycoMimetics, Inc.&#x2019;s Common Stock, $0.001 par value, were outstanding. </font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;font-size:8pt;">DOCUMENTS INCORPORATED BY REFERENCE</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:18pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">Portions of GlycoMimetics, Inc.&#x2019;s definitive proxy statement, to be filed pursuant to Regulation&nbsp;14A under the Securities Exchange Act of 1934, for its 2017 Annual Meeting of Stockholders are incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K.</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;border-top:1pt solid #000000 ;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 4pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 4pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item&nbsp;1. &#x201C;Business,&#x201D; Part I, Item&nbsp;1A. &#x201C;Risk Factors,&#x201D; and Part II, Item&nbsp;7. &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201D; but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by the words &#x201C;may,&#x201D; &#x201C;might,&#x201D; &#x201C;will,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;should,&#x201D; &#x201C;expect,&#x201D; &#x201C;intend,&#x201D; &#x201C;plan,&#x201D; &#x201C;objective,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;predict,&#x201D; &#x201C;project,&#x201D; &#x201C;potential,&#x201D; &#x201C;continue&#x201D; and &#x201C;ongoing,&#x201D; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Forward-looking statements include statements about: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our plans to develop and commercialize our glycomimetic drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our ongoing and planned clinical trials for our drug candidates GMI-1271 and GMI-1359, including the timing of initiation of and enrollment in the trials, the timing of availability of data from the trials and the anticipated results of the trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our ability to achieve anticipated milestones and potential royalties under our collaboration with Pfizer for our drug candidate rivipansel; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the timing of and our ability to obtain and maintain regulatory approvals for our drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the clinical utility of our drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our commercialization, marketing and manufacturing capabilities and strategy; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our intellectual property position; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our ability to identify additional drug candidates with significant commercial potential that are consistent with our commercial objectives; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our estimates regarding future revenues, expenses and needs for additional financing; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our beliefs about our capital expenditure requirements and that our capital resources will be sufficient to meet our anticipated cash requirements into the second quarter of 2018. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">You should refer to Item&nbsp;1A. &#x201C;Risk Factors&#x201D; section of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">TABLE OF CONTENT<a name="TOC"></a>S &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:03.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:79.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:03.10%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:07.24%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:13.14%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt 0pt 1pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:13.14%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTI_62679"><font style="display:inline;font-weight:bold;">PART&nbsp;I</font><font style="display:inline;">&nbsp;</a>&nbsp;</font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUSINESS_704658"><font style="display:inline;">ITEM&nbsp;1.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUSINESS_704658"><font style="display:inline;">BUSINESS</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1ARISKFACTORS_845333"><font style="display:inline;">ITEM&nbsp;1A.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1ARISKFACTORS_845333"><font style="display:inline;">RISK FACTORS</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>28&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_434071"><font style="display:inline;">ITEM&nbsp;1B.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_434071"><font style="display:inline;">UNRESOLVED STAFF COMMENTS</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM2PROPERTIES_674160"><font style="display:inline;">ITEM&nbsp;2.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM2PROPERTIES_674160"><font style="display:inline;">PROPERTIES</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM3LEGALPROCEEDINGS_697974"><font style="display:inline;">ITEM&nbsp;3.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM3LEGALPROCEEDINGS_697974"><font style="display:inline;">LEGAL PROCEEDINGS</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM4MINESAFETYDISCLOSURES_857992"><font style="display:inline;">ITEM&nbsp;4.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM4MINESAFETYDISCLOSURES_857992"><font style="display:inline;">MINE SAFETY DISCLOSURES</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56&nbsp;
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:13.14%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTII_834"><font style="display:inline;font-weight:bold;">PART&nbsp;II</font><font style="display:inline;">&nbsp;</a>&nbsp;</font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITY_65"><font style="display:inline;">ITEM&nbsp;5.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITY_65"><font style="display:inline;">MARKET FOR REGISTRANT&#x2019;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM6SELECTEDFINANCIALDATA_528251"><font style="display:inline;">ITEM&nbsp;6.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM6SELECTEDFINANCIALDATA_528251"><font style="display:inline;">SELECTED FINANCIAL DATA</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>59&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><font style="display:inline;">ITEM&nbsp;7.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><font style="display:inline;">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>60&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7AQUANTITATIVEANDQUALITATIVE_860953"><font style="display:inline;">ITEM&nbsp;7A.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7AQUANTITATIVEANDQUALITATIVE_860953"><font style="display:inline;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><font style="display:inline;">ITEM&nbsp;8.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><font style="display:inline;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><font style="display:inline;">ITEM&nbsp;9.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><font style="display:inline;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9ACONTROLSANDPROCEDURES_712204"><font style="display:inline;">ITEM&nbsp;9A.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9ACONTROLSANDPROCEDURES_712204"><font style="display:inline;">CONTROLS AND PROCEDURES</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9BOTHERINFORMATION_45602"><font style="display:inline;">ITEM&nbsp;9B.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9BOTHERINFORMATION_45602"><font style="display:inline;">OTHER INFORMATION</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77&nbsp;
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:13.14%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTIII_655348"><font style="display:inline;font-weight:bold;">PART&nbsp;III</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><font style="display:inline;">ITEM&nbsp;10.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><font style="display:inline;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM11EXECUTIVECOMPENSATION_298012"><font style="display:inline;">ITEM&nbsp;11.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM11EXECUTIVECOMPENSATION_298012"><font style="display:inline;">EXECUTIVE COMPENSATION</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><font style="display:inline;">ITEM&nbsp;12.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><font style="display:inline;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><font style="display:inline;">ITEM&nbsp;13.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><font style="display:inline;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><font style="display:inline;">ITEM&nbsp;14.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><font style="display:inline;">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78&nbsp;
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:13.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTIV_600453"><font style="display:inline;font-weight:bold;">PART&nbsp;IV</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><font style="display:inline;">ITEM&nbsp;15.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"><font style="display:inline;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:03.10%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.04%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM16FORM10KSUMMARY"><font style="display:inline;">ITEM&nbsp;16.</a></font></p>
				</td>
				<td valign="top" style="width:79.62%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM16FORM10KSUMMARY"><font style="display:inline;">FORM 10-K SUMMARY</a></font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79&nbsp;
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="top" style="width:92.76%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#SIGNATURES_192363"><font style="display:inline;font-weight:bold;">SIGNATURES </a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80&nbsp;
				</td>
			</tr>
			<tr>
				<td colspan="3" valign="top" style="width:92.76%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#EXHIBITINDEX_356727"><font style="display:inline;font-weight:bold;">EXHIBITS </a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">i</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PART <a name="PARTI_62679"></a>I &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt 55.05pt;text-indent: -55.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 1.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 31pt 0pt 0pt;"></font>BUSINES<a name="ITEM1BUSINESS_704658"></a>S &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Overview </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, we are developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are focusing our initial efforts on drug candidates for rare diseases that we believe will qualify for orphan drug designation. Our first drug candidate, rivipansel, is being developed for the treatment of vaso-occlusive crisis, or VOC, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. We have entered into a collaboration with Pfizer Inc., or Pfizer, for the further development and potential commercialization of rivipansel worldwide. Rivipansel has received fast track designation from the U.S. Food and Drug Administration, or FDA, as well as orphan drug designation from the FDA in the United States and from the European Medicines Agency, or EMA, in the European Union, or EU. We believe the clinical progress of rivipansel provides evidence of the significant potential of our lead program and our proprietary glycomimetics platform. Building on our experience with rivipansel, we are developing our second most advanced drug candidate, GMI-1271, to be used in combination with chemotherapy to treat either acute myeloid leukemia, or AML, or multiple myeloma, or MM, both of which are life-threatening hematologic cancers, and potentially other hematologic cancers as well. A third drug candidate, GMI-1359, has started clinical testing in a Phase 1 clinical trial in healthy volunteers.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our proprietary glycomimetics platform is based on our expertise in carbohydrate chemistry and our understanding of the role carbohydrates play in key biological processes. Most human proteins are modified by the addition of complex carbohydrates to the surface of the proteins. The addition of these carbohydrate structures affects the functions of these proteins and their interactions with other molecules. Our initial research and development efforts have focused on drug candidates targeting selectins, which are proteins that serve as adhesion molecules and bind to carbohydrates that are involved in the inflammatory component and progression of a wide range of diseases, including hematologic disorders, cancer and cardiovascular disease. For example, we believe that members of the selectin family play a key role in the onset and progression of VOC and also in tumor metastasis and resistance to chemotherapy. Inhibiting specific carbohydrates from binding to selectins has long been viewed as a potentially attractive approach for therapeutic intervention. The ability to successfully develop drug-like compounds that inhibit binding with selectins, known as selectin antagonists, has been limited by the complexities of carbohydrate chemistry. We believe our expertise in carbohydrate chemistry and our understanding of carbohydrate-protein binding interactions enable us to design selectin antagonists and other glycomimetics that may inhibit the disease-related functions of certain carbohydrates. We believe this expertise and knowledge may enable us to develop novel drug candidates to address unmet medical needs. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Rivipansel is a glycomimetic drug candidate that acts as a pan-selectin antagonist, meaning it binds to all three members of the selectin family, E-,&nbsp;P- and L-selectin. We believe that rivipansel, by acting as a pan-selectin antagonist, inhibits the role that selectins play in VOC for persons with sickle cell disease. VOC, one of the most severe complications of sickle cell disease, can result in acute ischemic tissue injury at one or more sites, with inflammation and pain of varying degrees of severity. The standard of care in the United States for people experiencing VOC is to manage its symptoms, which typically includes hospitalization, narcotic pain management and hydration. We believe that rivipansel, if approved, would be the first drug to interrupt the underlying cause of VOC, thereby potentially reducing the use of narcotics for pain management and enabling patients to leave the hospital more quickly. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have completed four clinical trials of rivipansel involving a total of 163 subjects. In April 2013, we completed a Phase 2 clinical trial in which 76 patients hospitalized for VOC, ranging from 12 to 60 years old, were treated with the standard of care plus either rivipansel or placebo. In this trial, patients treated with rivipansel experienced reductions in the time to reach resolution of VOC, length of hospital stay and use of opioid analgesics for pain management, in each case as compared to patients receiving placebo. This improvement was seen in both adult and pediatric patients. Adverse event rates and severity were comparable between those treated with rivipansel and those receiving placebo. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">1</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pfizer is responsible for the further clinical development, regulatory approval and potential commercialization of rivipansel. Pfizer enrolled the first patient in a Phase 3 clinical trial in June 2015 and has announced that it expects to complete enrollment in this trial in the second half of 2018.&nbsp;&nbsp;Under our license agreement with Pfizer, we are eligible to receive payments of up to $115.0 million upon the achievement of specified development milestones, up to $70.0 million upon the achievement of specified regulatory milestones, and up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties, with percentages ranging from the low double digits to the low teens, based on net sales of rivipansel worldwide, subject to reductions in specified circumstances. Under a separate research agreement with the University of Basel, or the University, we have agreed to pay 10% of any future milestone payments and royalties we may receive from Pfizer with respect to rivipansel. </font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are developing a pipeline of other drug candidates based on our expertise in carbohydrate chemistry, including compounds that are designed to be specific to particular selectins. We are developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with AML, MM and potentially other hematologic cancers. </font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">E-selectin plays a critical role in binding cancer cells within vascular niches in the bone marrow, which prevents the cells from entering circulation where they can be more readily killed by chemotherapy. In separate animal studies, GMI-1271 mobilized AML and MM cancer cells out of the bone marrow, making them more sensitive to chemotherapy. In both the AML and MM studies, tumor burden was significantly reduced in the animals treated with a combination of chemotherapy and GMI-1271 as compared to animals treated with chemotherapy alone. In addition, the combination of GMI-1271 with chemotherapy resulted in improved survival rates for the treated animals, compared to chemotherapy alone. In other animal studies, GMI-1271 appeared to also protect normal cells from some of the side effects of chemotherapy. Common side effects of chemotherapy include bone marrow toxicity resulting in neutropenia, which is an abnormally low number of neutrophils, the white blood cells that serve as the primary defense against infection, and mucositis, which is the inflammation and sloughing of the mucous membranes lining the digestive tract. Animals treated with GMI-1271 and chemotherapy had less severe neutropenia and mucositis and lower bone marrow toxicity as compared to animals treated with chemotherapy alone. We believe that treatment with GMI-1271 results in lower bone marrow toxicity due to its inhibition of E-selectin, which inhibition makes stem cells in the bone marrow divide less frequently, thereby protecting them from chemotherapy agents that target rapidly dividing cells. </font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have completed an initial Phase 1 trial in healthy volunteers for GMI-1271. Additionally, in a Phase 1/2 clinical trial in defined populations of patients with AML, we have completed the Phase 1 multiple ascending dose-escalation portion of the trial and dose expanded into the Phase 2 portion, for which we expect to complete enrollment in the first half of 2017. In December 2016, at the annual meeting of the American Society of Hematology, or ASH, we presented interim clinical data that showed preliminary high remission rates and suggested a favorable safety, pharmacokinetic, or PK, and biomarker profile for GMI-1271. We have also initiated a Phase 1 multiple ascending dose-escalation trial of GMI-1271 in defined populations of patients with MM and plan to continue enrollment of the trial in 2017.</font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have an additional drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. We intend to select a target clinical indication, most likely in oncology.&nbsp;&nbsp;&nbsp;In June 2016, we submitted an Investigational New Drug application, or IND, to the FDA for GMI-1359, and in August 2016, we dosed the first participant in a Phase 1 single-dose escalation trial of GMI-1359 in healthy volunteers.&nbsp;&nbsp;In this first-in-human trial, volunteer participants are receiving a single injection of GMI-1359, after which the subjects were evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics.&nbsp;&nbsp;In November 2016, we presented data from animal studies in which administration of GMI-1359, together with an antibody, reduced the time to complete tumor regression in a colon cancer model.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to our programs described above, we are also advancing other preclinical-stage programs. These programs include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9, which we believe may have potential to be used for the treatment of fibrosis, cancer and cardiovascular disease.</font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"> We have retained the worldwide development and commercialization rights to all of our drug candidates other than rivipansel. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our intellectual property portfolio includes ownership of, or exclusive rights to, issued patents and pending patent applications claiming fundamental features of glycomimetic therapeutics, as well as those claiming methods of use for and chemical modifications of our drug candidates. Given the importance of our intellectual property portfolio to our business operations, we intend to vigorously enforce our rights and defend against challenges that have arisen or may arise in this area. Our issued patents directed to rivipansel and methods of use are expected to expire between 2023 and 2030.&nbsp;&nbsp;We have a U.S. patent covering GMI-1271 which is expected to expire in 2032.&nbsp; In addition, we have several pending patent applications covering GMI-1271 and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2036.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"> &#x201C;GlycoMimetics,&#x201D; the GlycoMimetics logo and other trademarks or service marks of GlycoMimetics, Inc. appearing in this Annual Report are the property of GlycoMimetics, Inc. This Annual Report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Strategy </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our goal is to be the leader in the discovery, development and commercialization of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Leveraging the potentially broad applicability of our proprietary glycomimetics platform, our initial focus is to internally develop and advance orphan drug candidates targeted at hematologic cancers and other diseases, and to out-license any drug candidates we may develop that are targeted at larger market opportunities. The key elements of our strategy are to: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Advance GMI-1271 for the treatment of AML. </font><font style="display:inline;">We are building on our experience developing rivipansel to investigate GMI-1271 for the treatment of AML as an adjunct to standard chemotherapy. We have initiated a Phase 1/2 dose-escalation clinical trial in defined populations of patients with AML. The Phase 1 portion of the trial has been completed and the Phase 2 portion was initiated in 2016 and is currently enrolling subjects in sites in the United States, Ireland and Australia. We have retained worldwide development and commercialization rights to GMI-1271.&nbsp; </font><font style="display:inline;color:#000000;">In June 2016, GMI-1271 received fast track designation for the treatment of adult patients with relapsed or refractory AML and elderly patients aged 60 years or older with AML.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Advance GMI-1271 for the treatment of MM.</font><font style="display:inline;"> &nbsp;We have initiated a Phase 1 multiple dose-escalation clinical trial in defined populations of patients with MM and are enrolling subjects at trial sites in Ireland.&nbsp; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Advance GMI-1359 for the treatment of cancer.&nbsp; </font><font style="display:inline;">We are developing GMI-1359 which simultaneously inhibits both E-selectin and CXCR4, for potential use in the treatment of cancers with significant bone marrow involvement, such as hematologic cancers including AML and MM and certain solid tumors such as breast and prostate cancer. We completed enrollment in a Phase 1 single-dose escalation trial in healthy volunteers in 2016.&nbsp;&nbsp;We have retained worldwide development and commercialization rights to GMI-1359. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Support Pfizer&#x2019;s further development of rivipansel</font><font style="display:inline;color:#000000;">. We will continue to support Pfizer, if requested, as Pfizer proceeds with further clinical development of rivipansel, including the Phase 3 clinical trial, and pursues regulatory approval of rivipansel. We expect to use any milestone and royalty payments that we may receive from Pfizer to accelerate the development of our other drug candidates. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Identify and develop additional novel selectin antagonists to address unmet medical needs with significant market potential</font><font style="display:inline;color:#000000;">. We believe our glycomimetics platform will enable us to develop a broad pipeline of potential drug candidates that may be orphan drugs or may address larger market opportunities. We have identified a highly potent E-selectin antagonist which is being explored for subcutaneous delivery and which we believe could be of value in potential major market opportunities, such as the treatment of certain cancers and cardiovascular disease. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Apply our insights and our glycomimetics platform to other carbohydrate targets beyond selectins</font><font style="display:inline;color:#000000;">. We have identified additional opportunities where carbohydrates play critical roles in disease processes and where we believe we can apply our platform to create targeted glycomimetic drugs. We have begun to design and synthesize antagonists of a protein family known as galectins. We believe that compounds targeting galectins might potentially be used to treat certain forms of cancer and fibrosis. </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Platform </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our proprietary glycomimetics platform is based on our expertise in carbohydrate chemistry and our understanding of the role carbohydrates play in key biological processes. Carbohydrate structures on cell surfaces are responsible for complex carbohydrate-protein binding interactions. Inhibiting these binding interactions affects the functions of these proteins and their interactions with other molecules. We believe our expertise enables us to design specific glycomimetic molecules that can mimic carbohydrate structures and thereby inhibit their disease-related functions. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our initial focus is on selectin antagonists, which we believe have the potential to address unmet medical needs in a number of orphan and large market opportunities. Selectins have been shown to play a key role in a wide range of diseases, including hematologic disorders, cancer and cardiovascular disease. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our initial drug design efforts are focused on a naturally occurring, three-dimensional complex carbohydrate core structure known as the Lewis structure. This core structure is naturally modified in a variety of ways to form many different functional carbohydrates. These variations determine the biological functions of the carbohydrates, including functions related to conditions such as inflammatory diseases, cancer and infection. Accordingly, we believe that this structure provides the foundation for the design of glycomimetic drug candidates that could be used to address a variety of diseases. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Once we identify a carbohydrate structure involved in a disease pathway, we design molecules that mimic that carbohydrate structure and inhibit its disease-related functions by binding to the carbohydrate&#x2019;s target receptor, thereby blocking the binding by the native carbohydrate itself. For example, one of the naturally modified Lewis structures binds to selectins, which play a key role in VOC. Rivipansel mimics that carbohydrate structure and accordingly binds to selectins, which we believe thereby inhibits the progression of VOC. In addition, our glycomimetic molecules are designed to have greater affinity to the carbohydrate&#x2019;s target receptor than does the native carbohydrate. This means that the glycomimetic molecules possess stronger intermolecular forces between themselves and the target receptors, and thus &#x201C;outcompete&#x201D; the native carbohydrates in binding to the relevant target receptors, thereby inhibiting their disease-related functions. Using our glycomimetics platform, we have designed and synthesized a proprietary library of these structures targeting different biological processes. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our glycomimetics platform includes intellectual property, know-how, expertise, proprietary biological information and biochemical assays, all of which support the rational design of potent glycomimetic compounds. These include: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Know-how to successfully mimic the Lewis structure, which is common to a number of functional carbohydrates. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Use of empirical methods to determine critical interactions between variations of a particular functional carbohydrate and its target molecule. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Application of the empirically determined bioactive structure of the functional carbohydrate for docking into the binding area of the crystal structure of the target molecule. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Expertise in stabilizing the bioactive core of glycomimetic compounds and increasing the number of interaction contact points to improve affinity. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Experience and technology in synthetic organic chemistry required for the specialized synthesis of carbohydrates and their modifications. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Proprietary assays to determine the binding characteristics, inhibitory activity and biological activity of glycomimetic compounds. </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Pipeline </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have discovered our drug candidates internally through a rational drug design approach that couples our expertise in carbohydrate chemistry with our knowledge of carbohydrate biology. We are actively developing glycomimetic drug candidates based on this expertise.&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="glyc20161231x10k001.jpg" style="width: 6.75in; height: 3.991416in" alt="C:\Users\sirish\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Outlook\W07VDYU2\pipeline.jpg"></font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;font-style:italic;">Rivipansel &#x2014;Targeting Selectins to Treat VOC</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Rivipansel is being developed to treat VOC with the goal of reducing duration of VOC episodes, length of hospital stay and use of opioid analgesics for pain management. In our Phase 2 clinical trial, patients treated with rivipansel plus the standard of care demonstrated improvement in these endpoints, in each case as compared to patients receiving placebo plus the standard of care. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Sickle Cell Disease and VOC </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Sickle cell disease is a genetic disease that, according to the CDC, affects millions of people throughout the world, including an estimated 90,000 to 100,000 people in the United States. One of the most severe complications of sickle cell disease is VOC. VOC episodes are typically characterized by excruciating musculoskeletal pain, visceral pain and pain in other locations, and occur periodically throughout the life of a person with sickle cell disease. The CDC estimates that VOC resulted in approximately 73,000 hospitalizations in the United States in 2010. According to the National Hospital Discharge Survey conducted by the National Center for Health Statistics, these hospitalizations have an average duration of approximately six days. The standard of care in the United States for people experiencing VOC is to manage its symptoms, which typically includes hospitalization, narcotic pain management and hydration. There are no approved therapies that interrupt VOC once it has started or that treat the underlying cause of the pain. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Among both adults and children with sickle cell disease, VOC is the most common reason for seeking medical attention resulting in hospitalization. VOC affects multiple organ systems, and may result in significant clinical complications. Most sickle cell disease-related deaths occur during acute VOC, and are due to infection, acute chest syndrome, stroke or multi-organ failure. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Market Opportunity for Treatment of VOC </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe that effective treatment of VOC could provide significant clinical and pharmacoeconomic benefit. According to the U.S. Agency for Healthcare Research and Quality, the average hospital charges in the United States for a patient treated for VOC were approximately $20,000 in 2006. In some states, these charges may be substantially higher. For example, according to the California Office of Statewide Health Planning and Development, the average hospital charges for a patient treated for VOC in California were over $40,000 in 2006. A reduction in the length of a hospital stay could reduce these costs. If rivipansel is shown to be safe and effective in reducing the duration of VOC in hospitalized patients, it could also be tested to determine if hospitalization could be prevented with use of rivipansel in the emergency department, or if VOC could be managed safely and effectively in the home or in an outpatient setting through a self-administered dosage form, thereby avoiding costly emergency department visits. We believe that uses in each of these settings represent potentially significant market opportunities. </font>
		</p>
		<p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">The Role of Selectins in VOC </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The cause of vascular occlusion involves both an inflammatory component and a mechanical component. In the inflammatory component, white blood cells begin to roll along and then adhere to the endothelium, the thin layer of cells that lines the interior surface of blood vessels. These white blood cells then become activated and express adhesion receptors known as integrins, which bind and form aggregates with platelets, red blood cells and other white blood cells. These cell aggregates are responsible for the mechanical component of vascular occlusion, in which rigid sickled red blood cells are more easily caught in the post-capillary venules, which are very small blood vessels connecting the capillaries and the veins. The resulting vascular occlusion causes slowing of blood flow in the post-capillary venules, contributing to inadequate oxygen supply in the local tissue, known as ischemia, which in turn causes further tissue inflammation and pain. </font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The development of VOC is illustrated in the following diagram: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="glyc20161231x10k002.jpg" style="width: 5.196528in; height: 2.052083in" alt="Picture 2"></font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Selectins are important in this process because they act as adhesion molecules and play a key role in the initial recognition and binding of white blood cells to the endothelial cells, and their formation of aggregates with platelets, red blood cells and other white blood cells. White blood cells express carbohydrates on their surfaces that bind to E-selectin that is present on inflamed vascular endothelium. White blood cells bound to E-selectin on the endothelial cells then become activated and act as adhesion sites for platelets, red blood cells and other white blood cells, thereby leading to the formation of an occlusion. Rivipansel is a glycomimetic drug candidate designed to inhibit binding of all three types of selectins and inhibit the selectin-mediated recognition and binding of white blood cells to the endothelium. The rationale for the development of rivipansel to treat VOC is that, by blocking these steps in the vaso-occlusive process, it has the potential to decrease the duration and intensity of VOC. </font>
		</p>
		<p style="margin:13pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Limitations of the Current Standard of Care for VOC </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The current standard of care for VOC is focused on managing its symptoms. Narcotics are typically used for the management of acute pain associated with VOC. Pain management often starts with oral medications taken at home at the onset of pain. However, if the pain is not relieved, or if it progresses, patients may seek medical attention in a clinic setting or emergency department. Pain that is not controlled in these settings may require hospitalization for more potent </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">6</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">pain medications, typically administered intravenously. The patient must stay in the hospital to receive these intravenous, or IV, pain medications until the VOC resolves and the pain subsides. Other supportive measures during hospitalization include hydration, supplemental oxygen and treatment of any concurrent infections or other conditions. While pain medications can be effective in managing pain during VOC, they do not affect or resolve the underlying vascular occlusion, tissue ischemia or potential organ damage. </font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The only approved drug targeting VOC is hydroxyurea, which is available in both generic and branded formulations. Hydroxyurea has been approved as a once-daily oral treatment for reducing the frequency of VOC and the need for blood transfusions in adult patients with recurrent moderate-to-severe VOC. While hydroxyurea has been shown to reduce the frequency of VOC in some patient groups, it is not effective in relieving symptoms or accelerating the resolution of an ongoing VOC episode. Moreover, hydroxyurea is not suitable for all patients and can have significant toxicities and side effects. In particular, hydroxyurea is labeled to inform patients that it can cause a severe decrease in the number of blood cells in a patient&#x2019;s bone marrow, which may increase risks that the patient will develop a serious infection or bleeding, and that it may increase the risk that the patient will develop certain cancers. Additionally, since hydroxyurea is prescribed to be taken on a daily basis, lack of patient compliance can be a barrier to its optimal use. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since available therapies do not interrupt the VOC episode, opioid narcotics are generally prescribed to treat the pain until the VOC runs its natural course. Use of narcotics can lead to tissue or organ damage and resulting complications and morbidities, prolonged hospital stays and associated continuation of pain and suffering. Treatment of pain with IV narcotics and management of VOC-related complications typically require hospital stays ranging from a few days to a few weeks, with an average length of stay of approximately six days. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Rivipansel Clinical Results </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We completed a Phase 2 clinical trial of rivipansel in sickle cell patients hospitalized for VOC. This trial was a randomized, double-blind, placebo-controlled trial at 22 sites in the United States and Canada evaluating the safety, efficacy and PK of multiple IV doses of rivipansel or placebo in 76 patients hospitalized for VOC, ranging from 12 to 60 years old. Of these patients, 43 received rivipansel and 33 received placebo, in both cases in addition to the standard of care. Patients receiving rivipansel in the trial received one of two dose levels. Patients in the low dose group received a loading dose of 20 mg/kg, followed by a 10 mg/kg dose every 12 hours. Patients in the high dose group received a loading dose of 40 mg/kg, followed by a 20 mg/kg dose every 12 hours. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In patients receiving rivipansel in this trial, there were reductions in multiple measures related to a VOC episode as compared to patients receiving placebo. Two widely used statistical methods, known as ANCOVA and Kaplan-Meier, were used to analyze the results of this trial. The time to reach resolution of VOC, the primary endpoint of the trial, was reduced in the patients receiving rivipansel by a mean of 41.0 hours, as measured by ANCOVA, with a p-value of 0.192, and reduced by a median of 63.3 hours, as measured by Kaplan-Meier, with a p-value of 0.187. P-value is a conventional statistical method for measuring the statistical significance of clinical results. A p-value of 0.05 or less represents statistical significance, meaning that there is a less than 1-in-20 likelihood that the observed results occurred by chance. In addition, in the patients receiving rivipansel, the time to hospital discharge was reduced by a mean of 54.7 hours, as measured by ANCOVA, with a p-value of 0.096, and a median of 83.9 hours, as measured by Kaplan-Meier, with a p-value of 0.092. The time to transition off IV analgesics was reduced by a mean of 47.0 hours, as measured by ANCOVA, with a p-value of 0.137, and a median of 75.7 hours, with a p-value of 0.089, as measured by Kaplan-Meier. The cumulative amount of opioid analgesic administered during hospitalization was reduced by 83%, as measured by ANCOVA, with a p- value of 0.01. Although the Phase 2 clinical trial was not large enough to detect statistically significant differences in these endpoints, other than with respect to the reduction in cumulative amount of opioid analgesic administered, we believe the observed reductions in these measures in patients treated with rivipansel, and the consistency of a positive response across multiple measures, demonstrate the potential benefit of rivipansel. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe the favorable effects we observed in our Phase 2 clinical trial are the result of mechanism-based resolution of VOC. Specifically, we believe that by inhibiting selectin-mediated adhesion of white blood cells to the endothelium, rivipansel prevents propagation of VOC and promotes early resolution. Results from the Phase 2 clinical trial provide the first clinical evidence of a positive effect of rivipansel in adult and pediatric patients experiencing VOC. No currently available therapies provide similar benefits to patients in VOC. Based on the data from our Phase 2 clinical </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">7</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">trial for rivipansel, we believe rivipansel has the potential to become the first drug approved to treat VOC in both adult and pediatric patient populations. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If rivipansel is demonstrated to be safe and effective for the treatment of VOC, we believe it may show substantial clinical and pharmacoeconomic benefit. If patients treated with rivipansel are discharged more quickly from the hospital, there is potential to reduce the costs of hospitalization, in addition to showing clinical benefit by reduced duration of VOC episodes and reduced use of opioid analgesics for pain management. In addition, if rivipansel is shown to be safe and effective for treating VOC in hospitalized patients, it is possible that it could be tested in patients experiencing VOC who are not hospitalized to determine if hospitalization could be prevented or if pain from VOC could be managed safely and effectively in the home or in an outpatient setting. We believe that uses in each of these settings could represent significant market opportunities for rivipansel. Following the completion of the Phase 2 clinical trial, Pfizer is now responsible for the further clinical development, regulatory approval and commercialization of rivipansel. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Following transfer of the IND, Pfizer has undertaken significant activity to work toward a New Drug Application, or NDA, for rivipansel including, an approved special protocol assessment, or SPA, agreement for the design, endpoints and statistical analysis approach of the Phase 3 clinical trial.&nbsp;&nbsp;Pfizer enrolled the first patient in this Phase 3 clinical trial in June 2015. The Phase 3 trial, entitled &#x201C;RESET&#x201D; (</font><font style="display:inline;font-weight:bold;">R</font><font style="display:inline;">ivipansel: </font><font style="display:inline;font-weight:bold;">E</font><font style="display:inline;">valuating </font><font style="display:inline;font-weight:bold;">S</font><font style="display:inline;">afety, </font><font style="display:inline;font-weight:bold;">E</font><font style="display:inline;">fficacy and </font><font style="display:inline;font-weight:bold;">T</font><font style="display:inline;">ime to Discharge), is assessing the efficacy and safety of rivipansel for the treatment of VOC in patients hospitalized with sickle cell disease.&nbsp;&nbsp;Pfizer intends to enroll at least 350 subjects with sickle cell disease, aged six and older who are hospitalized for VOC, in this Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in order to evaluate the efficacy and safety of treatment with rivipansel. Trial participants must be receiving treatment with intravenous, or IV, opioids for their VOC and must be able to receive the first dose of rivipansel within 24 hours of initiation of intravenous opioid therapy. The primary endpoint for the trial will be time to readiness-for-discharge. Key secondary endpoints will include time to discharge, cumulative IV opioid consumption and time to discontinuation of IV opioids.&nbsp;&nbsp;Pfizer has announced completion of enrollment in the Phase 3 clinical trial is expected in the second half of 2018.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">GMI-1271&#x2014;Targeting the Bone Marrow Microenvironment to Treat Hematologic Cancers </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are developing GMI-1271, a specific E-selectin antagonist, to be used adjunctively with standard chemotherapy to treat AML, MM and other hematologic cancers. We believe that GMI-1271 may be used as first-line treatment for elderly patients with AML or MM, for patients with relapsed or refractory AML, as well as for patients with relapsed or refractory MM. GMI-1271 targets interactions between cancer cells and the bone marrow microenvironment. In preclinical studies, combining GMI-1271 with chemotherapy made cancer cells more sensitive to chemotherapy. In other preclinical studies, GMI-1271 also reduced some of the toxic effects of chemotherapy, including neutropenia and mucositis, on normal cells. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Acute Myeloid Leukemia </font>
		</p>
		<p style="margin:11pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">AML, a hematologic cancer that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells, is a relatively rare disease, but one that accounts for the largest number of annual deaths from leukemia in the United States. According to the Surveillance, Epidemiology, and End Results Program managed by the National Cancer Institute, there were an estimated 20,000 new cases of AML diagnosed in 2016 in the United States. Approximately 300,000 patients in the world are diagnosed with AML annually.&nbsp;&nbsp;AML caused an estimated 10,000 deaths in 2016 in the United States. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">AML is more commonly present in elderly patients, with a median age at diagnosis of 67 years according to the National Cancer Institute. In a review published in the </font><font style="display:inline;font-style:italic;">Journal of Clinical Oncology</font><font style="display:inline;">, the median overall survival of patients 60 years old or older was nine months. The overall five-year relative survival rate for all AML patients is 27%, and only 8% for patients over 60 years old at diagnosis. Relative survival is a statistical measure of net survival that is calculated by comparing observed survival with expected survival from a comparable set of people who do not have AML, in order to measure the excess mortality that is associated with the AML diagnosis. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A number of published studies indicate that only some AML patients who receive chemotherapy achieve a complete response, which is defined as the disappearance of all signs of AML, and that most patients with a complete response will eventually relapse. Patients who do not enter remission are referred to as refractory, meaning that they are resistant to the chemotherapy treatment. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">8</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe there is a need for new treatment options for elderly patients with AML, as well as those AML patients who relapse or develop refractory disease. Most AML patients with relapsed or refractory disease have no established treatment options and, accordingly, may be referred for participation in clinical studies of potential new therapies. For patients who elect not to participate or are unable to participate, treatment options typically include chemotherapy regimens, hypomethylating agents and supportive care. Further, many elderly patients with AML are too frail to undergo chemotherapy as a result of other medical conditions, and may only be able to tolerate pain comfort or control measures. Without treatment, however, AML is uniformly fatal. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Multiple Myeloma</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">MM is a hematologic cancer that is characterized by the growth of abnormal white blood cells of the bone marrow that eventually infiltrates various organs and leads to bone destruction, bone marrow failure, including direct and indirect effects on the blood, skeleton, and kidneys.&nbsp;&nbsp;MM is the most frequent tumor that occurs primarily in bone and the second most common hematological malignancy in the United States and Europe.&nbsp;&nbsp;MM accounts for 10% to 15% of hematologic cancers, and 20% of deaths from these cancers.&nbsp;&nbsp;Approximately 114,000 new cases of MM were diagnosed worldwide in 2012.&nbsp;&nbsp;In the United States, according to the National Cancer Institute, an estimated 30,000 people were newly diagnosed with MM in 2016.&nbsp;&nbsp;MM caused an estimated 13,000 deaths in 2016 in the United States.&nbsp;&nbsp;MM is rare in individuals younger than 40 years old and the average age at diagnosis is approximately 70 years.&nbsp;&nbsp;More than 34% of patients are over 75 years of age, making treatment with chemotherapy more complicated due to fewer treatment options being available, patients being ineligible for transplant, and decreased ability to tolerate sustained chemotherapy due to poor general health. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Despite the fact that recent treatment options for MM have led to improved response rates and increased short-term survival, responses are transient and most patients with MM will ultimately relapse and succumb to their cancer.&nbsp;&nbsp;MM is not considered curable with current approaches.&nbsp;&nbsp;The five-year overall survival rate for all patients in the United States is less than 50%.&nbsp;&nbsp;Although second and later remissions can be achieved with additional treatment, tumors typically recur more aggressively after each relapse, leading to decreased duration of response and ultimately culminating in the development of treatment-refractory disease.&nbsp;&nbsp;Median survival for treatment-refractory disease typically ranges from five months for event-free survival and from nine months for overall survival and responses to treatment are characteristically short, most likely due to resistant disease. This loss of response complicates therapy of patients in later-line treatment, shortens survival and results in high mortality rates.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Role of E-selectin in AML and MM </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">E-selectin has been shown to play important roles in the progression of AML and MM. This has been observed in several studies, which have shown that levels of E-selectin correlate with tumor infiltration and relapse in AML and survival rates for both diseases. We therefore believe that our E-selectin antagonist, GMI-1271, has the potential to improve the current treatment of patients with AML or MM. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">GMI-1271 Preclinical Development </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Some leukemia cells, known as blast cells, bind to E-selectin in the bone marrow where they are relatively protected from the effects of chemotherapy. This phenomenon is known as cell adhesion-mediated drug resistance, or CAMDR. We believe that E-selectin inhibition disrupts the adhesion involved in CAMDR and mobilizes blast cells out of the bone marrow and into the bloodstream, making them more susceptible to chemotherapy. We believe that this mechanism of action may allow GMI-1271 to improve chemotherapy response rates, duration of remission and, ultimately, survival in patients with hematologic cancers such as AML. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In one </font><font style="display:inline;font-style:italic;">in vivo</font><font style="display:inline;"> study in a mouse model of AML, combining GMI-1271 with chemotherapy mobilized AML blast cells and significantly reduced tumor burden as compared to treatment with chemotherapy alone. In an </font><font style="display:inline;font-style:italic;">in vitro</font><font style="display:inline;"> study, AML cells bound to E-selectin were more resistant to chemotherapy. In a related study, when treated with GMI-1271, the resistance of such cells to chemotherapy was reduced. Tumor cells of patients who have relapsed AML, when tested in the laboratory, bound significantly higher levels of E-selectin than tumor cells of patients at initial diagnosis. In another </font><font style="display:inline;font-style:italic;">in vitro</font><font style="display:inline;"> study, GMI-1271 inhibited the E-selectin-mediated activation of the Wnt and Hedgehog signaling pathways, which are known to play important roles in the development and progression of AML. These pathways are activated in tumors when they are bound to E-selectin, and activation of these pathways may enhance the survival of </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">9</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">these tumor cells. We believe that all of this data supports our strategy for targeting E-selectin in these patients. GMI-1271 represents a novel agent that we believe could potentially be combined with many chemotherapeutic agents. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As GMI-1271 disrupts the interactions between cancer cells and bone marrow microenvironment, its mechanism of action is not limited to a single tumor type. In addition to our studies in AML, we have also tested the drug candidate in other cancer models. In three xenograft mouse models of MM, GMI-1271 was evaluated in combination with the proteasome inhibitors, bortezomib or carfilzomib. Treatment of mice with GMI-1271 plus bortezomib or GMI-1271 plus carfilzomib significantly improved survival when compared to chemotherapy alone.&nbsp;&nbsp;In addition, treatment with GMI-1271 resulted in mobilization of MM cells in the peripheral blood past the point of elimination of the drug from plasma and bone marrow, thereby making them more susceptible to chemotherapy. These data provide evidence that GMI-1271 is a potential treatment option to enhance response to chemotherapy in MM. Moreover, in in vivo studies involving animal models of chronic myelogenous leukemia and acute lymphoblastic leukemia, GMI-1271, as an adjunct to standard-of-care chemotherapy, decreased tumor burden and improved survival over standard-of-care chemotherapy alone.&nbsp; </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to its anti-tumor effects, GMI-1271, in animal models, has shown protection against some of the toxicities of chemotherapy. In particular, animals treated with GMI-1271 in combination with chemotherapy had less severe neutropenia and mucositis and lower bone marrow toxicity as compared to animals treated with chemotherapy alone. We believe that treatment with GMI-1271 results in lower bone marrow toxicity due to its inhibition of E-selectin, thereby making hematopoietic stem cells divide less frequently and protecting them from chemotherapy agents that target rapidly dividing cells. Hematopoietic stem cells are blood cells that give rise to all other types of blood cells and are heavily concentrated in the bone marrow. Similar effects have been demonstrated with rivipansel and were published in the journal </font><font style="display:inline;font-style:italic;">Nature Medicine</font><font style="display:inline;"> in December 2012. Based on these reductions in some of the toxicities of chemotherapy, we are evaluating these effects as secondary efficacy endpoints in our clinical trials. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">GMI-1271 Clinical Trials </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2014, we completed a Phase 1 trial of GMI-1271 in healthy volunteers. The single-site Phase 1 trial was a randomized, double-blind, placebo-controlled, single ascending intravenous dose trial. In the trial, we evaluated the safety, tolerability and PK of GMI-1271. Twenty-eight healthy adult subjects were enrolled in cohorts to receive study drug at three dose levels. In the trial, we observed that the subjects tolerated GMI-1271 well, and that the PK for GMI-1271 were as predicted based on preclinical data.&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Following the completion of the Phase 1 trial, we initiated a multinational, Phase 1/2, open-label trial of GMI-1271 as an adjunct to standard chemotherapy in patients with AML. This trial in males and females with AML is being conducted at a number of academic institutions in the United States, Ireland and Australia. The trial consists of two parts. In the Phase 1 portion, escalation testing was performed to determine a recommended GMI-1271 dose in combination with standard chemotherapy. We evaluated three different doses, with six to seven patients in each dose cohort. In the Phase 2 portion, dose-expansion testing is being conducted to obtain additional safety and efficacy data in defined sub-populations of AML. The Phase 1 portion of the study was completed in 2016 and we expect to complete the Phase 2 dose-expansion portion in 2017 in specific patient populations. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2016, we dosed the first patient in the Phase 2 portion of the trial. In this portion of the trial, dose-expansion testing is being conducted to obtain additional safety and efficacy data in two defined sub-populations of AML. One arm of the trial is enrolling relapsed or refractory AML patients; the second arm is enrolling patients over 60 years of age with newly diagnosed AML. We expect to enroll a total of approximately 72 patients in the Phase 2 portion of the trial. Unlike in the Phase 1 portion, some of the patients in the Phase 2 portion may be treated with multiple cycles of GMI-1271. The Phase 2 portion of the trial is being conducted in the United States, Ireland and Australia. The ongoing trial is expected to complete enrollment in the first half of 2017. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2016, we presented interim clinical data for the trial at the ASH annual meeting, including preliminary data from the Phase 2 portion. For a total of 33 study participants with relapsed or refractory disease taken together from the Phase 1 and one arm of the Phase 2 portion of the trial, the CR rate was 45%. For 11 newly diagnosed study participants 60 or more years of age in the second arm of the Phase 2 portion of the trial, the CR rate was 73%. We plan to provide additional updates from this study at scientific conferences in 2017.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">10</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have initiated a Phase 1 multiple dose-escalation clinical trial in defined populations of patients with MM to evaluate GMI-1271 as an adjunct to proteasome inhibitors (bortezomib or carfilzomib), therapies approved to treat MM. We are currently enrolling patients at clinical trial sites in Ireland.</font>
		</p>
		<p style="margin:17pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Other Indications </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2013, researchers at the University of Michigan received a grant from the National Heart Lung and Blood Institute to evaluate GMI-1271 as a potential treatment for venous thromboembolic disease, or VTE, a serious blood clotting disorder. VTE, which can occur after a major operation or severe illness, such as a heart attack, stroke or some cancers, refers to both pulmonary embolism and deep vein thrombosis, or DVT, which is the formation of blood clots in large veins, primarily in the legs. The clots become dangerous when they break loose and can affect blood flow to the heart and lungs. Because GMI-1271, as an E-selectin antagonist, also inhibits the activation of processes leading to thrombosis, we believe that it has therapeutic potential to decrease thrombosis and its inflammatory effects. </font>
		</p>
		<p style="margin:17pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The University of Michigan began dosing healthy volunteers in a Phase 1 randomized, partially blinded, active placebo-controlled trial in December 2014. The primary objective of the trial was to evaluate the safety and PK profile of GMI-1271 in a single and multiple ascending doses in healthy volunteers. The secondary objectives included evaluation of the incidence of bleeding and other adverse events and evaluation of the effects of GMI-1271 on biomarkers of coagulation, cell adhesion and leukocyte and platelet activation. The single and multiple ascending dose-escalation clinical trial in 32 healthy volunteers and a small Phase 1/2 clinical trial in patients with DVT were completed in 2016.</font>
		</p>
		<p style="margin:17pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">GMI-1359 - Drug Candidate Targeting E-selectin and CXCR4 </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The chemokine CXCR4 has emerged as an important pro-inflammatory cytokine that is involved in cell migration throughout the body. Like E-selectin, tumor cells may also use the CXCR4 cellular pathway, contributing to chemoresistance, metastatic disease and ultimately decreased survival. We have an additional drug candidate, GMI-1359, that simultaneously targets both both E-selectin and CXCR4. Since E-selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow, we believe that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that affect the bone marrow, such as hematologic cancers, including AML and MM, and certain solid tumors, such as breast and prostate cancer, as compared to targeting CXCR4 alone. At the ASH annual meeting in December 2016, we presented preclinical data suggesting that GMI-1359 has a unique tumor cell mobilization profile and enhanced the ability of chemotherapy to target and improve survival from a high-risk form of mutated AML.&nbsp;&nbsp;In November 2016, at the annual meeting of the Society for Immunotherapy of Cancer, we presented data from a preclinical study in which GMI-1359, in combination with an antibody against the cancer regulatory programmed death receptor ligand, or PD-L1, shortened time to complete tumor regressions in an animal model of colon cancer. In the preclinical study, the combination therapy also selectively reduced regulatory T cells, which are a class of lymphocytes that suppress immune responses, in the tumor, and created a more favorable immune-mediated anti-tumor environment.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In 2016, we completed enrollment in a first-in-human Phase 1 single-dose escalation trial of GMI-1359 in healthy volunteers.&nbsp;&nbsp;In this trial, volunteer participants received a single injection of GMI-1359, after which the subjects were evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics. The randomized, double-blind placebo controlled escalating dose study was conducted at a single site in the United States. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Galectin Inhibitors </font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Using our glycomimetics platform, we have designed galectin-3 and galectin-9 inhibitors that specifically block the binding of galectin-3 and galectin-9 to carbohydrate structures.&nbsp;&nbsp;Galectin-3 and galectin-9 are proteins that are known to play critical roles in many pathological processes, including fibrosis, checkpoints in T-cell exhaustion during cancer immunotherapy, chemotherapy resistance and cardiovascular disease. We plan to optimize these compounds and conduct preclinical experiments in 2017 to further characterize the effects of galectin-3 and galectin-9 inhibitors on immune processes and anti-fibrotic activity. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">11</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Collaboration with Pfizer for Rivipansel</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Overview </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In October 2011, we entered into a license agreement with Pfizer, under which we granted Pfizer an exclusive worldwide license to develop and commercialize rivipansel, for all fields and uses. The products licensed under the agreement also include certain backup compounds, along with modifications of and improvements to rivipansel that meet defined chemical properties. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the terms of the agreement, we received a $22.5 million upfront payment and are eligible to earn up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications, up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications, and up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties for each licensed product, with percentages ranging from the low double digits to the low teens, based on net sales of rivipansel worldwide, subject to reductions in specified circumstances. The first potential milestone payment under the Pfizer agreement was $35.0&nbsp;million upon the initiation of dosing of the first patient in a Phase 3 trial of rivipansel by Pfizer. Under the collaboration, Pfizer made a $15.0 million non-refundable payment to us in May 2014, and the dosing of the first patient in the Phase 3 clinical trial triggered the remaining $20.0 million milestone payment to us, which we received in August 2015. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Development and Commercialization Obligations </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pfizer will initially develop and seek approval for rivipansel in the field of sickle cell disease under the agreement. We were responsible for completion of the Phase 2 clinical trial relating to VOC associated with sickle cell disease. Following the completion of the Phase 2 clinical trial, we now have no further development or commercialization obligations, and Pfizer is required to use commercially reasonable efforts, at its expense, to develop, obtain regulatory approval for and commercialize rivipansel for sickle cell disease in the United States. Pfizer generally must notify us in writing promptly of any decision to cease development activities, efforts to obtain regulatory approval or commercialization of rivipansel for the first approved indication. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Governance </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The agreement establishes a non-voting, joint steering committee to facilitate the exchange of information regarding the development of licensed products and the initial commercialization plans for such products. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Exclusivity Restrictions </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the term of the agreement, we may not directly or indirectly commercialize any pharmaceutical compound or product that is labeled for the treatment, prevention or prophylaxis of a vaso-occlusive or painful crisis associated with sickle cell disease anywhere in the world, subject to specified exceptions if we or our affiliates were to undergo a change of control. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Term and Termination </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The agreement will expire on a licensed product-by-licensed product and country-by-country basis on the date of termination of the applicable royalty term with respect to each licensed product in each country and in its entirety upon the expiration of all applicable royalty terms for all licensed products in all countries. The royalty term for each licensed product in each country is the period commencing with the first commercial sale in the applicable country and ending on the expiration of specified patent coverage or 10 years following the first commercial sale in the applicable country, whichever is later. Pfizer has the right to terminate the agreement, subject to certain notice requirements. The agreement may also be terminated in its entirety either by Pfizer or by us in the event of an uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, insolvency or similar circumstances. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">12</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Effects of Termination </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Upon termination of the agreement by Pfizer for convenience or by us, all rights and licenses granted to Pfizer under the agreement will terminate and Pfizer is obligated to grant us a non-exclusive worldwide license to specified Pfizer proprietary rights to develop and commercialize licensed products in the form being used or sold by Pfizer at the time of such termination, to transfer to us specified data and regulatory materials and approvals, and to provide for the continued supply of licensed products subject to specified terms. If Pfizer has completed additional clinical trials for the applicable licensed product and we obtain such a license or obtain such data and materials and commercialize a licensed product, then, for a period of 10 years from the first commercial sale of such licensed product, Pfizer is eligible to receive royalties at defined percentages in the low single-digits on net sales of such licensed product worldwide, up to a defined aggregate payment cap. The applicable royalty rate and maximum royalty payment cap depend on the stage of clinical development at the time of such termination. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Research Services Agreement with University of Basel </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have a research services agreement with the University, under which University personnel have performed research services for us on an as-requested basis since 2004 pursuant to separately negotiated research plan work orders, each lasting one year. We have no obligation to continue to purchase services from the University under the agreement. Under the current research plan, the University is performing research services related to potential oral selectin antagonists and PK evaluation for new selectin antagonists in development by us. We have agreed to pay the University consideration for the research services performed, as determined in connection with each annual research plan work order. For the annual research terms ended in February 2015 and 2016, we paid the University approximately $200,000 and $100,000 respectively. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not license any intellectual property from the University under this agreement as the University assigns to us its rights in any intellectual property jointly developed under this agreement. However, as part of the original consideration for entering into the agreement, we granted to the University the right to receive payments from us under specified circumstances. Accordingly, if we receive any future milestone payments or royalties from Pfizer with respect to rivipansel, we have agreed to pay 10% of those amounts to the University, subject to specified exceptions. These potential payments to the University are our only affirmative obligation under the agreement other than payment for research services for ongoing research plan work orders. As of December&nbsp;31, 2015, we accrued $2.0 million that is payable to the University, which is equal to 10% of the $20.0 million non-refundable milestone payment we received from Pfizer in August 2015.&nbsp;&nbsp;The $2.0 million was subsequently paid in February 2016. The $1.5 million due upon receipt of the $15.0 million non-refundable payment received from Pfizer in May 2014 was accrued as of December 31, 2014 and subsequently paid in February 2015.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The agreement remains in effect until we are no longer obligated to make any potential payments. The agreement contemplates individual one year research terms, which have been implemented by annual amendments to the agreement effective as of February of each year. The agreement may be terminated by us if the investigator performing the services under the agreement becomes incapacitated to properly carry out his duties under the agreement. The agreement may also be terminated by either party upon material breach by the other party unless the breaching party cures the breach within 90 days.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Intellectual Property </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We strive to protect the intellectual property that we believe is important to our business, including seeking and maintaining patent protection intended to cover the composition of matter of our drug candidates and their methods of use. We have issued patents directed to rivipansel and methods of use that are expected to expire between 2023 and 2030.&nbsp;&nbsp;We also have an issued patent which covers GMI-1271 which currently will expire in 2032.&nbsp; In addition, we have several pending patent applications both in the United States and outside of the United States covering GMI-1271 and/or methods of using it, the last expiring of which, if issued, currently would be predicted to expire in 2036. We also rely on trade secret protection for our confidential and proprietary information and careful monitoring of such information to protect aspects of our business. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important inventions and know-how related to our business, defend and enforce our patents, preserve </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">13</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how and continuing technological innovation to develop, strengthen and maintain our proprietary position in the field of glycomimetics. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our drug candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties. If we are not able to obtain such a license, or are not able to obtain such a license on commercially reasonable terms, our business could be materially harmed. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We plan to continue to expand our intellectual property estate by filing patent applications directed to additional glycomimetic compounds and their derivatives, compositions and formulations containing them and methods of using them. Additionally, we will seek patent protection in the United States and internationally for novel compositions of matter covering the compounds and their use in a variety of therapies. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The patent positions of biotechnology companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance, including where a reissue application is filed in relation to an issued patent to correct issues or errors arising during prosecution that may render claims of the issued patent either wholly or partially invalid or unenforceable. Consequently, we do not know whether any of our drug candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, or USPTO, or a foreign patent office to determine priority of invention or in post-grant challenge proceedings, such as oppositions, that challenge priority of invention or other features of patentability. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Manufacturing </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacturing of our drug candidates for preclinical and clinical testing, as well as for commercial manufacturing if our drug candidates receive marketing approval. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the case of rivipansel, the initial process development, manufacturing and scale-up was managed by us and performed under contract by third parties. Under our license agreement with Pfizer, responsibility for manufacturing rivipansel has now transferred to Pfizer. With respect to our other drug candidates, we anticipate continuing to manage process development, scale-up and manufacturing under contracts with third parties. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">All of our drug candidates are small molecules and are manufactured in reliable and reproducible synthetic processes from readily available starting materials. The chemistry does not require unusual equipment in the manufacturing process. We expect to continue to develop drug candidates that can be produced cost-effectively at contract manufacturing facilities. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Commercialization </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have not yet established a sales, marketing or drug distribution infrastructure. With the exception of rivipansel, to which we have granted Pfizer exclusive commercialization rights, we generally expect to retain commercial rights in the United States for our current drug candidates, all of which are still in preclinical or early clinical development. We </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">14</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">believe that it will be possible for us to access the U.S. market for those drug candidates through a focused, specialized sales force. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the United States to sell our drugs. We believe that such an organization will be able to target the community of physicians who are the key specialists in treating the patient populations for which our drug candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our drug candidates that obtain marketing approval. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any drugs that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved drugs and establishing relationships with thought leaders in relevant fields of medicine. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Competition </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any drug candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The key competitive factors affecting the success of all of our drug candidates, if approved, are likely to be their safety, efficacy, convenience, price, the level of generic competition and the availability of coverage and reimbursement from government and other third-party payors.&nbsp; </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">Rivipansel: Sickle Cell Anemia</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The only approved drug for sickle cell anemia is hydroxyurea, an antineoplastic agent that was initially approved for the treatment of cancer.&nbsp;&nbsp;While hydroxyurea has been shown to reduce the frequency of painful crises and blood transfusions in adults with sickle cell anemia, it is not effective in relieving symptoms or accelerating the resolution of an ongoing VOC episode. Moreover, since it is a cytotoxic and myelosuppressive agent, hydroxyurea is not suitable for all patients and can have significant toxicities and side effects that warrant close monitoring and supervision. There are no drugs currently approved or in late-stage development for the treatment of sickle cell anemia patients experiencing an acute VOC episode.&nbsp;&nbsp;Notably, the Phase 3 trial of MST-188, conducted by Mast Therapeutics, Inc., failed to meet its primary endpoint of significantly reducing the mean duration of VOC episodes in sickle cell patients, and that clinical program has been discontinued.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In addition, there are a number of other compounds that are in clinical development as either prophylactic or gene therapy/blood transfusion approaches to treat patients with sickle cell anemia, including: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Prophylactic Approaches: Emmaus Life Sciences, Inc. (L-glutamine); Novartis Pharmaceuticals Corporation (crizanlizumab, formerly SelG1); Baxter International (Aes-103); and Global Blood Therapeutics (GBT440); and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Gene Therapy/Blood Transfusion Approaches: Blue Bird Bio (Lentiglobin BB305); Sangamo Biosciences/Bioverativ (ZFN Knockout); and Bellicum Pharmaceuticals (BPX-501). </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#1F140C;">&nbsp; In September 2016, Emmaus Life Sciences announced that the FDA had accepted its NDA requesting approval for L-glutamine as a prophylactic treatment for sickle cell disease.&nbsp;&nbsp;In December 2016, results from a Phase 2 clinical trial of crizanlizumab, an anti-P-selectin antibody, were published in the New England Journal of Medicine.&nbsp;&nbsp;In this trial, crizanlizumab reduced the median annual rate of sickle cell-related pain crises by 45.3% compared to placebo in patients.&nbsp;&nbsp;If one or both of these prophylactic agents were to be approved by the FDA prior to rivipansel, they could reduce the number of VOC episodes each year, reducing the market opportunity for rivipansel.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">15</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:22.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Although bone marrow transplant is currently available and can be curative for sickle cell disease, its use is limited by the lack of availability of matched donors and by the risk of serious complications, including graft versus host disease and infection. Attempts to develop a cure for sickle cell disease through gene therapy remain at an early stage, with significant variability in achieving target levels of anti-sickling hemoglobin demonstrated to date with Lentiglobin BB305.&nbsp;&nbsp;However, if these gene therapy approaches were to be successful and received regulatory approval, this could limit the market for a drug such as rivipansel. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">GMI-1271: Hematologic Malignancies</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;color:#000000;">Our drug discovery, development and commercialization activities in oncology face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies</font><font style="display:inline;font-family:Times;">. As the treatment landscape for AML and MM changes, there is substantial risk that GMI-1271 might not provide additional benefit over other therapies. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:22.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">While many chemotherapies in development for hematologic malignancies will likely be complementary to GMI-1271, there are also therapies in development that could be directly competitive with GMI-1271.&nbsp;&nbsp;In particular, there are a number of CXCR4 antagonists in clinical development that target </font><font style="display:inline;font-family:Times;background-color: #FFFFFF;">the bone marrow microenvironment in order to mobilize and sensitize cancer cells to chemotherapy, including </font><font style="display:inline;">Sanofi-Aventis </font><font style="display:inline;font-family:Times;background-color: #FFFFFF;">(Mozobil), Bristol Myers Squibb (BMS-936564), NOXXON Pharma (NOX-A12), Eli Lilly (LY2510924) and BioLine RX (BL-8040).&nbsp;&nbsp;While early clinical results have been encouraging, inhibition of CXCR4 remains an unproven therapeutic target for the treatment of cancer.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Many of the companies against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Government Regulation and Product Approval </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Government authorities in the United States, at the federal, state and local levels, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products, such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">United States Government Regulation </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the drug development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve pending new drug applications, or NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The process required by the FDA before a drug may be marketed in the United States generally involves: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#x2019;s good laboratory practice, or GLP, regulations; </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">16</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">performance of human clinical trials, including adequate and well-controlled clinical trials, in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug for each indication; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">submission to the FDA of an NDA; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">satisfactory completion of an FDA advisory committee review, if applicable; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity, as well as satisfactory completion of an FDA inspection of selected clinical sites to determine GCP compliance; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">FDA review and approval of the NDA. </font></p></td></tr></table></div>
		<p style="margin:18pt 0pt 0pt 24.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Preclinical Studies </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 24.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Clinical Trials </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being conducted. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined. In Phase 1, the drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an initial indication of its effectiveness. In Phase 2, the drug typically is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. In Phase 3, the drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the safety and efficacy of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Progress reports detailing the results of the clinical trials must be submitted, at least annually, to the FDA, and more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">17</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements, or if the drug has been associated with unexpected serious harm to patients. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A sponsor may request a Special Protocol Assessment, or SPA, the purpose of which is to reach agreement with the FDA on the Phase 3 clinical trial protocol design and analysis that will form the primary basis of an efficacy claim. According to FDA&#x2019;s published guidance on the SPA process, a sponsor that meets the prerequisites may make a specific request for an SPA and provide information regarding the design and size of the proposed clinical trial. The FDA is supposed to evaluate the protocol within 45 days of the request to assess whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to effectiveness of the indication studied, and that evaluation may result in discussions and a request for additional information. An SPA request must be made before the proposed trial begins, and all open issues must be resolved before the trial begins for an SPA to be approved. If a written agreement is reached, it will be documented in an SPA letter or the minutes of a meeting between the sponsor and the FDA and made part of the administrative record. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if the FDA agrees to the design, execution and analyses proposed in protocols reviewed under the SPA process, the FDA may revoke or alter its agreement under the following circumstances: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">public health concerns emerge that were unrecognized at the time of the protocol assessment, or the director of the review division determines that a substantial scientific issue essential to determining safety or efficacy has been identified after testing has begun; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">a sponsor fails to follow a protocol that was agreed upon with the FDA; or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the relevant data, assumptions, or information provided by the sponsor in a request for SPA change, are found to be false statements or misstatements, or are found to omit relevant facts. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A documented SPA may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. An SPA, however, does not guarantee that a trial will be successful. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt 24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Marketing Approval </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#x2019;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has agreed to certain performance goals regarding the timing of its review of an application. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans and elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">18</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#x2019;s continued safety, quality and purity. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA typically refers questions regarding novel drugs to an external advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The testing and approval process for an NDA requires substantial time, effort and financial resources, and takes several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval of an NDA on a timely basis, or at all. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 24.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Special FDA Expedited Review and Approval Programs </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA may give a priority review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. These six and ten month review periods are measured from the &#x201C;filing&#x201D; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">19</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A sponsor can also request designation of a product candidate as a &#x201C;breakthrough therapy.&#x201D; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</font>
		</p>
		<p style="margin:18pt 0pt 0pt 24.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Post-Approval Requirements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications, manufacturing changes or other labeling claims, are subject to further testing requirements and prior FDA review and approval. There also are continuing annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as application fees for supplemental applications with clinical data. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">20</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">fines, warning letters or holds on post-approval clinical trials;&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">product seizure or detention, or refusal to permit the import or export of products; or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications, pharmaceutical companies generally are required to promote their drug products only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 24.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Federal and State Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws include anti-kickback and false claims laws and regulations, data privacy and security, and transparency laws and regulations. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#x201C;remuneration&#x201D; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting some common activities from prosecution, the exemptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Several courts have interpreted the statute&#x2019;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The reach of the federal Anti-Kickback Statute was also broadened by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively PPACA, which, among other things, amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">21</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Federal false claims laws, including the federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#x201C;any request or demand&#x201D; for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#x2019; marketing of products for unapproved, and thus non-reimbursable, uses. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the Final HIPAA Omnibus Rule published on January&nbsp;25, 2013, imposes specified requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#x2019;s security standards directly applicable to &#x201C;business associates,&#x201D; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, </font><font style="display:inline;color:#000000;">additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, </font><font style="display:inline;">contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">22</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt 24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Coverage and Reimbursement </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The future commercial success of our drug candidates and our or any of our collaborator&#x2019;s ability to commercialize any approved drug candidates successfully will depend in part on the extent to which governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers and other third-party payors provide coverage for and establish adequate reimbursement levels for our drug candidates. Government health administration authorities, private health insurers and other organizations generally decide which drugs they will pay for and establish reimbursement levels for healthcare. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government, through the Medicare or Medicaid programs, provides reimbursement for such treatments. In the United States, the EU and other potentially significant markets for our drug candidates, government authorities and third party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical coverage and reimbursement policies and pricing in general. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Third-party payors are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for medical products. For example, federal and state governments reimburse covered prescription drugs at varying rates generally below average wholesale price. These restrictions and limitations influence the purchase of healthcare services and products. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our drug candidates may not be considered medically necessary or cost-effective. A payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our drugs and drug candidates or exclusion of our drugs and drug candidates from coverage. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform could significantly reduce our revenues from the sale of any approved drug candidates. We cannot provide any assurances that we will be able to obtain and maintain third party coverage or adequate reimbursement for our drug candidates in whole or in part. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Impact of Healthcare Reform on our Business </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The United States and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives </font><font style="display:inline;color:#000000;">to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing</font><font style="display:inline;">. &nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There have been several U.S. government initiatives over the past few years to fund and incentivize certain comparative effectiveness research, including creation of the Patient-Centered Outcomes Research Institute under PPACA. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#x2019;s product could adversely affect the sales of our product candidates. If third-party payors do not consider our drug candidates to be cost-effective compared to other available </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">23</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">therapies, they may not cover our drug candidates, once approved, as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">PPACA became law in March 2010 and substantially changes the way healthcare is financed by both governmental and private insurers. Among other measures that may have an impact on our business, PPACA establishes an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; a new Medicare Part D coverage gap discount program; and a new formula that increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Additionally, PPACA extends manufacturers&#x2019; Medicaid rebate liability, expands eligibility criteria for Medicaid programs, and expands entities eligible for discounts under the Public Health Service pharmaceutical pricing program.&nbsp;&nbsp;At this time, we are unsure of the full impact that PPACA will have on our business.&nbsp;&nbsp;There have been judicial and Congressional challenges to certain aspects of PPACA, and we expect such challenges and amendments to continue. </font><font style="display:inline;color:#000000;">In January, Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of PPACA. The Budget Resolution is not a law, however, it is widely viewed as the first step toward the passage of repeal legislation. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of PPACA that are repealed.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font><font style="display:inline;"> In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system, some of which could further limit the prices we are able to charge for our drug candidates, once approved, or the amounts of reimbursement available for our drug candidates once they are approved. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.&nbsp;&nbsp;Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As a result of PPACA, Medicare payments are increasingly tied to quality of care and value measures, and reporting of related data by providers such as physicians and hospitals. So called &#x201C;value based reimbursement&#x201D; measures may present challenges as well as potential opportunities for biopharmaceutical manufacturers. Medicare incentives for providers meeting certain quality measures may ultimately prove beneficial for manufacturers that are able to establish that their products may help providers to meet such measures. However, manufacturers&#x2019; ability to market their drug products based on quality or value is highly regulated and not always permissible. In addition, the potentially decreased Medicare reimbursement to those providers that fail to adequately comply with quality reporting requirements could translate to decreased resources available to purchase products and may negatively impact marketing or utilization of our drug candidates if they are approved for marketing. We cannot predict at this time what impact, if any, the longer-term shift towards value based reimbursement will have on any of our drug candidates in either the Medicare program, or in any other third party payor programs that may similarly tie payment to provider quality. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, other legislative changes have been proposed and adopted since PPACA was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, as amended, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee on Deficit Reduction did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#x2019;s automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, which began in 2013 and, following passage of the Bipartisan Budget Act of 2015, will continue through 2025 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These and other healthcare reform initiatives may result in additional reductions in Medicare and other healthcare funding. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt 24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Exclusivity and Approval of Competing Products </font>
		</p>
		<p style="margin:6pt 0pt 0pt 48.95pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Hatch-Waxman Patent Listing </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#x2019;s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#x2019;s Approved Drug Products with Therapeutic </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">24</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application, or ANDA, or 505(b)(2) NDA. Generally, an ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths, dosage form and route of administration as the listed drug and has been shown to be bioequivalent through </font><font style="display:inline;font-style:italic;">in vitro </font><font style="display:inline;">or </font><font style="display:inline;font-style:italic;">in vivo </font><font style="display:inline;">testing or otherwise to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or efficacy of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as &#x201C;generic equivalents&#x201D; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. 505(b)(2) NDAs generally are submitted for changes to a previously approved drug product, such as a new dosage form or indication. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The ANDA or 505(b)(2) NDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#x2019;s Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. Specifically, the applicant must certify with respect to each patent that: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the required patent information has not been filed; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the listed patent has expired; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the listed patent is invalid, unenforceable or will not be infringed by the new product. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except when the ANDA or 505(b)(2) NDA applicant challenges a listed drug. A certification that the proposed product will not infringe the already approved product&#x2019;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all the listed patents claiming the referenced product have expired. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of notice of the Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 48.95pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Hatch-Waxman Non-Patent Exclusivity </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Market and data exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications for competing products. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the activity of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or noninfringement. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA or 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by the FDA to be essential to the approval of the application or supplement. Three-year exclusivity may be awarded for changes to a previously approved drug product, such as new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">25</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. &nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt 48.95pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Orphan Drug Exclusivity </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA or biologics license application. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. We have received orphan drug designation for rivipansel and GMI-1271, and we intend to seek orphan drug designation and exclusivity for our other drug candidates whenever it is available. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If a product that has orphan designation subsequently receives the first FDA approval for such drug for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the EU has similar, but not identical, benefits. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 48.95pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Pediatric Exclusivity </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan drug exclusivity periods described above. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or Orange Book listed patent protection cover the drug are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve an ANDA or 505(b)(2) application owing to regulatory exclusivity or listed patents. If any of our drug candidates is approved, we anticipate seeking pediatric exclusivity when it is appropriate. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Foreign Regulation </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our drug candidates. For example, in the EU, we must obtain authorization of a clinical trial application, or CTA, in each member state in which we intend to conduct a clinical trial. Whether or not we obtain FDA approval for a drug, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the drug in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">26</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Employees </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, we had 42 full-time employees, all of whom are located in the United States. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Legal Proceedings </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results or financial condition. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Information about Segments </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We operate only in one business segment. See &#x201C;Note 2&#x2014;Summary of Significant Accounting Policies&#x2014;Segment Information&#x201D; to our financial statements contained in Part&nbsp;II, Item&nbsp;8 of this Annual Report. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Customer Concentration and Geographic Information </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Substantially all of our revenue for the years ended December&nbsp;31, 2016, 2015 and 2014 was derived from Pfizer and was earned in the United States. All of our long-lived assets are located in the United States. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Corporate Information </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We were incorporated under the laws of the State of Delaware in April 2003 and commenced operations in May 2003. Our principal executive offices are located at 9708 Medical Center Drive, Rockville, Maryland 20850. Our telephone number is (240)&nbsp;243-1201. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Available Information </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our internet website address is www.glycomimetics.com. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through our website as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission, or SEC. The public may read and copy the materials we file with the SEC at the SEC&#x2019;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Additionally the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address of the SEC&#x2019;s website is www.sec.gov. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">27</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp;1A.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 37pt 0pt 0pt;"></font>RISK FACTORS <a name="ITEM1ARISKFACTORS_845333"></a></font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Our business is subject to numerous risks. You should carefully consider the following risks, as well as general economic and business risks, and all of the other information contained in this Annual Report, together with any other documents we file with the SEC. Any of the following risks could have a material adverse effect on our business, operating results and financial condition and cause the trading price of our common stock to decline. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We have incurred significant losses since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since inception, we have incurred significant operating losses. As of December&nbsp;31, 2016, we had an accumulated deficit of $119.0 million. We have financed our operations to date with $64.1 million raised in private placements of convertible debt and convertible preferred stock, an aggregate of $57.5 million received from upfront and milestone payments under our license agreement with Pfizer and approximately $80.9 million from registered public offerings of our common stock. We have not generated any meaningful revenue since our inception other than from the upfront and milestone payments from Pfizer. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials. We are still in the early stages of development of our drug candidates, and we have not completed development of any drugs. We expect to continue to incur significant expenses and operating losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. Although responsibility for further development, regulatory approval and potential commercialization of our first drug candidate, rivipansel, has transferred to Pfizer under our collaboration with them following the completion of our Phase 2 clinical trial, we anticipate that our expenses will increase substantially as we: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">conduct clinical trials of GMI-1271 in AML and MM;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">conduct clinical trials of GMI-1359; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">continue the research and development of our other drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">seek to discover and develop additional drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">seek regulatory approvals for any drug candidates that successfully complete clinical trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drugs other than rivipansel for which we may obtain regulatory approval; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">maintain, expand and protect our intellectual property portfolio; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">hire additional clinical, quality control and scientific personnel; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our drug development and planned future commercialization efforts; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">incur additional legal, accounting and other expenses in operating as a public company. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To become and remain profitable, we must succeed in developing and eventually commercializing drugs that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our drug candidates other than rivipansel, obtaining regulatory approval for these drug candidates and manufacturing and commercializing any drugs for which we may obtain regulatory approval, as well as discovering additional drug candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the case of rivipansel, our ability to generate revenue is dependent upon the achievement of development, regulatory and commercial milestones and sales sufficient to generate royalties under our license agreement with Pfizer, and the achievement of such milestones is largely out of our control. If Pfizer fails, or chooses not to continue, to further develop, seek regulatory approval for or commercialize rivipansel, our ability to generate revenue with respect to </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">28</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">rivipansel will be significantly reduced or eliminated.&nbsp;&nbsp;Because all of our drug candidates other than rivipansel are still in preclinical or early clinical development, if we are unable to generate revenue from our license agreement with Pfizer, we may never become profitable, and we may not be able to invest in the further development of our other drug candidates. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our drug candidates, our expenses could increase. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We will need substantial additional funding to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or potential commercialization efforts. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe that our cash and cash equivalents as of December&nbsp;31, 2016 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2018, without giving effect to any potential milestone payments we may receive under our agreement with Pfizer. However, we will need to obtain substantial additional funding in connection with our continuing operations. Our future capital requirements will depend on many factors, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our agreement with Pfizer remaining in effect and our ability to achieve milestones under this and any other license or collaboration agreement that we may enter into in the future; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the progress and results of the Phase 3 clinical trial of rivipansel; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other drug candidates, including our ongoing and planned clinical trials of GMI-1271 and GMI-1359; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the number and development requirements of other drug candidates that we may pursue; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the costs, timing and outcome of regulatory review of our drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our drug candidates other than rivipansel for which we receive marketing approval; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">any royalties we receive from Pfizer with respect to sales of rivipansel, if it receives marketing approval; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the revenue, if any, received from commercial sales of our drug candidates other than rivipansel for which we receive marketing approval; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the extent to which we acquire or in-license other drug candidates and technologies. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Identifying potential drug candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we and Pfizer or any future collaborators may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our drug candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from the sale of drugs that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">29</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our drug candidates. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Until such time, if ever, as we can generate substantial revenue from the sale of our drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings and license and development agreements. We do not currently have any committed external source of funds other than possible milestone payments and possible royalties under our license agreement with Pfizer. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our research programs or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third parties when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to third parties to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We commenced operations in 2003, and our operations to date have been largely focused on raising capital, developing our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, identifying potential drug candidates, undertaking preclinical studies and conducting clinical trials. All but three of our drug candidates are still in preclinical development. We have not yet demonstrated our ability to successfully complete later stage clinical trials, obtain regulatory approvals, manufacture a commercial scale drug, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. With respect to our drug candidates other than rivipansel, we will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#x201C;ownership change,&#x201D; generally defined as a greater than 50% change by value in its equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership. As of December&nbsp;31, 2016, we had federal and state NOL carryforwards of $87.3 million, research and development tax credit carryforwards of $7.4 million and orphan drug credit carryovers of $7.6 million, each of which could be limited if we experience an ownership change. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to the Discovery and Development of Our Drug Candidates &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our research and development is focused on discovering and developing novel glycomimetic drugs, and we are taking an innovative approach to discovering and developing drugs, which may never lead to marketable drugs. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A key element of our strategy is to use and expand our platform to build a pipeline of novel glycomimetic drug candidates and progress these drug candidates through clinical development for the treatment of a variety of diseases. The discovery of therapeutic drugs based on molecules that mimic the structure of carbohydrates is an emerging field, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">30</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">and the scientific discoveries that form the basis for our efforts to discover and develop drug candidates are relatively new. The scientific evidence to support the feasibility of developing drug candidates based on these discoveries is both preliminary and limited. Although our research and development efforts to date have resulted in a pipeline of glycomimetic drug candidates, we may not be able to develop drug candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential drug candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize drug candidates based upon our glycomimetics platform, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We are very early in our development efforts and have only three drug candidates that are in clinical trials. All of our other drug candidates are still in preclinical development. If we or our collaborators are unable to commercialize our drug candidates or experience significant delays in doing so, our business will be materially harmed. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are very early in our development efforts and rivipansel, GMI-1271 and GMI-1359 are our only drug candidates that are in clinical trials. All of our other drug candidates are still in preclinical development. We have not completed the development of any drug candidates, we currently generate no revenue from the sale of any drugs and we may never be able to develop a marketable drug. We have invested substantially all of our efforts and financial resources in the development of our glycomimetics platform, the identification of potential drug candidates using that platform and the development of our drug candidates. Other than with respect to rivipansel, for which our collaborator Pfizer now has the responsibility for further development and commercialization, our ability to generate revenue from our other drug candidates, which we do not expect will occur for many years, if ever, will depend heavily on their successful development and eventual commercialization. The success of those drug candidates will depend on several factors, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;"> successful completion of preclinical studies and clinical trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">receipt of marketing approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">making arrangements with third-party manufacturers for, or establishing, commercial manufacturing capabilities; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">launching commercial sales of the drugs, if and when approved, whether alone or in collaboration with others; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">acceptance of the drugs, if and when approved, by patients, the medical community and third-party payors; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">effectively competing with other therapies; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">obtaining and maintaining healthcare coverage and adequate reimbursement; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">protecting our rights in our intellectual property portfolio; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">maintaining a continued acceptable safety profile of the drugs following approval. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our drug candidates, which would materially harm our business. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">All but three of our drug candidates are in preclinical development, and their risk of failure is high. It is impossible to predict when or if any of our drug candidates will prove safe or effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we or a collaborator must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">31</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">and efficacy of the drug candidate in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of development. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their drug candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We or our current or future collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our or their ability to receive marketing approval or commercialize our drug candidates, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">clinical trials of our drug candidates may produce negative or inconclusive results, including failure to demonstrate statistical significance, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the cost of clinical trials of our drug candidates may be greater than we anticipate; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our drug candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these clinical trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">be delayed in obtaining marketing approval for our drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">not obtain marketing approval at all; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">obtain approval for indications or patient populations that are not as broad as intended or desired; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">be subject to additional post-marketing testing requirements; or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">have the drug removed from the market after obtaining marketing approval. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">32</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">periods during which we may have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do, and thereby impair our ability to successfully commercialize our drug candidates. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we or our collaborators experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We or our collaborators may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, because our lead drug candidates are intended to treat patients with orphan diseases such as sickle cell disease, AML and MM, our or our collaborators&#x2019; ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same or similar indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#x2019; drug candidates. Patient enrollment is also affected by other factors, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the severity of the disease or condition under investigation;&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the eligibility criteria for the trial; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the perceived risks and benefits of the drug candidate; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the availability of drugs approved to treat the disease or condition under investigation; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the efforts to facilitate timely enrollment in clinical trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the patient referral practices of physicians; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the ability to monitor patients adequately during and after treatment; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the proximity and availability of clinical trial sites for prospective patients. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our or our collaborators&#x2019; inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us or them to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our drug candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If serious adverse or unacceptable side effects are identified during the development of our drug candidates, we may need to abandon or limit the development of some of our drug candidates. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If our drug candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many drug candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented their further development. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for which there is a greater likelihood of success. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Because we have limited financial and management resources, we focus on a limited number of research programs and drug candidates. As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">33</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Our Dependence on Third Parties </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our success is highly dependent on our existing collaboration with Pfizer, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have limited capabilities for drug development and do not yet have any capabilities for sales, marketing or distribution. Under our license agreement with Pfizer, Pfizer is responsible for all further development, regulatory approval and potential commercialization efforts with respect to rivipansel. Other than rivipansel, GMI-1271 and GMI-1359, all of our drug candidates are still in preclinical development, and therefore our success is highly dependent on our collaboration with Pfizer. We cannot assure you that Pfizer will continue to develop rivipansel in a timely manner, or at all, or, if it achieves regulatory approval, that Pfizer will successfully commercialize rivipansel. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"> Our Pfizer collaboration, and any future collaborations we might enter into, may pose a number of risks, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators may not perform their obligations as expected; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators may not pursue the commercialization of any drug candidates that achieve regulatory approval or may elect not to pursue, continue or renew development or commercialization of drug candidates based on clinical trial results, changes in such collaborators&#x2019; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators could experience delays in initiating or conducting clinical trials for any number of reasons; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drugs or drug candidates if such collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">drug candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own drug candidates or drugs, which may cause such collaborators to cease to devote resources to the commercialization of our drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">a collaborator with marketing and distribution rights to one or more of our drug candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such drug or drugs; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of drug candidates, might lead to additional responsibilities for us with respect to drug candidates or might result in litigation or arbitration, any of which would be time consuming and expensive; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable drug candidates. </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">34</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If our collaboration with Pfizer or any other collaborations we might enter into in the future do not result in the successful development and commercialization of drugs, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. In addition, even if we are eligible to receive these payments, they could be substantially delayed. For example, under our license agreement, Pfizer has the option to commence another Phase 2 clinical trial of rivipansel, and such commencement would delay or inhibit our ability to receive some of the milestone payments we might otherwise have received under the agreement. If we do not receive the funding we expect under these agreements, the development of our drug candidates could be delayed and we may need additional resources to develop our drug candidates. All of the risks relating to drug development, regulatory approval and commercialization described in this report also apply to the activities of our collaborators. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If Pfizer or a future collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate development or commercialization of any drug candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the business and financial communities could be adversely affected. For our drug candidates other than rivipansel, we may in the future determine to collaborate with pharmaceutical and biotechnology companies for their development and potential commercialization. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of a collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market, which would impair our business prospects. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We expect to rely on third parties to conduct our future clinical trials for drug candidates other than rivipansel, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We currently expect to engage a third-party contract research organization, or CRO, to conduct our ongoing and planned clinical trials for GMI-1271 and GMI-1359 and any of our other drug candidates that may progress to clinical development. We expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our drug development activities. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our reliance on these third parties for research and development activities will reduce our control over these activities, but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and significant civil and criminal sanctions. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our drug candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">35</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our drug candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We contract with third parties for the manufacturing of some of our drug candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not have any manufacturing facilities or personnel. For our drug candidates other than rivipansel, for which manufacturing responsibility has shifted to Pfizer, we rely, and expect to continue to rely, on third parties for the manufacturing of our drug candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our drug candidates receive marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our drug candidates or drugs, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our ability to timely conduct our clinical trials or our other development or commercialization efforts. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We also expect to rely on third-party manufacturers or third-party collaborators for the manufacturing of commercial supply of any other drug candidates for which we or our collaborators obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">reliance on the third party for regulatory compliance and quality assurance; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the possible breach of the manufacturing agreement by the third party; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our drugs. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our drug candidates and any drugs that we may develop may compete with other drug candidates and drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may incur added costs and delays in identifying and qualifying any such replacement. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our current and anticipated future dependence upon others for the manufacturing of our drug candidates or drugs may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to the Commercialization of Our Drug Candidates </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Even if any of our drug candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If any of our drug candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If our drug candidates do not </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">36</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:4pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">achieve an adequate level of acceptance, we may not generate significant revenue from drug sales and we may not become profitable. The degree of market acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the efficacy and potential advantages compared to alternative treatments; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our ability to offer our drugs for sale at competitive prices; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the convenience and ease of administration compared to alternative treatments; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the strength of marketing and distribution support; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the availability of third-party coverage and adequate reimbursement; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the prevalence and severity of any side effects; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
				<font style="margin:4pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">any restrictions on the use of our drugs together with other medications. </font></p></td></tr></table></div>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we are unable to establish sales, marketing and distribution capabilities for drug candidates other than rivipansel, we may not be successful in commercializing those drug candidates if and when they are approved. </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical drugs. Under our collaboration with Pfizer, Pfizer is responsible for the commercialization of rivipansel, our first drug candidate, if it receives regulatory approval. To achieve commercial success for any other drug candidate for which we may obtain marketing approval, we will need to establish a sales and marketing organization to market or co-promote such drugs. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a drug candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Factors that may inhibit our efforts to commercialize our drugs on our own include: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more products; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </font></p></td></tr></table></div>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third parties to perform these services, our revenue and our profitability, if any, are likely to be lower than if we were to sell, market and distribute any drugs that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our drug candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drugs effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our drug candidates. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do. </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The development and commercialization of new drugs is highly competitive. We face competition with respect to our current drug candidates, and we will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, governmental agencies and public and private research institutions. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">37</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:4pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">Should any competitors&#x2019; drug candidates receive regulatory or marketing approval prior to ours, they may establish a strong market position and be difficult to displace or diminish the need for our drug candidates. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With respect to rivipansel, we are not aware of any therapies that have been approved for treatment of patients experiencing VOC. The only drug approved for the prevention of VOC, but not for the resolution of an ongoing VOC episode, is hydroxyurea, which is available in both generic and branded formulations. Notably, the Phase 3 trial of MST-188, conducted by Mast Therapeutics, Inc., failed to meet its primary endpoint of significantly reducing the mean duration of vaso-occlusive crises in sickle cell patients, and that clinical program has been discontinued.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In addition, there are a number of other compounds that are in clinical development as either prophylactic or gene therapy/blood transfusion approaches to treat patients with sickle cell anemia, including: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Prophylactic Approaches: Emmaus Life Sciences, Inc. (L-glutamine); Novartis Pharmaceuticals Corporation (crizanlizumab, formerly SelG1); Baxter International (Aes-103); and Global Blood Therapeutics (GBT440).</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Gene Therapy/Blood Transfusion Approaches: Blue Bird Bio (Lentiglobin BB305); Sangamo Biosciences/Bioverativ (ZFN Knockout); and Bellicum Pharmaceuticals (BPX-501). </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#1F140C;">In September 2016, Emmaus Life Sciences announced that the FDA had accepted its New Drug Application requesting approval for L-glutamine as a prophylactic treatment for sickle cell disease.&nbsp;&nbsp;In December 2016, results from a Phase 2 clinical trial crizanlizumab, an anti-P-selectin antibody, were published in the New England Journal of Medicine.  In this trial, crizanlizumab reduced the median annual rate of sickle cell-related pain crises by 45.3% compared to placebo in patients.&nbsp;&nbsp;If one or both of these prophylactic agents were to be approved by the FDA prior to rivipansel, they could reduce the number of VOC episodes each year, reducing the market opportunity for rivipansel.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Although bone marrow transplant is currently available and can be curative for sickle cell disease, its use is limited by the lack of availability of matched donors and by the risk of serious complications, including graft versus host disease and infection. Attempts to develop a cure through gene therapy remain at an early stage, but if these approaches were to be successful and received regulatory approval, this could limit the market for a drug such as rivipansel. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, numerous non-profit and non-commercial foundations and interest groups also are committed to improving outcomes for patients with sickle cell disease. Advances in the understanding of the signaling pathways associated with sickle cell disease may lead to further interest and development of treatment options. There is also increasing interest among for-profit companies in developing drugs for rare diseases, which may have the effect of increasing the development of drug candidates to treat sickle cell disease generally or VOC in particular. Legislative action, such as the potential to expand the priority review voucher system to rare pediatric diseases, may generate further interest in developing drug candidates to treat sickle cell disease or VOC and increase competition. If an alternative effective treatment or cure for VOC or sickle cell disease receives regulatory approval, the potential commercial success of rivipansel could be jeopardized. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;color:#000000;">Our drug discovery, development and commercialization activities in oncology face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies</font><font style="display:inline;font-family:Times;">. As the treatment landscape for AML and MM changes, there is substantial risk that GMI-1271 might not provide additional benefit over other therapies. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;">While many chemotherapies in development for hematologic malignancies will likely be complementary to GMI-1271, there are also therapies in development that could be directly competitive with GMI-1271.&nbsp;&nbsp;In particular, there are a number of CXCR4 antagonists in clinical development that target </font><font style="display:inline;font-family:Times;background-color: #FFFFFF;">the bone marrow microenvironment in order to mobilize and sensitize cancer cells to chemotherapy, including </font><font style="display:inline;">Sanofi-Aventis </font><font style="display:inline;font-family:Times;background-color: #FFFFFF;">(Mozobil), Bristol Myers Squibb (BMS-936564), NOXXON Pharma (NOX-A12), Eli Lilly (LY2510924) and BioLine RX (BL-8040).&nbsp; </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Many of the companies against which we are competing, or against which we may compete in the future, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">38</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, because we have no patents with respect to our glycomimetics platform, our competitors may use our methods, or acquire similar expertise, in order to develop glycomimetic drug candidates and progress these drug candidates through clinical development and commercialization, which could impair our ability to successfully commercialize our drug candidates or otherwise limit our commercial opportunities. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Even if we or our collaborators are able to commercialize any of our drug candidates, the drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our and our collaborators&#x2019; ability to commercialize any of our drug candidates successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from government payor programs at the federal and state levels authorities, including Medicare and Medicaid, private health insurers, managed care plans and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs. Coverage and reimbursement may not be available for any drug that we or our collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Inadequate reimbursement levels may adversely affect the demand for, or the price of, any drug candidate for which we or our collaborators obtain marketing approval. Obtaining and maintaining adequate reimbursement for our drugs may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we or our collaborators may not be able to successfully commercialize any drug candidates for which marketing approval is obtained. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, one payor&#x2019;s determination to provide coverage for a drug does not assure that other payors will also provide coverage for the drug. Our or our collaborators&#x2019; inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved drugs that we develop could adversely affect our operating results, our ability to raise capital needed to commercialize drugs and our overall financial condition. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">39</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we or our collaborators might obtain marketing approval for a drug in a particular country, but then be subject to price regulations that delay commercial launch of the drug, possibly for lengthy time periods, and negatively impact our ability to generate revenue from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain marketing approval. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There can be no assurance that our drug candidates, if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that third-party payors&#x2019; reimbursement policies will not adversely affect our ability to sell our drug candidates profitably if they are approved for sale. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any drugs that we may develop. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We face an inherent risk of product liability exposure related to the testing of our drug candidates in human clinical trials, and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our drug candidates or drugs caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">decreased demand for any drug candidates or drugs that we may develop; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">injury to our reputation and significant negative media attention; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">withdrawal of clinical trial participants; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">significant costs to defend the related litigation; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">substantial monetary awards paid to trial participants or patients; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">loss of revenue; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">reduced resources of our management to pursue our business strategy; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the inability to commercialize any drugs that we may develop. </font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We currently hold $5.0 million of clinical trial insurance coverage in the aggregate for our clinical trials being conducted in the United States, with a per incident limit of $5.0 million, which may not be adequate to cover all liabilities that we may incur. In addition, we have increased our clinical coverage above this amount in foreign countries where we plan to have sites as part of our clinical trials for GMI-1271, including Ireland and Australia. We may need to further increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our drug candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </font>
		</p>
		<p style="margin:14pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Our Intellectual Property </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we are unable to obtain and maintain patent protection for our drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize our drug candidates may be impaired. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our drug candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our drug candidates. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">40</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our drug candidates, in whole or in part, or which effectively prevent others from commercializing competitive drug candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&nbsp;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Moreover, we may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or become involved in opposition, derivation, reexamination, </font><font style="display:inline;font-style:italic;">inter partes</font><font style="display:inline;"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our drug candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative drug candidates in a non-infringing manner. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical drug candidates, or limit the duration of the patent protection of our drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">41</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">invalid or unenforceable, in whole or in part, construe the patent&#x2019;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A third party may hold intellectual property, including patent, rights that are important or necessary to the development of our drug candidates. It may be necessary for us to use patented or proprietary technology of third parties to commercialize our drug candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our drug candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our drug candidates, including interference or derivation proceedings before the U.S. Patent and Trademark Office. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we are found to infringe a third party&#x2019;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our drug candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing drug. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#x2019;s former employer. Litigation may be necessary to defend against these claims. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">42</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to seeking patents for our drug candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. For example, our platform is based on trade secrets that consist largely of expertise in carbohydrate chemistry and knowledge of carbohydrate biology. We do not believe that we can obtain patent protection for our platform. Thus, our competitors may use our methods, or acquire similar expertise, in order to develop glycomimetic drug candidates and progress these drug candidates through clinical development and commercialization, which could impair our ability to successfully commercialize our drug candidates. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Regulatory Approval of Our Drug Candidates and Other Legal Compliance Matters </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize our drug candidates and our ability to generate revenue will be materially impaired. </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our drug candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the European Medicines Agency, or EMA, and similar regulatory authorities outside the United States. Failure to obtain marketing approval for a drug candidate will prevent us or our collaborators from commercializing the drug candidate. We have not received approval to market any of our drug candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process for drug candidates other than rivipansel. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the drug candidate&#x2019;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, applicable regulatory authorities. Our drug candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our ability to obtain marketing approval or prevent or limit commercial use. If </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">43</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:4pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">any of our drug candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit sales of the drug. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted drug application may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application, or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a drug candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For marketing exclusivity in the treatment of an ongoing VOC episode in sickle cell disease, we expect to rely primarily on the orphan drug designation that the FDA has granted us for rivipansel, which includes the treatment of the complications of sickle cell disease. However, in order to obtain marketing exclusivity, we must receive the first marketing approval of rivipansel for such indication. In addition, the orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we experience delays in obtaining approval or if we fail to obtain approval of our drug candidates, the commercial prospects for our drug candidates may be harmed and our ability to generate revenue will be materially impaired. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Even though we have obtained orphan drug designation for our most advanced drug candidate, rivipansel, and for GMI-1271, we may not be able to obtain orphan drug marketing exclusivity for these drug candidates or any of our other drug candidates. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Regulatory authorities in some jurisdictions, including the United States and the European Union, or EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We have obtained orphan drug designation from the FDA and the EMA for rivipansel for the treatment of VOC. We have also obtained orphan drug designation from the FDA for GMI-1271 for the treatment of AML. We may seek orphan drug designation for our other drug candidates or for GMI-1271 for additional indications, such as MM. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug for the same indication for that time period. The applicable period is seven years in the United States and 10 years in the EU. The EU exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if we obtain orphan drug exclusivity for a drug candidate, that exclusivity may not effectively protect the candidate from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The FDA fast track designation for rivipansel and GMI-1271 may not actually lead to a faster development or regulatory review or approval process. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If a drug is intended for the treatment of a serious or life-threatening disease or condition and the drug demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation. If fast track designation is obtained, the FDA may initiate review of sections of a new drug </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">44</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">application, or NDA, before the application is complete. This &#x201C;rolling review&#x201D; is available if the applicant provides, and the FDA approves, a schedule for submission of the individual sections of the application. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Although we have obtained a fast track designation from the FDA for rivipansel to treat VOC and for GMI-1271 to treat AML, we may not experience a faster development process, review or approval compared to conventional FDA procedures. Our fast track designation may be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development programs. Our fast track designation does not guarantee that we will qualify for or be able to take advantage of the expedited review procedures or that we will ultimately obtain regulatory approval of rivipansel or GMI-1271. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Failure to obtain marketing approval in international jurisdictions would prevent our drug candidates from being marketed abroad. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In order to market and sell our drugs in the EU and any other jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the drug be approved for reimbursement before it can be approved for sale in that country. We or our collaborators may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, failure to obtain approval in one jurisdiction may impact our ability to obtain approval elsewhere. We or our collaborators may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our drugs in any market. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">A variety of risks associated with marketing our drug candidates internationally could hurt our business. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We or our collaborators may seek regulatory approval for rivipansel and our other drug candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">differing regulatory requirements in foreign countries; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">economic weakness, including inflation or political instability in particular foreign economies and markets; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">foreign taxes, including withholding of payroll taxes; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations related to doing business in another country; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">difficulties staffing and managing foreign operations; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">workforce uncertainty in countries where labor unrest is more common than in the United States; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">potential liability under the Foreign Corrupt Practices Act or comparable foreign regulations; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">challenges enforcing our contractual and intellectual property rights, especially in foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">45</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">business interruptions resulting from geo-political actions, including war and terrorism. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These and other risks associated with our potential international operations may compromise our ability to achieve or maintain profitability. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Any drug candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may therefore be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our drug candidates, when and if any of them are approved. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Any drug candidate for which we obtain marketing approval, along with manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such drug candidate, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a drug candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a risk evaluation and mitigation strategy. If any of our drug candidates receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit its sales. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the drug. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off-label use, and if we do not market our drugs for their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, later discovery of previously unknown adverse events or other problems with our drugs, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may have negative consequences, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">restrictions on such drugs, manufacturers or manufacturing processes; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">restrictions on the labeling or marketing of a drug; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">restrictions on product distribution or use; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">requirements to conduct post-marketing studies or clinical trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">warning letters; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">recall or withdrawal of the drugs from the market; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">refusal to approve pending applications or supplements to approved applications that we submit; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">clinical holds; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">fines, restitution or disgorgement of revenue or profit; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">suspension or withdrawal of marketing approvals; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">refusal to permit the import or export of our drugs; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">product seizure; or </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">46</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of drugs for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU&#x2019;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our current and future business and relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we conduct clinical research, sell, market and distribute any drugs for which we obtain marketing approval. In addition, we may be subject to transparency laws and patient data privacy and security regulation by the U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs, such as Medicare and Medicaid; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the federal Open Payments program, pursuant to the Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to &#x201C;payments or other transfers of value&#x201D; made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members, with disclosure of such information to be made by CMS on a publicly available website; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that </font></p></td></tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">47</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:6pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;;"><font style="display:inline;color:#000000;">may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, individual imprisonment, </font><font style="display:inline;color:#000000;">additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws,</font><font style="display:inline;"> contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any drug candidates for which we obtain marketing approval. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives </font><font style="display:inline;color:#000000;">to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug</font><font style="display:inline;">. In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively PPACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, improve quality of care, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Among the provisions of PPACA of importance to our business and potential drug candidates are: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">48</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">extension of a manufacturer&#x2019;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level beginning in 2014, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the new requirements under the federal Open Payments program and its implementing regulations; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </font></p></td></tr></table></div>
		<p style="margin:6pt 0pt 0pt 42.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There have been judicial and Congressional challenges to certain aspects of PPACA, and we expect there will be additional challenges and amendments in the future. </font><font style="display:inline;color:#000000;">In January, Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of PPACA. The Budget Resolution is not a law, however, it is widely viewed as the first step toward the passage of repeal legislation. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of PPACA that are repealed. We cannot predict how PPACA, its possible repeal, or any legislation that may be proposed to replace PPACA will impact our business.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"> In addition, other legislative changes have been proposed and adopted since PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, which began in 2013, pursuant to the Budget Control Act of 2011. On March&nbsp;1, 2013, the President signed an executive order implementing the 2% Medicare payment reductions, and on April&nbsp;1, 2013, these reductions went into effect. Pursuant to the Bipartisan Budget Act of 2015, these reductions will stay in effect through 2025, unless additional Congressional action is taken.&nbsp;&nbsp;In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and, accordingly, our financial operations. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Although we are unsure of the full impact that PPACA will have on our business, we expect that PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.&nbsp;&nbsp;Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#x2019;s </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">49</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In some countries, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our drug candidate to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Employee Matters and Managing Our Growth </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are highly dependent on the management, research and development, clinical, financial and business development expertise of Rachel King, our President and Chief Executive Officer; John Magnani, our Senior Vice President of Research and Chief Scientific Officer; Helen Thackray, our Senior Vice President of Clinical Development and Chief Medical Officer; and Brian Hahn, our Chief Financial Officer, as well as the other members of our scientific and clinical teams. In particular, we are dependent upon Dr.&nbsp;Magnani for key expertise in carbohydrate chemistry and knowledge of carbohydrate biology with respect to our glycomimetics platform, and the loss of his services would materially impair our future drug discovery efforts. Although we have entered into employment agreements with our executive officers, each of them may currently terminate their employment with us at any time. We do not maintain &#x201C;key person&#x201D; insurance for any of our executives or employees other than Ms.&nbsp;King. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of our drug pipeline other than rivipansel toward scaling up for commercialization, sales and marketing personnel, will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">50</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">breadth of skills and experience required to successfully develop, gain regulatory approval for and commercialize our drug candidates. Competition to hire qualified personnel in our industry is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, drug development, regulatory affairs and, if any of our drug candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our employees and employees of our collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We and our collaborators are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent improper activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, or any such actions are instituted against any of our collaborators, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions and diminished royalties. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Ownership of Our Common Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">An active trading market for our common stock may not continue to develop or be sustained. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Prior to our IPO in January 2014, there was no public market for our common stock. Although our common stock is listed on The NASDAQ Global Market, we cannot assure you that an active trading market for our shares will continue to develop or be sustained. If an active market for our common stock does not continue to develop or is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">51</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The trading price of the shares of our common stock has been and is likely to continue to be volatile. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since our IPO, our stock price has been volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">announcements relating to development, regulatory approvals or commercialization of our drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">actual or anticipated variations in our operating results; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">changes in financial estimates by us or by any securities analysts who might cover our stock; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">conditions or trends in our industry; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">changes in laws or other regulatory actions affecting us or our industry; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">capital commitments; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">investors&#x2019; general perception of our company and our business; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">disputes concerning our intellectual property or other proprietary rights; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">recruitment or departure of key personnel; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">sales of our common stock, including sales by our directors and officers or specific stockholders. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#x2019; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#x2019;s attention and resources from our business. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business. As a newly public company, we have only limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plan, our employee stock purchase plan or otherwise will dilute all other stockholders. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our certificate of incorporation authorizes us to issue up to 100,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plan, our employee stock purchase plan or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">52</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If a substantial number of our total outstanding shares are sold into the market, or if the market perceives that such sales may occur, it could cause the market price of our common stock to drop significantly, even if our business is doing well. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or if the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. All of our outstanding shares of common stock are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, we have filed registration statements on Form S-8 registering the issuance of approximately 3.7&nbsp;million shares of common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. Shares registered under these registration statements are available for sale in the public market subject to vesting arrangements and exercise of options, as well as Rule 144 in the case of our affiliates. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Additionally, some of the holders of our common stock who acquired their shares of our stock prior to the IPO, as well as some of the holders of outstanding warrants to purchase our common stock, or their transferees, have rights, subject to some conditions, to require us to file one or more registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. If we were to register the resale of these shares, they could be freely sold in the public market. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There are provisions in our certificate of incorporation and bylaws that may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by some or all of our stockholders. For example, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our charter documents also contain other provisions that could have an anti-takeover effect, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">only one of our three classes of directors is elected each year; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">stockholders are not entitled to remove directors other than by a 66 2/3% vote and only for cause; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">stockholders are not permitted to take actions by written consent; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">stockholders cannot call a special meeting of stockholders; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, we are subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General Corporation Law, which regulates corporate acquisitions by prohibiting Delaware corporations from engaging in specified business combinations with particular stockholders of those companies. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">53</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates beneficially own a majority of our common stock. Further, funds controlled by one investor, New Enterprise Associates, or NEA, beneficially own approximately 40% of our common stock. As a result, NEA is able to significantly influence, and together with these other persons would be able to control, all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets or other significant corporate transactions. The interests of this group of stockholders may not coincide with our interests or the interests of other stockholders. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We are an &#x201C;emerging growth company,&#x201D; and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are an &#x201C;emerging growth company&#x201D; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; disclosure; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">reduced disclosure obligations regarding executive compensation; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">not being required to hold a non-binding advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved. </font></p></td></tr></table></div>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2019, (2)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.0 billion, (3)&nbsp;the last day of the fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June&nbsp;30th and (4)&nbsp;any date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under Section&nbsp;107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules and regulations of The NASDAQ Global Market. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting and perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting. This requires that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">54</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#x2019;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we are unable to maintain proper and effective internal controls in the future, we may not be able to produce timely and accurate financial statements, and we may conclude that our internal controls over financial reporting are not effective. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by NASDAQ, the SEC or other regulatory authorities. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We do not anticipate paying any cash dividends on our common stock in the foreseeable future and our stock may not appreciate in value. </font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. There is no guarantee that shares of our common stock will appreciate in value or that the price at which our stockholders have purchased their shares will be able to be maintained. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We will incur increased costs and demands upon management as a result of being a public company. </font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As a newly public company listed in the United States, we have begun, and will continue, particularly after we cease to be an &#x201C;emerging growth company,&#x201D; to incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and NASDAQ, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#x2019;s time and attention from revenue-generating activities to compliance activities. If we do not comply with new laws, regulations and standards, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt 55.45pt;text-indent: -55.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 1B.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 28pt 0pt 0pt;"></font>UNRESOLVED STAFF COMMENT<a name="ITEM1BUNRESOLVEDSTAFFCOMMENTS_434071"></a>S &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">None. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt 55.45pt;text-indent: -55.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp;2.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 34pt 0pt 0pt;"></font>PROPERTIE<a name="ITEM2PROPERTIES_674160"></a>S &nbsp;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our principal offices occupy approximately 42,000 square feet of leased office space in Rockville, Maryland, pursuant to a lease agreement that expires in October 2023. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business. We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt 55.45pt;text-indent: -55.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 3.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 31pt 0pt 0pt;"></font>LEGAL PROCEEDING<a name="ITEM3LEGALPROCEEDINGS_697974"></a>S &nbsp;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">From time to time, we are subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">55</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt 55.45pt;text-indent: -55.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 4.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 31pt 0pt 0pt;"></font>MINE SAFETY DISCLOSURE<a name="ITEM4MINESAFETYDISCLOSURES_857992"></a>S &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Not applicable. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;text-transform:uppercase;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">56</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;text-transform:uppercase;">PART I<a name="PARTII_834"></a>I &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt 55.05pt;text-indent: -55.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 5.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 31pt 0pt 0pt;"></font>MARKET FOR REGISTRANT&#x2019;S COMMON EQUIT<a name="ITEM5MARKETFORREGISTRANTSCOMMONEQUITY_65"></a>Y, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Market Information for Common Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our common stock commenced trading on The NASDAQ Global Market under the symbol &#x201C;GLYC&#x201D; on January&nbsp;10, 2014. Prior to our IPO, there was no public market for our common stock. The following table sets forth, for the periods indicated, the high and low reported sales price of our common stock as reported on the NASDAQ Global Market: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">High</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Low</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">First quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.55
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.70
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Second quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.25
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.82
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Third quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.89
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.58
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Fourth quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.42
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.50
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">High</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Low</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">First quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.00
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.66
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Second quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.22
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.51
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Third quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.00
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.47
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Fourth quarter</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.18
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.88
				</td>
				<td valign="bottom" style="width:00.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Dividend Policy </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Stockholders </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of February&nbsp;27, 2017, we had 23,329,900 shares of common stock outstanding held by approximately 37 holders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">57</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Performance Graph </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following graph compares the performance of our common stock since January&nbsp;10, 2014, the date of our IPO, with the performance of the NASDAQ Composite Index (U.S.) and the NASDAQ Biotechnology Index. The comparison assumes a $100 investment on January&nbsp;10, 2014 in our common stock, the stocks comprising the NASDAQ Composite Index, and the stocks comprising the NASDAQ Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any. Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Comparison of Cumulative Total Return </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Among GlycoMimetics, Inc., the NASDAQ Composite Index and the NASDAQ Biotechnology Index </font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"><img src="glyc20161231x10k003.jpg" style="width: 5.891667in; height: 4.124166in" alt="Picture 4"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Sales of Unregistered Securities </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">None.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"> Purchases of Equity Securities by the Issuer and Affiliated Parties </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">None. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">58</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt 55.45pt;text-indent: -55.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 6.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 31pt 0pt 0pt;"></font>SELECTED FINANCIAL DAT<a name="ITEM6SELECTEDFINANCIALDATA_528251"></a>A &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following selected financial data as of and for the years ended December&nbsp;31, 2016, 2015, 2014, 2013 and 2012 is derived from our audited financial statements, which have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm. The statement of operations data for the years ended December&nbsp;31, 2013 and 2012, and the balance sheet data as of December&nbsp;31, 2014, 2013 and 2012, have been derived from our audited financial statements which are not included herein. Our historical results are not necessarily indicative of the results to be expected in the future. The selected financial data should be read together with Item&nbsp;7. &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; and in conjunction with the financial statements, related notes, and other financial information included elsewhere in this Annual Report.</font><font style="display:inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2012</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Statement of Operations Data:</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,071
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,027
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,993
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,257
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Costs and expenses:</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,282
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,571
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,701
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,438
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,650
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,805
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,596
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,899
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,184
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total costs and expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,932
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,855
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,167
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,600
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,622
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Loss) income from operations</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,914)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,784)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,140)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,607)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,635
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>104
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net (loss) income and comprehensive (loss) income</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,810)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,122)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10,606)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,656
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net (loss) income per share of common stock&#x2014;basic</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.50)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.67)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8.87)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.93
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net (loss) income per share of common stock&#x2014;diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.50)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.67)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8.87)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Weighted average common shares outstanding, basic</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,256,312
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,587
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,452,252
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,196,162
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>929,619
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Weighted average common shares outstanding, diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,256,312
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,587
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,452,252
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,196,162
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,016,532
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As of&nbsp;December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2013</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2012</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Balance Sheet Data:</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,042
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,803
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,199
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,311
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17,373
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,388
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,462
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,264
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,283
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,420
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,087
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,991
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,461
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,376
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,891
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total stockholders&#x2019; equity</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,301
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,472
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50,803
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,907
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,528
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">59</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp;7.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS <a name="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a></font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review Item&nbsp;1A. &#x201C;Risk Factors&#x201D; and &#x201C;Special Note Regarding Forward-Looking Statements&#x201D; in this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis</font><font style="display:inline;">.</font><font style="display:inline;font-style:italic;">&nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Overview </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using our expertise in carbohydrate chemistry and knowledge of carbohydrate biology, we are developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. We believe this represents an innovative approach to drug discovery to treat a wide range of diseases. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are focusing our initial efforts on drug candidates for rare diseases that we believe will qualify for orphan drug designation. Our first drug candidate, rivipansel, is being developed for the treatment of vaso-occlusive crisis, or VOC, one of the most severe complications of sickle cell disease. We have entered into a collaboration with Pfizer Inc., or Pfizer, for the further development and potential commercialization of rivipansel worldwide. Rivipansel has received fast track designation from the U.S. Food and Drug Administration, or FDA, as well as orphan drug designation from the FDA in the United States and from the European Medicines Agency in the European Union. We believe the clinical progress of rivipansel provides evidence of the significant potential of our lead program and our proprietary glycomimetics platform.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Building on our experience with rivipansel, we are developing a pipeline of other glycomimetic drug candidates. Our second glycomimetic drug candidate, GMI-1271, is a specific E-selectin inhibitor, which we are developing to be used in combination with chemotherapy to treat patients with either acute myeloid leukemia, or AML, or multiple myeloma, or MM, both of which are life-threatening hematologic cancers, and potentially other hematologic cancers as well. GMI-1271 received orphan drug designation in AML from the FDA in May 2015. In June 2016, GMI-1271 received fast track designation for the treatment of adult patients with relapsed or refractory AML and elderly patients aged 60 years or older with AML. We are currently conducting clinical trials in both AML and MM.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In May 2015, we commenced a multinational, Phase 1/2, open-label trial of GMI-1271 as an adjunct to standard chemotherapy in patients with AML. The trial consists of two parts. In the Phase 1 portion, dose escalation testing was performed to determine a recommended GMI-1271 dose in combination with standard chemotherapy to be used in the Phase 2 portion. The primary objective of the trial is to evaluate the safety of GMI-1271 in combination with chemotherapy. Secondary objectives are to characterize pharmacokinetics, or PK, and pharmacodynamics, and to observe anti-leukemic activity.&nbsp;&nbsp;There were a total of 19 patients enrolled and dosed with GMI-1271 and chemotherapy in the Phase 1 portion of the trial. Patients had relapsed or refractory AML.&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the Phase 1 portion of the trial, the combination of GMI-1271 and chemotherapy was well-tolerated, with no dose-limiting toxicities observed and no mortality reported during the treatment phase of 44 days. Serious adverse events, including sepsis, pneumonia, device-related infection, enterocolitis, hypernatremia and adjustment disorder, were observed in five patients, with all such events resolving during the treatment phase. Mucositis, which often develops following treatment with this intensive therapy, was noted in only 6 of the 19 patients.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In terms of efficacy, nine of the 19 patients achieved complete remission, with a full bone marrow response, or CR, and full blood count recovery. The total of nine patients achieving remission represents an overall response rate of 47%. This same standard high-dose chemotherapy regimen for relapsed/refractory AML patients typically has remission rates of between 25-30%. One additional patient achieved a status known as morphologic leukemia-free state, which is not included in the overall response rate. Seven patients who achieved remission proceeded to receiving a hematopoietic </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">60</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">stem cell transplant. PK data showed a dose-dependent increase in plasma concentrations of GMI-1271, such that all were above levels associated with anti-leukemic activity in animal models of AML. In addition, biomarker analysis showed a biological on-target effect of GMI-1271 at all dose levels.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With an optimal dose of 10 mg/kg having been determined for the remainder of the trial, in June 2016, we dosed the first patient in the Phase 2 portion of the trial. In this portion of the trial, dose-expansion testing is being conducted to obtain additional safety and efficacy data in two defined sub-populations of AML. One arm of the trial continues to enroll relapsed or refractory AML patients; the second arm is enrolling patients over 60 years of age with newly diagnosed AML. We expect to enroll a total of approximately 72 patients in the Phase 2 portion of the trial. Unlike in the Phase 1 portion, some of the patients in the Phase 2 portion may be treated with multiple cycles of GMI-1271. The Phase 2 portion of the trial is being conducted in the United States, Ireland and Australia. The ongoing Phase 2 portion of the trial is expected to complete enrollment in the first half of 2017. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2016, we presented interim clinical data for the trial, including preliminary data from the Phase 2 portion, at the 58th American Society of Hematology (ASH) Annual Meeting and Expo in San Diego. For a total of 33 study participants with relapsed or refractory disease taken together from the Phase 1 and one arm of the Phase 2 portion of the trial, the CR rate was 45%. For 11 newly diagnosed study participants 60 or more years of age in the second arm of the Phase 2 portion of the trial, the CR rate was 73%.&nbsp;&nbsp;We plan to provide additional updates from this study at scientific conferences in 2017.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In September 2016, we dosed the first patient in a Phase 1 clinical trial of GMI-1271 combined with bortezomib-or carfilzomib-based chemotherapy, for the treatment of MM. The multi-center, open-label dose escalation trial, which has begun enrolling in Ireland, will evaluate the efficacy, safety and pharmacokinetics of GMI-1271 in combination with proteasome inhibitor chemotherapy regimens among patients who have been diagnosed with MM and have not responded optimally to standard chemotherapy.&nbsp; </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During 2016, we were also collaborating with the University of Michigan to evaluate GMI-1271 as a potential new class of anticoagulant to treat persons at risk for venous thromboembolic disease, a serious blood-clotting disorder. The University of Michigan began dosing healthy volunteers in a Phase 1 randomized, partially blinded, active placebo-controlled trial in December 2014. The primary objective of the trial was to evaluate the safety and PK profile of GMI-1271 in a single and multiple ascending doses in healthy volunteers. The secondary objectives included evaluation of the incidence of bleeding and other adverse events and evaluation of the effects of GMI-1271 on biomarkers of coagulation, cell adhesion and leukocyte and platelet activation. The single and multiple ascending dose-escalation clinical trial in 32 healthy volunteers and a small Phase 1/2 clinical trial in patients with DVT were completed in 2016.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are also developing a pipeline of other preclinical drug candidates based on our expertise in carbohydrate chemistry. We have designed a family of small molecule drug candidates that simultaneously inhibit both E-selectin and CXCR4. We have selected one of these compounds, GMI-1359, for the development as a potential treatment for certain malignancies. Since E-selectin and CXCR4 are both adhesion molecules that keep cancer cells in the bone marrow, we believe that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that affect the bone marrow such as hematologic cancers, including AML and MM, and certain solid tumors such as breast and prostate cancer, as compared to targeting CXCR4 alone. In December 2016 at the annual meeting of the American Society of Hematology, we presented preclinical data suggesting that GMI-1359 has a unique tumor cell mobilization kinetic profile and enhanced the ability of chemotherapy to target and improve survival from a high-risk form of mutated AML.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In 2016, we completed enrollment in a Phase 1 single-dose escalation trial of GMI-1359 in healthy volunteers.&nbsp;&nbsp;In this trial, volunteer participants received a single injection of GMI-1359, after which the subjects were evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics. The randomized, double-blind placebo controlled escalating dose study was conducted at a single site in the United States. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Using our glycomimetics platform, we have designed galectin-3 and galectin-9 inhibitors that specifically block the binding of galectin-3 and galectin-9 to carbohydrate structures.&nbsp;&nbsp;Galectin-3 and galectin-9 are proteins that are known to play critical roles in many pathological processes, including checkpoints in T-cell exhaustion during cancer immunotherapy, chemotherapy resistance, fibrosis and cardiovascular disease. We plan to optimize these compounds and conduct preclinical experiments in 2017 to further characterize the effects of galectin-3 and galectin-9 inhibitors on immune processes and anti-fibrotic activity. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">61</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:9pt;">We </font><font style="display:inline;font-size:10pt;">commenced operations in 2003, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our glycomimetics platform, identifying potential drug candidates, undertaking preclinical studies and conducting clinical trials of rivipansel, GMI-1271 and GMI-1359. To date, we have financed our operations primarily through private placements of our securities, upfront and milestone payments under our collaboration with Pfizer and the net proceeds from our IPO in January 2014, net proceeds from our at-the-market facility with Cowen and Company LLC, or Cowen, and net proceeds from our public offering of common stock in June 2016. We have no approved drugs currently available for sale, and substantially all of our revenue to date has been revenue from the upfront and milestone payments from Pfizer, although we have received nominal amounts of revenue under research grants. Prior to our IPO, we raised an aggregate of $86.6 million to fund our operations, of which $22.5 million was an upfront payment under our collaboration with Pfizer and $64.1 million was from the sale of our convertible promissory notes and convertible preferred stock. The IPO provided us with net proceeds of $57.2 million, and we received a non-refundable milestone payment from Pfizer in May 2014 of $15.0 million. In August 2015, we received another non-refundable milestone payment from Pfizer of $20.0 million following the dosing of the first patient in the Phase 3 clinical trial of rivipansel. In 2016, we received an additional $19.7 million in net proceeds from our public offering in June 2016 and $3.9 million of net proceeds under the at-the-market facility with Cowen.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Since inception, we have incurred significant operating losses. We have generated cumulative revenue of $58.6 million since our inception through December 31, 2016, primarily consisting of the $22.5 million upfront payment from Pfizer in 2011, the $15.0 million non-refundable milestone payment in May 2014 and the $20.0 million non-refundable milestone payment in August 2015. We had an accumulated deficit of $119.0&nbsp;million as of December 31, 2016, and we expect to continue to incur significant expenses and operating losses over at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the timing of our clinical trials, the receipt of milestone payments, if any, under our collaboration with Pfizer, and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially as we: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">initiate and conduct our planned clinical trials of GMI-1271 and GMI-1359; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">continue the research and development of our other drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">seek to discover and develop additional drug candidates; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">seek regulatory approvals for any drug candidates other than rivipansel that successfully complete clinical trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drug candidates other than rivipansel for which we may obtain regulatory approval; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">maintain, expand and protect our intellectual property portfolio; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">hire additional clinical, quality control and scientific personnel; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To fund further operations, we will need to raise capital. We may obtain additional financing in the future through the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute on our business plan. Although it is difficult to predict future liquidity requirements, we believe that our existing cash and cash equivalents, together with interest thereon, will be sufficient to fund our operations into the second quarter of 2018. However, our ability to successfully transition to profitability will be dependent upon achieving a level of revenues adequate to support our cost structure. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Collaboration with Pfizer </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In October 2011, we entered into the license agreement with Pfizer under which we granted Pfizer an exclusive worldwide license to develop and commercialize products containing rivipansel for all fields and uses. The license also covers specified back-up compounds along with modifications of and improvements to rivipansel that meet defined </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">62</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">chemical properties. Pfizer is required to use commercially reasonable efforts, at its expense, to develop, obtain regulatory approval for and commercialize rivipansel for sickle cell disease in the United States. Under the terms of the agreement, we received a $22.5 million upfront payment. We are also eligible to earn potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications, up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications, and up to $135.0&nbsp;million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties for each licensed product, with percentages ranging from the low double digits to the low teens, based on net sales worldwide, subject to reductions in specified circumstances. </font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The first potential milestone payment under the Pfizer agreement was $35.0&nbsp;million upon the initiation of dosing of the first patient in a Phase 3 clinical trial of rivipansel by Pfizer. Under the collaboration, Pfizer made a $15.0 million non-refundable milestone payment to us in May 2014, which we recognized as revenue in May 2014, when earned, and the dosing of the first patient in the Phase 3 clinical trial in June 2015 triggered the remaining $20.0 million milestone payment to us.&nbsp;&nbsp;We recorded the $20.0 million milestone payment as revenue in June 2015. There were no milestones payments received from Pfizer for the year ended December 31, 2016.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have a research services agreement with the University of Basel, or the University, under which University personnel have performed research services for us on an as-requested basis since 2004. The agreement includes one-year research terms, and we have no affirmative obligation to purchase any minimum amount of services in any year beyond what we commit to at the beginning of each term, if any. For the research terms ended in February 2016 and 2015, we paid the University approximately $100,000 and $200,000, respectively. As part of the original consideration for entering into this agreement, we granted to the University the right to receive payments from us under specified circumstances. If we receive any future milestone payments or royalties from Pfizer with respect to rivipansel, we have agreed to pay 10% of those amounts to the University.&nbsp;&nbsp;In February 2016 and 2015, we paid $2.0 million and $1.5 million, respectively, to the University based upon the non-refundable milestone payments from Pfizer.&nbsp;&nbsp;We recorded these payments during the years ended December 31, 2015 and 2014, respectively, at the time the payments became due to the University. There were no additional payments due to the University for the year ended December 31, 2016.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates are reflected in our financial statements prospectively from the date of the change in estimate. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We define our critical accounting policies as those accounting principles generally accepted in the United States that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. While our significant accounting policies are more fully described in Note 2 to our financial statements appearing elsewhere in this Annual Report, we believe the following are the critical accounting policies used in the preparation of our financial statements that require significant estimates and judgments. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Revenue Recognition </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">License and Collaboration Agreements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have entered into a license agreement with Pfizer. Under the agreement, Pfizer made a nonrefundable $22.5&nbsp;million upfront payment to us in 2011, a $15.0 million milestone payment in 2014 and a $20.0 million milestone </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">63</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">payment in 2015. Pfizer may become obligated to make additional milestone payments to us upon the achievement of significant clinical development milestones, regulatory approvals and sales-based events. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The agreement also contemplates royalty payments to us on any future net sales of rivipansel worldwide. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Collaborative research and development agreements can provide for one or more of upfront license fees, research payments and milestone payments. Agreements with multiple components, such as deliverables or similar items, are referred to as multi-element revenue arrangements and are evaluated according to the provisions of Accounting Standards Codification, or ASC, Topic 605-25, </font><font style="display:inline;font-style:italic;">Revenue Recognition</font><font style="display:inline;">&#x2014;</font><font style="display:inline;font-style:italic;">Multiple-Element Arrangements</font><font style="display:inline;">, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered to be a separate unit of accounting if both of the following criteria are met: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the delivered item(s) has value to our customer on a standalone basis; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the arrangement includes a general right of return relative to the delivered item(s), and delivery or performance of the undelivered item(s) is considered probable and substantially in our control. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is then allocated among the separate units based on a selling price hierarchy. The selling price hierarchy for each deliverable is based on vendor-specific objective evidence, or VSOE, if it is available; third-party evidence of selling price, or TPE, if VSOE is not available; or an estimated selling price, if neither VSOE nor TPE is available. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our license agreement with Pfizer represents a multiple-element revenue arrangement. To account for this transaction, we determined the elements, or deliverables, included in the arrangement and allocated arrangement consideration to the various elements based on each element&#x2019;s relative selling price. The identification of individual elements in a multiple-element arrangement and the estimation of the selling price of each element involve significant judgment, including consideration as to whether each delivered element has standalone value to our collaborator. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The primary deliverable under our license arrangement with Pfizer is an exclusive worldwide license to rivipansel, which is currently being developed to treat people experiencing VOC. The arrangement also includes deliverables related to research and preclinical development activities to be performed by us on Pfizer&#x2019;s behalf and our participation on a joint steering committee. We concluded that these deliverables should be accounted for as a single unit of accounting, and we therefore determined to recognize the upfront payment of $22.5 million as revenue over the expected development period of 1.5 years, which was the period over which we expected to provide our research and development services and participate on the joint steering committee under the arrangement. Our determination of the appropriate length of the period over which to recognize revenue was consistent with the research plan agreed to with Pfizer and the actual development timeline. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In reaching this conclusion, we evaluated whether the license to rivipansel has standalone value to Pfizer. Factors we considered in determining whether the license has standalone value included whether or not Pfizer can use the license for its intended purpose without the receipt of the remaining deliverables, the value of the license without the undelivered items, Pfizer&#x2019;s or other vendors&#x2019; ability to provide the undelivered items, the proprietary nature of the license and know-how, and the availability of our glycomimetics expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of our platform and the related proprietary nature of our research services, we concluded that standalone value does not exist for the license and, therefore, the license is not a separate unit of accounting under the collaboration and should be combined with the research and development services we are obligated to provide, including our participation on the joint steering committee. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We also evaluated whether our participation on the joint steering committee is a substantive obligation and therefore a separate unit of accounting. The joint steering committee is responsible for overseeing the general working relationships, determining the protocols to be followed in the research and development performed and evaluating the results from the continued development of the drug candidate. The factors we considered in determining if our participation on the joint steering committee is a substantive obligation included: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">which party negotiated or requested the steering committee; </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">64</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">how frequently the steering committee meets; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">whether or not there are any penalties or other recourse if we do not attend the steering committee meetings; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">which party has decision-making authority on the steering committee; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">whether or not Pfizer has the requisite experience and expertise associated with the research and development of rivipansel. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We considered that we may terminate our participation on the joint steering committee at any point during the agreement. Further, the estimated selling price of our obligation was not material to the overall license agreement. Based on all relevant facts and circumstances, we concluded that our participation on the joint steering committee is not a substantive obligation and, therefore, is not a separate unit of accounting under the collaboration. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We were not able to establish VSOE or TPE for the separate unit deliverables under the arrangement with Pfizer, as we do not have a history of entering into such arrangements or selling the individual deliverables within such arrangements separately. Accordingly, we determined that the selling price for the deliverables under the Pfizer license agreement should be determined using the best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on our part and included consideration of multiple factors, including market conditions and company-specific factors, such as those factors contemplated in negotiating the agreement and internally developed models that included assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a drug candidate pursuant to the license. In validating the best estimate of selling price, we considered whether changes in key assumptions used to determine the best estimate of selling price would have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our license agreement with Pfizer also includes contingent milestone payments related to specified development, regulatory and commercial milestones. Pursuant to ASC-605-28, </font><font style="display:inline;font-style:italic;">Revenue Recognition-Milestone Method</font><font style="display:inline;">, we may recognize revenue contingent upon the achievement of a substantive milestone in its entirety in the period the milestone is achieved. Milestones are considered substantive if all of the following conditions are met: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the milestone is nonrefundable; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">achievement of the milestone was not reasonably assured at the inception of the arrangement; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">substantive effort is involved to achieve the milestone; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the amount of the milestone appears reasonable in relation to the effort expended or the risk associated with achievement of the milestone; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">a reasonable amount of time passes between the upfront license payment and the first milestone payment, as well as between each subsequent milestone payment. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our determination as to whether a payment meets these five conditions involves management&#x2019;s judgment. If any of these conditions are not met, the resulting payment would not be considered a substantive milestone and would instead be considered part of the consideration for the single unit of accounting. In addition, if we determine that one milestone is not substantive, it could prevent us from concluding that subsequent milestones are substantive and, as a result, any additional milestone payments could also be considered part of the consideration for the single unit of accounting and would be recognized as revenue as those performance obligations are performed under either the proportional performance method or the straight-line method. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have evaluated whether each milestone under the Pfizer arrangement is substantive and at risk to both parties on the basis of the contingent nature of that milestone. This evaluation included an assessment of whether: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the consideration is commensurate with either our performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the consideration relates solely to past performance; and </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">65</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Based on this evaluation, we concluded that the milestones under the Pfizer collaboration are substantive, due to the uncertainty of future clinical development success and the additional effort and time that is expected before the milestones could be achieved. Accordingly, each milestone will be recognized as revenue upon its achievement, assuming all other revenue recognition criteria are met. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Stock-Based Compensation </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We issue stock-based compensation awards to our employees and non-employee directors, including stock options. We measure stock-based compensation expense related to these awards based on the fair value of the award on the date of grant and recognize stock-based compensation expense, less estimated forfeitures, on a straight-line basis over the requisite service period of the awards, which generally equals the vesting period. We grant stock options with exercise prices equal to the estimated fair value of our common stock on the date of grant. We have selected the Black-Scholes-Merton option pricing model to determine the fair value of stock option awards, which requires the input of various assumptions that require management to apply judgment and make assumptions and estimates, including: </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risk-Free Interest Rate</font><font style="display:inline;">&#x2014;The risk-free interest rate assumption is based on observed interest rates for constant maturity U.S. Treasury securities consistent with the expected life of our employee stock options. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Expected Term</font><font style="display:inline;">&#x2014;The expected life represents the period of time the stock options are expected to be outstanding and is based on the simplified method. Under the simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the simplified method due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock options </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Expected Volatility</font><font style="display:inline;">&#x2014;Expected volatility is based on the historical volatilities of a peer group of comparable publicly traded companies with drug candidates in similar stages of development along with the Company&#x2019;s historical volatility since its public offering, to determine its expected volatility.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Expected Dividend Yield</font><font style="display:inline;">&#x2014;We have assumed no dividend yield because we do not expect to pay dividends in the future, which is consistent with our history of not paying dividends. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. Our estimate of pre-vesting forfeitures, or forfeiture rate, is based on our analysis of historical behavior by stock option holders. The estimated forfeiture rate is applied to the total estimated fair value of the awards, as derived from the Black-Scholes-Merton model, to compute the stock-based compensation expense, net of pre-vesting forfeitures, to be recognized in our statements of operations. We estimate forfeitures for employee grants at the time of grant and revise the estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Expenses </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development costs are charged to expense as incurred and include employee-related expenses, including salaries, benefits and travel, expenses incurred under agreements with CROs and investigative sites that conduct preclinical studies and clinical trials, as well as the cost of acquiring, developing and manufacturing clinical trial materials, facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies and costs associated with preclinical activities and regulatory operations. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We record costs for some development activities, such as clinical trials, based on our evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">66</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Income Taxes </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We recorded deferred tax assets of $54.7&nbsp;million as of December&nbsp;31, 2016, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily composed of federal and state tax net operating loss, or NOL, carryforwards and research and development tax credit carryforwards. As of December&nbsp;31, 2016, we had federal and state NOL carryforwards of $87.3 million, research and development tax credit carryforwards of $7.4 million, and $7.6 million of orphan drug tax credit carryforwards available to reduce future taxable income, if any. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. In general, if we experience a greater than 50 percentage point aggregate change in ownership of specified significant stockholders over a three-year period, utilization of our pre-change NOL carryforwards will be subject to an annual limitation under Section&nbsp;382 of the U.S. Internal Revenue Code of 1986, as amended, and similar state laws. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization and may be substantial. If we experience a Section&nbsp;382 ownership change as a result of changes in our stock ownership, some of which changes may be outside our control, the tax benefits related to the NOL carryforwards may be further limited or lost. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Components of Operating Results </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Revenue </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">To date, we have not generated any revenue from the sale of our drug candidates and do not expect to generate any revenue from the sale of drugs in the near future. Substantially all of our revenue recognized to date has consisted of the upfront and milestone payments under our agreement with Pfizer. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since our inception, we have also recognized a nominal amount of revenue under research grant contracts, generally to the extent of our costs incurred in connection with specific research or development activities. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Research and Development </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to CROs and other consultants and other outside expenses. Other preclinical research and platform programs include activities related to exploratory efforts, target validation, lead optimization for our earlier programs and our proprietary glycomimetics platform. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To date, our research and development expenses have related primarily to the development of rivipansel and our other drug candidates. As of April 2013, when we completed our Phase 2 clinical trial of rivipansel, all further clinical development obligations associated with rivipansel have shifted to Pfizer. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not currently utilize a formal time allocation system to capture expenses on a project-by-project basis because we are organized and record expense by functional department and our employees may allocate time to more than one development project. Accordingly, we only allocate a portion of our research and development expenses by functional area and by drug candidate. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development activities are central to our business model. Drug candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials. We expect our research and development expenses to increase over the next several years as we seek to progress GMI-1271, GMI-1359 and our other drug candidates through clinical development. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical studies and clinical trials of our drug candidates, or if, when or to what extent we will generate </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">67</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">revenues from the commercialization and sale of any of our drug candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our drug candidates. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The duration, costs and timing of clinical trials and development of our drug candidates will depend on a variety of factors that include: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">per patient trial costs; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the number of patients that participate in the trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the number of sites included in the trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the countries in which the trial is conducted; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the length of time required to enroll eligible patients; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the number of doses that patients receive; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the drop-out or discontinuation rates of patients; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">potential additional safety monitoring or other studies requested by regulatory agencies; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the duration of patient follow-up; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:30pt;"><p style="width:30pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">the safety and efficacy profile of the drug candidate. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, the probability of success for each drug candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each drug candidate, as well as an assessment of each drug candidate&#x2019;s commercial potential. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">General and Administrative </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters and fees for accounting and consulting services. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Other Income </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Other income consists of interest income earned on our cash and cash equivalents. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">68</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Results of Operations for the Years Ended December&nbsp;31, 2016 and 2015 </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth our results of operations for the years ended December&nbsp;31, 2016 and 2015. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="6" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="6" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER&nbsp;31,&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,071
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(20,053)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Costs and expenses:</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,282
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,768)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,650
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,805
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>845
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total costs and expenses</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,932
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,855
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(923)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,914)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,784)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19,130)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>104
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss and comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,810)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(19,041)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Revenue </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our revenue for the year ended December 31, 2016 was not material.&nbsp; The revenue recorded in the year ended December 31, 2015 was due to the $20.0 million non-refundable milestone payment from Pfizer triggered upon the dosing of the first patient in the Phase 3 clinical trial of rivipansel. There were no milestone or royalty payments due from Pfizer during the year ended December 31, 2016.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Expense</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expense decreased by $1.8 million to $23.3 million for the year ended December&nbsp;31, 2016, from $25.1 million in the year ended December&nbsp;31, 2015, reflecting a decrease of 7%. This decrease was primarily due to a milestone license fee of $2.0 million payable to the University based on a Pfizer milestone payment received during the year ended December 31, 2015 that did not recur during the year ended December 31, 2016. As part of the original consideration for entering into an agreement with the University, we granted to the University the right to receive 10% of payments related to rivipansel under specified circumstances including any future milestone payments or royalties we receive from Pfizer.&nbsp;&nbsp;The milestone license fee reflected in the year ended December 31, 2015 was based on 10% of the associated non-refundable milestone payments of $20 million due from Pfizer to us.&nbsp;&nbsp;In contrast, there were no milestone or royalties received from Pfizer in year ended December 31, 2016. In addition, during the year ended December 31, 2016, as compared to the same periods in 2015, there was an increase in the costs associated with the clinical development for GMI-1271 and GMI-1359 of $3.6 million offset by a decrease in expenses related to manufacturing and process development for GMI-1271 of $4.3 million. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">69</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our research and development expense by functional area for the years ended December&nbsp;31, 2016 and 2015: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Clinical development</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,729
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,135
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,594
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Manufacturing and formulation</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,449
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,769
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,320)
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Contract research services, consulting and other costs</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,998
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,285
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(287)
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory costs</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,719
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,508
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>211
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Personnel-related</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,354
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,549
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>805
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,033
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>802
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>231
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Milestone license fee</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,002
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,002)
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,282
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,768)
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our research and development expense by drug candidate for the years ended December&nbsp;31, 2016 and 2015:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:17.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:17.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GMI-1271</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,483
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,770
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(287)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GMI-1359</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,875
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,256
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(381)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Rivipansel</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,026
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,016)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other research&nbsp;and development</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,527
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,647
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(120)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Personnel-related and stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,387
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,351
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,036
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:00.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,282
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,768)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">General and Administrative Expense </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table discloses the components of our general and administrative expense for the year ended December&nbsp;31, 2016 and 2015: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:16.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER&nbsp;31,</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Personnel-related</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,829
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,363
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>466
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,932
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>411
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Legal, consulting and other professional expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,249
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,334
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(85)
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>640
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>587
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,650
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,805
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>845
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">General and administrative expense increased for the year ended December 31, 2016 by $845,000, or 11%, compared to 2015 primarily due to an increase in labor-related costs and stock-based compensation expense.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Results of Operations for the Years Ended December&nbsp;31, 2015 and 2014 </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth our results of operations for the years ended December&nbsp;31, 2015 and 2014. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">70</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER 31,</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,071
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,027
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,044
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Costs and expenses:</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,571
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,479
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,805
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,596
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,209
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total costs and expenses</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,855
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,167
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,688
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,784)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,140)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,644)
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3)
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss and comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:00.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,122)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,647)
				</td>
				<td valign="bottom" style="width:00.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Revenue </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Revenue increased by $5.0 million to $20.0 million for the year ended December&nbsp;31, 2015, or 34%, compared to the same period in 2014. The revenue recorded for the year ended December 31, 2015 was due to the $20.0 million non-refundable milestone payment from Pfizer triggered upon the dosing of the first patient in the Phase 3 clinical trial of rivipansel in June 2015. The revenue recorded for the year ended December 31, 2014 was based on the $15.0 million non-refundable milestone payment received from Pfizer in May 2014. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Expense </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expense increased by $5.5 million to $25.1 million for the year ended December&nbsp;31, 2015, from $19.6 million in the year ended December&nbsp;31, 2014, reflecting an increase of 28%. The increase in research and development expense was primarily attributable to the costs associated with the Phase 1/2 clinical trial of GMI-1271 in AML, including the services provided by the contract research organization supporting the trial as well as by the investigator sites enrolling the patients. The first patient was dosed in the Phase 1/2 clinical trial of GMI-1271 in May 2015. In addition, the preclinical development of GMI-1359, our next drug candidate, has resulted in increased expenses in manufacturing and for the toxicology studies required to support an IND filing.&nbsp;&nbsp;Personnel-related fees increased by $1.1 million for the year ended December 31, 2015 compared to December 31, 2014 primarily attributable to an increased number of research and development employees to support our clinical programs.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The milestone license fees increased by $482,000 for the year ended December 31, 2015 compared to the year ended December 31, 2014 based on the fees due to the University of Basel upon our receipt of the Pfizer milestone payments. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our research and development expense by functional area for the years ended December&nbsp;31, 2015 and 2014: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.02%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Clinical development</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,135
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,119
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,016
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Manufacturing and formulation</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,769
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,410
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,359
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Contract research services, consulting and other costs</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,285
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,386
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(101)
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory costs</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,508
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,216
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>292
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Personnel-related</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,549
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,407
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,142
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>802
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>513
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>289
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Milestone license fees</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,002
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,520
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>482
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,571
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,479
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">71</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our research and development expense by drug candidate for the years ended December&nbsp;31, 2015 and 2014: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER&nbsp;31,</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GMI-1271</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,770
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,611
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,159
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GMI-1359</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,256
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>311
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,945
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Rivipansel</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,026
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,567
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>459
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other research&nbsp;and development</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,647
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,168
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(521)
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Personnel-related and stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,351
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,914
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,437
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:00.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,571
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,479
				</td>
				<td valign="bottom" style="width:00.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">General and Administrative Expense </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table discloses the components of our general and administrative expense for the year ended December&nbsp;31, 2015 and 2014: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR&nbsp;ENDED</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD-TO</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DECEMBER&nbsp;31,</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PERIOD</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CHANGE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Personnel-related</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,363
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,048
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,123
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>398
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Legal, consulting and other professional expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,334
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,916
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>418
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>587
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>509
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,805
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,596
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,209
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the year ended December 31, 2015, our general and administrative expense increased by $1.2 million compared to the same period in 2014, reflecting an increase of 18%. This increase in general and administrative expense was primarily attributable to additional professional fees, including patent costs and market research studies, as well as increased stock-based compensation expense, which increased due to new awards granted to employees and directors in 2015.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Liquidity and Capital Resources </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Sources of Liquidity </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We have financed our operations primarily through the private placements of our capital stock, our IPO, our at-the-market facility with Cowen, our public offering of common stock in June 2016 and upfront and milestone payments from Pfizer. As of December 31, 2016, we had $40.0 million in cash and cash equivalents. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We are potentially eligible to earn a significant amount of milestone payments and royalties under our agreement with Pfizer. Our ability to earn these payments and their timing is dependent upon the outcome of Pfizer&#x2019;s activities and is uncertain at this time. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">On March 1, 2016, we entered into an at-the-market sales agreement with Cowen, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $40 million through Cowen acting as our sales agent. Also on March 1, 2016, we filed a prospectus supplement offering up to $19 million of shares of our common stock in accordance with the sales agreement.&nbsp;&nbsp;On June 2, 2016, we filed an amendment to the prospectus supplement to increase the offering to up to a total of $40 million of shares of our common stock, including the shares of common stock that had already been sold in accordance with the sales agreement.&nbsp; As of December 31, 2016, we have sold an aggregate of 668,791 shares of our common stock under the at-the-market facility, for net proceeds of $3.9 million. Subsequent to December 31, 2016, we sold an additional 461,989 shares under the facility for an additional $2.8 million in net proceeds.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">72</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2016, we completed a public offering in which we sold 3,476,793 shares of common stock at a price of $6.10 per share.&nbsp; We received net proceeds of $19.7 million from this offering, after deducting underwriting discounts and commissions and other offering expenses.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Funding Requirements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The successful development of any of our drug candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of GMI-1271, GMI-1359 or our other drug candidates. We are also unable to predict when, if ever, material net cash inflows will commence from rivipansel, GMI-1271 or GMI-1359. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:48pt;"><p style="width:48pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">successful enrollment in, and completion of, clinical trials; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:48pt;"><p style="width:48pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">receipt of marketing approvals from applicable regulatory authorities; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:48pt;"><p style="width:48pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:48pt;"><p style="width:48pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for drug candidates; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:48pt;"><p style="width:48pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">launching commercial sales of drugs, if and when approved, whether alone or in collaboration with others. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A change in the outcome of any of these variables with respect to the development of any of our drug candidates would significantly change the costs and timing associated with the development of that drug candidate. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Because our drug candidates are in various stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our drug candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements, including our existing collaboration with Pfizer. Except for Pfizer&#x2019;s obligation to make milestone payments under our agreement with them, we do not have any committed external source of liquidity. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of convertible debt securities, these securities could contain covenants that would restrict our operations. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may require additional capital beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements in the future, we may have to relinquish valuable rights to our drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Outlook </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of December&nbsp;31, 2016 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2018, without giving effect to any potential milestone payments we may receive under our license agreement with Pfizer. We have based this estimate on assumptions that may </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">73</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing drug candidates in clinical trials is costly, and the timing of progress in these trials is uncertain. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Cash Flows </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our cash flows for the years ended December&nbsp;31, 2016, 2015 and 2014. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR ENDED DECEMBER&nbsp;31,</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net cash provided by (used in):</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating activities</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,731)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,242)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,282)
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Investing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(704)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(269)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(213)
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Financing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,674
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,383
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net change in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,761)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,397)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,888
				</td>
				<td valign="bottom" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In assessing cash used in operating activities, we consider several principal factors: (i)&nbsp;net loss for the period; (ii)&nbsp;adjustments for non-cash charges including stock-based compensation expense and depreciation and amortization of property and equipment; and (iii)&nbsp;the extent to which receivables, accounts payable and other liabilities, or other working capital components increase or decrease. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Year Ended December&nbsp;31, 2016 compared to Year Ended December&nbsp;31, 2015 </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Operating Activities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash used in operating activities was $29.7 million during the year ended December&nbsp;31, 2016 compared to $8.2 million during the year ended December&nbsp;31, 2015. For the year ended December 31, 2015, we received a $20.0 million non-refundable milestone payment from Pfizer.&nbsp; In contrast, we did not receive any milestone payments in the year ended December 31, 2016.&nbsp;&nbsp;In addition, there was an increase in expenses of $3.6 million related to clinical development for GMI-1271 and GMI-1359 in 2016 as compared to 2015.&nbsp; </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Investing Activities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash used in investing activities was $704,000 for the year end December 31, 2016 compared to $269,000 during the year ended December 31, 2015. Net cash used in investing activities for the year ended December 31, 2016 relates to the costs associated with the build-out of our additional leased space.&nbsp;&nbsp;Net cash used in investing activities for the year ended December 31, 2015 was the result of purchases of additional furniture and equipment related to moving into our new office headquarters in June 2015.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Financing Activities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash provided by financing activities of $23.7 million during the year ended December&nbsp;31, 2016 reflects net proceeds received from our public offering of $19.7 million in June 2016 and $3.9 million received from our at-the-market facility with Cowen. Net cash provided by financing activities of $114,000 during the year ended December&nbsp;31, 2015 is comprised primarily of employee stock option exercises.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Year Ended December&nbsp;31, 2015 compared to Year Ended December&nbsp;31, 2014 </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Operating Activities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash used in operating activities was $8.2 million during the year ended December&nbsp;31, 2015 compared to $4.3 million during the year ended December&nbsp;31, 2014. The increase in cash used in operating activities in the year ended December&nbsp;31, 2015 compared to the year ended December&nbsp;31, 2014 was driven by the increased Phase 1/2 clinical trial expenses for GMI-1271 and the expenses related to the preclinical studies and manufacturing development of GMI-1359 which were offset by the receipt of the $20.0&nbsp;million non-refundable milestone payment from Pfizer. Net cash used in operating activities for the year ended December&nbsp;31, 2014 reflects the amounts used for the manufacturing and process development of GMI-1271 offset by the receipt of the $15.0&nbsp;million non-refundable milestone payment from Pfizer.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">74</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Investing Activities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash used in investing activities relates primarily to the purchase of property and equipment. The increase in property and equipment purchases from $213,000 for the year ended December 31, 2014 to $269,000 for the year ended December&nbsp;31, 2015 was the result of purchases of additional furniture and equipment related to moving into our new office headquarters in June 2015. Net cash used in investing activities for the year ended December 31, 2014 primarily included the acquisition of additional lab equipment needed to further our research and development activities. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Financing Activities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash provided by financing activities of $114,000 during the year ended December&nbsp;31, 2015 is comprised primarily of employee stock option exercises. Net cash provided by financing activities of $57.4 million during the year ended December&nbsp;31, 2014 reflects net proceeds received from our IPO of $57.2 million with the remaining cash inflows provided from the exercise of employee stock options.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Contractual Obligations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 5pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, our significant contractual obligations consisted solely of rent obligations under a non-cancelable lease, as amended, for our current office space in Rockville, Maryland, which has a term through October 2023.</font>
		</p>
		<p style="margin:0pt 0pt 5pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table depicts our obligations under this lease as of December&nbsp;31, 2016. </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:50.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="20" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Payments&nbsp;Due&nbsp;by&nbsp;Period</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">After</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2021</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="20" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(In&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating lease</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,923
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>942
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>990
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,014
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,040
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,972
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The foregoing table does not include various agreements that we have entered into for services with third-party vendors, including agreements to conduct clinical trials, to manufacture products, and for consulting and other contracted services due to the cancelable nature of the services. We accrue the costs of these agreements based on estimates of work completed to date. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The contractual obligations table does not include any potential future payments we may be required to make under our research agreement with the University, under which we have agreed to pay 10% of any future milestone payments or royalties we may receive from Pfizer with respect to rivipansel. Due to the uncertainty of the achievement and timing of the events requiring payment under that agreement, the amounts to be paid by us cannot be determined as of the date of this report. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Off-Balance Sheet Arrangements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">JOBS Act </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section&nbsp;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">75</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 7A.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 34pt 0pt 0pt;"></font>QUANTITATIVE AND QUALITATIV<a name="ITEM7AQUANTITATIVEANDQUALITATIVE_860953"></a>E DISCLOSURES ABOUT MARKET RISK </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of December&nbsp;31, 2016 and 2015, we had cash and cash equivalents of $40.0 million and $46.8 million, respectively. We generally hold our cash in interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 55.1pt;text-indent: -55.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp;8. <font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 31pt 0pt 0pt;"></font>FINANCIAL STATEMENTS AND SUPPLEMENTARY DAT<a name="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a>A &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The financial statements and related financial statement schedules required to be filed are listed in the Index to Financial Statements and are incorporated herein. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 55.05pt;text-indent: -55.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 9.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 31pt 0pt 0pt;"></font>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANT<a name="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a>S ON ACCOUNTING AND FINANCIAL DISCLOSURE </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">None. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 9A.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 34pt 0pt 0pt;"></font>CONTROLS AND PROCEDURE<a name="ITEM9ACONTROLSANDPROCEDURES_712204"></a>S &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Evaluation of Disclosure Controls and Procedures </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the supervision of and with the participation of our management, including our chief executive officer, who is our principal executive officer, and our chief financial officer, who is our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December&nbsp;31, 2016, the end of the period covered by this Annual Report. The term &#x201C;disclosure controls and procedures,&#x201D; as set forth in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#x2019;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&nbsp;31, 2016, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Management&#x2019;s Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting Firm </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as defined in the Exchange Act Rule 13a-15(f). Management conducted an assessment of our internal control over financial reporting based on the original framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control&#x2014;Integrated Framework. Based on the assessment, management concluded that, as of December&nbsp;31, 2016, our internal control over financial reporting was effective. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting as required by Section&nbsp;404(c) of the Sarbanes Oxley Act of 2002. Because we&nbsp;</font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">76</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">qualify as an emerging growth company under the JOBS Act, management's report was not subject to attestation by our independent registered public accounting firm. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Changes in Internal Control over Financial Reporting </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December&nbsp;31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </font>
		</p>
		<p style="margin:18pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp;9B.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 37pt 0pt 0pt;"></font>OTHER INFORMATIO<a name="ITEM9BOTHERINFORMATION_45602"></a>N &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">None. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">77</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PART II<a name="PARTIII_655348"></a>I &nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We will file a definitive proxy statement for our 2017 annual meeting of stockholders, or the 2017 Proxy Statement, with the SEC, pursuant to Regulation 14A, not later than 120 days after the end of our fiscal year. Accordingly, certain information required by Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2017 Proxy Statement that specifically address the items set forth herein are incorporated by reference.</font>
		</p>
		<p style="margin:12pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 10.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 34pt 0pt 0pt;"></font>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANC<a name="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a>E &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The information required by Item 10 is hereby incorporated by reference to the relevant information to be included in the 2017 Proxy Statement under the captions &#x201C;Information Regarding the Board of Directors and Corporate Governance,&#x201D; &#x201C;Election of Directors,&#x201D; &#x201C;Executive Officers&#x201D; and &#x201C;Section 16(a) Beneficial Ownership Reporting Compliance.&#x201D;</font>
		</p>
		<p style="margin:18pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 11.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 34pt 0pt 0pt;"></font>EXECUTIVE COMPENSATIO<a name="ITEM11EXECUTIVECOMPENSATION_298012"></a>N &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The information required by Item 11 is hereby incorporated by reference to the relevant information to be included in the 2017 Proxy Statement under the captions &#x201C;Executive Compensation&#x201D; and &#x201C;Non-Employee Director Compensation.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp;12. <font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 34pt 0pt 0pt;"></font>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNER<a name="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a>S AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The information required by Item 12 is hereby incorporated by reference to the relevant information to be included in the 2017 Proxy Statement under the captions &#x201C;Security Ownership of Certain Beneficial Owners and Management&#x201D; and &#x201C;Securities Authorized for Issuance under Equity Compensation Plans.&#x201D;</font>
		</p>
		<p style="margin:18pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp;13.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 37pt 0pt 0pt;"></font>CERTAIN RELATIONSHIPS AND RELATED TRANSACTION<a name="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a>S, AND DIRECTOR INDEPENDENCE </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The information required by Item 13 is hereby incorporated by reference to the relevant information to be included in the 2017 Proxy Statement under the captions &#x201C;Transactions with Related Persons&#x201D; and &#x201C;Independence of the Board of Directors.&#x201D;</font>
		</p>
		<p style="margin:18pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 14.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 34pt 0pt 0pt;"></font>PRINCIPAL ACCOUNTING FEES AND SERVICE<a name="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a>S &nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The information required by Item 14 is hereby incorporated by reference to the relevant information to be included in the 2017 Proxy Statement under the caption &#x201C;Ratification of Selection of Independent Auditors.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">78</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PART I<a name="PARTIV_600453"></a>V &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 15.</font><font style="display:inline;">&#x2003;</font><font style="display:inline;font-weight:bold;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULE<a name="ITEM15EXHIBITSANDFINANCIALSTATEMENTSCHED"></a>S &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 61.2pt;text-indent: -61.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(a)&#x2003;The following documents are filed as part of this Annual Report on Form 10-K: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 49pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(1)&#x2003;Financial Statements:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 49pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 90.00%;margin-left:46.8pt;">
			<tr>
				<td valign="top" style="width:386.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 7.2pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:386.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ReportofIndependentRegisteredPublicAccou"><font style="display:inline;">Report of Ernst&nbsp;&amp; Young LLP, Independent Registered Public Accounting Firm</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.20pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:386.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#BalanceSheets_656978"><font style="display:inline;">Balance Sheets</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.20pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:386.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#StatementsofOperationsandComprehensive_1"><font style="display:inline;">Statements of Operations and Comprehensive Loss</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.20pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:386.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#StatementsofStockholdersEquity_712246"><font style="display:inline;">Statements of Stockholders&#x2019; Equity</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.20pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:386.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#StatementsofCashFlows_755635"><font style="display:inline;">Statements of Cash Flows</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.20pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:386.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#NotestoFinancialStatements_432888"><font style="display:inline;">Notes to Financial Statements</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.20pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 49pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(2)&#x2003;Financial Statements Schedules: </font>
		</p>
		<p style="margin:0pt 0pt 0pt 49pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 48.95pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 49pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(3)&#x2003;Exhibits </font>
		</p>
		<p style="margin:0pt 0pt 0pt 49pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM&nbsp; 16.</font><font style="display:inline;">&#x2003;</font><font style="display:inline;font-weight:bold;">FORM 10-K SUMMARY<a name="ITEM16FORM10KSUMMARY"></a></font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Not applicable</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">79</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">SIGNATURE<a name="SIGNATURES_192363"></a>S &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:46.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">GLYCOMIMETICS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:00.98%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.02%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:03.70%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:46.30%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.02%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">By:</font></p>
				</td>
				<td valign="bottom" style="width:46.30%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;/s/ Rachel K. King</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.02%;padding:0pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.70%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:46.30%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;Rachel K. King</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:00.98%;padding:0pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:49.02%;padding:0pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.70%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:46.30%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-style:italic;">&nbsp;&nbsp;President and Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">March 1, 2017 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Rachel K. King and Brian M. Hahn, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of GlycoMimetics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:37.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">
						<font style="display:inline;font-size:0.5pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">
						<font style="display:inline;font-size:0.5pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">
						<font style="display:inline;font-size:0.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Signature</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.84%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Title</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.66%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Date</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Rachel K. King</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Rachel K. King</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">President, Chief Executive Officer and Director</font></p>
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-style:italic;">(Principal Executive Officer)</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Brian M. Hahn</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Brian M. Hahn</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Financial Officer</font></p>
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(</font><font style="display:inline;font-style:italic;">Principal Financial Officer and Principal <br />Accounting Officer)</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ John J. Baldwin, Ph.D.</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">John J. Baldwin, Ph.D.</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Director</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ M. James Barrett, Ph.D.</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">M. James Barrett, Ph.D.</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Director</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Mark A. Goldberg M.D.</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Mark A. Goldberg M.D.</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Director</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Daniel M. Junius</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Daniel M. Junius</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Director</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ John L. Magnani, Ph.D.</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">John L. Magnani, Ph.D.</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Director</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Timothy Pearson</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Timothy Pearson</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Director</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.50%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ Franklin H. Top, Jr., M.D.</font></p>
					<p style="margin:0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Franklin H. Top, Jr., M.D.</font></p>
				</td>
				<td valign="top" style="width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Director</font></p>
				</td>
				<td valign="top" style="width:16.66%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 1, 2017</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font><font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">80</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:431.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:4.00pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:25.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:4.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:4.00pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:431.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">
						<font style="display:inline;font-size:0.5pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:25.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">
						<font style="display:inline;font-size:0.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:461.15pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ReportofIndependentRegisteredPublicAccou"><font style="display:inline;">Report of Independent Registered Public Accounting Firm</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:24.85pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:461.15pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#BalanceSheets_656978"><font style="display:inline;">Balance Sheets as of December&nbsp;31, 2016 and 2015</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:24.85pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>83&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:461.15pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#StatementsofOperationsandComprehensive_1"><font style="display:inline;">Statements of Operations and Comprehensive Loss for the years ended December&nbsp;31, 2016, 2015 and 2014</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:24.85pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:461.15pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#StatementsofStockholdersEquity_712246"><font style="display:inline;">Statements of Stockholders&#x2019; Equity for the years ended December&nbsp;31, 2016, 2015 and 2014</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:24.85pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:461.15pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#StatementsofCashFlows_755635"><font style="display:inline;">Statements of Cash Flows for the years ended December&nbsp;31, 2016, 2015 and 2014</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:24.85pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>86&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:461.15pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#NotestoFinancialStatements_432888"><font style="display:inline;">Notes to Financial Statements</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:24.85pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">81</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Report of Independent Registered Public Accounting Fir<a name="ReportofIndependentRegisteredPublicAccou"></a>m &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Board of Directors and Stockholders of GlycoMimetics, Inc. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have audited the accompanying balance sheets of GlycoMimetics, Inc. (the &#x201C;Company&#x201D;) as of December&nbsp;31, 2016 and 2015, and the related statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows for each of the three years in the period ended December&nbsp;31, 2016. These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company&#x2019;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of GlycoMimetics, Inc. at December&nbsp;31, 2016 and 2015, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2016, in conformity with U.S. generally accepted accounting principles. </font>
		</p>
		<p style="margin:12pt 0pt 0pt 330.45pt;text-indent: -12.25pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">/s/ Ernst&nbsp;&amp; Young LLP </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">McLean, Virginia </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">March 1, 2017 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">82</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">GLYCOMIMETICS, INC. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Balance Sheet<a name="BalanceSheets_656978"></a>s &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Current assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,041,641
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,802,560
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478,503
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>441,810
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total current assets</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,520,144
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,244,370
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,056,332
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,378
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>759,531
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>696,531
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deposits</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,320
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,388,327
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,462,279
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Liabilities&nbsp;&amp; stockholders&#x2019; equity</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Current liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,565,210
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>564,235
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued bonuses</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,432,485
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,037,112
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,267,371
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,145,631
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68,551
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,333,617
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,746,978
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred rent, net of current portion</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>753,579
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243,647
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,087,196
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,990,625
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stockholders&#x2019; equity:</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2016 and December 31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Common stock; $0.001 par value; 100,000,000 shares authorized, 23,250,023 shares issued and outstanding at December 31, 2016; 100,000,000 shares authorized, 19,050,204 shares issued and outstanding at December&nbsp;31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,249
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,049
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Additional paid-in capital</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>154,254,193
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,619,078
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(118,976,311)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(87,166,473)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total stockholders&#x2019; equity</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,301,131
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,471,654
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities and stockholders&#x2019; equity</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42,388,327
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48,462,279
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">See accompanying notes.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">83</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">GLYCOMIMETICS, INC. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Statements of Operations and Comprehensiv<a name="StatementsofOperationsandComprehensive_1"></a>e Loss </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:40.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,500
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,070,750
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,027,004
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Costs and expenses:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,281,820
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,050,179
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,571,073
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,650,165
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,805,396
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,595,738
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total costs and expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,931,985
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32,855,575
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,166,811
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,913,485)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,784,825)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,139,807)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103,647
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,327
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,241
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss and comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,809,838)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769,498)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,121,566)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.50)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.67)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted weighted average number of common shares</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,256,312
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,587
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,452,252
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">See accompanying notes. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">84</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">GLYCOMIMETICS, INC. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Statements of Stockholders&#x2019; Equit<a name="StatementsofStockholdersEquity_712246"></a>y &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:18.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Series&nbsp;A-1&nbsp;Convertible</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Additional</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:18.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Preferred&nbsp;Stock</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:17.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Common&nbsp;Stock</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Paid-In</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Accumulated</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Stockholders&#x2019;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Capital</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Deficit</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Equity</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at December&nbsp;31,&nbsp;2013</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,726,326
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,726
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,426,593
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,428
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>66,150,674
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(63,275,409)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,907,419
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of common stock, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,050,000
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,050
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,240,169
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,248,219
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Conversion of preferred stock to common stock</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(30,726,326)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(30,726)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,305,359
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,305
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,421
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Exercise of options and warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>157,886
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>157
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134,134
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134,291
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,635,065
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,635,065
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,121,566)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,121,566)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,939,838
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,940
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>125,181,463
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(74,396,975)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50,803,428
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Exercise of options and warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110,366
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114,012
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114,121
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,603
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,603
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769,498)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769,498)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,050,204
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,049
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127,619,078
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(87,166,473)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,471,654
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of common stock, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,145,584
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,146
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,597,809
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,601,955
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Exercise of options and warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,235
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,539
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,593
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964,767
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964,767
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,809,838)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,809,838)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,250,023
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,249
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>154,254,193
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(118,976,311)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,301,131
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">See accompanying notes. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">85</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">GLYCOMIMETICS, INC. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Statements of Cash Flow<a name="StatementsofCashFlows_755635"></a>s &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:40.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;Ended&nbsp;December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Operating activities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,809,838)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769,498)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,121,566)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Depreciation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>190,540
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>191,484
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158,708
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on disposal of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,001
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,424
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964,767
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,603
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,635,065
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Changes in assets and liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(36,693)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>474,439
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,656,823
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(63,000)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(696,531)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deposits</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(52,320)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,000,975
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(309,792)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(270,867)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued expenses and bonuses</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,504,179)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,693,238
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,459,292
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred rent </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>578,483
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>146,635
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(103,935)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net cash used in operating activities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29,731,265)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,241,890)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,281,587)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Investing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Purchases of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(704,202)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(268,594)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(212,603)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net cash used in investing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(704,202)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(268,594)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(212,603)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Financing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Proceeds from issuance of common stock, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,601,955
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,248,219
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Proceeds from exercise of stock options </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72,593
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114,121
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134,291
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net cash provided by financing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,674,548
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114,121
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>57,382,510
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net change in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,760,919)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,396,363)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,888,320
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Cash and cash equivalents, beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,802,560
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,198,923
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,310,603
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Cash and cash equivalents, end of period</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40,041,641
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46,802,560
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55,198,923
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Supplemental disclosure of cash flow information</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Cash paid for taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,000
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Non-cash investing and financing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property asset acquisition included in accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,292
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Conversion of Series A convertible preferred stock to common stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,805,055
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">See accompanying notes. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">86</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">GLYCOMIMETICS, INC. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Notes to Financial Statement<a name="NotestoFinancialStatements_432888"></a>s &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">1. Description of the Business </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated on April&nbsp;4, 2003 and commenced operations on May&nbsp;21, 2003. The company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company has incurred significant losses in the development of its drug candidates. The losses in prior periods were primarily attributable to the research and development of the Company&#x2019;s first drug candidate, rivipansel, as well as GMI-1271 and GMI-1359. The Company has not generated revenues from product sales. As a result, the Company has consistently reported negative cash flows from operating activities and net losses, had an accumulated deficit of $118,976,311 at December&nbsp;31, 2016 and expects to continue incurring losses for the foreseeable future. The Company currently anticipates that its cash and cash equivalents will be sufficient to meet its anticipated cash requirements into the second quarter of 2018. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s operations are subject to certain risks and uncertainties. The risks include the need to manage growth, the need to retain key personnel, the need to protect intellectual property, the availability of additional capital financing on terms acceptable to the Company and reliance on its collaboration with Pfizer Inc. (Pfizer). The Company&#x2019;s current operating assumptions and projections, which reflect management&#x2019;s best estimate of future revenue and operating expenses, indicate that anticipated operating expenditures into the second quarter of 2018 can be met by available working capital; however, the Company&#x2019;s ability to meet its projections is subject to uncertainties, and there can be no assurance that the Company&#x2019;s current projections will be accurate. If the Company&#x2019;s cash requirements are more than projected, the Company may require additional financing. The type, timing and terms of financing selected by the Company, if required, will be dependent upon the Company&#x2019;s cash needs, the availability of financing sources and the prevailing conditions in the financial markets. There can be no assurance that such financing will be available to the Company at any given time or available on favorable terms. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Management believes that the Company has access to capital resources through private investments of equity from its existing stockholders. However, it has not secured any commitment for new financing as of the date of this report, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it will be required to curtail its operations, and if these measures fail, it may not be able to continue its business. Curtailment of operations would cause significant delays in the Company&#x2019;s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2. Summary of Significant Accounting Policies </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Basis of Accounting </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Segment Information </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">87</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Use of Estimates </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December&nbsp;31, 2016 and 2015, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, </font><font style="display:inline;font-style:italic;">Fair Value Measurements</font><font style="display:inline;">. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 2&#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December&nbsp;31, 2016 and 2015. The carrying value of cash held in money market funds of approximately $38.0 million and $45.5 million as of December&nbsp;31, 2016 and 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;font-style:italic;">Concentration of Credit Risk</font><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">88</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Property and Equipment </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.60%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">ESTIMATED&nbsp;USEFUL&nbsp;LIVES</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">7&nbsp;years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer software</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp; life</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Impairment of Long-Lived Assets </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="display:inline;font-style:italic;">Property, Plant, and Equipment</font><font style="display:inline;">. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&nbsp;31, 2016 and 2015, the Company determined that there were no impaired assets and had no assets held for sale. </font>
		</p>
		<p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Revenue Recognition </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has entered into a collaborative research and development agreement with Pfizer. The agreement is in the form of a license agreement. The agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the arrangement that contain material financial consequences to the Company. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The primary deliverable under this arrangement is an exclusive worldwide license to the Company&#x2019;s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer&#x2019;s behalf. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of ASC 605-25, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Multiple-Element Arrangements</font><font style="display:inline;">, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1)&nbsp;the delivered item(s) has value to the customer on a stand-alone basis and (2)&nbsp;if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">89</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:10pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i)&nbsp;vendor-specific objective evidence (VSOE), if available; (ii)&nbsp;third-party evidence (TPE) of selling price if VSOE is not available; or (iii)&nbsp;an estimated selling price, if neither VSOE nor third-party evidence is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer collaboration agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company&#x2019;s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to ASC 605-25, each required deliverable under the Pfizer collaboration agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company&#x2019;s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company&#x2019;s technology and the related proprietary nature of the Company&#x2019;s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the contract and will be combined with the research and development services (including participation on a joint steering committee). </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to ASC 605-28, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Milestone Method</font><font style="display:inline;">, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#x2019;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#x2019;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#x2019;s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment. There were no revenue milestones met in the year ending December 31, 2016.</font>
		</p>
		<p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;"> Accrued Liabilities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company&#x2019;s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i)&nbsp;an evaluation by the project manager of the work that has been completed during the period; (ii)&nbsp;measurement of progress prepared internally and/or provided by the third-party service provider; (iii)&nbsp;analyses of data that justify the progress; and (iv)&nbsp;the Company&#x2019;s judgment.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">90</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Costs </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Stock-Based Compensation </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&#x2014;Stock Compensation</font><font style="display:inline;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows: </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Dividend Yield</font><font style="display:inline;">&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Volatility</font><font style="display:inline;">&#x2014;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company&#x2019;s initial public offering, there was not a market for the Company&#x2019;s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#x2019;s historical volatility since its initial public offering to determine its expected volatility. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Risk-Free Interest Rate</font><font style="display:inline;">&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Term</font><font style="display:inline;">&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Forfeiture Rate</font><font style="display:inline;">&#x2014;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;font-style:italic;">Income Taxes </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,</font><font style="display:inline;font-style:italic;"> Income Taxes</font><font style="display:inline;">. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">91</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Comprehensive Loss&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&nbsp;31, 2016, 2015 and 2014, the Company&#x2019;s net loss equals comprehensive loss and, accordingly, no additional disclosure is presented. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recently Issued Accounting Standards </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;">On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. The Company is evaluating the Pfizer collaboration agreement to determine the impact of the new revenue standard on the upfront and milestone payments within this specific collaboration agreement. The Company intends to select a transition method in the second quarter 2017 and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.</font>
		</p>
		<p style="margin:0pt;font-family:Georgia;color:#000000;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"> On August 27, 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern, which requires management to assess a company&#x2019;s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Before this new standard, there was minimal guidance in U.S. GAAP specific to going concern. Under the new standard, disclosures are required when conditions give rise to substantial doubt about a company&#x2019;s ability to continue as a going concern within one year from the financial statement issuance date. The Company adopted the standard for the reporting period ending December 31, 2016.</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).&nbsp;&nbsp;The final guidance will require lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. This standard is effective for annual reporting periods beginning after December&nbsp;15, 2018. Early adoption will be permitted.&nbsp;&nbsp;The Company is currently evaluating the effect the new standard will have on the Company. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In March 2016, the FASB issued ASU No. 2016-09, Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&nbsp;&nbsp;The ASU includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in financial statements including the income tax effects of share-based payments, minimum statutory withholding requirements and forfeitures. The new guidance will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It will also allow an employer to repurchase more of an employee&#x2019;s shares than the current standard for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. This ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. In evaluation of the new standard, the Company will elect a policy at adoption of the standard to account for forfeitures as they occur. &nbsp;The Company has evaluated the standard and has determined the implementation will not have a material impact on the financial statements.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With the exception of the new standards discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">3. Net Loss Per Share of Common Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per share is computed by dividing net income by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method was used to determine the dilutive effect of the Company&#x2019;s stock option grants, restricted stock units and warrants. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">92</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth the computation of basic and diluted earnings per share for the years ended December&nbsp;31, 2016, 2015 and 2014: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,809,838)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769,498)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,121,566)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.50)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.67)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted weighted average common shares outstanding </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,256,312
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,587
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,452,252
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following potentially dilutive securities outstanding at December&nbsp;31, 2016, 2015 and 2014 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>553,868
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>578,687
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock options and restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,817,674
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,235,775
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,806,980
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4. Prepaid Expenses and Other Current Assets </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of the Company&#x2019;s prepaid expenses and other current assets at December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>199,195
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>393,857
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other receivables</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>268,659
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,683
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deposits</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,649
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,270
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478,503
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>441,810
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">5. Property and Equipment </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment, net consisted of the following at December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>262,135
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,987
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,130,180
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,586
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,610
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,723
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,423
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,053
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Construction in progress</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>508,417
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,112,893
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,423,477
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Less accumulated depreciation</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,056,561)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(902,099)
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,056,332
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,378
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Depreciation of property and equipment totaled $190,540, $191,484 and $158,708 for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">93</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">6. Accrued Expenses </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of the Company&#x2019;s accrued expenses at December 31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,513,243
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423,220
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued license and milestone fees</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,000,000
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued consulting and other professional fees</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148,579
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242,227
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315,002
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,152
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>290,547
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,442
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued franchise and other taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,590
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,267,371
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,145,631
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">7. Operating Leases </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The Company leases office and research space in Rockville, Maryland under an operating lease with a term through October 31, 2023 (as amended to date, the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances.&nbsp;&nbsp;In connection with the Lease, the Company received rent abatement as a lease incentive. The annual rent increases and rent abatement have been recognized as deferred rent that is being adjusted on a straight-line basis over the term of the Lease.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space beginning on June 1, 2016. In addition to the other terms of the Lease, the Lease Amendment provided for a tenant improvement allowance reflected in the Company&#x2019;s financial statements as an increase in capitalized leasehold improvements as incurred and an increase in deferred rent. In May 2016, the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company&#x2019;s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company&#x2019;s renewal option set forth in the Lease. The Company also has a one-time option to terminate the Lease effective as of October 31, 2020. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Deferred rent related to the Lease was $822,130 and $243,647 at December 31, 2016 and December 31, 2015, respectively. Total rent expense under the Company&#x2019;s leases was $784,739, $595,497 and $385,668 for the years ended December 31, 2016, 2015 and 2014, respectively.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents the future minimum lease payments as of December&nbsp;31, 2016 under the Lease: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AMOUNT</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>941,822
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,368
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>989,502
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,014,239
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2021</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,039,595
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">After 2021</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,972,254
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,922,780
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">8. Stockholders&#x2019; Equity </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Convertible Preferred Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Series A-1 Convertible Preferred Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October&nbsp;20, 2009, the Company entered into a Series A-1 Preferred Stock Purchase Agreement with certain investors. In connection with the financing, the Company issued 30,726,326 shares of Series&nbsp;A-1 Convertible Preferred Stock for an aggregate amount of $38,979,412, which included the conversion of principal and accrued interest related to an earlier bridge financing of $16,099,770. In connection with the Series&nbsp;A-1 Preferred Stock financing, all then-</font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">94</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">outstanding shares of Series A and Series B Preferred Stock were converted into common stock, and all then outstanding warrants to purchase Series B Preferred Stock were converted into warrants to purchase common stock. Immediately prior to the Series A-1 Preferred Stock financing, the Company effected a 1-for-10 reverse stock split of the outstanding common stock. All prior-period applicable share amounts have been retroactively adjusted to reflect the reverse stock split. As of December&nbsp;31, 2013, the Company&#x2019;s Amended and Restated Certificate of Incorporation authorized the issuance of 130,601,021 shares of stock, of which 70,258,276 were designated as common stock with a par value of $0.001, and of which 60,342,745 were designated as Series A-1 Convertible Preferred Stock with a par value of $0.001. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Upon closing of the Company&#x2019;s initial public offering in January 2014, all outstanding shares of convertible preferred stock converted into an aggregate of 9,305,359 shares of common stock. In addition, immediately following the closing of the initial public offering, the Company&#x2019;s certificate of incorporation was amended to authorize 5,000,000 shares of undesignated preferred stock and 100,000,000 shares of common stock. Both the common stock and undesignated preferred stock have a par value of $0.001 per share. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Common Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 1, 2016, the Company entered into an at-the-market sales agreement with Cowen and Company, LLC to sell the Company&#x2019;s securities under a shelf registration statement filed in March 2015. As of December 31, 2016, the Company had issued and sold 668,791 shares of common stock under the at-the-market sales agreement. The shares were sold at a weighted average price per share of $6.336, for aggregate net proceeds of $3.9 million, after deducting commissions and offering expenses. Subsequent to December 31, 2016, the Company sold an additional 461,989 shares at a weighted average price per share of $6.228 under the at-the-market facility for an additional $2.8 million in net proceeds.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2016, the Company completed a public offering in which the Company sold 3,476,793 shares of its common stock at a price of $6.10 per share.&nbsp;The Company received net proceeds of $19.7 million from this offering, after deducting underwriting discounts, commissions and other offering expenses.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Warrants to Acquire Company Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following common stock warrants were outstanding as of December&nbsp;31, 2016 and 2015: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">12/31/2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">12/31/2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER&nbsp;OF&nbsp;SHARES</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER&nbsp;OF&nbsp;SHARES</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">UNDERLYING&nbsp;OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">UNDERLYING&nbsp;OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PRICE</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXPIRATION</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WARRANTS</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WARRANTS</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PER&nbsp;SHARE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DATE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236,632
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259,907
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">July&nbsp;18,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>301,986
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>301,986
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">January&nbsp;16,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">January&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 33.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">-</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,544
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.92
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">October&nbsp;13,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For the year ended December&nbsp;31, 2016, a total of 23,275 warrants were exercised at a weighted average exercise price of $0.33 per share. For the year ended December&nbsp;31, 2015, a total of 11,908 warrants were exercised at a weighted average exercise price of $0.33 per share.&nbsp;&nbsp;For the year ended December 31, 2016, a total of 1,544 warrants expired. No warrants expired during the year ended December&nbsp;31, 2015. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">2003 Stock Incentive Plan </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60&nbsp;days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May&nbsp;21, 2013. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">95</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2003 Plan for the year ended December&nbsp;31, 2016 is as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL TERM</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC VALUE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE PRICE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(YEARS)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(IN THOUSANDS)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>758,187
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.27
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,368)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.58
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,819
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,801
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercisable as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,240
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.25
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,534
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During 2016, 2015 and 2014 the Company issued 28,368, 99,029 and 114,836 shares of common stock, respectively, in conjunction with exercises of stock options granted under the 2003 Plan. The Company received cash proceeds from the exercise of these stock options of approximately to $44,771, $114,124 and $133,957 during 2016, 2015 and 2014, respectively. Total intrinsic value of the options exercised during the years ended December&nbsp;31, 2016, 2015 and 2014 was $97,707, $667,258 and $629,232, respectively. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, there was $1,382 of total unrecognized compensation expense related to unvested options under the 2003 Plan that will be recognized over the first quarter of 2017. The total fair value of shares vested in the years ended December&nbsp;31, 2016, 2015 and 2014, was $16,024, $50,310 and $63,865, respectively. There were no options granted from this plan in 2016, 2015 or 2014.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">2013 Equity Incentive Plan </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Internal Revenue Code (the Code), to the Company&#x2019;s employees and its parent and subsidiary corporations&#x2019; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#x2019;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 90&nbsp;days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Authorized Shares </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The maximum number of shares of common stock that may be issued under the 2013 Plan was 1,000,000&nbsp;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2015 and ending on January&nbsp;1, 2023, by 3% of the total number of shares of common stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#x2019;s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of January&nbsp;1, 2017, the number of shares of common stock that may be issued under the 2013 Plan was automatically increased by 697,500 shares, representing 3% of the total number of shares of common stock outstanding on January&nbsp;1, 2017, increasing the number of shares of common stock available for issuance under the 2013 Plan to 2,837,201 shares. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">96</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2013 Plan for the year ended December&nbsp;31, 2016 is as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">VALUE&nbsp;(IN</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PRICE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">TERM(YEARS)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">THOUSANDS)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,470,338
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.5
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,250
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.36
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,500)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.95
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,983)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.28
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,066,105
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.9
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,057,409
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.9
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>500
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercisable as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>910,202
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.4
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted-average fair value of the options granted during the year of December&nbsp;31, 2016, 2015 and 2014 was $3.39, $5.08 and $6.70 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected term </font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">68.98%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">80.76%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">90.27%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">1.70%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">1.70%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">2.14%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, there was $4,308,701 of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately 2.0 years. The total fair value of shares vested in the years ended December 31, 2016 and December&nbsp;31, 2015 was $3,053,086 and $2,668,712, respectively. There were no shares vested as of December&nbsp;31, 2014 under the 2013 Plan.&nbsp;&nbsp;During 2016, the Company received cash of $27,825 and issued 3,500 shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan.&nbsp;&nbsp;The intrinsic value of the options exercised during 2016 was $2,275.&nbsp;&nbsp;There were no option exercises under the 2013 Plan for the years ended December 31, 2015 and 2014.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">An RSU is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#x2019;s stock on the date of grant. The Company has granted RSUs with service conditions (service RSUs) that vest in three equal annual installments provided that the employee remains employed with the Company. As of December&nbsp;31, 2016, $60,108 of unrecognized compensation costs related to unvested service. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">97</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of RSU activity for the 2013 Plan for the year ended December&nbsp;31, 2016: </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">GRANT DATE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OF SHARES</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">FAIR VALUE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,833
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.61
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,417
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,916
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.04
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-based compensation expense was classified as follows on the statement of operations for the years ended December&nbsp;31: </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,033,005
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>802,329
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>512,345
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,931,762
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,274
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,122,720
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964,767
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,603
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,635,065
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">9. Income Taxes </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The components of the gross deferred tax asset and related valuation allowance at December&nbsp;31 were as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net operating loss carryforward</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,451,814
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,745,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Capitalized start-up costs</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,708,479
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,986,272
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Patent amortization</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,203
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238,378
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and orphan drug credits</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,988,522
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,110,590
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123,744
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>96,107
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,107,964
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,206,920
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,511
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,985
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total gross deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,667,237
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,436,788
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(54,667,237)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,436,788)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Depreciation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Based on the Company&#x2019;s operating history and management&#x2019;s expectation regarding future profitability, management believes the realization of the Company&#x2019;s deferred tax assets does not meet the more-likely-than-not criteria under ASC 740, </font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;">. Accordingly, a full valuation allowance has been established as of December&nbsp;31, 2016 and 2015. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, the Company had $87,591,753 of U.S. Federal and state net operating losses, of which $250,359 will be recognized as a benefit through additional-paid-in-capital when realized, $7,394,601 of research and development tax credits and $7,593,921 of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#x2019;s ability </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">98</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">to utilize its net operating losses and credits. As of December 31, 2016, the Company does not believe that an ownership change has occurred. Any future ownership changes may cause a limitation on the Company&#x2019;s ability to utilize existing tax attributes. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company files income tax returns in the U.S. federal jurisdiction and in the State of Maryland. The Company&#x2019;s federal income tax returns for tax years 2003 and after remain subject to examination by the U.S. Internal Revenue Service. The Company&#x2019;s Maryland income tax returns for the tax years 2006 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company did not have unrecognized tax benefits as of December&nbsp;31, 2016 and 2015, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">U.S. Federal statutory tax rate</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">State taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.6
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.7
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.6
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research credit</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.6
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.4
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Orphan drug credit</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.5
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.7
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.7)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.8)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.3)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.4
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47.9)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53.0)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55.8)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">10. Research and License Agreements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2004, the Company entered into a research services agreement (the Research Agreement) with the University of Basel (the University) for biological evaluation of selectin antagonists. Certain patents covering the rivipansel compound are subject to provisions of the Research Agreement. Under the terms of the Research Agreement, the Company will owe a 10% payment to the University for all future milestone and royalty payments received from Pfizer with respect to rivipansel. A milestone license fee of $2.0 million was recorded in the year ended December&nbsp;31, 2015 for the payment due to the University of Basel representing 10% of the $20.0 million non-refundable milestone payment that the Company received from Pfizer in August 2015. The accrued license and milestone fee of $2.0 million was paid in February 2016.&nbsp;&nbsp;There were no payments recorded for the year ended December 31, 2016. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In October 2011, the Company and Pfizer entered into a licensing agreement (the Pfizer Agreement) that provides Pfizer an exclusive worldwide license to rivipansel for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. The Company was responsible for completion of the Phase 2 trial, after which Pfizer will assume all further development and commercialization responsibilities. Upon execution of the Pfizer Agreement, the Company received an up-front payment of $22.5 million. The Pfizer Agreement also provides for potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications; potential milestone payments of up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of the Company&#x2019;s filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications; and potential milestone payments of up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. Pfizer has the right to terminate the Pfizer Agreement by giving prior written notice. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales-based milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. The Company is also eligible to receive royalties on future sales contingent upon annual net sales thresholds. In addition, the Company and Pfizer have formed a joint steering committee that will oversee and coordinate activities as set forth in the research program. The $22.5 million up-</font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">99</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">front payment was recognized over a period of 1.5 years. In May 2014, the Company received a non-refundable payment of $15.0 million from Pfizer as a partial milestone payment owed to the Company upon the dosing of the first patient in the Phase 3 clinical trial. The dosing of the first patient in a Phase 3 clinical trial of rivipansel in August 2015 triggered the remaining $20.0 million of the scheduled milestone payment under the Pfizer Agreement. During the years ended December&nbsp;31, 2015 and 2014, the Company recorded revenue of $20.0 million and $15.0 million, respectively, pursuant to the Pfizer Agreement in the Company&#x2019;s statement of operations. There was no revenue recognized under the Pfizer Agreement for the year ended December 31, 2016.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In November 2014, the Company executed a worldwide license agreement with UniQuest Pty Limited (UniQuest) to secure the exclusive rights to two method-of-use patent applications relating to the use of E-selectin antagonists to reduce the risk of deadly infections in patients undergoing chemotherapy. Under the terms of the agreement, UniQuest received an upfront fee of $20,000 in 2014, and is eligible for a milestone payment of $2.0 million from the Company upon the Company&#x2019;s receipt of marketing authorization from the FDA for a drug incorporating the licensed patents, as well as low single-digit royalties on any net sales for this indication. There were no expenses for this arrangement in 2016 and 2015. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">11. &nbsp;Employee Benefit Plan</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has a defined contribution plan under the Internal Revenue Code Section&nbsp;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis.&nbsp;&nbsp;For the year ended December 31, 2016, the Company made a discretionary match of 50% up to the first 3% of employee contributions. All matching contributions have been paid by the Company. The Company&#x2019;s matching contributions vest in full at the employee&#x2019;s third anniversary of employment and all employer contributions thereafter vest immediately. The total Company matching contributions were $79,000 for the year ended December&nbsp;31, 2016.&nbsp;&nbsp;There were no Company matching contributions for the years ended December&nbsp;31, 2015 and 2014.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">12. Quarterly Financial Information (Unaudited) </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Summarized quarterly financial information for each of the years ended December&nbsp;31, 2016 and 2015 are as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,500
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,328,597)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,854,693)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,071,570)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,554,978)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss per share&#x2014;basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.36)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.41)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.40)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:50.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,375
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,035,375
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net (loss) income</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,881,703)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,168,071)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,389,405
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,109,129)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Loss) income per share&#x2014;basic</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.47)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.55
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.37)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Loss) income per share&#x2014;diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.47)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.51
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.37)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">100</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">EXHIBIT INDEX <a name="EXHIBITINDEX_356727"></a></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 101.48%;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:85.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.78%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">
						<font style="display:inline;font-size:0.5pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:85.76%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">
						<font style="display:inline;font-size:0.5pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:12.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Exhibit<br />Number</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:85.76%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Description of Document</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.78%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:85.76%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;3.1(1)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Amended and Restated Certificate of Incorporation.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;3.2(2)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Amended and Restated Bylaws.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;4.1(3)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Specimen stock certificate evidencing shares of Common Stock.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.1*(4)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">License Agreement, dated as of October 7, 2011, as amended to date, by and between the Registrant and Pfizer Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.2(5)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Second Amended and Restated Investor Rights Agreement, dated as of October 20, 2009, by and among the Registrant and certain of its stockholders.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.3(6)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Common Stock Warrant issued in July 2008 bridge financing.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.4(7)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Common Stock Warrant issued in January 2009 bridge financing.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.5+(8)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2003 Stock Incentive Plan, as amended.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.6+(9)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Incentive Stock Option Agreement under 2003 Stock Incentive Plan.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.7+(10)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Nonqualified Stock Option Agreement under 2003 Stock Incentive Plan.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.8+(11)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2013 Equity Incentive Plan.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.9+(12)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Stock Option Grant Notice and Stock Option Agreement under 2013 Equity Incentive Plan.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.10+(13)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under 2013 Equity Incentive Plan.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.11+(14)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2013 Employee Stock Purchase Plan.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.12+(15)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Indemnification Agreement.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.13+(16)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Amended and Restated Employment Agreement, dated as of January 15, 2014, by and between the Registrant and Rachel King.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.14+(17)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Amended and Restated Employment Agreement, dated as of January 15, 2014, by and between the Registrant and Brian Hahn.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.15+(18)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Amended and Restated Employment Agreement, dated as of January 15, 2014, by and between the Registrant and Helen Thackray.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.16+(19)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Executive Employment Agreement, dated as of May 19, 2003, by and between the Registrant and John Magnani.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.17+(20)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non-Employee Director Compensation Policy.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.18(21)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Lease Agreement, dated July 23, 2014, by and between the Registrant and BMR-Medical Center Drive, LLC.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;height:5.75pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.75pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;height:5.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;height:5.75pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.19(22)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Tms Rmn;color:#000000;background-color: #FFFFFF;">Sales Agreement, dated March 1, 2016, by and between the Registrant and Cowen and Company, LLC</font><font style="display:inline;">.</font></p>
				</td>
			</tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">101</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 101.48%;margin-left:0pt;">

  <tr>

    <td colspan="2" valign="middle" style="width:12.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

      <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

        <font style="display:inline;font-size:1pt;">&nbsp;</font>

      </p>

    </td>

    <td colspan="2" valign="middle" style="width:85.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

      <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

        <font style="display:inline;font-size:1pt;">&nbsp;</font>

      </p>

    </td>

  </tr>

  <tr>

    <td colspan="2" valign="middle" style="width:12.78%;padding:0pt;">

      <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">

        <font style="display:inline;font-size:0.5pt;">&nbsp;</font>

      </p>

    </td>

    <td colspan="2" valign="middle" style="width:85.76%;padding:0pt;">

      <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 0pt;">

        <font style="display:inline;font-size:0.5pt;">&nbsp;</font>

      </p>

    </td>

  </tr>

  <tr>

    <td colspan="2" valign="bottom" style="width:12.78%;padding:0pt;">

      <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">

        <font style="display:inline;font-weight:bold;font-size:8pt;">Exhibit<br />Number</font>

      </p>

      <p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">

        <font style="display:inline;font-size:8pt;">&nbsp;</font>

      </p>

    </td>

    <td colspan="2" valign="bottom" style="width:85.76%;padding:0pt 0pt 0pt 7.2pt;">

      <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">

        <font style="display:inline;font-weight:bold;font-size:8pt;">Description of Document</font>

      </p>

      <p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">

        <font style="display:inline;font-size:8pt;">&nbsp;</font>

      </p>

    </td>

  </tr>


			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;10.20(23)</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">First Amendment to Lease, dated March 24, 2016, by and between the Registrant and BMR-Medical Center Drive LLC.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;height:5.75pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.75pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:5.75pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:5.75pt;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;23.1</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;24.1</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Power of Attorney (contained on signature page hereto).</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;31.1</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;31.2</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;32.1&#94;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules&nbsp;13a-14(b) and 15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to section 906 of The Sarbanes-Oxley Act of 2002.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:3.60pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:3.60pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.INS</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Instance Document</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.SCH</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Schema Document</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.CAL</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Calculation Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.DEF</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Definition Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.LAB</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Label Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="middle" style="width:12.48%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:83.86%;height:6.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:12.48%;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.PRE</font></p>
				</td>
				<td colspan="2" valign="top" style="width:83.86%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Presentation Linkbase Document</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.45pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&#94;<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section&nbsp;1350, and are not being filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">+<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>Indicates management contract or compensatory plan. </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">*<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>Confidential treatment has been granted with respect to portions of this exhibit (indicated by asterisks) and those portions have been separately filed with the Securities and Exchange Commission. </font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:#000;background-color:#000;" align="left"></hr></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No.&nbsp;001-36177), filed with the Commission on January&nbsp;15, 2014, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K (File No.&nbsp;001-36177), filed with the Commission on January&nbsp;15, 2014, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 4.2 to Amendment No.&nbsp;2 to the Registrant&#x2019;s Registration Statement on Form S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on October&nbsp;31, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (4)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.1 to Amendment No.&nbsp;2 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on October&nbsp;31, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (5)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.2 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No.&nbsp;333-191567), filed with the Commission on October&nbsp;4, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">102</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (6)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.6 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No.&nbsp;333-191567), filed with the Commission on October&nbsp;4, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (7)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.7 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No.&nbsp;333-191567), filed with the Commission on October&nbsp;4, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (8)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.8 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No.&nbsp;333-191567), filed with the Commission on October&nbsp;4, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (9)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.9 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No.&nbsp;333-191567), filed with the Commission on October&nbsp;4, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (10)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No.&nbsp;333-191567), filed with the Commission on October&nbsp;4, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (11)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.11 to Amendment No.&nbsp;1 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on October&nbsp;28, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (12)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.12 to Amendment No.&nbsp;1 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on October&nbsp;28, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (13)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.13 to Amendment No.&nbsp;1 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on October&nbsp;28, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (14)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.14 to Amendment No.&nbsp;1 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on October&nbsp;28, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (15)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.15 to Amendment No.&nbsp;1 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on October&nbsp;28, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (16)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.16 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-36177), filed with the Commission on March 31, 2014, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (17)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.17 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-36177), filed with the Commission on March 31, 2014, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (18)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.18 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-36177), filed with the Commission on March 31, 2014, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (19)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.19 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-36177), filed with the Commission on March 31, 2014, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (20)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.17 to Amendment No.&nbsp;3 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1 (File&nbsp;No.&nbsp;333-191567), filed with the Commission on December&nbsp;20, 2013, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (21)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No.&nbsp;001-36177), filed with the Commission on July&nbsp;28, 2014, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (22)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No.&nbsp;001-36177), filed with the Commission on March 1, 2016, and incorporated by reference herein. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-size:10pt;font-family:Times New Roman,Times,serif;;"> (23)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Previously filed as Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No.&nbsp;001-36177), filed with the Commission on March 29, 2016, and incorporated by reference herein. </font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:6pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">103</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>glyc-20161231ex231e0da66.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/1/2017 8:17:12 AM-->
<html>
	<head>
		<title>
			Ex_23_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Exhibit 23.1 </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">Consent of Independent Registered Public Accounting Firm</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">We consent to the incorporation by reference in the following Registration Statements:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;line-height:100%;font-family:Times New Roman,Times,serif;font-size:11pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Registration Statement (Form S-8 No. 333-193317) pertaining to the 2003 Stock Incentive Plan, as amended, 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-family:Times New Roman,Times,serif;font-size:11pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Registration Statement (Form S-3 No. 333-202808) of GlycoMimetics, Inc.,</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-family:Times New Roman,Times,serif;font-size:11pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Registration Statement (Form S-8 No. 333-206166) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc., and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
				<font style="margin:12pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;line-height:100%;font-family:Times New Roman,Times,serif;font-size:11pt;;"> (4)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;margin:12pt 0pt 0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Registration Statement (Form S-8 No. 333-209814) pertaining to the 2013 Equity Incentive Plan and 2013 Employee Stock Purchase Plan of GlycoMimetics, Inc.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">of our report dated March 1, 2017, with respect to the financial statements of GlycoMimetics, Inc. included in this Annual Report (Form 10-K) of GlycoMimetics, Inc. for the year ended December 31, 2016.</font>
		</p>
		<p style="margin:12pt 91.8pt 0pt 180pt;text-indent:36pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">/s/ Ernst &amp; Young LLP </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">McLean, Virginia </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">March 1, 2017</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>glyc-20161231ex31160ffc0.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/1/2017 8:17:15 AM-->
<html>
	<head>
		<title>
			Ex_31_1
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">EXHIBIT 31.1 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">I, Rachel K. King, certify that: </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">1.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>I have reviewed this annual report on Form 10-K of GlycoMimetics, Inc. (the &#x201C;registrant&#x201D;); </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">2.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">3.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">4.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">5.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Date: March 1, 2017 </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:50.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:50.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:50.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Rachel K. King</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Rachel K. King</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">President&nbsp;&amp; Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">(principal executive officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>glyc-20161231ex31258d33f.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/1/2017 8:17:18 AM-->
<html>
	<head>
		<title>
			Ex_31_2
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">EXHIBIT 31.2 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">I, Brian M. Hahn, certify that: </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">1.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>I have reviewed this annual report on Form 10-K of GlycoMimetics, Inc. (the &#x201C;registrant&#x201D;); </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">2.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">3.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">4.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">5.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font>
		</p>
		<p style="margin:6pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.45pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Date: March 1, 2017 </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="middle" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:50.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:50.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:50.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Chief Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">(principal financial officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:5pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>glyc-20161231ex3211bfe4e.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/1/2017 8:17:21 AM-->
<html>
	<head>
		<title>
			Ex_32_1
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">EXHIBIT 32.1 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">CERTIFICATIONS OF </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">PURSUANT TO 18 U.S.C. SECTION 1350, </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">AS ADOPTED PURSUANT TO </font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#xA7;1350), Rachel K. King, Chief Executive Officer of GlycoMimetics, Inc. (the &#x201C;Company&#x201D;), and Brian M. Hahn, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge: </font>
		</p>
		<p style="margin:6pt 0pt 0pt 48.95pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">1.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>The Company&#x2019;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2016 (the &#x201C;Annual Report&#x201D;), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act, and </font>
		</p>
		<p style="margin:6pt 0pt 0pt 48.95pt;text-indent: -24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">2.<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font>The information contained in the Annual Report fairly presents, in all material respects, the financial condition of the Company as of the end of the period covered by the Annual Report and results of operations of the Company for the periods covered by the Annual Report. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">In Witness Whereof, </font><font style="display:inline;font-size:10pt;">the undersigned have set their hands hereto as of the 1</font><font style="display:inline;font-size:10pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">st</font><font style="display:inline;font-size:10pt;"> day of March, 2017. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:43.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:25.00pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:43.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:25.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:43.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Rachel K. King</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Brian M. Hahn</font></p>
					<p style="margin:1pt 0pt 0pt;border-top:1pt solid #000000;line-height:1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Rachel K. King</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">President&nbsp;&amp; Chief Executive Officer</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt 0pt 0pt 7.2pt;">
					<p style="margin:0pt;line-height:2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt 12.2pt;text-indent: -12.25pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">*<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 6pt 0pt 0pt;"></font>This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of GlycoMimetics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>glyc20161231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc20161231x10k001.jpg
M_]C_X  02D9)1@ ! 0$       #_X0!F17AI9@  34T *@    @  P$&  ,
M   !  (   $2  ,    !  $  (=I  0    !    ,@       Z !  ,    !
M  $  * "  0    !   #1Z #  0    !   !\        /_A"2%H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^#0H\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)835 @0V]R92 U+C0N
M,"(^#0H)/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q
M.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX-"@D)/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(O/@T*"3PO<F1F.E)$1CX-"CPO>#IX;7!M971A/@T*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_^T +%!H;W1O<VAO
M<" S+C  .$))300E       0U!V,V8\ L@3I@ F8[/A"?O_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( ? #
M1P,!$0 "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_
MQ "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($
M! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_W0 $ &G_
MV@ , P$  A$#$0 _ /[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^.O_  3Y_P"%$>-M!_X4K\*] ^)?_"[;W5/.\.>)O[:B\)S?V8OAW_A'[?\
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M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\BO\
M@L;\:OBGX(^ _P )_P!GSX&:]=>$/B]^W!\?O '[*WASQU8>8+_P#X?\=2W4
MOCGQ=ISPS031:A9^';.;38+B"6&ZLDU:;4;*YM;ZSMIT^O\ #SA_+N*>-L%E
MN=Q<^'<FR/B+CCB3#KEOF&3<)8?#8BOE:YHS@UC*V+P]2K3J1E1Q6&PN(P->
M$Z.*G$\CBG/L1PEP?G7$F!C">=+%9/PSPO"I=T_]:^*,16PN45*BC:471I87
M'U,'5C+]QFZRRI4IUL/&O2E]N?LF_LB_ O\ 8K^#WAWX+? ;P7IOA?P]HUG:
MC6=96UMV\5>.]>CBQ?>+O'&NK$M[XA\1:G.\T\ES>2M#80RQZ5I%OI^D6=E8
M6_/Q9Q;F_&&:5<RS2KRTU*<<ORVBY1R_*<(VE3P> P[?+3IPA&'M:SYL1C*R
MEBL95KXJK5K3Y.&N&L#PU@?JV';Q.,Q#C6S7-:T5]=S;&M?O,5BJEY2LY.2P
M^'4G1PE'EH4(QA'WO6?BE\*?AM\;O ?B/X8?%SP1X;^(GP_\66$NF^(?"?BO
M2[;5M'U&VE4@,]O<HY@N[9R+BPU"U:#4--O(X;W3[JVO(89T^9A*I2JT<10K
M5L-B<-5C7PV*PU:IA\5AJ\/AK8?$490K4:L4VN>G.,G&4HN\)3C+Z6%24.=6
MISIU8.E6H5J5+$8;$T9-.>'Q6&KPJ8?%8>IRI5</B*56A5C[M2G*.AX+\&?V
M6_A3^QQ^RWK?P&^"L/BFU^'?AK0?B+J6B6/BWQ=KOC._TX>(4U?5YM-LM0UV
MZN9;+1M/>Y%GI>EV2V]I;V\(GF2YU2ZU+4K_ %\1^)LVXKRK-\RSJK0KXZAP
MI5RV6(I87#X6IB88#*JM&.)Q?U>G35;%XB2E6K5&E3IN:PN#I83+L-@L%A:\
M.\@RSA[B+*L/E-&IA\-CN,L)FLL-+$5Z]'#U<9F6$OA\)&O4J2H86C3ITZ=.
MFI2J590GB\95Q688G%XS%?B!^PU^TI\7?V0?^"%?[&?[1'P[\(^&/''@+X=^
M-M<NOVC]"U;2->U+Q19_ #5/C[\1-(\;^+/AW<:-XCT6WL?%?@]KRPUQCK>F
M>(])FT6WU5KBQM_(%TO[]XD9?E6=>.N%R#/,74R[ <0<.\*9/@LRIU:5&GE_
M$V+X$X?_ -6JV93KTJT)9-B,?!Y?C:-*-+%U:^,P4<-BJ#Y_:_C'AY/,J'AE
MQ;F.1X>GC<[R;B#BS.\/EU=.5/-<MRSB#%U\^RZBU7POU7'_ -D_6,PP>85*
M]7#X59=7I5<NQT\52C2_I<TOQ/X?UOPUIWC+2M8TZ^\*ZMH=IXFT[Q!;W<,F
MDW?A^_L(]4M-8AOE?[.^G3Z=+'>QW8?R6MG68/L.ZOP#-*%7):^8X;-:<\%7
MRFKBZ&8TJ\7"IA*N!G.&+IUHN\H3H3I5(U(M73BUJS]9RC%T,]P>68[*9/&X
M;.,-@\7ELZ,92>+HYA2I5L'*E"W,W7A6IN$;<S<DK7T/SD_9&_;PU;XT? _]
MI/\ ;%^,Z^ _A?\ LD^#OB1\2(O@'XM33M>L==\1? ?X5-<:/K'Q7\;7U[XA
MUJTU5_%OB33=97PKIOAOP_H,Z6>GQV:6>N7FH6=S+]3Q/P[2X9RW@W!8B&.J
M\:9UE&"S7/LGI^SE'+L7Q)B*<N&.&L-A%15=9S]0K82>.J5,77P^+JYCA)X:
M.#I*<)>=D^8UL^XFXMPF72P=3AC(<PAD67YO.I",,?F.1X.I+C7.?[2CB)X"
M?"^$QT9PP&,E1PM7!X?+\R>:-SHR=+YR\)_M>_\ !5_]LK1H/BI^Q#^S%^R[
M\#OV?=89[WX;^._V]O%GQ5D\:_&/PG)C^R_&FA_#7X'VXU/P%I.M12+>Z1'X
MGU#5$U/2XTU2POI[34;)Z]_$<)\+\*36"XYSG,:V?*"^O\/\)T<)7J9'7G[T
M<+C\US&2P=?%T(0DL=A:%&E6PN)Q$,,U+ZI6KU_&I\1YAQ![6IP=@:%;*:=6
M5/#\1YY*OA<%FKPTIT,7_9^5T:<<Q6'EBKO X^M-4<3A*$JM2C0Q.(>#PGM?
M[.O[:_[5VG_M#>'/V1OV\/V5[7X9?$SQOH&MZU\+?CW^S[J?B+XD?LS_ !8;
MPCIZ7OBZV6?4]._X2WX37MG$5NM.TWQ[<7$]S%/#;7]QI<USH<OB+CQG#G"^
M:9+FN?<'YYBE+(U0KYMPUQ/#"8//,-@,9BXX7"8O"8O"U%EV<?O:U*CB:6!2
M=)Q]I&52I.I@\+HLVXARC'97@^),LP=?!YWC'EV7Y]P[+%XC T<R^KXK%1R_
M,\#B8?7< ZN'P5:MAL74E*&)C[64</##9?F&,H=%^V!^W_XK^$_QA\(?LB_L
MH?!&Y_:A_;%\<^'V\92^!SXDM?!WPX^#WP[%Q]D/Q'^-7CBXBN5T#29IR1HN
M@6T":IXB:(6EM>V-_J/AZVUSQ^&.%ZO$.'SC-\5F&'R'ACAZ='#YKG^,HU,3
M&>9XFC]8PN295@:4Z57,\UK494JM6E"M26$P]>&+?UFE0QL<+[&?9UAL@AE=
M"5"OF6>9^J\LAR#!RA3Q6+PV&J2HXK-L9B*D:E/+LGPU:%:BL;6IRIXK&8>I
M@8RHVJ8G#_-GBK]I;_@M/^RYX=NOC#^TO^S!^QC^T7\&O#]J-7^('AW]B;Q=
M\9]&^-?@;PM:A9=>\1P:%\9H]1T;QY+HME*]\?#WAAA/=)I=\)M5TZRF35;3
MZ&.#\)\97CE]'/.+<CK5JL:%#/,\PF58C(8U9N<:3Q=/!.AC<)A:M2$(5,;B
M94:6#IXBG6K*7LJM,\B#\0YQEB*&5\.9C-4W4IY!AL5F-#.<4VX3^K87%2I8
MG!5\;2I>TC'"4:-:OF.)5/#Y="M7J4J%7]-?!_[4'PK^+W[*W_#5WPJ\2+K_
M ,+M9^%/B+XEZ)K2P>5=0V.B:+J=]J5CJ5@Y9['6]"OM,OM*UK2YB9+'5K"[
MLI"QBW5^>>('#V;\+?ZR</YA3C2S7"8+$T:4J,W.CB'C,%[3+<7A*KC2=3#8
MZEB,-B<)5<82G1K4Y2A";E"/U7 6:97QE7X>Q6#E4>!S+-<)@L31KQ4,3A*L
M<PC@\?@L73IU)QAB<)5C6HU?8UJE&;A[7"XBOAIT<1/^<'_@B?;^)_V*)?V2
M[_QCK.KW?P?_ ."K'PV\3>*3>:M/+<V'A#]KGP9XH\9>(?#U@DPQ9:3:_%SX
M'W5A:6:R,]_K?B?P7;P<A%2#^C?$BEA<[J\6<#X6E2AF7A=EG#7$O#<*<8PJ
M8SA+'\,<.8/C?+8*SJ8BKP]Q"L/G2^&A@LKS"O&/OR;G^-<.8W$N>7>*6*G*
M%'CWC3BK@_B^@Y+V&#S2?%?$M7P_S:"WOFDL/F^2UJ&%HODQ6+HXG%5(8>-/
MV7]*_P"U+^T'X0_95_9Z^+?[0GCER?#WPM\&:KXD>QC/^E:YJT40MO#OAK3U
M_CU/Q-X@N=,T'3D^ZU[J,&]D3>Z_S;2P>8YIB\!DV34EB,ZSS'X3)LGH.,IQ
MGF68UHX?#SJPA>I+#89S>,QKIISIX'#XFLE+V=C]RPT<(IU,1F-=X3*L!AL5
MF>;XM6;PF4Y;AZF-S'$0B])U:>$H5G0I+WJ]?V5""E.I")_.Y_P2W^%OQ;_9
MN_X*E:K!\>-3O[OXN_MS_L"O^U=\78[EW^Q6'Q>U3X]W6I7WA&PA_?1VR^ _
M"FM6OAD6<4RVUJUA=&#S89[=Z_?N(:F35O#3C3A3A^4:^5>%WB)P=D>58KFC
M.MF&6QX,KX/.,[J55R>WCG7%V(S+&0Q3C[3$4YT'4C&<:C/QFA4S+&\9^'_B
M)F4/JM3Q(R7CK+Y96F_9Y9&ACLMSOAW 4E.,:T(Y9P1E7#N$E1JQC*E6JXBG
M*3G2<(_LC\./VM?B/XP_X*6?M'?L;:GHO@F#X8_"#]GOX4?%CPUKMCIVNQ^/
M+[Q%XZU0V6KV6N:G<>)+GP_<Z+;1#=IMM8>%],OH9.;G4KU?EK\JP>1X3$>'
M>9<6SJ8E9E@_$&API2H0G26"EEU3AN><2K5*;I2KO&K$Q4%4CB84/87B\/*I
M>I'] S3-,1@N->%^&Z4*,L#G?AYG/%N*JU(S>+IYEEW&-+AZA0P\XU8T8X*6
M"FZM6G4H5:\L5:<,12I)T)?F9\$_^"IG_!1?]K?XA_M&?L^_LL?LT_ +7/BC
M\"_VC_BYX \1_&CXJ7?CWP9^SG\.OA5X:\1MX=^&"^*[31_%GB/X@?$#XJ>+
M;C1O%<^N67@EM'L=.L;'3=1@T$6MS>&R^LH\$<.T.$. ^-<[SG&9=E?$7!62
MYICL'1C1Q6:9KQ7CJ3S#,LNX=H>QI4L#E&7Y5B,KF\7FE7&\N,QZH8C%4[89
M8WQ<?Q-F5#C'C7@[+\NIYCCLEXJS/+\JDI/#X;+N&L%[3!4<WXDQ<ZDHUL9B
M<X4Z6'P674,/6QF%P./GAL/:C6K8?UVS_P""J'[1G[)WQ,U/]GO_ (*9_ [X
M>V7Q=\4^!Y?&'[-'B7]CBY\:>+O W[37B,^)K'PG:_!KP1X3\>M-XUT3XEW.
MLZWH=I:#7[Z#3[F&XNM5U&'P_I265SJ&%/@W(^+LOQ.)\-L3FV(S3*LPP&$S
MG(.*I9?@JV!RW,*6*J0XIJYM@[Y=A^'\)#+\PQ&95:BJ5\)@\)B*D8U\1AYX
M6=5L]S?AK&9>^-HY1A\@S?"YQ5P?$&2O&5:5#'Y%@L-C\7D=?+\7;&8C,L51
MQ6'H9=*E&C0Q>9XS+LLPTL3/&5,1A;/Q>_:Q_P""SG[/O@S6/VI/B?\ LG?L
M9ZO^S=X1TX^,?B)\!OAS\5/B;K7[5WP_^']E ;SQ)JNH>.M3L].^"GB34_"F
MF07>J:I:>$](U07,2B#3XYTAN;U<L#E7A>\;@\AQ_$W$<\=CL7A\KI<583*\
M)1X7AF&.KT,+@9O*\34GGTL-B,7B*>%@ZD\-'GE[;$XG!X9.K'HJXGCG'4*F
M8Y)D>54J=*AB,=3X<S?&UY<1X[#4/K-=X6&)P-.6583,7@X4JLJ$99C4E4IU
M</@Z&88ZOA\"?ICXY_;0^ /PZ_9*B_;6\5>*WL_@3=_#;PS\3M,UB&T-WJ^L
MZ5XTL=-NO"6B:1I$,C27OBGQ%>:QIFB:;HZ3 MK-Y';7%Q#$DUQ%\CF7#6=Y
M?Q55X*A@IX[B59[6X<PN78-^TEC\SHU:U-K"SDHJ6&=+#UL:\4TJ<,OI5,9.
MU&$I1]G(,YR_/LAPW$L,1'+LGGE3SG'XK,;THY/@Z-/FQJS*--5YT\3@:W-@
MJ^$HQK8FKF$5E^$I5\95H4*OY[Z1\;?^"X_QVTJQ^*'P:_9G_83_ &</AOK=
MJFJ^&_AI^UYXY^./B;X\:GH5QON=*U#6U^#EG8^$O!6JZQIGV>:7PKKT1U7P
MW>W8L-9E::TN@GUU;)?#WAVM4R_B+.\]XAS/#3=/'+@NEEM++,/B*=OK."PV
M89Q*4,R]E4E+#4LRP\:>%Q$Z%3$JC"C6ITX_/TLXXDX@I1QG#678#*<LQ'OY
M=CN+?K;Q&-P=:$%A,?5RK*F\1@$^6>*KX.K7JU/95Z5##UJWLI8K$?4/[)O[
M;GC7XI?$[Q3^R_\ M2? Z\_9D_:T\%^&%\=+X)3Q-9>.OAO\6OAL=2_L8_$S
MX,?$"Q@LUU_1;74VM[7Q'X>U&QM=>\)75_9V-\;V=-0>P\C.>&<O_L27$_"6
M;O.\FH8NEEF;4<7A98#..'<TQ%&5;"4,UP7/4A4P6.A3J_4,UPE2>&Q-2A7H
MM4[8:>*[L)G.8X;-,+DO$>6PR[%9G1Q&*R+'X3$?6\HSJEA84ZN.P>'Q,H0E
MA\ZRN%6,L=E5=>W>$]GF=%O"UG"A^(?Q=_X>X_\ #YKX2_V9_P .Y/\ A??_
M  R?\6_^%3?;O^&F?^%0_P#"B/\ A9-UYW_"Q/L__%9_\+;^T_9_*_X1K_BC
MO(\[=\^RONN!_P#4K_B'?B![7_6GEOP/_KI[/^R>;^U>:A]7_P!5^;3^S_KG
M/[;^UO\ :?JW+R?O>8\'CK^W_P#6/P^]A_8_U#_7#Q"_U']K]=^N<O\ JU1^
MM?ZU\G[GF_L+ZM]7_LC3^UO;^T_V/D/V6^(O[7'QY^%W[:W_  3L_9/\2Z)\
M(KR+]IOX8?&W7/CKK6AZ;XRN)-(\=_"/X<Z3XA:/X2ZC?^)-/6P\)7OB>XU"
M()XQ\.:]K%SH(LT,NG:@)YV^-R?(,@SZEXQYA@*F<4\LX(RCAK.>%(XR>"AC
ML1AN(.,<=D<:?$,:-&MAZU>EE5"A4<<MJ82$,P=::J5\,X48^GF^;9[D66>%
M2S"&4U,YXMXAS/(.*/J4<9/+*-;*^',KS.M4R#V]6CBZ=*>88O$PI3S'ZQ.6
M"C0C*C"NISG%^U;_ ,% _&'P^^.&B_L>?L@_ JX_:H_:XU7PY!XV\4^&9?%=
MIX$^%GP,^']Y*D%EXT^,OC^ZM+]-,?49)89M$\':?!_;NM6;Q21W%E<:IX;M
MM?\ .X9X6J9]@LTS['9CA^'^%,EQ,,OQF?8RC5Q+Q><5*3Q%+)<ER^C.G6S/
M'2I1?UB<)TZ&#YI5.;$K YO# >UGV<T<C66X..'KYGQ!GM.K7R;(L)*%.M4R
M^A7>#Q.=YAB:BE3R_*,)BOW;K3ISEBJ].6$A["5:AB)>!:]\;_\ @N?\ ]'O
M?B=\7_V9?V$/VG/A]HMLU_XA^&G['_CGX[>$OCC8Z3#MGU#5-&_X7)8:KX:\
M6W>EV(GD7PQH%E<:WKEU"+72LO-'N]OV/A)5G#"O-^-,FYZBC//LRP63XS)\
M)",91=7$X/!UJ&81HU:DJ4XUY5:=#!T8U9YA5H4>?$X?RH_\1 JN=?#8#AC$
MW2>'R+Z[C\/FF(G4JTY0P\<SJTWE2K4*$:U&LW#_ &C$5*-3 TJ\H+!8CW3]
MH_\ X*:>&?A5^PA\/_VROAI\,/%WC35?CCJGP\\%_!3X5^/+6Z^&6MWWQ#^*
M&I2Z1H.C>.9=4M[E?#=CI%Q:ZE<ZIJ$3W6EZI!IR?V'K4UAJVG:VW!2X"S2M
MXB8'PXCCLL^OXO&5:=3-L/5>-RVCEU#+_P"TZF8TXTYT:]9SPTJ%.&!G]7QE
M'$8E4L71HSPV)IPWP_%>7/@?.^.\9A,QPN7Y!E.)S''9;6H^QS%XC#9KA\DG
M@(.2E2LLQQ"4L=35>@\'3J8O#4\7)T</B)?V:_B__P %1=*^,OAGX7_MN?LW
M?L_ZKX*^(/A[7M=TCX\?L@>+/%T_@KX6:IHEE!>1^!_C!X6^+^HIXF?4]7W2
MVNF^)?!EQJ6DW.I2V5C9Z=>VJ:OJVE=&99=X?8G+<VK<.YYG>%S/)8X6<,)Q
M'AL-]7XFI5L9'"UJF0U\NI\^%JX95J.(>"S6G3K5,-3Q5=U(>RC YJ..XPH8
MO*JN891EE;*\WQ53"5:&5XJI4S;ANI+"5L;AJF<+$2A@\9A7##5\+B,;EDY8
M>EBXT:2E[?'9;A<;^H-? 'UQ_/OXQ^.'P6^ W_!?3Q[XI^.7Q?\ A=\&/#.J
M?\$T?!VA:;XC^*_C_P )_#O0M0UN;X\2WT6CV.K^+]6T?3[O59;*QO;R/3X+
ME[M[6SNKA86AMIG3]2X1P6,S/P;\0,#EV$Q./QLO&KAS$QP>"H5<5BI8:AX;
M4*=?$+#T(SJNA1J8G#TZM51Y*<\11C.4958*?PW&E6EA?$;PLQF*JT\-A*7A
MIQ32JXK$3C1PU.K7XTS3V-.I7J.-*%2LJ55TH2FI5/9SY%+EERXO_!8G]M+]
MC3]HG]BSQW^RS\#OBI\)OVM_VA/V@M3\(^"O@=\*O@)XS\*?&/Q*OCY?%FC:
ME8^*9Y/ NIZ];^$[?PQ:65[J;ZIJUUIOGQ126,;O;75XZ8\!\&\8PX[X2S%9
M=FG#>'R#.<-GF:<1YKA,3E.7Y/D^$IXG^TJU7%XR%&E4CB\(ZV6U:5&<ZE"G
MCOK=:$,/1G5CZV<\5\+X+AKB:>+S++\RI8_A_-LIP^48&M0S7'9IFF88>.%R
M>C0RS"RKU:U3"9Q7R_-J$JD%>MEJ>7^VS6E@\+5^UOBM^T[\9OV:OC]_P2N_
M95%EX(\267[2EE\1? WQJ\3>(;#7;[Q3:ZG\'?@_X=UV'4_!6H:9XETK2;&Y
MU;Q#+>G5YM<T;Q+#<V31I916,V^Y:,%EN3<9Y]XQYG2^LX3+\@RBOQ=P]1PK
MI44_[3XDS##T,-C85L/6<L+2P4:/)2H?5*T*G-S5I1<81\:A+-.#_#C@!8B%
M*IG$<Y\.N",VAB)>WI0CF&7SPV:UJ<L/5AS8RG7P?^SU_:SPWO2E.C73BCYY
M_:W_ ."K'QL_9R_X*$7'[%_P]_9YM_VA]3\:_LV^%O''P+^'W@R'5-#^(?B_
MXU^(?'&L:;>V7C#XAZGKUWX'\&_"7PYX&\.Z]XFUW6KWP:+O37T_S;G65L99
M&M,N"N"</Q=PGQ+G$LQCE6+X?XVP>4XO,<94A'(\KX2_U6P&:YEFV.P_LGC,
M;FD<XS7+<NRW"83&8=8Z>,H8.%!8B?UD]+BWB3_5;/>$L+4H2Q66Y]PKF69U
M,-AZ-2OG./XCCQ#F.49-D^4^SFJ.'PV*PV K8O,<5B<+BOJ&%PV.Q\75=*AE
MV*W]7^*G_!>_P%I]S\3=?_9K_P""=WQ;\&V22ZM=?L__  B^)GQQ\/\ [0!T
MG:]V=&L_'WCJVG^$VH^(M-M8VM+F73M.NX=7OVC.B:;,'2U=^P\)J=L+7S7C
M=5+1IU,]HY;EE7*J4N:'M,;_ &1%RSJMAU%RE'"4Y?67RVYW9(SIU./,5RUJ
M."X8P473<HY7F&-Q<L=4JJE*$,-_:5'ERFA4JXKDK1KXB<<'2PUZ->O3G?$T
MOOO]C;]LSX4_MK?!"+XT_#V+6_"PTG6-;\'_ !+\ ^.;5-&\:_";XA>%2D?B
MSP3XWT]I&2QU+1F>*Y%QO$-WIEQ:7Q6V>26TM_G^,>&ZO!U>C+$X[!8_)L?E
M=//<FX@P513RS-<CKQJ3IYC0JW<81@J56GB8>TG&E5I3=*K7PTL/B:OH\-YW
M+B%XO!2R_%Y=Q!E.8O)L[R#$1<\=E^;PY8RPT4H1EB:-:<K8.O&C3G6M.C6P
M^%QU#%X+#_ EK^W/^WM^V9J_BG4?^"8WP(_9YC_9_P#"GB34_"VD?M6?ME^)
M_B-I?@'XRZOX>NKC3O$Q^$GPW^%5G'X]O/"^FZK;OI]AX]U.[;1-:N4NK>&T
MM;K3[ZW@]^CPED^08+ 8WQ Q^8Y=CLTPE/,,+PEDV&HU>(,+EN)2E@<9G&(Q
MLE@LKQ&-IS6)IY36I/%TL'3C6J5'+&4:=#CQF?8G&YCC\IX3PV'S264UZF7Y
MKQ!BZ[IY!A\XHNG4Q.78'V$7B,ZA@Z?/AL1F.!DL)+,*MJ#J8'"T\;FG<?#_
M /;@_:Z^ WQ-^'/PA_X*7_ 3X6> M,^+_B>P\ ?#3]JS]F/Q9XC\4?L[ZM\3
M-:DN1X?^'OC7PWX^A@^(OPNU'Q'Y,5CX8US7Y]0TKQ!K$ZV,:V,<-[<V5QX:
MX5XEIXV/ ^:9O'.L!@L3F7^JW$V'PM/,LTRW+Z*GF6*R7,,NG/+\;B</"-7&
MO*)1I8Q9?"I)2J8B%*GBN6OF_$?#]&GC^)\%E>(R/V]+#X_/.'ZF+='(IXRO
M3A@<1G& QT?K5'*I3Q-'+L7G$)O"87,:4958QPV/P\J'">*?^5A#X6_]HO?%
M_P#ZT%<57"/_ ":/Q<_[+_@K_P!4.'.KC+_D=^#'_8]\1?\ UE<(?1/[+O[9
M/Q/^-GQ6_P""D7@7Q5H7@/3](_8]^,(^'WPSN/#^F>(+74=<T8^!;GQ/]I\=
M3:CXHU6VU/4_M\*Q>?H%GX8M/L9,?V$3$3U\AQ'EM#)_"WAGC?#3JU,VSJGX
M@3Q6'KRA++Z;X4QU+#9=]7I4X4L3%5J=1O&^TQ=7VDTG0^KQ5I>]DU>>8^*V
M:<"UE&.48'+O"W%TL323CF,JG&^ Q.*S:-2K.53#.&'J48QRY1PL94H.2Q,\
M8VI1_-O]C7_@J?\ \%*_^"B7P8\,7G[)_P"S#^SK8^/M"M=5M/CC^T#\=M2^
M)O@C]E[P_P".T\07]SHWPZ^''@CPSK/BWXM>-]7'@'^PM0\1:M9^))]-T#7=
M8A748[2PN=-6_P#U7BWPYX4X/S-XK-L\S.AD&)H9=/),JHQPF.XKSN^6X6.=
MX]5%0P66Y5E>"S^6.P.!JXVA)YA2P6)IT)3Q&&KS/SKA[C7.L^P]7 X7*\+B
ML]HXS,EC\5!UL'D&18..-KT\DHXR=2KBL5F.:YCE\*.88G#8&=/ZG0K8:<XM
MXJ=/!?<?[,?[;W[46E_M1V'[#O\ P4&^#OPJ^'OQQ\9^ ]?^)?P5^+?[/7B#
MQ-J_P%^-6@^%;HIXLT#0]-\?9\;>&/%OA:Q,>I7.G:O>7\^H:?'=W]Q8>'[9
MM&;7/E<;PWPSFW#N=<2\$YAF\X<+U\MI<29!Q%1P<<VP6#S6I#"8#/*&)RYK
M!XC+<9F,G@XP4.>C5_=>VKU:&-CA?=6<9_DV;</Y9Q3ALJEAN*YYCA<BSC)*
MN)6$EFN5X6698W)L;AL?;$TL31RUTJWUB#]A5J3I0HQFJ\72]"_:S_;L\>?#
MOXQ^&OV2/V1/@@O[37[6_B7PPOCW7/#&I>*8_ WPN^"GPT>[-A;_ ! ^,/CB
M6SO%L(=4OE:V\/>$M-0:_KVQG@DMI+G1+?6O"X:X9EGV&S;.<=F.'R#A?(J]
M+ 9CGN*H5,6ZV<XG#QQ>$R+*<NH3I8C,<QJX:4,17Y)PI8/#5%B9NM1H8_ZE
M[V>9O0R195A5AZV9Y[G[JU,FR+"SA1KU<MPU;ZMCL^Q^+J1J4\NR7 XB]'ZU
M4HU7CL92J9;A8K%2A*/@5Y\</^"V_P  [2?XA_'O]F7]B3]IGX8Z3']O\4^#
M_P!B?QM\:?#?QOT/0+5E?6-8T+1?CI;S:!\0-3L;&1[ZP\'Z%-9:KKDNFW.F
M6MY;W&H64J>Y.CX35_\ 9XYSQCD,I-K^V\ZP>4XW)<*^67+4QV'RV=/,*.$E
M4C&%?&<SIX"C6^MXF+H8>NSQZ?\ Q$*?[VAE_"^.D^7V.24\=C\'F6)E5G&U
M&EF%>G5RU5J%/G4X3C_M=;DIX3FG*%.?ZF? ;XY?#;]I3X0> OCE\(M='B+X
M>_$;0H->\/:B\#VEY&C22VM_I6K6$A,VF:YH>IV]YHVN:7.?.TW5K"\LI2SP
M[F^5XBR#,>&,XQF29I"G'%X.5-\]"I[;#8K#XBC3Q.#QV#K<L/;8/'82M0Q>
M$K<L74H5J<I1A)RA'U\DSG"9]EU+,<'&O2C*IB,-B<)C*7L,=E^/P=>IA<?E
MV.H*4U1QF!Q=&MAZ\(3J47.#J8>M7P\Z5>?KM>*>L% !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]+^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M;E^>>$44^'<VQ#2]KBN+N(Y5I)6YW@\8LKH-^<<%E^%I-]>2_4;^W):6Z?\
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MJOA#Z\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MRZOBU%U'-5Z=/FPC=>4J=7$SIX2G.O7H0Q-23Q-;%UL5]$?LF_\ !-K]E_\
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M*"PE3+<QSV/$->OB(2I2K2QL<;!4J52G7I4(X6\)X>K5:KQ9^RO^R/\ #?\
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MY2HXBA54J56'/"%6*G&7LZU.E6I\M:E3G#VG4?\ @AI^SWXGD@T#XB_M4?\
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MIXN.%Q*FE2Q5+^'B</6HSHXK"UHN,.:>&KT76C"G3K^TI04)?$>G_P#!#_\
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MX;#8>G&E0H4*45"G2I4X*,(4X1BHQC%))*RV-&L#H"@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]3^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M3GB*V'HSIT:E>4JLXRJ2DSMZYC<* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * /_]7^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /_UO[^* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MF/"'_08^+'_A^OCG_P#/%H_URS?_ * ^%?\ Q!."/_H>#_B'/#__ $,.//\
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M -%X?\*8\(?]!CXL?^'Z^.?_ ,\6C_7+-_\ H#X5_P#$$X(_^AX/^(<\/_\
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MSP__ -##CS_Q:?B=_P#1>'_"F/"'_08^+'_A^OCG_P#/%H_URS?_ * ^%?\
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M_P#%I^)W_P!%X?\ "F/"'_08^+'_ (?KXY__ #Q:/]<LW_Z ^%?_ !!."/\
MZ'@_XASP_P#]##CS_P 6GXG?_1>'_"F/"'_08^+'_A^OCG_\\6C_ %RS?_H#
MX5_\03@C_P"AX/\ B'/#_P#T,.//_%I^)W_T7A_PICPA_P!!CXL?^'Z^.?\
M\\6C_7+-_P#H#X5_\03@C_Z'@_XASP__ -##CS_Q:?B=_P#1>'_"F/"'_08^
M+'_A^OCG_P#/%H_URS?_ * ^%?\ Q!."/_H>#_B'/#__ $,.//\ Q:?B=_\
M1>'_  ICPA_T&/BQ_P"'Z^.?_P \6C_7+-_^@/A7_P 03@C_ .AX/^(<\/\
M_0PX\_\ %I^)W_T7A_PICPA_T&/BQ_X?KXY__/%H_P!<LW_Z ^%?_$$X(_\
MH>#_ (ASP_\ ]##CS_Q:?B=_]%X?\*8\(?\ 08^+'_A^OCG_ //%H_URS?\
MZ ^%?_$$X(_^AX/^(<\/_P#0PX\_\6GXG?\ T7A_PICPA_T&/BQ_X?KXY_\
MSQ:/]<LW_P"@/A7_ ,03@C_Z'@_XASP__P!##CS_ ,6GXG?_ $7A_P *8\(?
M]!CXL?\ A^OCG_\ /%H_URS?_H#X5_\ $$X(_P#H>#_B'/#_ /T,.//_ !:?
MB=_]%X?\*8\(?]!CXL?^'Z^.?_SQ:/\ 7+-_^@/A7_Q!."/_ *'@_P"(<\/_
M /0PX\_\6GXG?_1>'_"F/"'_ $&/BQ_X?KXY_P#SQ:/]<LW_ .@/A7_Q!."/
M_H>#_B'/#_\ T,.//_%I^)W_ -%X?\*8\(?]!CXL?^'Z^.?_ ,\6C_7+-_\
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M_P!##CS_ ,6GXG?_ $7A_P *8\(?]!CXL?\ A^OCG_\ /%H_URS?_H#X5_\
M$$X(_P#H>#_B'/#_ /T,.//_ !:?B=_]%X?\*8\(?]!CXL?^'Z^.?_SQ:/\
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M]P% !0 4 % !0!__T/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H __1_OQGNK:U56NKF"V5CA6GFCA5B.<*9'0$
MX[ YH J_VOI/_04T[_P-MO\ X_0 ?VOI/_04T[_P-MO_ (_0 ?VOI/\ T%-.
M_P# VV_^/T ']KZ3_P!!33O_  -MO_C] !_:^D_]!33O_ VV_P#C] !_:^D_
M]!33O_ VV_\ C] !_:^D_P#04T[_ ,#;;_X_0 ?VOI/_ $%-._\  VV_^/T
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M=_X&VW_Q^@ _M?2?^@IIW_@;;?\ Q^@ _M?2?^@IIW_@;;?_ !^@ _M?2?\
MH*:=_P"!MM_\?H /[7TG_H*:=_X&VW_Q^@ _M?2?^@IIW_@;;?\ Q^@ _M?2
M?^@IIW_@;;?_ !\_R_.@#1H HR:GIL+M%-J%C%(AP\<EU CJ?1D:564^Q'Y=
M* &?VOI/_04T[_P-MO\ X_0 ?VOI/_04T[_P-MO_ (_0 ?VOI/\ T%-._P#
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M_P #;;_X_0 ?VOI/_04T[_P-MO\ X_0 ?VOI/_04T[_P-MO_ (_0 ?VOI/\
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M -!33O\ P-MO_C] !_:^D_\ 04T[_P #;;_X_0 ?VOI/_04T[_P-MO\ X_0
M?VOI/_04T[_P-MO_ (_0 ?VOI/\ T%-._P# VV_^/T ']KZ3_P!!33O_  -M
MO_C] !_:^D_]!33O_ VV_P#C] !_:^D_]!33O_ VV_\ C] !_:^D_P#04T[_
M ,#;;_X_0!)%J.GSR+%!?V4\K9VQ174$DC;1N;:B2NQPJEC@< 9/ H N$A06
M8A54$LQ.  .223@  <DD\>U &?\ VOI/_04T[_P-MO\ X^/Y?E0 ?VOI/_04
MT[_P-MO_ (_0 ?VOI/\ T%-._P# VV_^/T ']KZ3_P!!33O_  -MO_C] !_:
M^D_]!33O_ VV_P#C] !_:^D_]!33O_ VV_\ C] !_:^D_P#04T[_ ,#;;_X_
M0 ?VOI/_ $%-._\  VV_^/T ']KZ3_T%-._\#;;_ ./T ']KZ3_T%-._\#;;
M_P"/T ']KZ3_ -!33O\ P-MO_C] !_:^D_\ 04T[_P #;;_X_0 ?VOI/_04T
M[_P-MO\ X\?Y?E0!HT % !0 4 % '__2^\/^#K2_L[2__P""?<FK>'_#_BO2
M['Q;\=;^;P]XITN#5]$U _V-\-H98KNTG4E?.MI)8!<6[P7D D,EM<0RA7K]
ME\#,)A\9QI7HXJA1KTWD>.DH5Z-*O&,UB<"E-0JPG'F2;5[7LVKI-J7Y7XP8
MS$8'A.EB,-5J4JBS?!Q;IU*E-R@Z.+<H2E3E"3B[+2^Z36J1_,_'XT_9Q9$9
M_P!DOX.*Y12ZKX=1U5B 6"L;E2R@Y 8JI(Y*C.%_KK_5S*^F79;;SR_!+_W5
M?Y_<?S0N)L:TG[;&*ZO;Z[B=/_*Z_+[A_P#PF?[-_P#T:9\'O_";C_\ DNC_
M %<RS_H799_X08+_ .9!_P"LV-_Y_P",_P#"W$__ "\/^$S_ &;_ /HTSX/?
M^$W'_P#)='^KF6?]"[+/_"#!?_,@?ZS8W_G_ (S_ ,+<3_\ +P_X3/\ 9O\
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M9_T+LL_\(,%_\R!_K-C?^?\ C/\ PMQ/_P O#_A,_P!F_P#Z-,^#W_A-Q_\
MR71_JYEG_0NRS_P@P7_S('^LV-_Y_P",_P#"W$__ "\/^$S_ &;_ /HTSX/?
M^$W'_P#)='^KF6?]"[+/_"#!?_,@?ZS8W_G_ (S_ ,+<3_\ +P_X3/\ 9O\
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M]7,L_P"A=EG_ (08+_YD#_6;&_\ /_&?^%N)_P#EX?\ "9_LW_\ 1IGP>_\
M";C_ /DNC_5S+/\ H799_P"$&"_^9 _UFQO_ #_QG_A;B?\ Y>'_  F?[-__
M $:9\'O_  FX_P#Y+H_U<RS_ *%V6?\ A!@O_F0/]9L;_P _\9_X6XG_ .7A
M_P )G^S?_P!&F?![_P )N/\ ^2Z/]7,L_P"A=EG_ (08+_YD#_6;&_\ /_&?
M^%N)_P#EX?\ "9_LW_\ 1IGP>_\ ";C_ /DNC_5S+/\ H799_P"$&"_^9 _U
MFQO_ #_QG_A;B?\ Y>'_  F?[-__ $:9\'O_  FX_P#Y+H_U<RS_ *%V6?\
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MP]7$2PN PRYL3C<0J,)NCA,/%WKXFJH4:2UJ5(IHXZNLY0H * "@ H @N?\
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M&4))QE&47:491=FI)JS35T]':S.7\7_\@*__ .O:?_T6U<F._P!UQ'_7F?\
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ME6&EE#S:G45&I6IRQL)5,=@OT*\*?"+]D;]C#X_?\%%?A;X5_98U.3PA;?\
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M>K_%3Q)\6[2]F^&]_:VFF^*1XA\4QPWD&K:G&LUQJ%IIEGI6BQ&\%G:Z8OV
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MZ[;W7P[DM[7PKX.T30X[?4(M)@T>UO=9N(X=,U&]UEIFOM-GZ/#''\3Y/@_
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M^RYX:^$GPU^(WCKP?K?PB^'W@YC-H_Q$\1-\+]%U3Q!K6MWZ3Q6[W.IZ-?\
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MC*-2+Q^7<-YK"EBZ4>0_9L_X)D?LK:;X7_:9^(WQ,_9U\6_&[Q-X-_:W\=?
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MEG^&UPV>2I*@Z;SC#M+V&9N#QM*UX5X6-?[=SM8C#8M9SFJQ6#RFOD.#Q/\
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M^27R?_L?4/\ U6YB?J/@9_R4>:_]B.?_ *L,&?VY_MN_\F<_M3?]F^_%[_U
MM>K^5\C_ .1UE'_8TR__ -2Z1_26;?\ (JS/_L7XW_U&JG^5?I'_ "#[;_KF
MO_H*U_I6MEZ(_P _8_:_Q,WM.U'4-'U"QU;2;^\TO5=+O+;4=,U/3KJ>QU#3
MM0LIH[FSOK&]MI(KFTO+2XBCN+:YMY8YX)HXY8I$=59:3:=TVFNJ=G]Z"<(5
M83IU(1J4ZD90G"<5.$X25I0G&5XRC)-J46K-.SO<ZS5/B=\2=<\?M\5];^(7
MCC6/BDVNV/BAOB5JGBS7M0\?MXETR6WGTWQ$WC&[U";Q$==T^>SM)K'5CJ7]
MH6DMK;R07,;P1LO%@LNR_+<$LMR[ X/ 9=&GB:2P&"PM#"X)4L8ZLL936%H4
MZ=!4\7+$5WB8*GRUW6JNJINI-R[<?C\=FN)GC,TQN+S+&5(4*=3%8_$UL9B:
ME/"T*6&PT)U\1.K5E##8:A1P]",I.-&A1I4J?+3A!&SJ/QP^-6L0_$>WU?XO
M_%'58/C%>Z9J7Q<@U'X@>++Z'XIZCHMX^H:-?_$>.YU:5/'%[I%_))?:9=>)
MAJ<]A>.]S:/#,S/7-3R+)*-+*J%')LJI4,BK8G$Y)1IY?A(4LFQ&-A[+&5\J
MIQHQAEU;%TFZ>)JX2-*=>#Y*KE%V.JIGN=U<3CL;5SC-:F,S3!4\MS/%U,PQ
M<\3F.74:<*-' 8ZO*JZN,P5*C3I4J>%Q$IT*=.G"G"FH1BH]?X9_:Q_:G\%^
M'?#_ (0\'?M+?M >$O"?A/[7_P (MX7\,_&3XBZ%X=\-?;[6]LK_ /X1_1-*
M\1VFFZ-]MLM1U"TN_P"SK:W^TVM]>V\V^*ZG27''\,\-YK6Q6(S3A_),RKXW
M#?4L97Q^4X#&5L7@[T9?5,55Q&'J3KX;FP^'E["JYTKT*+Y&Z4'%X#/\]RNE
M1H99G6;9=0P^,CF&'HX#,L9@Z5#'P]IRXZC3P]:G"EC(^UJ\N)A%5H^TJ6J+
MGGS<G<_'3XVWOPUM_@Q>?&+XJ7?P>M+S^T+3X47/Q"\6S_#6UO\ [7+?_;K?
MP++J[>%X;S[=//>_:8]*2;[7-+<[A-([OT5,ER>KF5+.:N4Y94SBA25&AFM3
M 86>94:,:/U>-*ECI4WBJ=*-!*BJ<*J@J*]FDH>[+*EG&;T,%BLMH9IF-'+L
M=4JU<;@*6.Q5/!8RK7K1Q%:KBL+"K&AB*E;$1C7JSJTYRJ5HQJ2;G%..AJ?[
M1?[0>M?#:R^#.L_';XR:M\']-BL[?3OA3J?Q/\;7_P -K"#3YOM%A#9>!;K7
M)?"]K%8SYGLXX-+1+:8^;"$?+-$\AR.IFBSRIDN4U,Z4W46;SR[!RS15)4_8
MN:S"5%XOG=']TY>UYG3_ ';M%\I5#.\YPV J95ALWS/#Y75A4IU<MH8_%TL!
M4IUI^UJPJ8.%:.'G"K4O4J1E3E&<_?DG+4\CM+N[T^[M;^PNKBROK*X@N[*]
MM)Y+:[M+NVD6:VNK6YA9)K>XMYD26">)TDBD19(V5U!KV(RE"49PE*$X24HS
MBW&491=U*,E9J2>J:=T]5;0\FK2IUJ=2C6IPJTJL)4ZM*K"-2G4ISBXSIU(2
M3C.$XMQE&2<91;333:.@\:>./&OQ(\3ZOXW^(GB_Q1X]\9Z_/%<Z[XN\:>(-
M6\4^)]:N8+:&SAN-7U_7+N_U74IXK2VM[6*6\NYWCMK>&!6$42(O#@,NR_*L
M+3P.5X'!Y;@J4JTZ6#P&%HX/"TYXBM4Q.(E3P^'A3HPE7Q%:K7K2C!.I6JU*
ML^:<YR._'YAC\TQ,L;F>.QF8XR=.A2GB\?B:V+Q,Z6%H4\-AJ<J^(J5:LJ>'
MPU&CAZ$'-QI4*5.E3480C Y"Y_X]Y?\ <-=4MOO_ /29'(MUZH_L0_X-(?\
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MCL%.I.>$Q<(QKX:4YNC5IN4G+JP>,Q>78AXS+\5B<#BY83%X"6*P=>KA<1+
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M)\??&CXL^./B+X<^Q?\ "/>/O%_Q&\8>)?&N@_V;/]JT[^QO%.LZQ?:[I?\
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MK4J<KG-ZRDW;E\/\3^*/$WC;Q#K/B[QGXBUWQ;XK\1ZC=:QXA\3^)]7O]?\
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MQWWT/_E@?\0,Q'_0UP_W5O\ Y6'_ !#O?ME_]#'X(_\  O7_ /YFZ/\ B83
M?]"K'??0_P#E@?\ $#,1_P!#7#_=6_\ E8?\0[W[9?\ T,?@C_P+U_\ ^9NC
M_B83 ?\ 0JQWWT/_ )8'_$#,1_T-</\ =6_^5A_Q#O?ME_\ 0Q^"/_ O7_\
MYFZ/^)A,!_T*L=]]#_Y8'_$#,1_T-</]U;_Y6'_$.]^V7_T,?@C_ ,"]?_\
MF;H_XF$P'_0JQWWT/_E@?\0,Q'_0UP_W5O\ Y6'_ !#O?ME_]#'X(_\  O7_
M /YFZ/\ B83 ?]"K'??0_P#E@?\ $#,1_P!#7#_=6_\ E8?\0[W[9?\ T,?@
MC_P+U_\ ^9NC_B83 ?\ 0JQWWT/_ )8'_$#,1_T-</\ =6_^5A_Q#O?ME_\
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M?_+ _P"(&8C_ *&N'^ZM_P#*P_XAWOVR_P#H8_!'_@7K_P#\S='_ !,)@/\
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MKTL+2ITI1J<T50P]*E)R:C)7E*,FK;1M>[;Y?#?^(=[]LO\ Z&/P1_X%Z_\
M_,W7UO\ Q,)@/^A5COOH?_+#YG_B!F(_Z&N'^ZM_\K#_ (AWOVR_^AC\$?\
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MZ%6.^^A_\L#_ (@9B/\ H:X?[JW_ ,K#_B'>_;+_ .AC\$?^!>O_ /S-T?\
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M 3"^@_*@ POH/RH ,+Z#\J #"^@_*@ POH/RH ,+Z#\J #"^@_*@ POH/RH
M,+Z#\J #"^@_*@ POH/RH ,+Z#\J #"^@_*@ POH/RH ,+Z#\J #"^@_*@ P
M/0?E0 M "8!Z@?EG_/\ GTH ,+Z#\J #"^@_*@ POH/RH ,+Z#\J #"^@_*@
M POH/RH ,+Z#\J #"^@_*@ POH/RH 7 '3_#_/\ GUH * $P/0?E0 87T'Y4
M &%]!^5 !A?0?E0 87T'Y4 &%]!^5 !A?0?E0 87T'Y4 &%]!^5 !A?0?E0
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MB*> O_#YZ_\ _./H_P")>G_T553_ ,,4?_GR'_$:X?\ 0@I_^'BI_P#.8/\
MB(F\-?\ 1%/ 7_A\]?\ _G'T?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\
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M_P#HJJG_ (8H_P#SY#_B-</^A!3_ /#Q4_\ G,'_ !$3>&O^B*> O_#YZ_\
M_./H_P")>G_T553_ ,,4?_GR'_$:X?\ 0@I_^'BI_P#.8/\ B(F\-?\ 1%/
M7_A\]?\ _G'T?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\ YS!_Q$3>&O\
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M?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\ YS!_Q$3>&O\ HBG@+_P^>O\
M_P X^C_B7I_]%54_\,4?_GR'_$:X?]""G_X>*G_SF#_B(F\-?]$4\!?^'SU_
M_P"<?1_Q+T_^BJJ?^&*/_P ^0_XC7#_H04__  \5/_G,'_$1-X:_Z(IX"_\
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MU_T13P%_X?/7_P#YQ]'_ !+T_P#HJJG_ (8H_P#SY#_B-</^A!3_ /#Q4_\
MG,'_ !$3>&O^B*> O_#YZ_\ _./H_P")>G_T553_ ,,4?_GR'_$:X?\ 0@I_
M^'BI_P#.8/\ B(F\-?\ 1%/ 7_A\]?\ _G'T?\2]/_HJJG_ABC_\^0_XC7#_
M *$%/_P\5/\ YS!_Q$3>&O\ HBG@+_P^>O\ _P X^C_B7I_]%54_\,4?_GR'
M_$:X?]""G_X>*G_SF#_B(F\-?]$4\!?^'SU__P"<?1_Q+T_^BJJ?^&*/_P ^
M0_XC7#_H04__  \5/_G,'_$1-X:_Z(IX"_\ #YZ__P#./H_XEZ?_ $553_PQ
M1_\ GR'_ !&N'_0@I_\ AXJ?_.8/^(B;PU_T13P%_P"'SU__ .<?1_Q+T_\
MHJJG_ABC_P#/D/\ B-</^A!3_P##Q4_^<P?\1$WAK_HBG@+_ ,/GK_\ \X^C
M_B7I_P#155/_  Q1_P#GR'_$:X?]""G_ .'BI_\ .8/^(B;PU_T13P%_X?/7
M_P#YQ]'_ !+T_P#HJJG_ (8H_P#SY#_B-</^A!3_ /#Q4_\ G,'_ !$3>&O^
MB*> O_#YZ_\ _./H_P")>G_T553_ ,,4?_GR'_$:X?\ 0@I_^'BI_P#.8/\
MB(F\-?\ 1%/ 7_A\]?\ _G'T?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\
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M_P#HJJG_ (8H_P#SY#_B-</^A!3_ /#Q4_\ G,'_ !$3>&O^B*> O_#YZ_\
M_./H_P")>G_T553_ ,,4?_GR'_$:X?\ 0@I_^'BI_P#.8/\ B(F\-?\ 1%/
M7_A\]?\ _G'T?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\ YS!_Q$3>&O\
MHBG@+_P^>O\ _P X^C_B7I_]%54_\,4?_GR'_$:X?]""G_X>*G_SF#_B(F\-
M?]$4\!?^'SU__P"<?1_Q+T_^BJJ?^&*/_P ^0_XC7#_H04__  \5/_G,'_$1
M-X:_Z(IX"_\ #YZ__P#./H_XEZ?_ $553_PQ1_\ GR'_ !&N'_0@I_\ AXJ?
M_.8/^(B;PU_T13P%_P"'SU__ .<?1_Q+T_\ HJJG_ABC_P#/D/\ B-</^A!3
M_P##Q4_^<P?\1$WAK_HBG@+_ ,/GK_\ \X^C_B7I_P#155/_  Q1_P#GR'_$
M:X?]""G_ .'BI_\ .8/^(B;PU_T13P%_X?/7_P#YQ]'_ !+T_P#HJJG_ (8H
M_P#SY#_B-</^A!3_ /#Q4_\ G,'_ !$3>&O^B*> O_#YZ_\ _./H_P")>G_T
M553_ ,,4?_GR'_$:X?\ 0@I_^'BI_P#.8/\ B(F\-?\ 1%/ 7_A\]?\ _G'T
M?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\ YS!_Q$3>&O\ HBG@+_P^>O\
M_P X^C_B7I_]%54_\,4?_GR'_$:X?]""G_X>*G_SF#_B(F\-?]$4\!?^'SU_
M_P"<?1_Q+T_^BJJ?^&*/_P ^0_XC7#_H04__  \5/_G,'_$1-X:_Z(IX"_\
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MU_T13P%_X?/7_P#YQ]'_ !+T_P#HJJG_ (8H_P#SY#_B-</^A!3_ /#Q4_\
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M1_\ GR'_ !&N'_0@I_\ AXJ?_.8/^(B;PU_T13P%_P"'SU__ .<?1_Q+T_\
MHJJG_ABC_P#/D/\ B-</^A!3_P##Q4_^<P?\1$WAK_HBG@+_ ,/GK_\ \X^C
M_B7I_P#155/_  Q1_P#GR'_$:X?]""G_ .'BI_\ .8/^(B;PU_T13P%_X?/7
M_P#YQ]'_ !+T_P#HJJG_ (8H_P#SY#_B-</^A!3_ /#Q4_\ G,'_ !$3>&O^
MB*> O_#YZ_\ _./H_P")>G_T553_ ,,4?_GR'_$:X?\ 0@I_^'BI_P#.8/\
MB(F\-?\ 1%/ 7_A\]?\ _G'T?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\
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M_P#HJJG_ (8H_P#SY#_B-</^A!3_ /#Q4_\ G,'_ !$3>&O^B*> O_#YZ_\
M_./H_P")>G_T553_ ,,4?_GR'_$:X?\ 0@I_^'BI_P#.8/\ B(F\-?\ 1%/
M7_A\]?\ _G'T?\2]/_HJJG_ABC_\^0_XC7#_ *$%/_P\5/\ YS!_Q$3>&O\
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M@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z
M#+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,
MMZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RW
MJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I
M_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\
MZ #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH
M ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@ RWJ?SH ,MZG\Z #+>I_.@
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M#ESX1BT:+4-6M;H:KH>K:7:WVK)J6L^/E&09KEO#'BUG&0Y)Q)E6&Q'!3R7
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M 0J+$U<NI4,%C\=A:L9X/'YIA:-+#YIC,/7Q^&H8?#UZ6'H?)5?>'Y^% !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % &=JO_'A<?[A_D:SJ?"_\+_- ?Z;/_!([_E&I^Q1_
MV;G\*O\ U$-*K_./BS_DJN)O^R@SG_U8XD_O3AC_ ))KA[_L1Y3_ .H&'/T8
MKY\]P* "@ H _]/Z#_X./OV:_CY\6_V[/@UXT^&?PA^(/CGPGI?[.%MX?O\
MQ#X6\+:OKFEV>NQ_$+QAJ#:1<7.G6MPL=\+*^M+HP,5807$4AR&%?N'@IQ+D
MW#6+X@KYOC*6$CB</E].@JCLZLH5,5*?+WY%*+EKIS+25_=_(/%OAS-.(\)D
MN'RS#3Q#H8G&5:[A%R5.,J>'4.:S3O-Q:CH]G>UD?A!_PQM^UM_T;U\7O_#<
M^+/_ )6G^?YU_0?_ !%G@W_H;8;_ ,#/Q/\ XA=Q7_T!5_\ P3_]NOR^X/\
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M (&'_$+N*_\ H"K_ /@G_P"Z!_PQM^UM_P!&\_%[_P -SXL_^5M'_$6>#?\
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MO_0VPW_@8?\ $+N*_P#H"K_^"?\ [H'_  QM^UM_T;S\7O\ PW/BS_Y6T?\
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M(7<5_P#0%7_\$_\ W0/^&-OVMO\ HWGXO?\ AN?%G_RMH_XBSP;_ -#;#?\
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M  QM^UM_T;S\7O\ PW/BS_Y6T?\ $6>#?^AMAO\ P,/^(7<5_P#0%7_\$_\
MW0/^&-OVMO\ HWGXO?\ AN?%G_RMH_XBSP;_ -#;#?\ @8?\0NXK_P"@*O\
M^"?_ +H'_#&W[6W_ $;S\7O_  W/BS_Y6T?\19X-_P"AMAO_  ,/^(7<5_\
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M&_\  P_XA=Q7_P! 5?\ \$__ '0/^&-OVMO^C>?B]_X;GQ9_\K:/^(L\&_\
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M ,K:/^(L\&_]#;#?^!A_Q"[BO_H"K_\ @G_[H'_#&W[6W_1O/Q>_\-SXL_\
ME;1_Q%G@W_H;8;_P,/\ B%W%?_0%7_\ !/\ ]T#_ (8V_:V_Z-Y^+W_AN?%G
M_P K:/\ B+/!O_0VPW_@8?\ $+N*_P#H"K_^"?\ [H'_  QM^UM_T;S\7O\
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M^ 4- !_PA'A#_H6](_\  *&@ _X0CPA_T+>D?^ 4- !_PA'A#_H6](_\ H:
M#_A"/"'_ $+>D?\ @%#0 ?\ "$>$/^A;TC_P"AH /^$(\(?]"WI'_@%#0 ?\
M(1X0_P"A;TC_ , H: #_ (0CPA_T+>D?^ 4- !_PA'A#_H6](_\  *&@ _X0
MCPA_T+>D?^ 4- !_PA'A#_H6](_\ H: #_A"/"'_ $+>D?\ @%#0 ?\ "$>$
M/^A;TC_P"AH /^$(\(?]"WI'_@%#0 ?\(1X0_P"A;TC_ , H: #_ (0CPA_T
M+>D?^ 4- !_PA'A#_H6](_\  *&@ _X0CPA_T+>D?^ 4- !_PA'A#_H6](_\
M H: #_A"/"'_ $+>D?\ @%#0 ?\ "$>$/^A;TC_P"AH /^$(\(?]"WI'_@%#
M0 ?\(1X0_P"A;TC_ , H: #_ (0CPA_T+>D?^ 4- !_PA'A#_H6](_\  *&@
M _X0CPA_T+>D?^ 4- !_PA'A#_H6](_\ H: #_A"/"'_ $+>D?\ @%#0 ?\
M"$>$/^A;TC_P"AH /^$(\(?]"WI'_@%#0 ?\(1X0_P"A;TC_ , H: #_ (0C
MPA_T+>D?^ 4- !_PA'A#_H6](_\  *&@ _X0CPA_T+>D?^ 4- !_PA'A#_H6
M](_\ H: #_A"/"'_ $+>D?\ @%#0 ?\ "$>$/^A;TC_P"AH /^$(\(?]"WI'
M_@%#0 ?\(1X0_P"A;TC_ , H: #_ (0CPA_T+>D?^ 4- !_PA'A#_H6](_\
M *&@ _X0CPA_T+>D?^ 4- !_PA'A#_H6](_\ H: #_A"/"'_ $+>D?\ @%#0
M ?\ "$>$/^A;TC_P"AH /^$(\(?]"WI'_@%#0 ?\(1X0_P"A;TC_ , H: #_
M (0CPA_T+>D?^ 4- !_PA'A#_H6](_\  *&@ _X0CPA_T+>D?^ 4- !_PA'A
M#_H6](_\ H: #_A"/"'_ $+>D?\ @%#0 ?\ "$>$/^A;TC_P"AH /^$(\(?]
M"WI'_@%#0 ?\(1X0_P"A;TC_ , H: #_ (0CPA_T+>D?^ 4- !_PA'A#_H6]
M(_\  *&@ _X0CPA_T+>D?^ 4- !_PA'A#_H6](_\ H: #_A"/"'_ $+>D?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@#_];^A_\ X+*?M^_'3]B?QE^R-IOPAUNWT?0OBEJ'Q>'Q%A_L'PQJ
M^J:G8>$[+P ^C)I%YXGT37;72KFREU_4IBT=H4O2Z0W/R)')%^R^!?!V1<<\
M:U<DXAPU3%8!9)CL9&G2Q-?"R6)HXC TZ<W4P\Z=1Q4:]5.'-RN]W?E2/Y^^
MDIQ_Q+X;>'='B/A7%TL%F3XBRW 3JU<)A<9&6$Q&$S*K6IJEC*->C&4IX>BU
M4]FY146E;F9\'^#?^"OWQ^\?^*O"W@CPI\2?&6I^*?&>O:+X8\.:0W@[X'V+
MW^O>(+^VTO2=/:]U#X>6NFVC75_=P6YN;V\M[* OYEQ<PP*\J_UYC/HY>%&
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MQ>_Z*UXP_P#"$^#O_P [.C_B6GPO_P"A/B/_  \YM_\ -P?\3D>,'_0]I_\
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MH8:G)T<ZS+"T8QHX:E1HQ5+#4*-+FA2A[1P=245.4C]$J_/#]7"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MIZ/X]^&^@>$_#5C;^&+C6+6?3[%[SPMI4'C&QTV*6_M]831K+4Y_&X@XCRO
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MZM['1?NN31;'YM](:567BWFDL1S?7)<,^&<LPYW)U?[4?AAP>\T]LYMR=?\
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M_P!FTJ4YU,=R2^JPJV]WY,\4?M__  4DG^"/B'X,_$G]FOXV_!GX@_%'Q_\
M#[XJ_&G0OVN/@7HGA3X,Z?\ #CX2>-_BGXFURW2[U^_C^*&M:%;^#O*\5^ _
M"FHVWB/P=X6N-7^(FOK;>%O"NL3*J"7UJ#Q\O[/R>MPAGG%6$SJHO:T,7_9F
M<<.9-@L/1HQY9RRS,<7G\L/6XC526597CZ&!RW%R>,SO+Z<MJU.K]6Q4,%2G
MCL\PG%/"_#-7(81=/$PK<1U\92G[:M)2CA\TPT<-"I@,AJT_[2SZ56='+:<I
MX:H?7MQ\2?AW:7'@*SN_'W@NUN_BK-+;_"^UN/%.APW'Q(N(/#M[XOG@\!02
M7RR^,)H?"6G:AXHEB\/+J+Q^';"]UMPNFVL]RFE3#XBEC,7EU6A6IYA@,-C,
M9CL!4I3AC,%@\NQN!R[,,7B\+**KX;#8',,RR[ 8RO6A3I8;&X_ X6O.G7Q5
M"$^:GB</5P-#-*5>C4RW%5L#A\+F-.K">!Q%?,Z5:OEM&ABXMX>M6S&AAL16
MP-.G4E/%TL/6J4%.%*;/-?A[^U?^RW\6_B%XJ^$?PI_:4^ /Q-^*W@4W@\;?
M#'X>_&/X=^,_B%X..GW7V&_'BKP7X<\1ZEXD\/FQOO\ 0[P:MIMF;:Z_T>;9
M-\C8X1?VA@99I@/]MRV#IJ6883_:<#%UI3C24L71YZ$75E3J1IIS7/*$U"[C
M-1VQ?^P8RGE^._V+'U8RG2P.+_V;&58PITZTY4\-6Y*TXPI5:564HPDHTZM.
M;]R<9'OU !0 4 % 'Y5_MO\ _!470/V,/C;X#^!EQ\&/$7Q/\2>/_A\GC_2[
MK2/%^C^&K=(&\0Z[X?.D"+4M,O6N+X2:'+=(5EC$R3I#%&TJ'=^Q^%OA!C/%
M"CFM7"9[@LG>5U:%.4,9A:]=5U6A*?-"5&<>5P4=8R6JU35GS?S_ .-7CY@/
M!C$9'0QW#.8\0+.Z6(J4YY?C<-AGAY4*D8*%2&(I3YE4YO=G&2M)*#3<HL^:
M_P#A]OJW_1E/Q(_\.9X8_P#F>K]9_P")2,Y_Z+?(_P#PW8W_ .7GX?\ \3T9
M'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=
MC?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG
M_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^
M9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/
MQ(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^
M'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B
M;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9
M'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=
MC?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG
M_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^
M9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/
MQ(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^
M'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B
M;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9
M'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=
MC?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG
M_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^
M9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/
MQ(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^
M'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B
M;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9
M'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=
MC?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG
M_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^
M9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/
MQ(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^
M'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B
M;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9
M'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=
MC?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG
M_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^
M9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/
MQ(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^
M'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B
M;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG_HM\C_\ #=C?_EX?\3T9
M'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^9ZC_ (E(SG_HM\C_ /#=
MC?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H#_A]OJW_1E/Q(_\.9X8_P#F>H_XE(SG
M_HM\C_\ #=C?_EX?\3T9'_T;3B;_ ,.F7?\ R@/^'V^K?]&4_$C_ ,.9X8_^
M9ZC_ (E(SG_HM\C_ /#=C?\ Y>'_ !/1D?\ T;3B;_PZ9=_\H*.J?\%K-8O]
M,U&Q3]BOXC1O>V-W:([?$SPR51KBWDA5V \/9*J7!(') X[54/HE9U"<)_Z[
M9&^2496>7XU7Y6G:ZK.U[;V?H]B9_3ER*I"=-^&W$\5.$H.2S/+I-<T6K\OL
M8WM>]N:-]KK<_C=U;P?\1/A?XL\)>-/"VI>(OA?\:/AAJFF^(/"_B71YY--U
M[0];T\*]O<6\ZYCO-.U&U:2QU*PN4N]$\2:#>WVC:M:ZAH^HWEG<?U!QIX?Y
M3QIP_++<SH0J2=*T*L.7VU"O33C"OAZKYN2K#[,E=.-Z<^:$I1/XO\./%?//
M#GBM9IE6)J4J2Q#]KAJRJ*C7PU62E4PV+H-P=2A53NX^[*+Y*U&<9QA4/[<O
M^"3/_!6;P9^W;X.;X;_$A-(^'W[57@'3(6\=> TG>UTGQ?IT<OV5?B!\,AJ5
M[=:EJOA2Y?[,FM:;-+=:OX%UF\@T36Y[ZPOO#/B?Q/\ YK\=<"YQP)G%3+<R
MIRGAYRG+ X^,&J.,HQ>ZTM"O!-*M1;O"6J<X2A.7^P'AQXD9!XEY#1SC)JT8
M8B$:<<RRV52,L3E^(DOAE:WM,/5<92PV)C%1K034HTZU.K2A^TU?$GZ$% !0
M 4 % 'G]U_R5#1/^Q)\1_P#IY\-4 >@4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!Y9X:_Y*?\ $3_L'>%?_1.H4 >IT % !0 4 % '_]#].?\ @Y<_Y'7]
MA#_KK^T+_P"D'PHK^COHN?\ )S*G_9-YE_ZF98?R5]-'_DSM+_LK<H_]0,X/
MYUJ_T<G\3^7Y'^0@5(!0!ZGX:^+GB3PK\*_BA\(=/LM$F\-?%K5?A]J_B.^O
M+:_DURRN?AM>:]?:&FB7,&I6]A;07<OB*]75EO\ 3=2DGCBM19RV+),\_AYE
MP_@\TSGAG/,15Q4,7PK4SRIE].C.E'#UI9_@<-E^,6-A.C4JU%3HX6$L-["M
MAG"JYNJZT'&$?I\EXLS'(L@XRX=PE'!5,%QQ@,FR[-JN)IUYXK#T,CSW"<0X
M2>73I8BC1I5:F-P5*EB)8FCBX3PLJD*5.C5<:\:'PM^%7CGXS>+H? WP\TS3
M]4\13:3K^O-%JWB;PMX.TFST3PMHM]XB\0ZMJGB;QIK/A_PSH^G:3HFFWVH7
MEWJNKV<"06[@2&0HC;YWG>6\.Y9B,XS>O/#8##5,%1JU:6%Q>-K.MF./PN5X
M&C1P> P^*QF)KXK,,;A<+1HX;#UJDZE:/NJ*E*''PWPYG'%V>Y?PUP_A(X[.
M<T>-^I86>+P>!IU(Y;EF-SC'3J8S,<3A,#AJ6%RS+L=C*M7%8JA2C2P\_?<W
M"$M_XF? 7XF?"32/#OB+Q?I_A>Z\,>++O5M/\/\ BSP%\2?AI\6?"-_JFA+9
MR:QHW_"6?"KQ=XS\.VNN:;#J6GW-WHE[J=OJT-I?6EVUG]FN(96X<FXLR3/<
M9B\NP-7,*.8X+#X;&8C+\WR3/.'\>L%BZE>CA\;2P6?Y;EF)Q&#JU\+B*"Q>
M&I5L,J]&I1E5C5BX1]?B#@'B;AK*\)GF8T,JQ.2XW,,1E-'-N'^)N&.+,LAF
MN&PU#&5<MQ>.X6SC.<-E^8/!XFCBZ.#Q]3#8C$X9SKX:G5I4:\X>.5]&?&A0
M 4 >J?#3XO>)OA;IOQ0T?0[/1=2TKXN?#?5/ACXML-=@U"XM_P"Q=0U?1-?M
MM4TX:=J>ER6^OZ)K?A[2]2T>[N)+RQBGA>.]TV^MII;=_"SWA_!<01R=8RIB
M:-3(N(<MXER^OA)T85H8_+88NA&G-UJ&(C+"8S!X[&8+&TU"-2>'Q$_8UJ%:
M-.M#ZCA/BW,N#L5G>*RRC@\0^(.$N(^"\RHX^GB*E"KD_$V$AA\6XK#8K"U(
MXK"8C#X+,\OJ2J3HT\QP&$J8C#XG#PK8:OC>*OAIXV\$^'OA]XJ\4:+_ &7H
M/Q3\/W_BKP'>G4M(O&UW0-,\0:IX6O=1-E87]U?Z6D>O:+J=BD&M6NG75Q]E
M:ZMH);.6&XEZ<'G668_,LYRG"8GVV8</UL#A\WH>QQ$%A*V99=A\UP5/VU2E
M##XAU<OQ6'Q#^K5:RI>U5.M[.LI0./&\-YUEV0\/<3XS!^QR/BN6=PR#&_6<
M)4_M!\.YD\HSFV&I5YXS#+!YBI87FQF'P\<1*,YX1UZ49S.$KU#PSI/!WA'Q
M%\0/%WACP+X1TYM8\5^,_$&C^%O#6E+<V=D=2U[7]0M]+TFQ%YJ-Q::?:?:[
MZZ@@^U7UW:V=OO\ -NKB&!7D7FQN+PV78+'9CC*BHX++<#C,RQM=QG-4,%E^
M&JXS%UG"G&I5J>QP]"K4]G2IU*L^7DITYS<82Z<'A,1F&,P>7X.FZV,S#&87
M 8.@I0BZ^+QM>GA<+14JDH4XRK5ZM.G&4YP@G*\I1BFS1\0?#_Q'X7T^YU'6
MV\-VWV/Q9K?@F]TJW\;^"M3\3V>O^'MHU3[7X0TOQ#>^*K71%D8P67BJ?18O
M"NK7,<]KI&LWUS;W$47'@<ZP&8SPD<&\;5ACLIPV=X7$O*\TI8&KE^+ERX>^
M85L%2P-/'3352655<3#-:5"4<16P4*$XS/8S?A;.,B><4\UAE^$Q.0\2XWA+
M-<O>>9'6S7#YWE\:DL9&GE.'S&KF>,RNC*E.@^(<%A*_#T\9!X&GF<\9^X.*
MKU3YX* "@#IO!?B:7P5XP\*^,8-)T;7I_"GB/1?$D&A^(X+NZ\/ZO-HFI6VI
M1:;KEK87VF7USI-[);+;ZC;VFHV-Q-:22Q17=N[K*N&*HO$X3%X6->OA98K"
M8K"QQ6%E"&*PDL30J4%BL).K3JTH8K#.I[?#3JT:M*->%.52E5@I0GMAZL:&
M)PU>IA\/BZ=#$4*]3!XN$ZF$Q<*-6%2>$Q<*=2C4GA<3&+H8B-*M1JRHU)JE
M6I5'&I%_Q$\;^(/B7XT\9_$/Q7<K>>)O'/B37/%FOW*!TBFU?Q!J-SJE^T$<
MDLTD5N+FYD6WA::4PPK'%YC!0S<.19-@>'<DRK(,MA*GE^2Y9A<KP4:CC*I]
M6P.%CAJ3JSC&$9UI0IJ56HH1]I4E*=E<]_BKBC-.-N*\^XNSN5*6:\29QCLX
MQT</&I#"T:V.Q%2N\+@J5:K7J4,#A(S6%P.'E6J_5L)2HT%.2IQ9_9%_P04_
MY1X>!_\ LH?Q@_\ 5E>)Z_S)\>/^3L<7?]?\L_\ 5)EI_LK]&?\ Y,?P)_V"
MYO\ ^M#FY^SM?D1^[!0!A^)_#6A>,_#7B'P?XHTRTUOPSXKT/5?#?B+1K^)9
MK'5M#URPGTS5M,O(6RLMK?6%S<6L\;##Q2NISDUY^;99A<ZRO,,HQT92P>9X
M+$X'$JG+DJ*EB:4Z,Y4IV?LZT%/GI5$KTZD8S5G%'7@,=B<LQV#S+!570QF
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M#_A(_$'_ $'-7_\ !C=__'Z+OLONB%Y?SS_\&2#_ (2/Q!_T'-7_ /!C=_\
MQ^B[[+[HA>7\\_\ P9(/^$C\0?\ 0<U?_P &-W_\?HN^R^Z(7E_//_P9(/\
MA(_$'_0<U?\ \&-W_P#'Z+OLONB%Y?SS_P#!D@_X2/Q!_P!!S5__  8W?_Q^
MB[[+[HA>7\\__!D@_P"$C\0?]!S5_P#P8W?_ ,?HN^R^Z(7E_//_ ,&2#_A(
M_$'_ $'-7_\ !C=__'Z+OLONB%Y?SS_\&2#_ (2/Q!_T'-7_ /!C=_\ Q^B[
M[+[HA>7\\_\ P9(/^$C\0?\ 0<U?_P &-W_\?HN^R^Z(7E_//_P9(/\ A(_$
M'_0<U?\ \&-W_P#'Z+OLONB%Y?SS_P#!D@_X2/Q!_P!!S5__  8W?_Q^B[[+
M[HA>7\\__!D@_P"$C\0?]!S5_P#P8W?_ ,?HN^R^Z(7E_//_ ,&2#_A(_$'_
M $'-7_\ !C=__'Z+OLONB%Y?SS_\&2#_ (2/Q!_T'-7_ /!C=_\ Q^B[[+[H
MA>7\\_\ P9(/^$C\0?\ 0<U?_P &-W_\?HN^R^Z(7E_//_P9(/\ A(_$'_0<
MU?\ \&-W_P#'Z+OLONB%Y?SS_P#!D@_X2/Q!_P!!S5__  8W?_Q^B[[+[HA>
M7\\__!D@_P"$C\0?]!S5_P#P8W?_ ,?HN^R^Z(7E_//_ ,&2#_A(_$'_ $'-
M7_\ !C=__'Z+OLONB%Y?SS_\&2#_ (2/Q!_T'-7_ /!C=_\ Q^B[[+[HA>7\
M\_\ P9(/^$C\0?\ 0<U?_P &-W_\?HN^R^Z(7E_//_P9(/\ A(_$'_0<U?\
M\&-W_P#'Z+OLONB%Y?SS_P#!D@_X2/Q!_P!!S5__  8W?_Q^B[[+[HA>7\\_
M_!D@_P"$C\0?]!S5_P#P8W?_ ,?HN^R^Z(7E_//_ ,&2#_A(_$'_ $'-7_\
M!C=__'Z+OLONB%Y?SS_\&2#_ (2/Q!_T'-7_ /!C=_\ Q^B[[+[HA>7\\_\
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M"/Z[5X)]*% !0 4 >?W7_)4-$_[$GQ'_ .GGPU0!Z!0 4 % !0 4 % !0 4
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M/_N8?\)-!_T!_%'_ (2VO_\ R#1_KYE'_/K%?^"JG_RL/^(4<2_SX'_PH_\
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M .""G_*/#P/_ -E#^,'_ *LKQ/7^6GCQ_P G8XN_Z_Y9_P"J3+3_ &W^C/\
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MX/ Y]5ACL[XHP>;X3"X:.9U<GI9+0HX;"XC#X?\ 8VO*-PH * "@ H * "@
MH ^;OC]^R?\  K]I6"P'Q:^&O@?QC?:7 +/3]6\1>$] UO5K.Q$\ES]AM-1U
M/3[N[MK/[1--/]FBE6#SI99?+#R.S;TL5BJ$91H8FO1C)J4HTJU2G&4EHG)0
ME%-I:)M:>6G-S5\%@\3*,\3A,-B)P3C"=>A2JRA%N[C&4X2E%-J[2<4WJ[V]
MWY0_X=$_L3_]$3^&_P#X0WA;_P"5-:_VCC_^@[&?^%-?_P"6&/\ 965_]"W
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M_E31_:./_P"@[&?^%-?_ .6!_965_P#0MP'_ (24/_E8?\.B?V)_^B)_#?\
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M_P#+ _LK*_\ H6X#_P )*'_RL/\ AT3^Q/\ ]$3^&_\ X0WA;_Y4T?VCC_\
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M *%N _\ "2A_\K#_ (=$_L3_ /1$_AO_ .$-X6_^5-']HX__ *#L9_X4U_\
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MW_\ "&\+?_*FC^T<?_T'8S_PIK__ "P/[*RO_H6X#_PDH?\ RL/^'1/[$_\
MT1/X;_\ A#>%O_E31_:./_Z#L9_X4U__ )8']E97_P!"W ?^$E#_ .5A_P .
MB?V)_P#HB?PW_P#"&\+?_*FC^T<?_P!!V,_\*:__ ,L#^RLK_P"A;@/_  DH
M?_*P_P"'1/[$_P#T1/X;_P#A#>%O_E31_:./_P"@[&?^%-?_ .6!_965_P#0
MMP'_ (24/_E8?\.B?V)_^B)_#?\ \(;PM_\ *FC^T<?_ -!V,_\ "FO_ /+
M_LK*_P#H6X#_ ,)*'_RL/^'1/[$__1$_AO\ ^$-X6_\ E31_:./_ .@[&?\
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M#E*A1^KX/+,LS:EA<5E."6*EBL1+!O X-SQ=?$XRK2EB,56K5?TEKN/Y\"@
MH * "@#RSPU_R4_XB?\ 8.\*_P#HG4* /4Z "@ H * "@#__T_TY_P"#ES_D
M=?V$/^NO[0O_ *0?"BOZ.^BY_P G,J?]DWF7_J9EA_)7TT?^3.TO^RMRC_U
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M8*OG?A5A?">OQ!D6!SW"Y5DWB'0XLX[RW,L+A,TP^.PE?$PX/P&!P=:-7VV
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M97@H5L56G7J0P>699AL'EV786,ZCCA\#E^$PN"PE%0P^$PU"A3A2C2^TP?\
M/6/_ +[6MN>/\\?OB<OL*W_/N?W!]I@_YZQ_]]K1SQ_GC]\0]A6_Y]S^X/M,
M'_/6/_OM:.>/\\?OB'L*W_/N?W#))X6C<"6,DJ< ,O/MV_SZ]*.>-G[T?AEU
M79]K?UWV*A1JJ46Z<TD]78_M4_X(*?\ */#P/_V4/XP?^K*\3U_EMX\?\G8X
MN_Z_Y9_ZI,M/]L_HS_\ )C^!/^P7-_\ UH<W/V=K\B/W8* "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MZ=_T(?C?_P %UI_\LJ #_AI73O\ H0_&_P#X+K3_ .65 !_PTKIW_0A^-_\
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M_#/_ $<7\9?_  /^&O\ \Z^C_B/7B3_T.*7_ (3R_P#E@?\ $K?@Y_T3L_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S6^*7_!3'X/\ P+_;
MLT#]BOXQPCP8WQ#^%_@7QK\,?B;<7;/X>U;Q=XH\2^/= N_A_P")@T$</AJ\
MN(_"FG7'A+6)[N73]?U"_O/#]Q_9NJKH4>O_ %>'X/S7&\*5^+<%3>)P."S.
MOEV8TJ<&ZN$C3PV#KTL6[.\Z,WB9PJ<L;T?9J<KPE*4/BL5QWDN XVPW V/J
MK"9EF.3X;-<KJU9I4<=*KB\PPM7 QT_=XBG]2C4I<TFL3[9TX\M2%.%7])89
MHKB*.>%UEBE57CD0AE96&0002""#Z_E7RA]J24 % !0 4 % !0 4 % !0 4
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MV.+O^O\ EG_JDRT_VZ^C/_R8_@3_ +!<W_\ 6AS<_9VOR(_=@H * "@ H *
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MF?[57_AJO"W_ ,\BC_B6OQ:_Z$6&_P##EA/_ )8'_$X/@-_T5E3_ ,-N+_\
ME8?\1 /[&?\ T3/]JK_PU7A;_P">11_Q+7XM?]"+#?\ ARPG_P L#_B<'P&_
MZ*RI_P"&W%__ "L/^(@']C/_ *)G^U5_X:KPM_\ /(H_XEK\6O\ H18;_P .
M6$_^6!_Q.#X#?]%94_\ #;B__E8?\1 /[&?_ $3/]JK_ ,-5X6_^>11_Q+7X
MM?\ 0BPW_ARPG_RP/^)P? ;_ **RI_X;<7_\K#_B(!_8S_Z)G^U5_P"&J\+?
M_/(H_P"):_%K_H18;_PY83_Y8'_$X/@-_P!%94_\-N+_ /E8?\1 /[&?_1,_
MVJO_  U7A;_YY%'_ !+7XM?]"+#?^'+"?_+ _P")P? ;_HK*G_AMQ?\ \K#_
M (B ?V,_^B9_M5?^&J\+?_/(H_XEK\6O^A%AO_#EA/\ Y8'_ !.#X#?]%94_
M\-N+_P#E8?\ $0#^QG_T3/\ :J_\-5X6_P#GD4?\2U^+7_0BPW_ARPG_ ,L#
M_B<'P&_Z*RI_X;<7_P#*P_XB ?V,_P#HF?[57_AJO"W_ ,\BC_B6OQ:_Z$6&
M_P##EA/_ )8'_$X/@-_T5E3_ ,-N+_\ E8?\1 /[&?\ T3/]JK_PU7A;_P">
M11_Q+7XM?]"+#?\ ARPG_P L#_B<'P&_Z*RI_P"&W%__ "L/^(@']C/_ *)G
M^U5_X:KPM_\ /(H_XEK\6O\ H18;_P .6$_^6!_Q.#X#?]%94_\ #;B__E8?
M\1 /[&?_ $3/]JK_ ,-5X6_^>11_Q+7XM?\ 0BPW_ARPG_RP/^)P? ;_ **R
MI_X;<7_\K#_B(!_8S_Z)G^U5_P"&J\+?_/(H_P"):_%K_H18;_PY83_Y8'_$
MX/@-_P!%94_\-N+_ /E8?\1 /[&?_1,_VJO_  U7A;_YY%'_ !+7XM?]"+#?
M^'+"?_+ _P")P? ;_HK*G_AMQ?\ \K#_ (B ?V,_^B9_M5?^&J\+?_/(H_XE
MK\6O^A%AO_#EA/\ Y8'_ !.#X#?]%94_\-N+_P#E8?\ $0#^QG_T3/\ :J_\
M-5X6_P#GD4?\2U^+7_0BPW_ARPG_ ,L#_B<'P&_Z*RI_X;<7_P#*P_XB ?V,
M_P#HF?[57_AJO"W_ ,\BC_B6OQ:_Z$6&_P##EA/_ )8'_$X/@-_T5E3_ ,-N
M+_\ E9_-I_P5E_:'^'/[=W[4]E\6_A[X6\?Z-X$'P.\(?#QD^(WAVR\/ZN?$
M?A[Q5X_UJ\>*RT_6-?MC9FR\3Z?]FF-ZDLT@ND,"+$KO_3O@GX9<0<)<-9MD
MG%V74J$\RS+$XFG356EBJ4J,L'@J*YI0<H*3E1J+E:E[NMG=H_C7Z17C3PIQ
MOQCD7$? .=2QD,IR?"8.O44*F%JQK0Q^8XB7)"?+4<(PQ%%JHDK3NEMS'ZB?
M\$=_^"PFJ:)JWAC]C7]L7Q//<WMW/:Z!\#?C;X@NF?\ X2)I"\6G?#OQ_J4D
M2PVWB*&-(+'PEXHO[C'B[=%H>K3#Q:+"Y\7?SCXT>#F)X/Q=?/,CP\ZF0UIR
MGB</33D\LG*2]^*O)RPDV^B7U=Z:4;<G]>?1\\?\%X@X##</<0XJG2XFH0C3
MPN)JRC'^V(P@WR3>B6/A&.[LL8O>7[]25?\ K-BECGC2:%UDBD4.CH0RLK#(
M(()!!'O^5?SN?U424 % !0 4 % !0 4 % !0 4 % !0 4 % 'G]U_P E0T3_
M +$GQ'_Z>?#5 'H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >6>&O^2G_$
M3_L'>%?_ $3J% 'J= !0 4 % !0!_]?].?\ @Y<_Y'7]A#_KK^T+_P"D'PHK
M^COHN?\ )S*G_9-YE_ZF98?R5]-'_DSM+_LK<H_]0,X/YUJ_T<G\3^7Y'^0@
M5(!0 4 % 'UC^PP_@:/]K#X+2?$.30(= C\2W;V<OBS[)_PBT7C%-!U=OAW)
MXE^WO'8C04\?CPTVJF^=+(60F-VZVWF-7Q7B0LZEX?<91X<6*EG<LAQ4<#'
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M>)M0@B5(5\0?$#7KG6/'?B214WOJ_B&>*265;>-Z]GA?),PRWA;/LUS^-/\
MUKXJH9IQ#Q*Z;<X87&8K+94L'DF'J2O*6!X<RNA@LCP2OR2IX)XB,8SQ$SY7
MQ&XBRC,.)\@X5X3KRK<"^'T,+POPO6Y52CG$Z>8/%<0\85J%-^R6-XQS^OCL
MZJ5%"-:.7U<KP%:ZR^ER^+_M;?\ )U/[2G_9>OB[_P"I]K]='A7_ ,FQ\.O^
MR&X3_P#5%@1_2!_Y/KXR?]G0X[_]:;,SY[K[T_(0H * "@".7_5O_NFCH_\
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M>+?#'[/'B_\ ;+NOCE\"?@]\,?BOH-I\0_ _[,>O:!^T'X!^+WQ+T'XA^.?
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M5A_PO;XD_P#0;C_\ +#_ .1*.2C_ ,^5_P"#*@?6\=_T&5/_  50_P#E8?\
M"]OB3_T&X_\ P L/_D2CDH_\^5_X,J!];QW_ $&5/_!5#_Y6'_"]OB3_ -!N
M/_P L/\ Y$HY*/\ SY7_ (,J!];QW_094_\ !5#_ .5A_P +V^)/_0;C_P#
M"P_^1*.2C_SY7_@RH'UO'?\ 094_\%4/_E8?\+V^)/\ T&X__ "P_P#D2CDH
M_P#/E?\ @RH'UO'?]!E3_P %4/\ Y6'_  O;XD_]!N/_ , +#_Y$HY*/_/E?
M^#*@?6\=_P!!E3_P50_^5A_PO;XD_P#0;C_\ +#_ .1*.2C_ ,^5_P"#*@?6
M\=_T&5/_  50_P#E8?\ "]OB3_T&X_\ P L/_D2CDH_\^5_X,J!];QW_ $&5
M/_!5#_Y6'_"]OB3_ -!N/_P L/\ Y$HY*/\ SY7_ (,J!];QW_094_\ !5#_
M .5A_P +V^)/_0;C_P# "P_^1*.2C_SY7_@RH'UO'?\ 094_\%4/_E8?\+V^
M)/\ T&X__ "P_P#D2CDH_P#/E?\ @RH'UO'?]!E3_P %4/\ Y6'_  O;XD_]
M!N/_ , +#_Y$HY*/_/E?^#*@?6\=_P!!E3_P50_^5A_PO;XD_P#0;C_\ +#_
M .1*.2C_ ,^5_P"#*@?6\=_T&5/_  50_P#E8?\ "]OB3_T&X_\ P L/_D2C
MDH_\^5_X,J!];QW_ $&5/_!5#_Y6'_"]OB3_ -!N/_P L/\ Y$HY*/\ SY7_
M (,J!];QW_094_\ !5#_ .5A_P +V^)/_0;C_P# "P_^1*.2C_SY7_@RH'UO
M'?\ 094_\%4/_E9E:W\6O&WB+3+G2-8U&"]T^[55F@>PLER4=9$=)%MDDCD1
MU5E>-E8$8Z$AG&-*+O&DD^_/-[Z;/1Z$5*^+JP<*F*G.#<6XNG12?+)36JIW
M7O13NG%^>K/#?%'AC3O$VFSV-]!'*LB,/G4'!QU'!P<\\%3G!'S [O-S3*\)
MFN%JX7%4H5:=6$H2C.*E&49*S335FFO6_96][V^'\_QV08^AC,%7JT:E&I"<
M)TYRC*,HR33BXR333U37*T]4]+G]-W_!''_@L'=:OJGA?]B_]K;Q$K^._+@T
M3X+?%K4I4"_$&UM((;>P\$^+I4BQ%X\MK:*0Z9KUU*L/C6WB^SWTB>+D6;Q-
M_G+XR>$5;@G&ULWRB/M<@KU;U*,9*4\LG4DE&+U<I82I.2C3FU>E-^RDVG&9
M_KO]'_QWPWB/EN'R7.ZBH\3X:ERTZ\ER4\XITH.4I+1*..I4X.5:&BKQ3K4T
MI*I _J?1TD19(V#HZAE93E64C(((Z@C_ #Q7X&?TV.H * "@ H * "@ H *
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M#X2=6.(K8?"XFM3IRIT*DH85=1PGM4_[27[15UX+/PVN?CY\:KGX=MIXTAO
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MU? 9EE<VI2J9U+)L'#$X+'8&7UK^SL-"OAJ]*E2C4@34R_CW#X2%"K@>+Z&
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M/:J2KX;V>68JOAN3!U</"?M/;5(2Q$(5CHJU:E:64RJ2YGD7]L_V4[)?5?\
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MVV_[_1__ !RC^VLK_P"@RC_X&'^K.??]"O%_^"9?_+ _M;3?^?VV_P"_T?\
M\<H_MK*_^@RC_P"!A_JSGW_0KQ?_ ()E_P#+ _M;3?\ G]MO^_T?_P <H_MK
M*_\ H,H_^!A_JSGW_0KQ?_@F7_RP/[6TW_G]MO\ O]'_ /'*/[:RO_H,H_\
M@8?ZLY]_T*\7_P""9?\ RP/[6TW_ )_;;_O]'_\ '*/[:RO_ *#*/_@8?ZLY
M]_T*\7_X)E_\L#^UM-_Y_;;_ +_1_P#QRC^VLK_Z#*/_ (&'^K.??]"O%_\
M@F7_ ,L#^UM-_P"?VV_[_1__ !RC^VLK_P"@RC_X&'^K.??]"O%_^"9?_+ _
MM;3?^?VV_P"_T?\ \<H_MK*_^@RC_P"!A_JSGW_0KQ?_ ()E_P#+ _M;3?\
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M7=.T%)R_KET^S33[&UL8V9TM8(X%9R2Q$:A023DDG'7OU."2*_)C]Q+E !0
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MTZ1/^(\#T^**U?CO/<IS+)5E&/\ %#CW&O*:W#N)QN<YA1R?/:^23PF!S?\
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M+?QC?X<7>BP^#=,U^\U#XF^(;7P-^S+;_MAG0_CK\/\ X;_#_P 5>-=3\/\
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M%YGBFJU6HJ3I4%3H0_LT_P"""G_*/#P/_P!E#^,'_JRO$]?Y?^/'_)V.+O\
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MQ&+J8;#SQ%2I*C3Y-'Q;\</C/X_\0Z+XN\=_%_XG^-?%?AMXY/#OB?Q;X_\
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MQWK5Y>Q^%K3P6DWB1+*[4)I"7.AW?N\08W_6?/.*\]S?"86O4XRX7XGX0SK
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M/W+#T)T^(9X?-<]X8SG%9G6BH3X5X<P6!P^18S#X7+.'</B?[3S;-OK6:06
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MXX:.#J8=0IYEA<JRS*:V;2I4,1B,RHY-E& R'*\5FN QE+$\/XS,\)E&5X'
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MS7$3Q.+Q$J.#P^$P5!2E)0A1PF%P]"%.$;4W-SG+WNN0Z H * "@ H * "@
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M5H7@/0K+0- LH;.SLX4B BC5"Y50-S$8R3CDD?ED5X)]*==0 4 % !0 4 %
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MCBOAM_X4-I_\<H /^'F/[#W_ $<5\-O_  H;3_XY0 ?\/,?V'O\ HXKX;?\
MA0VG_P <H /^'F/[#W_1Q7PV_P#"AM/_ (Y0 ?\ #S']A[_HXKX;?^%#:?\
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M'PE_GS__ ,.=3_Y6'_$/[\#_ /H:?''_ (4EM_\ *:C_ (F<\1?Y<J_\)?\
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MLU4J)1Y^6KB9QBVKJ"BFYM.<OJNOGCZH* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ./\6^
MO"7CF*W@\5:+9ZQ%:L6@2[B618V/4@,& /X?G_" <)_PSO\ !O\ Z$/1/_ 6
M'_XW0 ?\,[_!O_H0]$_\!8?_ (W0 ?\ #._P;_Z$/1/_  %A_P#C= !_PSO\
M&_\ H0]$_P# 6'_XW0 ?\,[_  ;_ .A#T3_P%A_^-T '_#._P;_Z$/1/_ 6'
M_P"-T '_  SO\&_^A#T3_P !8?\ XW0 ?\,[_!O_ *$/1/\ P%A_^-T '_#.
M_P &_P#H0]$_\!8?_C= !_PSO\&_^A#T3_P%A_\ C= !_P ,[_!O_H0]$_\
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MUB4J;E"3INFISI>.?\/;_@1_T('Q+Q_V%_@S_P#/7K]D_P")5?$#_H=<(_\
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M .#?X,__ #UZ/^)5?$#_ *'7"/\ X59__P#0V'_$Z_A?_P!$_P =?^$O"O\
M]%8?\/;O@1_T('Q+_P#!O\&?_GKT?\2J^('_ $.N$?\ PJS_ /\ H;#_ (G7
M\+_^B?XZ_P#"7A7_ .BL/^'MWP(_Z$#XE_\ @W^#/_SUZ/\ B57Q _Z'7"/_
M (59_P#_ $-A_P 3K^%__1/\=?\ A+PK_P#16'_#V[X$?]"!\2__  ;_  9_
M^>O1_P 2J^('_0ZX1_\ "K/_ /Z&P_XG7\+_ /HG^.O_  EX5_\ HK#_ (>W
M? C_ *$#XE_^#?X,_P#SUZ/^)5?$#_H=<(_^%6?_ /T-A_Q.OX7_ /1/\=?^
M$O"O_P!%8?\ #V[X$?\ 0@?$O_P;_!G_ .>O1_Q*KX@?]#KA'_PJS_\ ^AL/
M^)U_"_\ Z)_CK_PEX5_^BL/^'MWP(_Z$#XE_^#?X,_\ SUZ/^)5?$#_H=<(_
M^%6?_P#T-A_Q.OX7_P#1/\=?^$O"O_T5A_P]N^!'_0@?$O\ \&_P9_\ GKT?
M\2J^('_0ZX1_\*L__P#H;#_B=?PO_P"B?XZ_\)>%?_HK&O\ \%<?@-&C22>
MOB2D:*SN[ZS\&%1$499F8_%<!54 EF)P!R<8-'_$JOB!_P!#GA'_ ,*N(/\
MZ&P?TU_"Y:OA_CI):MO"\*:?^;6?9W[+?[3/P_\ VM_A'IOQF^&EKKEEX7U/
M7O%OAV&V\11:5%J0O?!WB;5/"^HS@Z)J^MZ;-8W=YI,UUIEU;ZA*+JPFMYV2
M%Y&A7\)XOX7QW!G$68\-9EB,'BL;EDL/&O7P$\1/"3>)PF'QD52EBL-A*[Y*
M>(A"ISX>G^\C)1YH)3G_ $GP'QGEOB%PIE/&&487,,%EV<1Q<\+ALTIX6ECH
M1P>/Q67SE6A@L9C\-%5:F%G5I>SQ=5NC.DY\E1SIP^B:^;/KPH * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * .8T+QKX1\3ZIXKT3P]XDT76=8\#:Y%X:\9:5IVHVUUJ'A?Q!/HND^([?2
M-=LXW-QIE_<:!KNC:U;V]U'$\^F:I8WL.^WN(Y'UJ4*U*%&I5I5*<,33=;#S
MG"48UZ2JU*+J4I-)5(*M1K4G*-TJE.I!M2C)&-+$8>O/$4Z-:E5J82JJ&*IT
MZD)SP]>5&CB8T:\8MRI5)8?$4*\83M)T:U*HDX5(,Z>LC8* "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H \:^),GQ5U+7
M?#WAKX5^-O!'@>\ETO6M9UB^\;?#76?B1#?6]G<Z/9V=KI]MI'Q.^&ITJ2.2
M^N);F>XGU<72F".**S\J1YP#B?\ A#?VOO\ HX'X#?\ B+GC3_Z*>@ _X0W]
MK[_HX'X#?^(N>-/_ **>@ _X0W]K[_HX'X#?^(N>-/\ Z*>@ _X0W]K[_HX'
MX#?^(N>-/_HIZ #_ (0W]K[_ *.!^ W_ (BYXT_^BGH /^$-_:^_Z.!^ W_B
M+GC3_P"BGH /^$-_:^_Z.!^ W_B+GC3_ .BGH /^$-_:^_Z.!^ W_B+GC3_Z
M*>@ _P"$-_:^_P"C@?@-_P"(N>-/_HIZ #_A#?VOO^C@?@-_XBYXT_\ HIZ
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M_P#'*ZN>7?\  X/9T_Y(?^ 1#^T;_P#Y_KS_ ,"9_P#XY1SR[_@'LZ?\D/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MAHU;4I5%-Q4OI"N<W"@ H * "@ H * "@ H * "@ H _C/\ ^#@SQAKV@?\
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M>'_"R/A3_P! ?XH_^%[=T?ZLY!_T(.'/_#'@/_E ?Z\<2?\ 14\:?^))C?\
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MA_;'^$.@?%SX1>(8M5TO4XS!JNDW/DVWB'POK=O\NH>'O$VD)<W$ND:SI\A
MFM9))8YX)+?4+"XO=,O+*]N/\V<^R'-.&LTQ63YQAIX7&X6;C*,D^2K"[Y*]
M";256A52O3J1T>L6HSC.$?\ 7OAKB7)N+LFP>?9%C*>,R_&TU.$XM>THU+)U
M,-B::;='$T6^6K2DW;247*G*$Y_3]>.>\% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % 'G]U_R5#1/^Q)\1_^GGPU0!Z!0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'EGAK_ )*?\1/^P=X5_P#1.H4 >IT
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M^6&.A@\'2P>*H9UCZ>*S]YCERQ];,ZJQN:8?&^B_L@?%K]C[QB?V<-:\1_\
M!1_]KG4?^"@OB;7/AZWQG^ VI?M#_&74?B8OQ-OH=(?XC?"WXH?\$W=4_P"$
MY^%WP&^$5KK#7.B:[XNTO]G3X?V?@;PHT7B;2_C/HWVU/&]_=2AE]#-\3A^
MG0XGX<AE_$<LLQ6-Q4LZP.;970P&95,+F_$G$6*C4Q/#>=4_9PQE'"4\;PU5
M6?4L/P_#)ZT:BX>Q!5KYG/*L36XTI/AWB!8["4\5A,!265SRC-*F.P]&.6\*
MY=@ZDJ/%65I3EA\/BJN&XJI9CD\JV>XBM)T99EA/S]/[2G[75SXH\=W7C?\
M:&^#WPX_X*"I\=O'^C^"/A=XW_X*G?MH>#O%GAJVTWXC>(=,^'7@?2O^"17P
M^_X)^^//AC\8_@Q/X)M=,BF\<:#H/Q*UKXB^&&O_ (A:?^T#H6L,FM>%O%X(
M_P!HP_AXZ"_M.OF-#@V7'M./_&1XFOCLSIY/+C?*\\I8^.$H^&V(PN*KXS+J
M%6C+A?+^#ZZP6*J9KFN5RKYEG_O\6_5<)F7&\L?[? 9)EBSN?"M:@H9&Z&1X
M18ZGPKG^48G!5\P7&^8X^A#"YS6R_%2X@K9UBJM3),5PUE>+I3R'+_0?#NG?
M$1OV8OVHOVG_ (O?\%$/CO\ #WQ/X@_X*:_'[X30:=\9/VR?VGOA#^RMX9^#
MGPA_:.^(,"_LYV/Q@^%UQ-=?LF^'?B%'X?&CZ;^TI+I-OXI\,RP>$_A3X;O;
M/PWX@7P!XA\S#5<'EW!W@M5E5Q.9T\]X/J<6YV\?C/J/$7$M=9-Q3E.64,NS
M.;K8>><9'-87B; \(^VJ4^/<VP>)P.>/-L+0P57)NW&8?'X[BCQ+PTJ=#+<3
MD-#A3)<#_8F74\QRG(\9F.1^&N=9YG$\DJK#XC,,%F+S''9#C,RJPBN#\GQV
M)XNP5++,PP^:8S%_T9?L%>/XOBG^QW^S[\0('^,4MKXF^']C?65Q\?=6T_Q%
M\6+NQCN[VTL;WQ1XJTW2-"@\917MI;PW?AWQO/I-GJGC3PM-HGBG6DDU?5[Z
M9_J\_H5*&84XUJ<*5>KE>18NO1_L^ED^+HU\;D>78RM1S?)L.WA,EXAI5:\J
M?$N38!4\NRG/XYCE^74*&!PV'H4OELFK4ZV&Q;HS52C1SWB7!T*E+,J^<X"I
M0P/$6:8.C/)<XQ2^NYMP[.E0C+AO,\?.MF&/R%Y=B\?B<5C*U?$5?KJO%/6"
M@ H * "@ H _BE_X.+/^4AOP*_[--\.?^K@^+]?UO]$[_D<\4_\ 7K)/SS<_
MA+Z<O_)/<%_]?>)/_2,B/QQK^\3_ "\"@ H * "@ H * "@ H * "@ H * "
M@#E/%_BG2O"NDW-_J<\<:1QL51\%G;!VJJ=69CPJ@9/7@5Y&<YOA<HPE3$8B
M<5:+Y8O5MN]M.NJLEU?HSW^'<AQ^?9A0PF"I3G*<TG*.BBKZR<ME&/63>^BO
M[Q^U_P#P02^$?[46A?&#4/CG%J?B#P7\-_'^G16K?"Z"-(-+\5Z6K2-I?B_Q
MC:7,4PM+VP2:XD\,"U6SUEK>]N99[R/2;M[#4O\ .GQPX[RWBO,Z>!PF$P=6
MOE]>I[3,Z=+EJTDTXRP-*K&7[V/-[^(YKTH5(PC2BIJ;C_KM]'#PSSC@?))9
MAF&88^G0S3"TO9Y35JN5*L_=G#,:U&:_<R4?<PG(J=6=&I.56].5.,O[88RY
MC0R !RBEP.@8@;@/QK\$/Z;'T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 >?W7_)4-$_[$GQ'_Z>?#5 'H% 'R'\5OVG_$7A
M[XBWGP>^"'P4\1?'_P")N@Z5I^N>,],T[Q/HG@'PKX+T[5T,^CPZ_P"-_$D%
MQI<&M:M:)+>Z=HZ6[R75LH83I)NCK]JX/\)<LS/ABAQOQ]QYEGAQPIF.,Q.7
MY'B\3E./XCSC/<5@I>SQM3+<@RNI3Q=7 8.LXX?%8UU8QHUG9TW%*<OROC#Q
M)Q>2Y]2X/X1X2S'COC"670SC%Y5@\=A,ERW*,LJ5?98>OG.?9A&>"P-?'<E>
M>78/V=2OBHT&Y>QA5P]2OS/B?]K_ ,5>"?@];?$CQO\ L]>,O _B2/XI^%?A
M;J_@?Q?XATW3[?[7XCN+>&;Q'X7\5Z;INLP>*O#EC]H"V^H)H^EP:I<PW5O;
MS1+ \]>KE/@GD^?\;5>%\@\2\CX@RN7".<<78+/\ERS%8FK['*Z=2<,KS;)\
M5BL#5R?-,1[-NIAI8W%U,)2G2JU(3=6-(\+-O%W.\@X#XBXMS_PXSG(\UX:S
M'*LLQ60YEFF$6#S"MF>+R_#2Q&2<0X/#XVEF>!PW]H1OC*670HUJ]*>&IM5(
MUI8?ZJ'Q.^&S>&;?QJOQ"\#MX-N]032;3Q:/%F@GPS=:K)J3:+'IEOKWV\Z5
M-J#ZPCZ2EE'=-<-J2-8"+[4IBK\@?"?%*S:KD+X:X@6>4,,\;6R5Y-F/]K4L
M''"+'RQ=7+OJRQE/#1P,HXUUYT?9+"26(<E1:F?JTN)N&XY7B<\EQ!DD<EP5
M>>%QF<2S; +*\)BJ6+CE]3#8G,'76$H5Z>/G# SHU:T:D,7..&DO;25.3+[X
MI?#'2_%MGX U/XC>!-.\=ZB(3I_@J^\7^'[3Q;?"X1W@-GX;N-1BUFZ$Z1N\
M/DV;>8B.T>X*QJL/PAQ9B\FK\1X3ACB+%</89S6)S[#Y+F5;)L.Z;4:BKYI3
MPTL#2=.4HQG[2O'E<DG9M*2QG$_#679GA<DS#B'(\!G..Y/J648S-L!A<SQG
MM>;V;PN K8FGBL1[3EER>RHSY^67+>SY7ZS\3_AKX=\2:9X-\0?$+P/H7B_6
M]G]C>%=9\6Z#I?B35_-)6/\ LS0[V^AU/4/,((3[+:R[R"%Y'S3@>$^*LSRO
M%YYEO#/$&89+@.;Z]G&!R;,<7E>"Y%>?UO,,/AJN$PW*K.7MJL.5:NU[CS'B
M7AS)\9@\OS?B#),KQ^8?[A@<QS7 X'&8[WU3_P!CPV)Q%*MB??:A^YA/WVHZ
M-GA.N?M6>'=!_:T\*_LJWNA8U#Q7X"F\66?B\ZTJQPZTIUBZM_"TFA'2SE[K
M1]#O-1CU,ZVC>:]M9+IDAF2XK]"R_P 'LSS'P:SCQ@H9A?#9-Q%#)J^2?4&Y
M3P#^HT:N<1S'ZXK*CCLPH866$_L^2Y%5Q#Q:Y'1/AL_\4\NX?\4>$/#/$X%S
MK<6Y/7S.GF_UM4Z6!KJIG%+ X&KA?JM159X^>2XBG3JO%T.2M7PE&-*K*NG'
MRW2OV\-)\3C]J./PGX)T.^G_ &<?$.A:%92^)/BQX9\!:%X]CU77K[P[>:E-
MXJ\6:;I_A[P7;6.HZ9=QVAU"_P!535]UE%#-!<WL-O7U^,^CQC,I_P"(1RSG
M/LPH4_%'+<QS"O#*N#LUXBS#AV6#R[#9I0PL,GR;%8G,\]JXC"XNC*M]6P^#
ME@N6O.I3JT:$ZI\_#QMPF+SKQ<R3+<GPF(Q'A?AL).AB,=Q)@,FP/$.,]MB,
M#F^%K9AF6'HY?P_1RG-*$<#]>Q6,QF&Q?MJ592PZE&G+ZNF^-WP@T^]BT?6O
MBI\,M&\1&^TC1[GP_??$'PG%JEKK^MV45_IFA-:RZG%<2:IJ%K*MQIMHL"W&
MHVK)=6D,L,B/7X[#@'C;$T)X[ \'\5X[+/J^-QU+,L/PWG,\'5RW 5Y8;%YB
MJT<'.E'"8:M%TL56=1TL+63HUJD9Q:C^C?Z]<)8>G2CFO$_#&58[V>3?6\!B
M>),G57!XK/<%]?RO"3F\7352>8X95*^634(K,\-3>*P<:M!\\>CT+X@^ O%&
MJ:_H?AGQOX0\1:UX5E6#Q1H^A>)=&U?5/#<[-(JPZ_I^GWMQ=Z/*S0S*L>H0
MVSEHI  2CA?+S#AKB/*,)EV89KD&=Y9@,X@ZF48W,,JQV"PF:4TH.4\NQ.)H
M4J..@E4IMRPTZJ2G!MKFBY^S@\]R/,,RQ^38#.<JQV<94X+,\JP>883$YEES
MJRY::Q^!HUIXK!NI*+C#ZQ2I\\E:-VCC+CX^_!Z7P]XYU_P]\4/AKXH3X>Z+
MJ6L>)K?1OB!X7O5T9=/BGQ%KMQ8ZA>C0EGNX/L(FU"% EPWEA'E7RV]VEX<<
M;PS/A_+LRX2XJRE\2X_"X'*JF.X;S>@\<\3.G>>7TL1AJ#S!TZ-3ZPZ>&G)R
MI+FYHP?/'S\+QGP=C9YI3P?%G#6+J9'0KXK.X8;/<KKSR;"X5U%BL3FL:>+E
M++\/AG1K*O6Q:H4Z+I554E#DFCQ7]GS]KNT^/]_X#ATKPYX,TRQ\6_##4?'.
MM?8OC/X-\0>*/"/B'3O$7]C3>#;SP!%:Z=XQO(8[)H-4NO%CZ7I^E6+W,&F7
M-NMS+$\OW?B5X+5O#C#\13QF:9[B\1DW%F%X?P'M^!<\RW*,ZRW%99]>AGE#
MB.=;%9'1J2KQJ82CDT<9B<9B(TJF+I572A.,?S?P[\8Z7B%_JH\'E63X19_E
MW$&(S/#PXSR?&9MD.8Y-C_J^'RN61.CA,XS%X_ 2H9K4Q='!8>C@,-BL-[>,
MH5Z-:K]'>'/BM\+O&-_K6E>$?B3X!\4ZGX;61_$6G>'/&/AW7+_04ADDAF?6
MK/3-2NKC2EBEBDBD:^CA"21R1MM=6"_E^:<'<79'A\#C,ZX6XCRC"9HX1RS%
M9ID>9Y?A\QE4C&<%@:^*PU&GBW.$X3@L/*IS1E&2NFG+]0P'%'#.:X_%Y5E?
M$619EFF7\WU_+<!F^ QF/P7+-TY?6\'A\35Q&&Y:B=.7MJ4+33B[231I>$/'
MW@7XA6%QJG@'QIX3\;Z9:7;V%WJ/A#Q'H_B6PM;Z-5:2SN+S1;R]MX;M%96>
MWDD695924 .6Y<[X<XAX:Q%+"<1Y%G.08NM1CB*.%SO*\=E6(K8>3:C7I4<=
M1H5*E&334:L8N#::4F;93Q!D.?PQ-3(L[RC.H8.N\-C)Y3F6#S*&$Q*7,\/B
M98.O75"NHZNE5<*EM>6UCK*\8]<\L\-?\E/^(G_8.\*_^B=0H ]3H * "@ H
M * /_]#].?\ @Y<_Y'7]A#_KK^T+_P"D'PHK^COHN?\ )S*G_9-YE_ZF98?R
M5]-'_DSM+_LK<H_]0,X/YUJ_T<G\3^7Y'^0@JC) S@$@9],GKW_E^=.G%3J4
MX2ERJ<XQ<GM%2DDY/T3N#V>E_+OY'Z:_M+?&KXN?LG_$N/\ 9_\ V<?%GB+X
M&_#[X?:#\/[ZRU;X:ZE+X7\1_&'4-9\':+XEN/B;X]\8Z%]BUCQW%XKNM9FN
M=+T;4]1N_">C:''INBZ9HUO%8ON_$N"\@R7Q#P&-XLXRR["\29MF&=<299'*
M<YH1Q^6\+83*\\QV48;(,LR;%^VPF!Q.%HX&$\9C_JW]JX_&XC%8FMBY4Z].
M!_1_B#Q3Q%X55>&N"/#['XSA#)Z/!O!/$U;B+(*\LNSKCC,^*.&,MXAS'/<P
MXBP7L<PQN60S#,L3E.7Y-2QSR3+\/E-&C]36/H8B<>^_9BN?%?Q[^._Q>\)?
MM)>%-#^%_P -/B!\-/#W@C]I/7H_#EO\)8M'\7M?:9)\'_B%>Z7>Z7-H6F_&
M'Q1\0O["CMHK'0M(M/$%GJ_BC69-,M=._P"$@U)?.XQPV6<+\&Y1C>"L5B<_
MSK*>*ZN=>'640Q\\\>+Q&&ABJ7$G">7UZ==XV7#=/A^.>4<;"IC:\\IE##48
M8CVU'*\!'V> LXXBXS\0\TP_B-@,%P]D&;^'-7(?%OB'%95'AV-/AS,Z5#'\
M+\?YY3JX>67U.*J>?8K@O&\-XNCEM)\28C"Y3!4:U3,LRS>O#K'CWQ;X6\!_
MM&?'VT\ Z'X>^*'P3^*7P^_9<^&7A"]T^R\2Z1^RA\.A:^.IKF_\-Z%KT.HZ
M<?%VHZSX730(_'=_93WA\3ZMXL\46\D'B/Q EU%AA<#@\?B?#[A]YYB\9E/B
M#EG$?'W$V?X>I6RW&<?9OA*'#;P65O%X.=#$X+*J>!S>KBXY/AZT/9Y)DV69
M.Y3P.#Q$)^MF.,QF3P\9,\CPW@L)F7@EC>%_#7@+A/&0P^;9?X=9-G&=\58+
M..,<1A<;3G@<^SZMF6486E5SJMAIT,1Q3QCB>(J>&BH93A\%\_\ A'X[?M)?
MM 1>%/AU\7-4\2?&SP/XL^,GPU\,Z?\ $+XI6.L>//$'PZ\6ZWXELYHM-\$_
M$S6)+C4?#MSXBTFWU.WO/!=UJM]X>U72%OKR/PV+VSAU*T^^7"G!7"F:87.L
MCPV!X7S;*LJS?,WEV15,-E%'/\IRS!S6*6;Y1AXPI9KA<OQ&)P>)_M'V/U_
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MX@K<.XW*,DRG,Z,<PR/-,)0SCBFOPW]=P4U@\17RNI5HXRC1BW/U+]E?X9_
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MXOU&347MK*PTN[-](^E7D7B#QCFV)_U;='A:?$N(XLXWRBAFV&I9D^',/D'
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >?W7_)4-$_[$GQ'_Z>?#5
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MX2L-%T:QMUO5MXEN[I845F945=BX7Y44 !%4@*.!C%?DC;;;;;;W;U;\WO\
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MCB\QGA*/U;"2Q^)ITXUL9+"X=*AAWB)U'0HKV5-Q@E".Y_PTKIW_ $(?C?\
M\%UI_P#+*O/.T/\ AI73O^A#\;_^"ZT_^65 !_PTKIW_ $(?C?\ \%UI_P#+
M*@ _X:5T[_H0_&__ (+K3_Y94 '_  TKIW_0A^-__!=:?_+*@ _X:5T[_H0_
M&_\ X+K3_P"65 !_PTKIW_0A^-__  76G_RRH /^&E=._P"A#\;_ /@NM/\
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M)-_"W_H(SO\ \*:/_P H#_B':_:*_P"CD?"W_AG5_P#GBT?\3-<??\^<L_\
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M0'_$.U^T5_T<CX6_\,ZO_P \6C_B9KC[_GSEG_@NM_\ + _XDW\+?^@C._\
MPIH__* _XAVOVBO^CD?"W_AG5_\ GBT?\3-<??\ /G+/_!=;_P"6!_Q)OX6_
M]!&=_P#A31_^4!_Q#M?M%?\ 1R/A;_PSJ_\ SQ:/^)FN/O\ GSEG_@NM_P#+
M _XDW\+?^@C._P#PIH__ "@/^(=K]HK_ *.1\+?^&=7_ .>+1_Q,UQ]_SYRS
M_P %UO\ Y8'_ !)OX6_]!&=_^%-'_P"4!_Q#M?M%?]'(^%O_  SJ_P#SQ:/^
M)FN/O^?.6?\ @NM_\L#_ (DW\+?^@C.__"FC_P#* _XAVOVBO^CD?"W_ (9U
M?_GBT?\ $S7'W_/G+/\ P76_^6!_Q)OX6_\ 01G?_A31_P#E ?\ $.U^T5_T
M<CX6_P##.K_\\6C_ (F:X^_Y\Y9_X+K?_+ _XDW\+?\ H(SO_P *:/\ \H#_
M (AVOVB_^CDO"W_AG5_^>*/Y_E1_Q,UQ]_SYRS_P76_^6!_Q)OX6_P#01G?_
M (4T?_E!_17_ ,$XOV4=?_8P_9?\,_ OQ-XJ@\9ZOHVO^+]<NO$%MHO_  C\
M-U)XJ\2ZGXA:*/2?[5UG[,EF=2^R*?[0G\X0^=B+S/)3\6XKXEQW%^?X_B+,
MH4:>-S%X>5>-!-4N;#83#X2+BI7:<H8>,I:OWW*UDTH_T3P/P?EO 7"V5<)9
M15Q-;+LHCBH86>+E&>(Y,5CL3CI1G.*2ER5,5*$'92Y(QYG*5YR^\*^=/K H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * (&MK=IEN&AC:=5VK*4!=5/8,02.G;'ZYH GH * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H C>**7'F
MQQR8Z;T5\?3<&Q^ _/\ A (_LEI_S[6__?F/_P"-T 'V2T_Y]K?_ +\Q_P#Q
MN@ ^R6G_ #[6_P#WYC_^-T 'V2T_Y]K?_OS'_P#&Z #[):?\^UO_ -^8_P#X
MW0 ?9+3_ )]K?_OS'_\ &Z #[):?\^UO_P!^8_\ XW0 ?9+3_GVM_P#OS'_\
M;H /LEI_S[6__?F/_P"-T 'V2T_Y]K?_ +\Q_P#QN@ ^R6G_ #[6_P#WYC_^
M-T 'V2T_Y]K?_OS'_P#&Z #[):?\^UO_ -^8_P#XW0 ?9+3_ )]K?_OS'_\
M&Z #[):?\^UO_P!^8_\ XW0!*D<<0(CC2,$Y(1%0$^I"A>?J/R_B 'T % !0
M 4 % '__T_[\)KNTMB%N+FW@9AN59IXXBR@XR [*2 >,@=?3G<[-[7^Z_P#7
M]=@NEO\ G;^OZ[D/]IZ;_P!!"Q_\"X/_ (Y1:79_<*\>Z^\/[3TW_H(6/_@7
M!_\ '*+2[/[@O'NOO#^T]-_Z"%C_ .!<'_QRBTNS^X+Q[K[P_M/3?^@A8_\
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MBTNS^X+Q[K[P_M/3?^@A8_\ @7!_\<HM+L_N"\>Z^\/[3TW_ *"%C_X%P?\
MQRBTNS^X+Q[K[P_M/3?^@A8_^!<'_P <HM+L_N"\>Z^\/[3TW_H(6/\ X%P?
M_'*+2[/[@O'NOO#^T]-_Z"%C_P"!<'_QRBTNS^X+Q[K[P_M/3?\ H(6/_@7!
M_P#'*+2[/[@O'NOO#^T]-_Z"%C_X%P?_ !RBTNS^X+Q[K[P_M/3?^@A8_P#@
M7!_\<HM+L_N"\>Z^\/[3TW_H(6/_ (%P?_'*+2[/[@O'NOO#^T]-_P"@A8_^
M!<'_ ,<HM+L_N"\>Z^\/[3TW_H(6/_@7!_\ '*+2[/[@O'NOO#^T]-_Z"%C_
M .!<'_QRBTNS^X+Q[K[P_M/3?^@A8_\ @7!_\<HM+L_N"\>Z^\/[3TW_ *"%
MC_X%P?\ QRBTNS^X+Q[K[P_M/3?^@A8_^!<'_P <HM+L_N"\>Z^\/[3TW_H(
M6/\ X%P?_'*+2[/[@O'NOO#^T]-_Z"%C_P"!<'_QRBTNS^X+Q[K[P_M/3?\
MH(6/_@7!_P#'*+2[/[@O'NOO#^T]-_Z"%C_X%P?_ !RBTNS^X+Q[K[P_M/3?
M^@A8_P#@7!_\<HM+L_N"\>Z^\/[3TW_H(6/_ (%P?_'*+2[/[@O'NOO#^T]-
M_P"@A8_^!<'_ ,<HM+L_N"\>Z^\/[3TW_H(6/_@7!_\ '*+2[/[@O'NOO#^T
M]-_Z"%C_ .!<'_QRBTNS^X+Q[K[P_M/3?^@A8_\ @7!_\<HM+L_N"\>Z^\/[
M3TW_ *"%C_X%P?\ QRBTNS^X+Q[K[P_M/3?^@A8_^!<'_P <HM+L_N"\>Z^\
M/[3TW_H(6/\ X%P?_'*+2[/[@O'NOO#^T]-_Z"%C_P"!<'_QRBTNS^X+Q[K[
MP_M/3?\ H(6/_@7!_P#'*+2[/[@O'NOO#^T]-_Z"%C_X%P?_ !RBTNS^X+Q[
MK[P_M/3?^@A8_P#@7!_\<HM+L_N"\>Z^\/[3TW_H(6/_ (%P?_'*+2[/[@O'
MNOO#^T]-_P"@A8_^!<'_ ,<HM+L_N"\>Z^\/[3TW_H(6/_@7!_\ '*+2[/[@
MO'NOO#^T]-_Z"%C_ .!<'_QRBTNS^X+Q[K[P_M/3?^@A8_\ @7!_\<HM+L_N
M"\>Z^\/[3TW_ *"%C_X%P?\ QRBTNS^X+Q[K[P_M/3?^@A8_^!<'_P <HM+L
M_N"\>Z^\/[3TW_H(6/\ X%P?_'*+2[/[@O'NOO#^T]-_Z"%C_P"!<'_QRBTN
MS^X+Q[K[P_M/3?\ H(6/_@7!_P#'*+2[/[@O'NOO#^T]-_Z"%C_X%P?_ !RB
MTNS^X+Q[K[P_M/3?^@A8_P#@7!_\<HM+L_N"\>Z^\/[3TW_H(6/_ (%P?_'*
M+2[/[@O'NOO#^T]-_P"@A8_^!<'_ ,<HM+L_N"\>Z^\/[3TW_H(6/_@7!_\
M'*+2[/[@O'NOO#^T]-_Z"%C_ .!<'_QRBTNS^X+Q[K[P_M/3?^@A8_\ @7!_
M\<HM+L_N"\>Z^\/[3TW_ *"%C_X%P?\ QRBTNS^X+Q[K[P_M/3?^@A8_^!<'
M_P <HM+L_N"\>Z^\/[3TW_H(6/\ X%P?_'*+2[/[@O'NOO#^T]-_Z"%C_P"!
M<'_QRBTNS^X+Q[K[P_M/3?\ H(6/_@7!_P#'*+2[/[@O'NOO#^T]-_Z"%C_X
M%P?_ !RBTNS^X+Q[K[P_M/3?^@A8_P#@7!_\<HM+L_N"\>Z^\/[3TW_H(6/_
M (%P?_'*+2[/[@O'NOO#^T]-_P"@A8_^!<'_ ,<HM+L_N"\>Z^\/[3TW_H(6
M/_@7!_\ '*+2[/[@O'NOO#^T]-_Z"%C_ .!<'_QRBTNS^X+Q[K[R]2&% !0
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MWQ1_T*'@7_PE=!_^0:/J4?\ GY/[Y!_:<O\ GS2_\%T__E8?\-6^*/\ H4/
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ME_X+I_\ RL/^&K?%'_0H>!?_  E=!_\ D&CZE'_GY/[Y!_:<O^?-+_P73_\
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M_P#!=/\ ^5A_PU;XH_Z%#P+_ .$KH/\ \@T?4Z?\]3_P9+_Y6']IR_Y\TO\
MP73_ /E8?\-6^*/^A0\"_P#A*Z#_ /(-'U.G_/4_\&2_^5A_:<O^?-+_ ,%T
M_P#Y6'_#5OBC_H4/ O\ X2N@_P#R#1]3I_SU/_!DO_E8?VG+_GS2_P#!=/\
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M_P#R#1]3I_SU/_!DO_E8?VG+_GS2_P#!=/\ ^5A_PU;XH_Z%#P+_ .$KH/\
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M_P#A*Z#_ /(-'U.G_/4_\&2_^5A_:<O^?-+_ ,%T_P#Y6'_#5OBC_H4/ O\
MX2N@_P#R#1]3I_SU/_!DO_E8?VG+_GS2_P#!=/\ ^5A_PU;XH_Z%#P+_ .$K
MH/\ \@T?4Z?\]3_P9+_Y6']IR_Y\TO\ P73_ /E8?\-6^*/^A0\"_P#A*Z#_
M /(-'U.G_/4_\&2_^5A_:<O^?-+_ ,%T_P#Y6'_#5OBC_H4/ O\ X2N@_P#R
M#1]3I_SU/_!DO_E8?VG+_GS2_P#!=/\ ^5A_PU;XH_Z%#P+_ .$KH/\ \@T?
M4Z?\]3_P9+_Y6']IR_Y\TO\ P73_ /E8?\-6^*/^A0\"_P#A*Z#_ /(-'U.G
M_/4_\&2_^5A_:<O^?-+_ ,%T_P#Y6'_#5OBC_H4/ O\ X2N@_P#R#1]3I_SU
M/_!DO_E8?VG+_GS2_P#!=/\ ^5A_PU;XH_Z%#P+_ .$KH/\ \@T?4Z?\]3_P
M9+_Y6']IR_Y\TO\ P73_ /E8?\-6^*/^A0\"_P#A*Z#_ /(-'U.G_/4_\&2_
M^5A_:<O^?-+_ ,%T_P#Y6'_#5OBC_H4/ O\ X2N@_P#R#1]3I_SU/_!DO_E8
M?VG+_GS2_P#!=/\ ^5A_PU;XH_Z%#P+_ .$KH/\ \@T?4Z?\]3_P9+_Y6']I
MR_Y\TO\ P73_ /E8?\-6^*/^A0\"_P#A*Z#_ /(-'U.G_/4_\&2_^5A_:<O^
M?-+_ ,%T_P#Y6'_#5OBC_H4/ O\ X2N@_P#R#1]3I_SU/_!DO_E8?VG+_GS2
M_P#!=/\ ^5A_PU;XH_Z%#P+_ .$KH/\ \@T?4Z?\]3_P9+_Y6']IR_Y\TO\
MP73_ /E8?\-6^*/^A0\"_P#A*Z#_ /(-'U.G_/4_\&2_^5A_:<O^?-+_ ,%T
M_P#Y6'_#5OBC_H4/ O\ X2N@_P#R#1]3I_SU/_!DO_E8?VG+_GS2_P#!=/\
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M]4N[3QO'X?UVZ8Z-I+7-Q+>6R7$47PE;C_$<0XSP1SJ4L5PQEN84_$WBSB'
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MP[#$8?$SIXO$XG"5\#B<QSGV>+I3Q6/Q.&K*%:IA9X*E-T:4W24W6E7YR_\
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M\>_X!YL7]]?\_P#;2B\>Z^\.>/?\ \V+^^O^?^VE%X]U]X<\>_X!YL7]]?\
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M\>_X!YL7]]?\_P#;2B\>Z^\.>/?\ \V+^^O^?^VE%X]U]X<\>_X!YL7]]?\
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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MA=PK_P! ];_P9'_Y6'_$,W^SQ_T/WQ)_\*+0?_F4H_XC-QE_S_PO_A/_ /=
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M O\ T7F$_P##=FW_ ,PA_P /W/V O^@U\9/_  ROC;_Y!H_XEY\7?^B1K?\
MA?EO_P W!_Q-?X"_]%YA/_#=FW_S"'_#]S]@+_H-?&3_ ,,KXV_^0:/^)>?%
MW_HD:W_A?EO_ ,W!_P 37^ O_1>83_PW9M_\PA_P_<_8"_Z#7QD_\,KXV_\
MD&C_ (EY\7?^B1K?^%^6_P#S<'_$U_@+_P!%YA/_  W9M_\ ,(?\/W/V O\
MH-?&3_PROC;_ .0:/^)>?%W_ *)&M_X7Y;_\W!_Q-?X"_P#1>83_ ,-V;?\
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M_,(?\/W/V O^@U\9/_#*^-O_ )!H_P")>?%W_HD:W_A?EO\ \W!_Q-?X"_\
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ME"<92C*+33::9UE9F@4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M4CG&8T:^9XS,:[AAL#'"_+6D_M5?"+X<WWBG6/@A^SSK/@C6_B)-9:;X[O\
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M,HM73C)---.S6JO<WZDH* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * //[K_ )*AHG_8D^(__3SX
M:H ] H * "@ H * "@ H * "@ H * "@ H * "@#RSPU_P E/^(G_8.\*_\
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M<;^&W%>.S?\ L7&T\=@N(<-X<9CAH91B\VJ9M2SGC>O/->',QPF'RS-\?F>
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M_#8:K5PV(>'KQH8NA&>%K3H5H4ZLYTYJ/L]?"GVYY9X:_P"2G_$3_L'>%?\
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M-3J-PJT:L8U*<TGK&<8M7VU7+^N]?*GV84 % '@?QN_93_9=_:8CT6']H_\
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M*(-4N0NBQVT6N:>,WB_6S+$XG)<EQ+WG2Q.)I3]W#P;M*A1E&4E]8:]VI/\
MY<J\(WFW[+G^CQ]'_"Y%@L)Q'Q#A8SJ24*^#PE:E:6)J*SCB:T9;81-<U&E+
M7$.U2=J"4,1_=M\#/@AX:^#'A2QT72;6'[8L$?VR[$48DEEVC<=ZA2><CD>_
M&!N_EQMMMMMMN[;W;[O?5^OWG]II6T6B6B2Z'N=( H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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ML_;#RSPU_P E/^(G_8.\*_\ HG4* /4Z "@ H * "@#_U?[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MMW:7YK_\1$/_  3;_P"@S^T3_P"(M_&W_P"92ON?^(->)O\ T1^>?^&[%_\
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M +,/COX=?#3X4>-OB%\=QX_OM2\':/XF^#VMWUOHVBZM';^&;_1/!^E>(?\
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ME7A[A+&Y+D>+PV S;&Y%G_!G$GU#,,9C\'EF%R^OAN'N)\TQ<<PK8W'X6C#
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MAP[D\ZF?Y5#!X?-,H_L_/LTQ^)RKBJE/'8G).:A@YSC\5?\ "ZY?^B<_#/\
M\):V_P#CE?IG-+_G_BO_  HE_P#*S\5O'_H"RC_PW?\ W</^%UR_]$Y^&?\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MM./[+2\=LRX@QG'='C[!91B,CXXX1SG(Z]'AK@O@_ 9G@<?A:.$Q_ +CF]+
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MO=8&P4 % !0 4 % !0 4 % !0 4 % '\Q_\ P<C75Q8Z'^Q9>6DK0W-KX_\
MBO/!*N-R2QZ#X+9&P<J0".58%6&58,I85_47T6&UQ?G5FU_PET%=.SL\39K2
MVZT_SV/XL^FVD^ >'DTFO[;Q#LU?6.#O%]=4TFGT:NK:,_GUC^/_ (\CC1#;
M^%92BJIDD\*Z+O?:,;GVVRKN/5MJJ"2<#IM_T$Y(=JGRK5/UN_O?WG^5BQM=
M)*V'E9)<TL-0YGYOEI1C=[NT8KLOY7_\-!>._P#GT\)?^$KH_P#\8HY(=JG_
M (.J#^O5_P"3#?\ A-1_^5G->*?BKXA\8Z:=+UK3_#30B198IK/0+"PO+>1?
MXH+NUCCF0./ED3<8Y%X=3A35148NZ4[Z_%5G)?<^JW5G%^9E5Q%2M%1DJ,;-
M-2IT*<)JS3:4E!-*27*_)]'9Q^=O'/@;2O&.F36EY"/,(#0S(6CF@FC820S0
MS1E989H9526&>*1)8)426)D95*^!Q#P]E_$.7XC 8[#TJ]*O2G2J4ZD5*,X2
MBTXM-=4^E^]UH?5\'<8YMPEFN$S++<76PU?#5J=:E5I3E"4)PE=-.,M&K>2>
MS23N?TY_\$4_^"O^N:YJ'AS]B']LCQ3=7OQ*B_XE'P*^,6M+\OQ.T;3=/#VW
M@KQKJF\K_P +-TJQL[B2SUZ]$*?$'3H@UU,WC2"X?Q)_F]XL^$N8< XZIC,'
M3J8CAZO5?LJWO2E@9SE:.'Q#;<I0;M&C7?Q:4ZG+/E=7_7_P/\<<J\4,KHX/
M&5:.%XIPU%/$89-0AF,*</WF+PL;14:B2YL3A5\&M6CST7-8?^K!'615=&#(
MX#*RG(92,@@CJ"*_%S^@!U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?GU\9?^4C'[$_\
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MW#_^#(G^6O\ 8.=/7^R\=K_U#5/UL_O7W!]MM/\ GY@_[^QT?VMEO_0;A_\
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M3:YK&LP6&K^#Y[_Q9:P:/X;U+PYI4ZZ[=R7NJW=Q- UO;OIMH;JWN'_8>%?
M/,>(>%.#N+\7C>(\!EO%/$&:91B%EO &?<3ULJP&!P-3$8+.Z>'R:M4QV:87
M,\93>7T8T,'0I0J*I5CBJRI5:<?S/BSQDR_AKB_.N#:.&R3&YGE? TN*L.\P
MXQRCAZ&+SA8UPCPK7J9G3CA,MQ<LFMQ \7B\9S1RQQKRP*PKABY?4NM_%KX9
M^$I_#^G^-?B'X!\&ZUXGM[:;1-%\1^-?#>DW^KO<F*-8]%AU#4+2765-Q,EO
M%-I\,L<\C((SF1%K\BP'!G%><T\RQ.0\,\1YY@,IJ588_'97D.:8S#X)4N>3
MECIX;#5H8%^RA*K.&)G"5.,9.5N63/T/$<8<.99A,GKY_GW#^05LZPV&K8*A
MF.?990CBJE>%)NEE^(JXFC3S*,:E6-*%?"*=.MS0E3NJD#3N_B'\/[#Q98>
M[[QSX.LO'.JVHO=+\&7?B;1;?Q9J5D1*1=V'AV:^36+RU(@F(N+>TEBQ#*0Y
MV.4Y:/#/$F(R?$\18?A_/*_#^#K/#XO/:.4X^KD^%KIP3HXG,X4)8*A63J4T
MZ=2M&:<X)KWX\W=B>(<@P>98')\7GF3X7-\SA[3+<JQ.9X*AF68P]_W\#@:M
M>.*Q</W<_>P]*JO<GK[LN7L:\,]@\*D_Y..M_P#LDUS_ .I+;T >ZT % !0
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MUP&&^KY6\RXHQO#^18G#9?EM22Q=/ T,)BIU\5@\LE6Q2HX-4#[S!X?-N#>
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MGU#%XK^R\@5.G4P6#JK$5\R6'PE"I+!JKCJ'W6=\&9?QGG?AIA,ZJ9IE?"'
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MO^B?I_\ A5B__FA_G]XG_#C;]D?_ *)KX$_\)VVH_P"(H\;_ /0X?_A+A/\
MY6'_ !!KPZ_Z)^G_ .%6+_\ EY_+/_P4\^!?A_\ 97_;9\7_  %^"_@Z">[U
M'P]\-K?P=X3\*:7'#-J.L>)/#<&I7/E6\&/^6TTEQ=7,S+!;6Z23W$D-O"\B
M?U?X1^(%7">'>/XAS_&4YXOZ_C<.L14A2H?NZ,*4DI>S48M04[*Z;DVHJ\I0
M4OX7\>?"JGF?BUEG"G"V JTL"\JRW$RPU*56O:KB)UXRY%.51\U1PN]8J.LG
M)13<?UI_X)4?\$D9]/N+'XN?%VVM];\?ZF(YM4UN:);BP\-V4R,9/#/@UYHP
M8X=C>1K.N((KK6'\R&%H=+"V\O\ ,7B/XE9CQICZU*E5JTLJA4?+3YG&6*:>
ME2LD[<B_Y=TM4EJ[R;D?V;X1>#^4>'.58><Z%&MG<Z2]I6Y(RC@^9>]2H2>O
MM'JJM9>]-WBN6"4#^L3PGX2T3P7HMGH6A64-G96<*0HD4:ID(H7)VJ,DXSD\
MGKS7Y8?M9TU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y]?&7_E(Q^Q/_V0K]L;_P!.
MO[-= 'Z"T ?,O[4_P:\4_%[P5X5N/A]J>D:9\2?A7\1/"_Q9\ #Q)'<2>&=5
M\1^$GNC#H?B$6A6[BTS5+:\N8&N;5EFM[C[.^Y(C(]?J_A#QSE'!6?9Q3XDP
MN-Q7"W%_#&;\&\1O*Y4HYK@\KSF-)3S#+/;_ +F>+PE6A2J*G5O"I2]K'EE/
MDC+\[\4>#<9QQPK#+<KQF'P.>9-GV1\7<.8C&TZE7+UQ!PWBGB\NI9E3HN-:
M> Q*J5\-7=*7/1]M#$JE7]C]7J_',?PI_;.^-GQU\-^-_&</Q5_9J\(Z-J6@
M7WC70M"_:FM?%?P_\96'AZWBC?2?!/PX\%:183Z$?$]W9(^N7'BSQ#<0BQU&
MZD,%U>HUO+^X3XQ\"^ O#W-,@R.?!_BIG6.PF8X?(<PS#PBK9/Q)D>)S.K.4
M<;G_ !1GV-Q%/,5E-'$2CE]+)\MI3>(PM&*JT:$O:0_&,5PSXT\=\9Y'CLVI
M<2^&.79=B<JI\08C(_%&&*X=SK+L!7JU,;+(^%\HP5/'X3,<U:]G'%9OF;AA
M<-7H2K8?&5L)4H5?$=7^$_QE_9P_9L_9[\3:9:6?@S]I7PY\6/B#\-?#/AV?
M5-)U>3Q3I'QYUSQ%:6NCI<>']0U/3+^XL9)-%\9V$4U[+;Z7)I=S<WD<5S$;
M=_OL%QEP-XH>*GB7E>*K5\]\*\TX.X:XJS7,Z>$QN#CE&-\.\ORNM6QTJ698
M7!XO#T\1&&/R+$3IT(5<7'%TJ=&4Z4U./RV8\,\5>''AUEO%<L+0ROCWACQ8
MS?%\)X&MB,'CO]8,-Q]C8Y)+A^G#!XJOAL35SBA5P^80P>(J>UI+)ZE3V-&K
M%SA[W\2?V0?%7@33OV;[KP)\*/"?[3OASX,^$/$OASQ5\&_'/B#0_#5GXI\6
M>+Y+2_U7XGVUYXLM=1\*W6L7.LC4+K4H-=MKF1;9[:.Q6><"2T_.>%O&O)^(
M<5XHT>(>,<X\)\TXYSK*\TRCCCA_+<?FM?*,FR6-;#X/A.K1R:KA<WHX&E@?
MJU'"U,OJ4HNK&K+$.G3;C5^NS[P@SK*.'/#!99D>6^(]7@RMG>.XKX2SO,:&
M"H<89]Q11H5<QX@>-S2%? 5L3@<U6,KT89RL1)8&O"A3G5E"<*^-XI_9B^*F
MI?#KX,^(M/\ V:OA%;GX>_%#Q[X_\2_LAV/C:P;P/XLLO&-F+32Y+[7M9TZX
M\(KXN\-[=OV+==^"/)9FTVV@M&&A)WY1XL\'X7B;CK+,3XI\:U?]9N$N'>',
MJ\:<1D.(6?Y-7R.O[;%QP^78'$T<Z>2YK=OV_P"ZS[G26+JUJR_M&7/F7AIQ
M1F7!^2XC#>&_".15<I\0\7QOC_"C"9SAZF3<38*O@EA:6#S3'O"SR:CG6"4(
MT<+1PUN&IX9R=;#QH1HY9#F=&_9'^->J#3)+[X4>%_AGX&^)'[57PM^*?BWX
M&^%/%/AG4_"OPG\ ?#S1-0@U:2:6";2=%U;5/&6JMIS:AIG@K3+VT6&QL7^S
M0Q!K.P]7'>-' 6$>+CA^,,WXJX@X7\'^+N$,F\0<XR?-<)F_&/$G$V/PU3!Q
MIPG3QF/P.$R+"+$K#8O/L52K2GB,1'VLI-5Z_C1\*^.L;1SC%8?@[*N"\LXW
M\1?"NMF? &39OE.(R_AGA3A%XJKQ+GTJV'>"RJOF.<8FEEM1X/)</[:<:--U
M*-6<>7#\3<_L'_'<>&OCY!)I@U75/A];^'_!_P"Q[$/$7AR&YD\&Z5\8KCXJ
MR3K=SZW%#H-_&C6.C03:Y-H]VL-O+:(@LXK>67WZ7TB/#QYKX<U(XMX/!\25
M<RSOQMD\LS2=*.>8S@>EP?&DZ-/ 2GF.'G+ZQCJD,OI8^BYU(5G:O*HH\&9>
M O%N-I^*F5>P7]AY9D&:99X+T*..P,'2>>\8RX^KJBIXM2R['Y=C,)@\@CC\
MP6"C5PF(J4:#IY?0A([%?V1/C#XIUUSXX^%5E?>&->_;[G^-?B/1M5\0^!M2
MT^Y^$]_X<>TN]4U"QC\1W,=_:O>2&RN?#VRXU>YCW[](EM'9F\1^-7!&3Y?'
M_5_C"OA\VR[Z.-+@+*\=@\LX@PN)I<98;-%6HX3#5YY71EAJT:$57I9GS0P5
M*7+RXZ%:,4=V9^%?'7$-;-*F<<+4YX?/_'?PVXSS7 U<SR.I1J<*8#*<UPO%
M56K&&9RC4HX:6/>$JX&+EC<93J2>#PV*IJ4Q/%_[!=_/X _;1MO#?P*\)1^+
M_%OQ&TW5/V<VM9_!%E/IOAFWO-"O9SX.NI-7AL_A];/,NKK<V$LWAJ:\MDBL
MIK>>SBL+=3)/I$X:GQ)X$U<T\0LZEDF3<,8K">)RK4^(*]/%9M4H9A0IK/*,
M<#4K\2U8P>"=+$1CF=.C5E.O3JPKRQ%0]'.? FAB(^.T,)P'D;IY]@\K_P"(
M;TH0R2E1HXN.2T_[2ED]%XBG2X=G5S>E2IXF=2.5K%4H1HN=7 1Y(\+\1_V)
M/COJOQ*^)::E\,)/B]H?Q?\ $ECK?_"RE^(/[/OAS5?!.E75O8P7&AZA??$7
MX%_$CXGZ5=^'TAEL[:_^&.NVUG)I]O8SPV5[>FXMV^@X7\?/#S"<+<*RPO%D
M>"L?P5E>(P'^JSX:\2,TP>?8RC5KU*>88;#\+^('"_">,HYE*<*]7#<69?5K
M1Q-3$4ZF(H8=4ZD?DN)?!GQ!Q&=YUB<3PP^-Z/%^6Y%1J9E5S[P_P>,X:]AD
M>$RS&X#%U^+."^*<WI?4<1[=83,.$LPIXFK@,/AL16J8G-7&<.X_:'_8A^('
MB+6OCQ<> _AK9>+I]=^ OP>\'^!?&&L:K\/8_%7B3QYX;\6Z*OC'5=0U?4+K
MP_=6_B;4?"FG,VO^)[VST6#Q!$K64<LI>.P7P/#/Q]X;RS ^'=/B+BFODM/+
M_$7C;.^(<DP.#XEED^5\.YIDN/>1X/#8+#4<SHU,JPN<8J*R[*:%?,*F73:Q
M$HT^6>(E]-QOX)YSB<QSB62\/T\[]GX%9=PCEF>9CC,AK9QC^-<!G6%P7UC%
MYAB5E>(JYS5X2H/!5^(:N#P%'$9?S9>ZU*$_J<=SQY^S1\6](^(OQ4U*3]E7
MX5_M3V7QAMO#7]A>-_B#XY\.Z#J'P=CL/#&G^'[GP]=V.L12Z[)I.F74+W=E
M=?#G4].U62QM\QZ@EZ]O!!YW#OBKP9C.&.#\+'Q@XO\ "&OP15S7^T,@X:X?
MS/,<-QO+$9KB,RI9G1Q&"G'+XXW%TIQHUZ7$^#Q6#AB*EGA98=5957G'AKQ=
ME^<X[,9^%W#?BI2XEX1X6R;#_P!O9WE6!K<!8O*.'L-DV-PRAF"JJM@ZN+C/
M,HU^&\1AL<^6LZ.,HXR<*]7I_%?[.?Q5;]J?X8>.?#?[-OPKCT#2;WX33^)/
MB-_PG6CZSHFG:1X*\/\ ]DW]E:^&?$6@V7Q TWQ-X<=5A\%ZKX-N;#0-1MM-
MT"X\:Z3KM['#-X;\K)_$_@]>$/%O#^:^*7%\LRQF'XRI97PQ_J_CL#C\5C<]
MS+ZYAL15S;+,QK\-XK*<TBW4S[!YY1Q.8X:KBLRIY#C,OH2G'-/0XD\..*JW
M&O F/RGPRX/GA\KPOA_AL=G:SS"8K+,HPO"]=8C&X'^S,VR^GG=.67.G0P_#
M68\.3H8JI3P>%EQ!_:6"KO*,J_5>OX]/ZM/"I/\ DXZW_P"R37/_ *DMO0![
MK0 4 % !0 4 ?__3_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _
M,WXI_P#!-CX2?$G]JOQ#^U7J]K+JWQ#\6Z7X4\.SZAJ9BEM_"WA?PIH5KH_]
MC^&+8*%M)M?EAEN]?U24R7UW";;2X7MK"*X2[]J>?YE/)</D$:[IY90Q%?%.
MA3O'V]>NXMSK.ZYU",8QIP^&.LK-RN?/TN&<II\0XOBAX>-7.,7A<-@EB:B4
MGA\-AHS4:>'37[MU'.3JU$^>:M#2$?>_0[PIX4T;P;HUGH>AV<-G96<*0HD,
M:H"$4#)P!G.,\Y]SR*\4^@.DH * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /S._;'NO
MB;\//VF/V8_C_P""/A%XG^+VB?#WX<?M"^"_$&C>$]3\,:=JEEJGQ*O_ (-7
M/AVY=?$^M:+!-8&#P/K_ -I>SEN)X9TLXI(4BNC<1 '/?\-__'/_ *,8^-G_
M (4OPF_^;J@ _P"&_P#XY_\ 1C'QL_\ "E^$W_S=4 '_  W_ /'/_HQCXV?^
M%+\)O_FZH P]5_;8^)VNWVAZIK?_  3W^*&LZGX8OI-3\-:CJM]\%]1OO#VI
M36[VDVH:'=W?C*:XTF^EM99+:2[L)+>=[>1X6D:-F6O0P>;9KE^'S#"8#,\P
MP.%S;#QPF:X;!XW$X;#YGA858UH8;,*-&I"GC</"M&-6-'$QJ4XU8QJ**G&,
MCBQN6Y=F+P<LPR_!8^67XVCF67RQN%H8IX',</&I"AC\&Z].H\-C:,*M6%'%
M4?9UZ<:M10J)3DI;G_#?_P <_P#HQCXV?^%+\)O_ )NJ\\[0_P"&_P#XY_\
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MU9Z'X'3P];#QAJ?A#4?[;N;O6/MY:Q'A?Q!K;PBSB@VW'VZ.U5S/";9IR)Q
M ?>5 !0 4 % !0!__]3^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H C>**7'FQQR8Z;T5\?3<&Q^ _/
M^$ C^R6G_/M;_P#?F/\ ^-T 'V2T_P"?:W_[\Q__ !N@ ^R6G_/M;_\ ?F/_
M .-T 'V2T_Y]K?\ [\Q__&Z #[):?\^UO_WYC_\ C= !]DM/^?:W_P"_,?\
M\;H /LEI_P ^UO\ ]^8__C= !]DM/^?:W_[\Q_\ QN@ ^R6G_/M;_P#?F/\
M^-T 'V2T_P"?:W_[\Q__ !N@ ^R6G_/M;_\ ?F/_ .-T 'V2T_Y]K?\ [\Q_
M_&Z #[):?\^UO_WYC_\ C= !]DM/^?:W_P"_,?\ \;H /LEI_P ^UO\ ]^8_
D_C= $B0PQ9\J*.//78BIGZ[57/X_I_$ 24 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>glyc20161231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc20161231x10k002.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_X0!*17AI9@  34T *@    @  P$:  4
M   !    ,@$;  4    !    .@$H  ,    !  (        #P     $   /
M     0  _^T9^E!H;W1O<VAO<" S+C  .$))300$      !A' %:  ,;)4<<
M @   @  ' )0  AR<C$Q-S4V,QP"!0! 36EC<F]S;V9T(%=O<F0@+2!';'EC
M;U]&;W)M(#$P:R Q,C,Q,C Q-"!21$0@=F5R<VEO;C,Q,#(P,34N9&]C>  X
M0DE-!"4      !#^LIJ%@G';G Q@-%,ZSI@Q.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%@            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P
M  $  0/      0 !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/T       2 #4    ! "T
M   &       !.$))30/W       <  #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@              Q0   ?,          0
M                       !              'S    Q0
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG    Q0    !29VAT;&]N
M9P   ?,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   ,4     4F=H=&QO;F<   'S     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    ".$))300,
M  _S     0   *     _   !X   =B    _7 !@  ?_8_^T #$%D;V)E7T--
M  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+
M"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# S_P  1"  _ * # 2(  A$! Q$!_]T !  *_\0!
M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M=3:6?-S_ %G_ .:BU?5#H-)EF*=\@A[K'EP(_<]VS_P-6_VR?] W_//_ )%
M9U"VJQSJH%3G%WH..YHGD,=[7,24M;]6\2RMS&':7:$OKK>/FUC*'^W^NLC)
MZ7TUEALZK1F6N,C(/3\?;BUO:2U[?T)MR/\ A?;_ (&RI=1C=2Q;W"N#7:>&
M'4'^J\?]^6)];>MY?2'L;@.]!^;67W9 8'N9Z)94S[,Q_P"C=DY#+?1>^WV4
M544O24Y]73?JDSIUO6JF.NQ:W-K;57<Y]S;"6AC<IM]C*\>__NM?^@I_P_K_
M .#5>7T++Q;K<>]N):QH:^OJ+*GL++B,?UZKL=S*G^EZF_\ G+'L_P!$F^JE
MM6=D9UO5[6Y3K*VUNKM(?:\2]US;V4-9Z^/6WTG_ *2O]7O_ */Z?Z9;O3/J
MY]5<>_U\7';:X&&BY[KV5Z\UTW;V5O\ ^$V>LDISL+H72NK.<ZA]]U3O<W*+
M112YI)UPZ-K\BRO3;78[]$__  ?J('[*^JF!ZF >HOMRQ9Z+K;F5/8+K-K*Z
M_3<PMV4V?]QO^+NL3XW6?K=7UE[<_'--%_Z*YXH(;2P@UMR:,QNZBUE$^I7[
MW^O_ ,'9_-C;T7-P^G9M%9ILNRA6UEE0=JQOMOW76[W569;7W;_=9^EL24V*
M.AX[?U:T8=F00YAM?B@LF3[ZZV6-]&]K6_\ "?X3TT0?4'I3JXRK;K2>37LI
M9_8;LN=_X*J.+D?LZK&IS7.LRP[]'BU$W7D!WZ.IK6[K+/39Z='J.72=)JS@
M[(ZAU,AF7F;&MQ6D.9C45[O1QMS?;9>Y]EEV5;_I?T?^#24__]'O,E^R[*\\
MD?\ MOC*I:\NXU4NK6BJV^9,Y79I=_VGQ_W1_P!4L:_JWI4V7AM>REP#J[+@
MRUP(G=12&6M?_P!N)*9O;OS+!:!!<6@'4'TZZ;:6G^3OR;[_ /C/^+5/JO6&
MLK]-C00-'-?K/;TF?2WH-OUDZ'D@5OMLQ['EH%CZG2T_0:7V5^HW:S>[^PLH
M;K*_5:_':?2::;;\AK:W..W>35[\BMK7[W_I?YQ)3O=)QA:VZ^IM;'6$->^"
M'/#!^C]6!^D]'>ZMCW?F*X[I@<27>D2=22TDS]RPV?6/%PL:@8]F/D%S?T]
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M_324G?@8-G\YCU/_ *S&G\H6?;T;H[^IU,?@8SF^@]T&FLB0^F#]!7OLE_\
MW-N^ZG_WG358S:\H669#[KO3+6M?L$-EI>YK*F5?G>FDI__9 #A"24T$(0
M    50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <
M !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $
M.$))300B      %&34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ #J8    G$  .I@
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-3HP,SHQ,2 P
M-#HQ-CHU,P!R<C$Q-S4V,P       Z !  ,    !__\  * "  0    !   !
M\Z #  0    !    Q0         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  D   "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$U.C S.C$Q(# T.C$V.C4S ')R
M,3$W-38S       #H $  P    '__P  H ( !     $   'SH , !     $
M  #%          8! P #     0 &   !&@ %     0   38!&P %     0
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M 0$! ?_  !$( ,4!\P,!$0 "$0$#$0'_Q  ?   !! (# 0$
M!@<("00% 0(#"@O_Q !G$   !@$"! ,$!0<%" H,#@,! @,$!08'"!$ $B$Q
M"1-!%!4B418C,E)A%T)Q@9&2T0H8&22A)3,T.5>9L? F0U-88G)UP=CA)R@I
M-U5T=XB7LK.V-45&8V5I<WAY@H.GM[C"U/'_Q  5 0$!
M     ?_$ "01 0 !! $#! ,           #P 1$A,6%!4:%Q@9&QP='A_]H
M# ,!  (1 Q$ /P#[^. . . . . . . . . . . . . . 2EWO-,QG4;#?LB6
MVM4:CU*+<S=JN-QGHFKU6M0S(@*/)>?L,X[81$-%-"?6.Y"2>MVK9,?,66(0
M-P!H\,ZMM*NHR0G(G3[J6P%G.4K#1I(V.-P[F;&^37T#'OUE6[)_-LZ19IQS
M%,GCANX2;.I%-NDX616224.<IB< _#N19,6KI^\>-FS)DW<.W;I9PDBW;MFB
M)W+A=994Y44446Z9U%EE#D3(F4YU#IE)P&-#SD+8HB,L$!+1TU"3D<QF(:6B
MGS.1BY:)DFZ#N-E8R09*N&3^/?-'#=TQ?M5UFCMNNBLBLHB=,_ :YG=*E)3R
MM6CK- O;(A!L;0M!-)J,<RZ5:E7TC&QEB5BT72D@2!DI&(EXZ.EC-RQKU_%R
M3)LY.Z8.4T VLM,15?C9&:G))C$Q,2Q=R<I)R3MLQ81L9'H'=/I"0>.E$6[1
MDR;D4<.G3A5-!NW3.LL<B9%#@"=J.2*%?PE1H]SJMO+!.VD?-GK%BAK G#2+
M^%B+*RCI4T.^>!'2#NM6& L39D\\A=Q!3D/+(E/'R;)RL&PC;A59FP6"JQ5A
M@Y&RU L2>T5]C*Q[N;K:<\W<.X%2>BFSI1]#I3C5JL[ACR#=N62;MUEV?FII
M&.0%-P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P$7
M-9N1\RXETX9!O^ J0[R)E&$<4Q*'K;"K35Y?H04S?:Q WZVL*%6Y*'L>0'^.
M\>R5IR$PH->E8^=O+VK(U6'=)R$PU#@*[L4:_;%#-;&.3L\4G(-7K.7\)4]S
M,K8!RAI_U"TJ'R96LBV*Q1VI'3AEJ4IEAQ6U;$HR\ECW)41%O6UM@"339#'#
MU]6'TY,AVRWXMAL:TW"^9L@8:O\ IMP%=LG8R?O<LYVCJH]JUUT_Y%QKFNWM
MI:H.<;9$L[BL98]NQY3U6^,+PR9W95A>*^PCJA,S4J[85T,FZ>+,PP]D+(AL
MU4@^-ZJ[Q+HLF<,XWOEGQ7CB_N\G:F+#KA>3<#D7(MWRS&8.I[".QCI:87E,
M)N[0AX--G:*][39KO+5BG*!@9#\8:#M&FB_Y<TIX8O6:+=2].F=<UW9O7Y_"
MEBKN!2XLF\G8UAY#([Z,S2TC,B0UAR9BC(;NO,,'6.]N[MC_ !S<;%6)!=5S
M46%H"X?'TV]LE#I-CD 3*_GZE79Q^5 BA&X.Y>'9R#D&Y%%%U4T"K+J%0356
M54(F!$U#J''S. 6/ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' 5
M\>*S4[=>O#DUCU"B5VS6RXS^"K?'5NN4RM2MSM4O+K-TQ;-("JPC&2F+%*F.
M0HLXF.8.WCU3=)%NL8W)P$&;):,QY.Q:YI%&SWK+O]DL6I'1/&6"P-M!V>M#
M=II.%Y+4O28/.J\%<IK#&-BS,9*8VDY12YR$<_=.Z-58J3L3@T6P4=R"(1\M
M\)J!KTCD'$V5K)XB/Y!Z4VU\LM.4QC)QJ1R!DVY90B[]0W. H3(%W@F=DNF4
M:XUH\];B8:8Y\G+!AC(R99]C?U[C]&HA-F&XQ3':B6Q,35F27UE534+!Y*T-
MXSI>/(EOJ"JNF>*T4.\2X"9ZBY*S)LHV+P6UN432E=0[B8N-QD29HH.H.)IU
M,I<C$/?H!"3(1RQ/IBSI5M(EMLV.4M<F/\PZ>O"865Q=!Q\AJ,J5MF]7V-<@
M:HK- T)W&323&R98;5RQIPS.NX3=DM6)[96KO&G1I%DBI.D/V8/#8QUTV[4/
MFM"P2>=%$YF^:YZA,X]:P.J>=Q].Z;&V&\Y1^GMHRK<K7V>DFO,9A0^$I>KW
MW&4K)9OMV1C/J/.!,(.<BQM=#1S:^K>-KT=C2:A=7M5J*V8FKR'GZROJXHU=
MBZG1-"NEV+AL?F/I6H$QGV5"=RA:,F2]'K%;L^-<:SF0\9WNO7NVR=B;P]"L
M(3_\)4<\6/Z9Y3U#5G(\3DK)6ECP[W5ZGLB4:;HTG8,L5_3_ "L?F-!PQE86
M#;^_H&]N'C*T1T<S30BI1P1$[9LBHU34"Z'@#@#@#@#@#@#@#@#@#@#@#@#@
M(C9GUMX*P/D]AAJX-\W67)4A1&N3OHMA72_J4U$/8ZBO[%*55G8YU3 V*<CM
MJZQ<ST+*1R(3BT>NNLU.=)(Q#IF.#_XTR70\QT&HY1QC:(RXT"]0K2PU.S1"
MBAF$S$OB"=!RB5=-%R@H'(JBZ9/&[=^Q=(KLWK9J\;+HIAB7'*]%H-JQ/2[9
M,FB[)G"[2V.\91X1TH^"Q6^#QKD#+TG%'=Q[)TSAP;8^Q?=Y[V^=<1D:N:&]
MU-7B\P_C(]X'6K97HETMN2J-7)DTA9\13,! Y C31THT+!RUGJ,'>H)J1X]9
M-V,H+VKV*&DO-B'+YNW,[,S<K(OV[ELD'.*<KT+-M KN4<:S9K!2+6F^5@9A
M2-E(8[U.-DWT2]-[NG&4;*MO*?QKQ$2.F:)E"H>:0ID3D.<'$YB_,/S0[_>$
M +^T1#;Y\ W<1E>ASN4KWAB,FSNLCXUIN-[_ '. &+E421%5RS*Y(A:#)EEE
MF"4+('G)/$=^;F8QL@\D(OW(FM*M6"$K#J/P<;@#@#@#@#@#@#@&'U"8?QWJ
M+Q7/XKOL_,0<,ZEJ/:6=FIMF3K%QH]SH5Y@;YC:[UF> '!8FR5/(-3@9^!5>
MM'L4\DX@D;,Q4S$KR,2\""V3='^FC#T!<,VZJ\VYJS98;!;,$GNF2\J+49U9
MK%#X\G[90\2XV3H.%L78[HS+',78]0MR4EV%1QU#2TA)WF5G[78GAB)N6P:Q
MAHSTPU3*N(=.V3L\:@LM3U5K4?F+!N,<PSM:FL<T_$&GHY<+MJ2T:P^-J]5Y
MZ+:.-3L%!2\MD-U9\VWY,M41F;_.0]*(U;!KJ-H3TCV:6R1%X[S'G.%R3IDM
MV"L%,LD2$W59"T8+MV#:-DW)N(XBCKY+QM8*3;V[#!?B$6'%S\;K6\D5N>QY
M88BJR:"MWKLI.+ YN0/#-Q5>:PK1Y+4-J7@WE[PQ>L"9EL,1D.C#>]1N*+?/
MVRW2M<R-*V/'4^+!"K67(=Y?T=?$3'&1L<PUVLE%J7N3'DK]%4 FBVR'C3&]
MIQ-I^//K&M]HKEB8T:),W=2#AY%8I@JZM/*2\BR:FC8IVTBIR%<$3DE6"DI[
M2<T<BMY"R:(//P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M#"ZE\\Q&FC"5US-,U^6MA:N2!C82G0)VJ$U<KI=+-#T7'U,C'3]1*.CW=QO=
MDKE81EI19O$0QI09:5<)1C)RL4('Y9\2/(F$+C7\-Y0T^T>G9HL;&_W"%6F,
M^OBX(M.-,=L<7GDK%4LFQN&9._.+'*V;*49C^,J5FPM4T4+'7+C+R4\A36,!
M8;0$4$O%"S=-YJC+?4:QDJPX?F9FMW6"TVL\;5LN=)VHRWA.Y5U@IX8:1IXY
M6?\ RK2V6ZS -6<8E,+/1LB8U!M(J0+A9LJ%I.C;5PCJNA,A/!B\:QTICJS1
MM;ERXPS"TRK&$=24$TG1C+!&2]1QEE3&MOA?:CQD]3,J8LI<LBZ1!]#C-0[I
M%^(30X X X X X X X X X X X X X X X"KG,VCC)&9M?4GE\N0\TX<Q2&C
M*JXJ;WS">1:E3YN7R"QS1D&TOZW*L)*,L<\JUC*[.Q<PPD@A&L05XZ,D22<O
M$%V:04WRWAK:W)FNX0KMTQE:!FJYI4P?B7%LWCEII+LBVEO.E,N>1ORF9<9Y
M$RU=7]LPC;+2>8H67WF9=-\+D>\71U7UH.SPKJ;J%)K,T$S\4:,\NPFL[37D
M:R:37">1L6:T-6V7,]:YE[1AI5++^&LH8)U4TS!<0U3;Y!<YIFV]9)E3%F/F
MM&FJ''16*2U=\A5B&J+]Y,N0RM0&C;+-UUC9QR!7])[R3N^0]06B2]8!UIHV
M[$":6!Z-AQGA4-0:8A(Y!8YFHIK;5Z-<J,ZA\>T673S>E/LJ3D86N/&PRJ 1
M@8>'QJKBZ.\I%ITQ/KKFF9Q9B:L:3M1C*ZX4=Q^@.^0F8,G3U^N"$I,9'CKQ
M2I%-*Q5C*LA*8,KMU=9BCH]EBZXJ>7 QL.<%S9]"FKV=87:)Q7AB0POJZ2_G
MY.<GZ^E;WC:*)JAJ^9,5Z@*KISQXRN50O4QG9TTA\@9!P)>XF+R+1*Y6\"CI
M^ *:NG(1U(3L(3F\.C36\PYJ'U59*K6B]31#A7)^%=&]/H^-%W^$BNI.\XDE
M=4CS*4LM6L'9!R# 0IRADRD(*RSQZW=71P+JRK>TRKV8,B%OO ' ' ' ' '
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MYJY&*+MX>&;O&\:S5>R<@1J:3E9)X\"1' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' 5RZL-16;Z?F. PCA*QX,QM)(Z<,W:G[1DK42PGY*@)U_#MBQE5TJFL
M-=M%0<5F%=/\BA,Y&R8Z?326.JRR8+-:C8%[$B>-"O&:\3?4E>INZMH>IU^'
MQ%/7[4MIPCYJ A9.*7AI[%&$\O6ICE#'N?Y+(,0SOMAD[7C=:3BL9PN(H>=;
MXKD29#93YW5:E&SD)U^%Q?KSD'&&4I&]W*U71_'W+ [2/>VNPRMB=,&LOX?.
MB&[2[5HXEG;M5LWE+E<+7;)!!%0B3VR66>FW)#R<H^<KA9[P!P!P!P!P!P!P
M!P&EL5A@ZE!2]GL\S%5ZNU^,D9N=G9Q^UBH>'AXEFO)2<I*2CY5NQCHZ.CVK
MEX_?/%D6K-H@LY<K$11.?@*Z\7Z\W^6IVSYOCX"NXX\/2G1Y(..U(Y97E:U.
MY[O=DL5<@*G8L(U@Q4S-\%MW\D>":9)NK=BOEFP3T$MC*'=TQF6XV '*U;YH
MRQ3[UIFPAA>PT?'MMU&W/),0;+&2JF_NU3J$1B[$]FR:^B(RJ,[71RV.]VM2
M&;)PT6ZM,6U:4N(R+:OZVK54F+D*PHKQ.]65ER$5"N5C$5ZQWBW*>DK"N3[;
MC12F2.$\K26HV-PM)SF2*!G+(&><=6:GP/LV9&\?@ZN-L*Y'_*;=ZG*T9&S2
M,M--_HZ$;-/6K75O6SV!#'ETG<E72XXJT85YG%WRQL,E6Q@C8\U^+Q.7ZSX5
MQ+DW,6)8O+^6W-7P?3$)JDPE^BK?+XNHTE8XR/N"V+8BHR ?0SH[S1(:@]-^
M,,MRLQ!6"8L\7)(3DI6ZG<*'$K6&MS\K5[$@G2K\0+?4WC";A9"/DZ_-K/58
MJ5:/&*$K*LT6TJ]"3? ' ' ' ' ' ' ' ' 1?U*Z<L?:CV^,1M]\ON.I[ ^2
M1S-0[CC&W1E2M-6M2^.,D8I</UGLI#SK,\4]HV2[M&N$'L=Y)O;/:TERJLB'
M($;P\-?2/+?2QA-V+(]TR!8?IQ+WW(EAS#)2F79.Q9+AL20[*\OK*W50?UFP
M4F*P-BA/#SBLLZU#4#Z$1JU7BVY_.45#(/H8T^F<L<PCGS+ 9H'(1;HVU6AD
MC'?Y27DPO0E,+IU03&HXX9=TM:F*!6R4$N,C5\T\FA;21GY0B!9N 3MK\+G2
MA/UJ6Q*UO.8J9 9%Q/#8VRO4ZCF$6$GGNMU&PSUGC[7D]_*,9:W6"Y%M]QLT
MQ:KM"2T')WM:SRD%D9S:JS(*0' 3\POE:DYTQ1CW,>-W[V5H.2ZG#W*H24A'
MNXAX]@)UJF^CG+F+?I(/6"JK=4@BU=(IJH;<@D+MU!SN . . . . . . . .
M . . K@\2.]6Z3QU0M(.(K._J><=<UV-@>LV:'6%O.8ZQ)[F?V34SF2*<I*H
MN(V3QU@Z+M9*9,E53(WR[9L7Q?G$<S+9,X3NH=%JF-:/3\<4>O157I5#K$!3
M:E6H5HFRB:]6*O%-(.OPL6V2*5)NPB8EDU8,T4P*"+9 B:8_5]0K6TUG/HTU
M:WW1/+N2L,(9X-=]2&B8%DA9P]=<!)EE]2NFJ&44,W8-/H/9[(RR]C&IPS90
MB6-KA<(Z*;LX3&*B*86M< < < < < < < < < < < < < < < < < < R>9=
M.& =1+6O1V>L*8JS/'U.5/.5ECE+']4OK. EED"-EY&);6F)E$6+MPW2(V<J
MM2IF=-P(@Z!9%,A. 8'49C;2CI\K^;-;]CTI4J\9 IN,+5,Y%N5 P[CN=S?9
M,=QE9(QNS-.6E4H:4L34E%CE6TQ"+3JCN;JT0, S:2ZR<5"JA)O$T!BB-J,;
M.8<@J7#TZ\1E9M3%[18:&B(:Q,#4NK5ZJ390AVK9!\FC0*[3J_".E"',WJL!
M78=L8L5$Q;9N#G\ < < < < < < S>=<^8ETTXVG<M9JN4;2*-7S-$'4D\3=
M/'TG+2KI%A UFM0,6@]GK;<K5+.64%4Z?6(J6LUHGWK.$@(M_)/6S<X5[5W!
MV9O$(FHO)NL^K2^*=)K5W&S^*M!,RHD2P9!6BWI)"O9!UPD9F=1D^N@Z1;SM
M5TR,I.5H-9<!&RF6#W&\Q;6 I0+WQ&V[&PUC1_IO0;$38ZA]=6F>L.VK4B!"
M_1;3_+3.M&U,SMTBD*6,DJOI=?5AX*9113:38)F3!$P <)O9:PEAS/E2/0,X
M8JQSF*C*/V4J>FY1I%8OU6/)QXF-'R1J[;(R6B!D8\RBAV;P6/M#7SE00.3S
ME.8$RZTNZ;'N0:'E=WI_PJZR=BV#9UG&F1'&+**K=\=5N.;OFD= 42UG@33U
M2A8YK)235E$P+^.8-&\F_3;HIE=N2JA@V725I:N=7FJ1;M-^![-2[(SK4=/5
M&?Q%CZ5K<VPI<]8K53F$O"OJZO'23.I6>W6RR5EN\;N$H&>M5EF(HK9].23A
MT#P5"G5/']9@:31*O7J53JO%LX2M56J0T=7:U7X6.1(V8Q,)!0[=I%Q4<R;(
MHH-&+%LW:H(E*1)$A"\G *;@#@#@#@#@#@#@#@#@*I-:FC?(V;M1>*[+0D(1
M3&&8JG6\$ZRD9B1:-2/L'XKR]7M0-7CTX9=LN>U-KN1IE_ $_%MP!TSK^?WL
M\*R3*$<F3"MP/#/U)3<YFF)N.-[!;UEJWKU1F+I^4?3'B*LZEF&J%E?FD%4&
MEYQ9B&3U-.)*V(VB F;4GGYPE3,8W&H1*U?6R3#5F!3.'24T):HY:@N9*;TN
MOI=PEF:\3M+KT=&>'E'Y=:Q=NP34L925ASOAARP7T*Y*B9WW1+5!Q-T:3I66
M(BDIP+Q@B=])6>)X!0X[\/#5LQS9B&5RG4&$C)1>5M%N99?*>+'VFZMXEQNQ
MT]XHPK WK$=>GK=C:R:T&\2C8<=Y#I%-I50E"T*^XYR"HA>[G375LR$!@NHT
M%XHNN"M&&F+#>1F+:+OF,\+4*F6V.9OVTLS93T#"-6,DW;2;%15D^1373,5-
MVV5415 .<ASDVV"7' ' ' ' ' ' ' ' ' ' =3G*F0QS#L4A1,8?P -QX"K?
M2(=#5#JJU$ZXU%DIS&U.6G]&>DJ2.IYC9:CXVN*2FIC(\"H@9:/?1N4M0%91
MJ<9.-73Q.5JF":I),CM&\NN@<+2N A?KHT]6?4-A 2XGG8NGZC</VJ#S=I@O
MLEY@QU5S?0SN5:ZVGU6R2CSZ!Y%A7T_B3*;-JFN>6Q;D*YQ14%S/$^ <?2IJ
M(KFJ?!%!S37XV1K3BRL'3*XT&=\M*V8MR/6W[JMY'Q5>&)%#FC+IC>[Q4[3;
M*P4Y?+EH=RHB"C8Z"QPD/SD^\7]X/X\ <Q>H<Q=P$"CU#H(]@'\1] [\ <Y/
MO%_>#^/ =N . Z\Y/O%_>#^/ =N . . . ZB8 [CMOZCOM^WMZ=M^ X,JF4
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ML[;@ "'J'* B @"86R=;&NZPO8HJ:91.J=> A/*(4@&,8YS R3';8HG,',
M7J #TV!W"98N#J0B:)L%/RU94(A:(BYVMUZ QK5:O.L5)2'R3>Y>=K$Q.1L!
M*128R5;@DE'UBNQ/)<UPHUF1+8F03=H&B" 8H25E+FY>\7JWHLU+=>%JI1'J
MLL+5)(S>,@FQ&!R5>I,E!.M$U:%<)1+8YE7YR.I!=X^< KS:.T$C<ZV2'ZQ!
M,&_EU&LHCML _G-U"E,;80'E+N0?EN' .!C/0!-Y9M"=2I5@D9!\0C95^_D&
M=0BXR.3?&<IL"K"C6I:67<OSQ[XK5./BGR*8M5?;W,?SMO:@9I+1#:J)G[5F
MN]DF<@EB&SXGP0#ALX@A"3LT+C6.S+8VD8:5Q^U9J!'(YW@XIV#M.' DLU>(
M.7+A)J@LB"5E2(,-T0?O6YP.9(QE(*A*BFNF82&(J!:>/*HBH04U.4Q@YRB(
M<X['$&]F)>?9 H1O,B)0Z%YZY1#;]!.7<1J("&X; (B.W3M\P9>;L%D\Q1P2
M09**%YE!*XKL%Y)B[;B7DCF$<8NX ;?E.&^^P]-@X#6Q6;HX'[6KS%9HDL]?
MN$&AU(]=_'SJ!7;IO'H."QH33WVWE=O&B((E2:F55<()$5*JLD4X3'A=(=MM
MS8TA!6/$#IJ<1%-,'-F7$P;%$/B:^U@&PGY%#"EN0W4.H<!Y2.BK+K-0Z/N7
M',HF!MN=G-RZ9#_%L8W)(,VYP, B/38X&Z#UWV ,,FBW(BG^&5N@-_AV,)WK
MIT;8!^P!2 0=OSM@ >81Z=QV#>U+P_<F7^P!5:74*;9+"#4KY9@QC3)D:,U7
M*C=!5V_E9B*BTS.UD5TV+<SPCY^#)^9DV<DCY Z0=,F^';F/$GF_3/&519JH
M!S*M&\=#R#KX2\_(FVC[HX=.%AV J:#-NX>+*_5(I&.)/,"-I8:%ADSI_0RA
M.56IC%4%Q6Y))P4Y0$IR'+[]342.4=^8JA><H]%"D.8-@3C^TM(T-T:3CX.7
M?;D@)0G4P[B !])3!\7J!"[[ /P]@X#<8PR8X7RSBMH2I5)N17(M(15.P1F6
M:ADQLL:40Z3#D!$H&$Q.8H$*8"CR#N&P?IHTM%-.IUXA$3B4(ED)>13X0 R)
M3  <ZI3]-]OB#?IW'N(0$U+B/]([X8@%]837)OV'H7%&/-_7U_:'8=AX"A3Q
M=---CR-JW>6.+84Y%!2JQR8OY5X_.]$23D^?<6K9B@ %V./+_7@/S;!\ =PK
M:1T@R4:!CNYNMK.A\M%!K&U.Q2KA9RLH1!%LU9A9?:'SIPN=-LU:M6B[ITY.
MBDBV,JNFEP#JR?AL:BH^O%MSFE/20!TQ.1VU+C!BBL !YFY4GULE7A1 H@!B
MJ)@(<P?#Z $.[A3;+CMT,:^5?PCE3G$A5XBA.?-3(<4UC-I%C772*WEF$"J&
M0?*+-C"0JP)'Y-P8V:-)>8H8)VQE./,8IT)Z7C]A,'/\*<8\9(D$NP%V*0I
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MRC6X8AN?S6T+8EK'"7%%CS'*)$)R2LSL@<X'D%/,'8-4II1U8+\J2N9L&'2
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MW00M$>0X&$1*QEF_QCYA0(HFD;@&#3\._3,P6.K5V65*2DL<14:5[,>0Y%H
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M&V0F28A.L-8*R1[VQPB:;JMUA)ZM;(B<A9-Z)8]Y[S&O/O<2<DR=K2!I@[$
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MQ&!LIMHCG:2\*E4+)"S40]1(?S6KQU4K>Z&+=EY1)Y$I"&4( &$R0 /*0%%
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M6YK/7K-8'(M40'EY"[<H;CL #MR@.^Y@ P#UZ==Q-T*'IQ1V%N0V_,',)!Z
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M!\09MD6")A#%#YV_QW[9&IOW4.FL\?9GLR3] U?8P3)D=1U(45G.(MCUMN1
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MG"'^(/,;S]4<0DZU5+OYA5FTBDL"@^<4W.1,X!JQTU7O':176G'4CD^K>R
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M( )2[&Z[B' (6-R$6T&53HL+9;^=%0$W)L?U.RWIHS4YSD\F3D:Q$2T;$["
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M C7SK8QBAL'KMOTV,"@;["/XCZ\H;CL  (!P"3>..@!S&V$3@8![]>X&Z;B
M]=A >@]?D A6A$ VUI9)?Y L:A)725AF].HK$50W\^OYZR]CR<4C9_,UJ*FL
M9K8\=XTNL7)UG$U?73>P,];8!]E%=-XDQHRJ0.4XRY=\HRSF,PHPBOHV@LY9
MN<L61%S(P;UX@JLV6+2:^P=L'%I9H+D4(>RO)J&KZYD_-@OI4U.HHB&XC<+S
M]S;N6T[GN\6)_'.#)RS.H2-/J*#!T//S-E"5&#;V-B("DHF#61GU5PY?C4,<
M@\ FIC3(S9 )D\@YH*N&YR.%<TY35* B;INR-;1C3 7KLD9CY0]>A!$>8&IF
M6>8,?N%5J[;QR T013 :M<@CXZ4<-4CFY_=-QAX]@1*0\E-0&J%DB91L^<B@
MVD)^+1 \D@$=M5DCDW4?IYG*_@B#H$WD:&ED)).G95^E%/MU;NE7.62A)3'U
M[KULKCG&66ZM* VEZ;8W:KFO2*CEDJI-MZU(FD9 (B>"YF;--HMNMJA:FC6A
MIGIOE*IY+M\7<(@8"40<VJO+5QR"4.#=DUCXYLRJ-<1AF<8T0B$H,\4:+*,:
M9H8P7N*.-A$ $#;[;_'MT$=OF.^VP?H[[]!V!I\W(OY?#V4(J,9NI&0D:':&
M3&-8(+.WKUVXAWB;=HT;-TU'+EPNL8I$$44SJ**""9"'/P$+:O2YAA*.S053
MEP@E;!IZ=.W##$\_B>.1D8#+47(RN].D@6<3CB/A1<2DM<TBI-(QBU%%R)"*
M&,4%$M=]1I&THK"-K?(7$M?R&XMD',TQ!E6*W)1LT@C2!Q](+PS-I9WKB#,[
M59L&<K92SATDG+](RP\I0VA+CDT)-JBA+965Q=],/9BVXV.E/RD V+357R+-
M2N?0DTHK!*74K9B>86JA0,7^YJKM..<',8!6HS,SIKQ33G\5.H.PG,6M[# A
M")+/BQH72-),$FX25B9,A6,:T,M*ODWS#V-$8\AY4B\61ZV6!)J2N3JM'6%G
M')9!K[)27SM/5KZ*T9Q/NYG(#C(LJ[I\=.I*5N<69UV5BW!'S)PL6)AY=)RL
ML>6%%%%0@9T[:M2[><DF#5K) 1NZ]@*NQ@6;UB*V2:N5&">L7I(=9)Q'XDMK
M=<TPJ*QDR1BZ3F>5<) 4. F8#]-LW(51=1R9-+D\\Y2E.N=("E%178I2D44$
M/.-RE*&Q]Q(0!Y!!'2M@E)"0CZW6V)IJRSZZC*#A2+I,2N%6S99X^D)%\L/D
M1,##1Z*\M/2[L3-XN+:JN5"K+%20<!/3!&C"L'EXZQY/CX3+2"< A8E;E(RC
M!UC>#E#"UD$(ZM4%8%64DU9L]I%G>[,24DE4A178!$(N5&2+Q),BR:(I;:/0
M0/'M6=@JCUB_<J BBS.=DR28)D:1,,R8M@4E471B*E\IR=9T)E3(BH.Q$E C
M)D+..&*TV=UNCEL$VZ1CS19#5ENW/5(!PB95P814F7"3)V[.HX407=PC&8+Y
MQ#H.GR*S;J#'1V4<%95G8YB5%]#Y/JC63>Q4'-"W16D$@00;24C!N6+PL0_Y
MMR'/'.",I5H1-9ZG#)L6IWA09:QVDA&3Q_-R"=B"">3;&;@*JDR=HO&[\R;(
MC"9CUE%_KXQ$XJODE5P3*F5<#^>1#G.$!;[25Z,1[D;'B2:^+EG)GCR$9*.3
MN*9&G5$!FF;5PW06+5$G J)R#% 3'JI"E=H$&K(.5H0%+5+BC)(I""QCG'E*
MF8NP[[E*)=C%Z@;8H'WWV'<-MMN@.6G(G.3[9AVW+O\ &)Q'UV$1  [_ *0Z
M>H= [C(+>AQ[&VW#[P '4 $ Z; (; (AU#<P#MP![Q6Z;E3'].YN^V_<W3\0
M#8._RWX#@LDX .4>4?43"41'KN'VM^FW3I^@=M]]P[!)+;"4>4>H]=AW[B(;
M"!@V /3]'X<!Y"^6-T'D$H&^QL'+MOS;;=!^77?<0  W[<!YB[7YN?F #=-Q
M  +]D [[#VV*'0>GZ]^ =/'^*KKDI1-5@V3C($%!(I8Y,OD,-P$W.FT+M[3)
M+%V!(Q&93((*\@/5F93BMP%@>,,653%S592+=KOYAZB5"1EWCE4AG!"G\P"H
MQY%/9&:8* 4Y1\M5WT#S'AR]@=H7J>^_M"8[=/[X']@ ;MN&^WZ-]^O$I?K3
MR(%>(-ILK&K+![BLR%F8T6T4*5-?Z'>)4H&A8>8BHF2:/V=KY5D%RTR;AWSE
M"<6(X 8=RA$VL6<JO7D8EW:7ZCYU7NB;4%FV1(LPP>_LBTUNN4@SV,UJ[9D8
MQ;V%O:X1M>K=4YMI!2HM4WL,M;*[7W[AHH@Z]VL_- G 1BSY@3.6#,EM<*6&
MO1E1M TB%NR[9O)0<PYAH:7=S*";:0<MCKTV$.R3AO/<.FTE9X<R,FR9-G*;
M\56R -74+/?<7J?16DZH&]8?#*.%UJU!YOLB*SB<>F$[GV^.1D/=CZ45.()G
M]K(Y$Q4T40W111*4++].'B('B[/'4/6QC_'.4:'(J%C!R:YIU(CYVH_4%20F
M+ T81;6EVNK-W1&8S3Q*.K\] QIY&Q!(61VS/ /@^@%UI=ID*2&A*^_GL6VL
M&K697CJ;<GL.NO'(.RB],YIL!+M:2^)N<8XLJXJCYJW4,F*::^P)G!)D;Y]H
MS5:4&RP4^C[_ %8N/JV1G$-5K!*HIB91BI$W*IHFKCB2DR@=./@W](9J*N$
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M OV#5FT* %3*78.@$#\0^UL([AT#X?LB;J/ *(LBFF0!+T-\@#80^#;]74
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M)P*/NM'8-S;[>UO@'ML!=]M^NWK\Q$0CC[U(&XBH ;@/3XQ[?MWV[^GS[;\
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MD&TL5_:8A49"#;Q::J4>XFZ]+HN8A%!RD9<KR+51#^KJ"00AWG[ FJF-J,W
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ME=(/Q"(;#,L [;CS=!,'3ML ].FX?0.P7Y634.< _JZ0[;!ZD ?4/7??\.W
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M7A*_!?E I$DY44&<DXMHW0C(R;CY-\5K(3S!%-E-"!7-A@7\Q) 2NSX6QO\
M7[I[G:=D#*M7S/B:7D:G!V:[QV.8F_1E)R+;X6$K[EZLA8*-<U:S:'MI;1B+
MWW''J,VB?OD&[9-XV%U[20/4=9^G2^!CQ[!9MA;).Y)0@\?UW"T"W<V.TM+S
M:)A".8!=HN+C7]FH+/WHL:%4LM]CH&J*(.$'WO59!VR]J"'^D*N6:"H.=7$+
M1F;5X&KW6@E)5UB](D]2E8W4G>63"$;N2MC,%V<:W!VW,X,<JG(U3*Q;NCK
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M1!4ABCS;#^D=QV[;CV'?<.O?UX#Q]Y$V'O\ K#I^S;]>W_7P ,H3;<.OX;@
M]M_N_P#5^/ =?>A1_,-^\7\._P#S?AUZ / <>] $/[V/;T, >G3IL7L/^H]
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M0?2"Y#/91Q[0^>G7<K&. 63L/!L\.M@)/^UW;K<O*'.]R;F-V/0>83?69$,
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M:N4Q3Z6<?H .X +)W:8_EWV  3%C/MC)%#\TJ9R@3E)R#N1,2 GW7@Z^&X\
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M#N'+[(T2Y1 ?N\ IP;H  %!%,"@  !0( % "B @&VW+WV'YC^(;\!V%)(0,
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M >4G]POIZ?=[;_/]??IOV#@,!W#1$@4R;^+CGR9P$#D>LV[HI]]NABKIJ%,
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M8=>PS9T%9F=<1C%NT5F9<[5%LV4E)15 S^14;-VZ)W2RITDD4^4I WW ' '
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M=.&$*B\GM/UVTS.Y.;QC8\V62X%CL:9*L]JOZK!@?(4,+RT2CU"KR$R^?P]
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M@*+*D23(HJ<"$)SJ&(4#'.!"II@<PB?E*5/;R^ R^ . . . . . . . . .
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MMX5U85"#H>9)"]2:VEU$99]+5&LP<+# Q2B65<9QZ!8QFB;G.<$G5X_PY*K
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)#@#@#@#@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>glyc20161231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc20161231x10k003.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /1M T#0
M9O"L.I:G#&N%D>:>2=D555FY)W   #K1X?M_ WB?[7_92PSFUF:)U2[+$@'
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ME#LA.Z$<J2I'^L]0:D_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
M] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_
M .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z
M ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5
M?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\
MXJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_WW#_\<H_M"Y_Z ][_ -]P_P#Q
MR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\ ] __ ,C2?_%5?_M"Y_Z ][_W
MW#_\<H_M"Y_Z ][_ -]P_P#QR@"A_P (7X?_ .@?_P"1I/\ XJC_ (0OP_\
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M% 'D6K:-CQ5X@U.6TU6+5Q<+)I?DZ+%>1R;8D$;"=H'V9=3QYB;>O'6MK4M
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M * .E_\ @''_ (5K45,:-..R-:V9XRO;VE1NWF9/_"+>'O\ H Z7_P" <?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *P?&G_(I7W_ &S_ /1BUO5@^-/^
M12OO^V?_ *,6@ \%_P#(I6/_ &T_]&-6]6#X+_Y%*Q_[:?\ HQJWJ "BBB@
MHHHH **** *&C_\ 'E)_U]7'_HYZOU0T?_CRD_Z^KC_T<]7Z "BBB@ HHHH
M**** "BBB@ HHHH **Y'XBZ]_8OAB2*)L7-[F"/'4 CYF_ <?4BF?#?7O[8\
M-);RONNK'$3Y/)7^ _EQ_P !K?ZO/V/MNE['/]9A[?V/6USL:***P.@****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?&G_(I7W_ &S_
M /1BUO5@^-/^12OO^V?_ *,6@ \%_P#(I6/_ &T_]&-6]6#X+_Y%*Q_[:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5@^-/^12OO\ MG_Z,6MZL'QI_P BE??]L_\ T8M !X+_
M .12L?\ MI_Z,:MZL'P7_P BE8_]M/\ T8U;U !1110 4444 %%%% %#1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWT):-"K $'H01GGB@#I:*** *&C_ /'E)_U]7'_HYZOU0T?_ (\I/^OJX_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!17*>,/B+X<\$P'^T[P-=E<I9P8:9_3C^$>YP*\=G\1?$7XR3O::';-I.@EM
MLDH<JA'</+C+G_94?4=Z /1/&_QG\.^$O,M+5QJNJ+QY%NXV1G_;?H/H,GU
MKY2OX+J"Z8WEM-!)*/-"RH5)5N0>>2#Z]Z^KO!'P8\.^$O+NKI!JFJ+SY]P@
MV1G_ &$Z#ZG)]Q76^(?"&@>*XDCUO2X+SR_N,V5=?8,I# ?C0!\0VEI/?WL%
MG:Q-+<3R+%%&O5F8X 'U)K[HT#3WTGPWI>FR-N>TM(H&;.<E$"G^5>/_ !,^
M#.E6GA?^T_"%@UI>Z>3,\4<KN9H^IP6).Y>HQ[CTKK_A'\0%\;>&1'=R#^V+
M$".Z7O(/X9!]>_N#ZB@#T*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?&G_(I7W_;/_T8M;U8
M/C3_ )%*^_[9_P#HQ: ,C3M,TC6_ %AI6L%/*NI&6$&7RW,H=V4QG.=XVD\>
MA[9JMHLVL:!\0(O"SZU<:WILFGFY#7BJ;BTVD*-\B@;PY)Y89X'H<Z6AZ3::
MW\/H;"]M[>>*59 %GB$BAM[8;:>I!YK3\,>&K#PKH=MIMC;VZ-'$BS30P",S
MNJ@%V ZDXSR3]: ,#Q1_R5#P+_O7W_HFM;4?#F@ZKJMU?R7%S#J$<*P7$UGJ
M<UNR(,LH<1N!QN)&X=ZFG\%^%;JXDN+CPSHTTTK%Y))+")F=B<DDE<DD]ZEO
M?"OAW4I$DOM TNZDCC$:-/9QN50=%!(X ]* /,QJE]=^&O"6L:I<-<V=CXC,
M8OY0 9+?,D<4S$8&#E1N[\'O76^(E%]\3?"-O P>6R6ZN[A1R8XVCV*3Z98X
M'K@^E=C-;6]Q:O:SP12V\B&-XG0%&4C!4@\$8[56TS1=*T6.2/2M,LK!)#N=
M;6!8@Q]2% S0!>JM<VTT[AH[ZXMP!@K$L9!]_F4U9HH P]*L;AK20C5;Q/\
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M_P!!B]_[XA_^-U?HKB.TH?V?<_\ 08O?^^(?_C=']GW/_08O?^^(?_C=7Z*
M*']GW/\ T&+W_OB'_P"-T?V?<_\ 08O?^^(?_C=7Z* *']GW/_08O?\ OB'_
M .-T?V?<_P#08O?^^(?_ (W5^B@"A_9]S_T&+W_OB'_XW1_9]S_T&+W_ +XA
M_P#C=7Z* *']GW/_ $&+W_OB'_XW1_9]S_T&+W_OB'_XW5^B@"A_9]S_ -!B
M]_[XA_\ C=']GW/_ $&+W_OB'_XW5^B@"A_9]S_T&+W_ +XA_P#C=']GW/\
MT&+W_OB'_P"-U?HH H?V?<_]!B]_[XA_^-T?V?<_]!B]_P"^(?\ XW5^B@"A
M_9]S_P!!B]_[XA_^-T?V?<_]!B]_[XA_^-U?HH H?V?<_P#08O?^^(?_ (W1
M_9]S_P!!B]_[XA_^-U?HH H?V?<_]!B]_P"^(?\ XW1_9]S_ -!B]_[XA_\
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ML^Y_Z#%[_P!\0_\ QNC^S[G_ *#%[_WQ#_\ &ZOT4 4/[/N?^@Q>_P#?$/\
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M H?V?<_]!B]_[XA_^-UB>+;.>+PQ>.^I74RC9F.18@#\Z_W4!_6NJK!\:?\
M(I7W_;/_ -&+0 >"_P#D4K'_ +:?^C&K>K!\%_\ (I6/_;3_ -&-6]0 4444
M %%%% !1110!0T?_ (\I/^OJX_\ 1SU?JAH__'E)_P!?5Q_Z.>K] !1110 4
M444 %%%% ",P52S'  R2>U>5?#@'6/&FM:XX) W%<]C(V1^BD5W7C&__ +-\
M(:G<@X;R#&I_VF^4?J:P/A18?9O"CW1'S74[,#_LK\H_4-7=1]S#3GWLO\S@
MK>_BJ<.UW^B.[HHHKA.\**** "BBB@#RGQG_ ,2;XH:1JH^6.;RR[?1MC?\
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M!\%_\BE8_P#;3_T8U;U !1110 4444 %%%% %#1_^/*3_KZN/_1SU?JAH_\
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M12OO^V?_ *,6@ \%_P#(I6/_ &T_]&-6]6#X+_Y%*Q_[:?\ HQJWJ "BBB@
MHHHH **** *&C_\ 'E)_U]7'_HYZOU0T?_CRD_Z^KC_T<]7Z "BBB@ HHHH
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MPR'W!S_.MFOGCX9:K=_#7XD7W@769/\ 0[N8"WD/"^8?]6X]G7 ^N/0U]#T
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MM5U23YFED6(-[CYF_P#0EKNPWN4:E3RM]YP8KWZU*GYW^X]-HHHKA.\****
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MG_IFG?\ WFX'IWJ;P9\#FEN_[=\>7#:AJ$K>8;0REU#>LC_QGV''U%>D>$/
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M;YP\;>JL.0?Y]Z /AJOJ[X V%U8_#17N5=5NKR2>$,,?NR%4$>Q*D_C3=/\
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M;'GA1110 4444 %%%% !45S;0WEK-:W,:RP3(8Y(V&0RD8(/L14M% 'RC>Z
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M[MMN;6]U_*_4]$_X79_U+W_D[_\ :ZZ71?B7HVH:*^H:C+%IKI*T?D-+YCL
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MD;O+_>,FW.,_=(]!^58XBFZE-P1Z64XR&#QD,143:5]M]4UY=SYBKT/X-_\
M(WW?_7@__HR.O0_^%9^$/^@1_P"3,O\ \76CHWA#0O#]V]UI=CY$SQF-F\UW
MRI(./F8]P*XJ."J0J*3:T/I\RXFPF*PDZ,(RO)6U2_S-RBBBO3/A@HHHH **
M** "BBB@ HHHH **** "BBB@#S[XS^(;SPY\.;J:PD:*XNI5M5E7J@;)8@]C
MM4C/O7R#7VYXZ\*1>-/"-[HLDGE22@/#*>B2+RI/MG@^Q-?*.I?"_P :Z7?M
M:2>'-0G8-M$MK TT;>X901CZXH T/A;\1G\ :Q.URL\^E7*8FMXL$[Q]UQD@
M9['V/L*]H@_:(\&2GY[?5X><?O+=#^/RN:POA!\'KC39Y-<\5V,.]HREM83J
MK[<]7<'(!QT'N<XKU&?X>^#;@8?PMHXX(^2S1/\ T$"@#G8/CKX FQOU6>#/
M_/2TE./^^5-:4'Q<\!7 RGB2U'&?WB.G_H2BFS_"#P#<9W^&[<9&/W<LB?\
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M_P"^1S^E;.22NV>=&C4G/DC%M]EN:E,EEC@B>6:1(XT&YG=L!1ZDGI7F.O\
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M?XT?VYI'_04LO_ A/\:OT4 4/[<TC_H*67_@0G^-']N:1_T%++_P(3_&K]%
M%#^W-(_Z"EE_X$)_C1_;FD?]!2R_\"$_QJ_10!0_MS2/^@I9?^!"?XT?VYI'
M_04LO_ A/\:OT4 4/[<TC_H*67_@0G^-8GBW5=.N?#%Y#!?VLLK;-J1S*Q/S
MJ>@-=56#XT_Y%*^_[9_^C%H ;X/C27P=:1R(KHXD5E89!!=L@BMR""*V@C@M
MXDBAB4)''&H544#   X  [5B^"_^12L?^VG_ *,:MZ@ HHHH **** "BBB@"
MAH__ !Y2?]?5Q_Z.>K]4-'_X\I/^OJX_]'/5^@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K!\:?\BE??]L__1BUO5@^-/\ D4K[_MG_ .C%H /!?_(I6/\
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M/A?JWER!KO1IWXQPK>X_NOCMW_E4U3QC<H+EGV[_ /!)@ZF"2C4?-#OV_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7QE%WDV_-GR_U.37H/PJUZ+3]6FTNX9$2]QY3M@?O!T7/OG\P/6O4?\ A&=
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MUHU57$KE]G15H_B_4FCA7S>UK.\OP7H%%%%<9VA1110 4444 %%%% !1110
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M$4ZRO!_+J24445B;A1110 5@^-/^12OO^V?_ *,6MZL'QI_R*5]_VS_]&+0
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M4;*M3^%_@^QS86K*[HU?BC^*[FC1117&=H4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%>;>+/';Z5XVL+6WE;[):'_ $Q5/#[NHQWVCD>YK:C0G6ER
MP,:]>%&/-,])KA?%OQ$M](9M/TD+=ZB3M)'*1'\/O-[#\?2L+6_&>J^+;XZ+
MX6AE6%N'G'RLZ]SG^!?U/Z5U'A+P%8^'%6YGVW6HD<RD?+'[(/Z]?I73&A"@
MN>OOTC_F<LJ]3$/DP^W67^1S_AWX?W>JW?\ ;7BR22660[Q;.?F;TW^@_P!D
M?ITKTV.-(8UCB14C0;551@ >@%.HKFK5YUG>7W=$=-##PHJT=^KZL****Q-P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,C7?#6E^(K?RM0MPS@
M829.)$^A_H>*\XGT7Q3\/9WN]*F:]TS.YUVDKC_;3M_O#].E>O45TT<5.FN5
MZQ[,Y:V$A4?,M)=T<GX9\?Z5XAV0.PL[X\>1(W#G_9;O].M/T?QE!JWBW4M%
M0($MQ^XD!_UA7A_R/3'8&N:^)?AK0[+3&U:)/LM\\@14B&%E)ZY7MQDY%>9Z
M3J4^D:M;:A;G][!(' S]X=P?8C(_&O0I8*C7IRJ4[J^R?1GG5L=6H5(TZEG;
M=KJCZ:HJO8WD.HV$%Y;MNAGC$B'V(JQ7CM-.S/:335T%8/C3_D4K[_MG_P"C
M%K>K!\:?\BE??]L__1BTAAX+_P"12L?^VG_HQJWJP?!?_(I6/_;3_P!&-6]0
M 4444 %%%% !1110!0T?_CRD_P"OJX_]'/5^J&C_ /'E)_U]7'_HYZOT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7A@5"1UQD#IP/RKTZ^9JI!Q@FF>90RMTYJ4VFNQ@Q?#CPK'S_9A<@]7GD/\
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MB@"AH_\ QY2?]?5Q_P"CGJ_5#1_^/*3_ *^KC_T<]7Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?_CRD_Z^KC_T<]7ZP]*EU06DFRSLV'VF?EKIASYKY_Y9GOG_ .MTJ[YNK_\
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M4>;J_P#SXV7_ (&/_P#&J +]%4/-U?\ Y\;+_P #'_\ C50VU]JEU$TB6%F
M)'C^:[;JK%3_ ,L_4&@#5HJAYNK_ //C9?\ @8__ ,:H\W5_^?&R_P# Q_\
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M?_XU0!?HK*NK[5+.SGN9+"S*0QM(P6[;) &3C]W4WFZO_P ^-E_X&/\ _&J
M+]%4/-U?_GQLO_ Q_P#XU1YNK_\ /C9?^!C_ /QJ@"_15#S=7_Y\;+_P,?\
M^-4>;J__ #XV7_@8_P#\:H OT50\W5_^?&R_\#'_ /C5'FZO_P ^-E_X&/\
M_&J +]%4/-U?_GQLO_ Q_P#XU4*WVJ->26PL+/?'&DA/VML88L!_RS_V3^E
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M*L?X9@#R._7Z[MCX*T*#0)=+GMUU&&Z?SKJ:[Q(]S)G.]V[G/3'3M0!T=%
M P!@"B@ HHHH ***R-1\5:#I-XMIJ.K6EK,Q Q-(% )Y )/ )]S0!J)-%)))
M&DJ-)$0)%5@2A(R,CMQS7G7BK0[B'Q??>(M(OH[#5[2PBG5YWQ!<QJT@DBE[
M;<"/GL3FK^N>%KVRU.3Q=X2E9]7?YKJUEE)BU&+LA[*P& C#Z'KFG0Q>'?B7
M!I^I223@6<C1W.FR-L/F9!,4Z=3M9 V.AQW% %GP%XYB\<V%U=)9?8FMW1#!
M),&DY0-N*@<*23M/\0&>.E==5*/2=/BU:358[.%+^2$0/<*N&:,'(4GTJ[0
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M!,DFG,>LL><EH^[+U'4=Z["_O+_4=%CG\+7.FRS3[7CFN69HA&?XP$Y8^@R
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MU8[5R?;@#)SM4 %%%% !112.ZQHSNP55&69C@ >M  S*BEF(55&22< "LKQ
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MAZ\A>YTPR,6:T9"N^#)_APP*_0^YKI[7PWI=IXBO=>CM8_[1NT1))MHR%48
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MHHH I6VD:?9ZA=W]O9PQWEX5-Q.J_/)@8&3Z =JNT44 %%%% !1110 4444
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M@ HHHH *P?&G_(I7W_;/_P!&+6]6#XT_Y%*^_P"V?_HQ: #P7_R*5C_VT_\
M1C5O5Q7ACQ/H^G^';6UNKSRYH]^Y?*<XRY(Y QT-:_\ PFGA_P#Z"'_D&3_X
MF@#>HK!_X33P_P#]!#_R#)_\31_PFGA__H(?^09/_B: -ZBL'_A-/#__ $$/
M_(,G_P 31_PFGA__ *"'_D&3_P")H WJ*P?^$T\/_P#00_\ (,G_ ,31_P )
MIX?_ .@A_P"09/\ XF@#>HK!_P"$T\/_ /00_P#(,G_Q-'_":>'_ /H(?^09
M/_B: -ZBL'_A-/#_ /T$/_(,G_Q-'_":>'_^@A_Y!D_^)H WJ*P?^$T\/_\
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MPFGA_P#Z"'_D&3_XF@#>HK!_X33P_P#]!#_R#)_\31_PFGA__H(?^09/_B:
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M#_\ T$/_ "#)_P#$T?\ ":>'_P#H(?\ D&3_ .)H WJ*P?\ A-/#_P#T$/\
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M!_X33P__ -!#_P @R?\ Q-'_  FGA_\ Z"'_ )!D_P#B: -ZBL'_ (33P_\
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2YYDTFS:OE.,X<$\D8Z"@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>glyc-20161231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 8:16:48 AM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:glyc="http://glyc.com/20161231" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="glyc-20161231.xsd" />
  <!--Context Section-->
  <context id="As_Of_12_31_2016_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_10_20_2009_To_10_20_2009_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">glyc:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-20</startDate>
      <endDate>2009-10-20</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">glyc:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">glyc:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_1_1_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-01</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_1_1_2017_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-01-01</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_5_31_2016_us-gaap_StatementGeographicalAxis_glyc_RockvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">glyc:RockvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-05-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_1_1_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-01-01</endDate>
    </period>
  </context>
  <context id="Duration_6_1_2016_To_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2016-06-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_3_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">glyc:AtMarketOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-03-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2015_To_8_31_2015_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-08-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_5_1_2014_To_5_31_2014_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-05-01</startDate>
      <endDate>2014-05-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniQuestPtyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniQuestPtyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">glyc:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_10_20_2009_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">glyc:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-20</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">glyc:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">glyc:FederalAndStateAuthoritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_10_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2016_To_9_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_3_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2015_To_6_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DefinedContributionPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2013_To_3_31_2013_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2012_To_12_31_2012_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_12_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementGeographicalAxis_glyc_RockvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">glyc:RockvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementGeographicalAxis_glyc_RockvilleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">glyc:RockvilleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_1_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">glyc:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_11_30_2014_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniQuestPtyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-11-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring30january2019Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring30january2019Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring18july2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring18july2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring16january2019Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring16january2019Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring13october2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring13october2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring30january2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring30january2019Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring18july2018Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring18july2018Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring16january2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring16january2019Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring13october2016Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">glyc:ClassOfWarrantExpiring13october2016Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">glyc:EmployeeStockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_3_31_2013_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2013-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:StockIncentivePlan2003Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2004_To_2_29_2004_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniversityOfBaselMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:ResearchServicesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-02-01</startDate>
      <endDate>2004-02-29</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniversityOfBaselMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:ResearchServicesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">glyc:AchievementOfSpecifiedRegulatoryMilestoneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">glyc:AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">glyc:AchievementOfSpecifiedDevelopmentMilestoneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="As_Of_1_1_2017_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-01-01</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">glyc:EquityIncentivePlan2013Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_11_1_2014_To_11_30_2014_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniQuestPtyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2014-11-30</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">glyc:AchievementOfSpecifiedRegulatoryMilestoneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">glyc:AchievementOfSpecifiedDevelopmentMilestoneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-10-01</startDate>
      <endDate>2011-10-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_20_2009_To_10_20_2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2009-10-20</startDate>
      <endDate>2009-10-20</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniversityOfBaselMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:ResearchServicesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">glyc:UniversityOfBaselMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">glyc:ResearchServicesAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="As_Of_2_27_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <instant>2017-02-27</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit16">
    <measure>glyc:segment</measure>
  </unit>
  <unit id="Unit15">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit14">
    <measure>glyc:item</measure>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2016_To_12_31_2016">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2016_To_12_31_2016">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2016_To_12_31_2016">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2016_To_12_31_2016">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2016_To_12_31_2016">2016-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2016_To_12_31_2016">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2016_To_12_31_2016">0001253689</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_2_27_2017" unitRef="Unit1" decimals="INF">23329900</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2016_To_12_31_2016">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2016_To_12_31_2016">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="As_Of_6_30_2016" unitRef="Unit12" decimals="-5">100400000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2016_To_12_31_2016">GLYCOMIMETICS INC</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2016_To_12_31_2016">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2016_To_12_31_2016">No</dei:EntityWellKnownSeasonedIssuer>
  <glyc:AccruedFranchiseAndOtherTaxes contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">3590</glyc:AccruedFranchiseAndOtherTaxes>
  <glyc:AccruedLiabilitiesPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt; Accrued Liabilities &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&amp;#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company&amp;#x2019;s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i)&amp;nbsp;an evaluation by the project manager of the work that has been completed during the period; (ii)&amp;nbsp;measurement of progress prepared internally and/or provided by the third-party service provider; (iii)&amp;nbsp;analyses of data that justify the progress; and (iv)&amp;nbsp;the Company&amp;#x2019;s judgment.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</glyc:AccruedLiabilitiesPolicyTextBlock>
  <glyc:AccruedLicenseAndMilestoneFees contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">2000000</glyc:AccruedLicenseAndMilestoneFees>
  <glyc:AccruedLicenseAndMilestoneFees contextRef="As_Of_12_31_2015_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember" unitRef="Unit12" decimals="-5">2000000</glyc:AccruedLicenseAndMilestoneFees>
  <glyc:AccruedLicenseAndMilestoneFees contextRef="As_Of_12_31_2016_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember" unitRef="Unit12" decimals="-5">0</glyc:AccruedLicenseAndMilestoneFees>
  <glyc:AccruedResearchAndDevelopmentExpenseCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">3423220</glyc:AccruedResearchAndDevelopmentExpenseCurrent>
  <glyc:AccruedResearchAndDevelopmentExpenseCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">2513243</glyc:AccruedResearchAndDevelopmentExpenseCurrent>
  <glyc:ClassOfWarrantOrRightExpirationsInPeriod contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="INF">0</glyc:ClassOfWarrantOrRightExpirationsInPeriod>
  <glyc:ClassOfWarrantOrRightExpirationsInPeriod contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="INF">1544</glyc:ClassOfWarrantOrRightExpirationsInPeriod>
  <glyc:ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount contextRef="Duration_10_20_2009_To_10_20_2009" unitRef="Unit12" decimals="0">16099770</glyc:ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount>
  <glyc:DeferredTaxAssetRecordedToAdditionalPaidInCapital contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">250359</glyc:DeferredTaxAssetRecordedToAdditionalPaidInCapital>
  <glyc:DeferredTaxAssetsCapitalizedStartUpCosts contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">2986272</glyc:DeferredTaxAssetsCapitalizedStartUpCosts>
  <glyc:DeferredTaxAssetsCapitalizedStartUpCosts contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">2708479</glyc:DeferredTaxAssetsCapitalizedStartUpCosts>
  <glyc:DeferredTaxAssetsPatentAmortization contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">238378</glyc:DeferredTaxAssetsPatentAmortization>
  <glyc:DeferredTaxAssetsPatentAmortization contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">216203</glyc:DeferredTaxAssetsPatentAmortization>
  <glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;8. Stockholders&amp;#x2019; Equity &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Convertible Preferred Stock &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Series A-1 Convertible Preferred Stock &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October&amp;nbsp;20, 2009, the Company entered into a Series A-1 Preferred Stock Purchase Agreement with certain investors. In connection with the financing, the Company issued 30,726,326 shares of Series&amp;nbsp;A-1 Convertible Preferred Stock for an aggregate amount of $38,979,412, which included the conversion of principal and accrued interest related to an earlier bridge financing of $16,099,770. In connection with the Series&amp;nbsp;A-1 Preferred Stock financing, all then-outstanding shares of Series A and Series B Preferred Stock were converted into common stock, and all then outstanding warrants to purchase Series B Preferred Stock were converted into warrants to purchase common stock. Immediately prior to the Series A-1 Preferred Stock financing, the Company effected a 1-for-10 reverse stock split of the outstanding common stock. All prior-period applicable share amounts have been retroactively adjusted to reflect the reverse stock split. As of December&amp;nbsp;31, 2013, the Company&amp;#x2019;s Amended and Restated Certificate of Incorporation authorized the issuance of 130,601,021 shares of stock, of which 70,258,276 were designated as common stock with a par value of $0.001, and of which 60,342,745 were designated as Series A-1 Convertible Preferred Stock with a par value of $0.001. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Upon closing of the Company&amp;#x2019;s initial public offering in January 2014, all outstanding shares of convertible preferred stock converted into an aggregate of 9,305,359 shares of common stock. In addition, immediately following the closing of the initial public offering, the Company&amp;#x2019;s certificate of incorporation was amended to authorize 5,000,000 shares of undesignated preferred stock and 100,000,000 shares of common stock. Both the common stock and undesignated preferred stock have a par value of $0.001 per share. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Common Stock &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 1, 2016, the Company entered into an at-the-market sales agreement with Cowen and Company, LLC to sell the Company&amp;#x2019;s securities under a shelf registration statement filed in March 2015. As of December 31, 2016, the Company had issued and sold 668,791 shares of common stock under the at-the-market sales agreement. The shares were sold at a weighted average price per share of $6.336, for aggregate net proceeds of $3.9 million, after deducting commissions and offering expenses. Subsequent to December 31, 2016, the Company sold an additional 461,989 shares at a weighted average price per share of $6.228 under the at-the-market facility for an additional $2.8 million in net proceeds.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June 2016, the Company completed a public offering in which the Company sold 3,476,793 shares of its common stock at a price of $6.10 per share.&amp;nbsp;The Company received net proceeds of $19.7 million from this offering, after deducting underwriting discounts, commissions and other offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Warrants to Acquire Company Stock &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following common stock warrants were outstanding as of December&amp;nbsp;31, 2016 and 2015: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;12/31/2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;12/31/2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;NUMBER&amp;nbsp;OF&amp;nbsp;SHARES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;NUMBER&amp;nbsp;OF&amp;nbsp;SHARES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXERCISE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;UNDERLYING&amp;nbsp;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;UNDERLYING&amp;nbsp;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;PRICE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXPIRATION&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WARRANTS&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WARRANTS&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;PER&amp;nbsp;SHARE&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;DATE&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;236,632
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;259,907
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;July&amp;nbsp;18,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;301,986
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;301,986
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;January&amp;nbsp;16,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;January&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 33.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,544
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.92
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;October&amp;nbsp;13,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;For the year ended December&amp;nbsp;31, 2016, a total of 23,275 warrants were exercised at a weighted average exercise price of $0.33 per share. For the year ended December&amp;nbsp;31, 2015, a total of 11,908 warrants were exercised at a weighted average exercise price of $0.33 per share.&amp;nbsp; For the year ended December 31, 2016, a total of 1,544 warrants expired. No warrants expired during the year ended December&amp;nbsp;31, 2015. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;2003 Stock Incentive Plan &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60&amp;nbsp;days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May&amp;nbsp;21, 2013. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the Company&amp;#x2019;s stock option activity under the 2003 Plan for the year ended December&amp;nbsp;31, 2016 is as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;REMAINING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AGGREGATE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;CONTRACTUAL TERM&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;INTRINSIC VALUE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OPTIONS&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(YEARS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(IN THOUSANDS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;758,187
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.27
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,368)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;729,819
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested or expected to vest as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;729,801
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercisable as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;729,240
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.25
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,534
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During 2016, 2015 and 2014 the Company issued 28,368, &amp;nbsp;99,029 and 114,836 shares of common stock, respectively, in conjunction with exercises of stock options granted under the 2003 Plan. The Company received cash proceeds from the exercise of these stock options of approximately to $44,771, &amp;nbsp;$114,124 and $133,957 during 2016, 2015 and 2014, respectively. Total intrinsic value of the options exercised during the years ended December&amp;nbsp;31, 2016, 2015 and 2014 was $97,707, &amp;nbsp;$667,258 and $629,232, respectively. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2016, there was $1,382 of total unrecognized compensation expense related to unvested options under the 2003 Plan that will be recognized over the first quarter of 2017. The total fair value of shares vested in the years ended December&amp;nbsp;31, 2016, 2015 and 2014, was $16,024, &amp;nbsp;$50,310 and $63,865, respectively. There were no options granted from this plan in 2016, 2015 or 2014.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;2013 Equity Incentive Plan &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&amp;nbsp;422 of the Internal Revenue Code (the Code), to the Company&amp;#x2019;s employees and its parent and subsidiary corporations&amp;#x2019; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&amp;#x2019;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 90&amp;nbsp;days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Authorized Shares &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The maximum number of shares of common stock that may be issued under the 2013 Plan was 1,000,000&amp;nbsp;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January&amp;nbsp;1 of each year, beginning on January&amp;nbsp;1, 2015 and ending on January&amp;nbsp;1, 2023, by 3% of the total number of shares of common stock outstanding on December&amp;nbsp;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&amp;#x2019;s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of January&amp;nbsp;1, 2017, the number of shares of common stock that may be issued under the 2013 Plan was automatically increased by 697,500 shares, representing 3% of the total number of shares of common stock outstanding on January&amp;nbsp;1, 2017, increasing the number of shares of common stock available for issuance under the 2013 Plan to 2,837,201 shares. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A summary of the Company&amp;#x2019;s stock option activity under the 2013 Plan for the year ended December&amp;nbsp;31, 2016 is as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AGGREGATE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;REMAINING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;INTRINSIC&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXERCISE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;CONTRACTUAL&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;VALUE&amp;nbsp;(IN&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OPTIONS&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;PRICE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;TERM(YEARS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;THOUSANDS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,470,338
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;627,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,500)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.95
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,983)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,066,105
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;505
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested or expected to vest as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,057,409
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercisable as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;910,202
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The weighted-average fair value of the options granted during the year of December&amp;nbsp;31, 2016, 2015 and 2014 was $3.39, &amp;nbsp;$5.08 and $6.70 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected term &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;6.25 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;6.25 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;6.25 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;68.98%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;80.76%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;90.27%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;1.70%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;1.70%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;2.14%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2016, there was $4,308,701 of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately 2.0 years. The total fair value of shares vested in the years ended December 31, 2016 and December&amp;nbsp;31, 2015 was $3,053,086 and $2,668,712, respectively. There were no shares vested as of December&amp;nbsp;31, 2014 under the 2013 Plan.&amp;nbsp;&amp;nbsp;During 2016, the Company received cash of $27,825 and issued 3,500 shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan.&amp;nbsp;&amp;nbsp;The intrinsic value of the options exercised during 2016 was $2,275.&amp;nbsp;&amp;nbsp;There were no option exercises under the 2013 Plan for the years ended December 31, 2015 and 2014.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;An RSU is a stock award that entitles the holder to receive shares of the Company&amp;#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&amp;#x2019;s stock on the date of grant. The Company has granted RSUs with service conditions (service RSUs) that vest in three equal annual installments provided that the employee remains employed with the Company. As of December&amp;nbsp;31, 2016, $60,108 of unrecognized compensation costs related to unvested service. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following is a summary of RSU activity for the 2013 Plan for the year ended December&amp;nbsp;31, 2016: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;NUMBER&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;GRANT DATE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OF SHARES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;FAIR VALUE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Unvested at December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,833
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.61
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,417
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Unvested at December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,916
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.04
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-based compensation expense was classified as follows on the statement of operations for the years ended December&amp;nbsp;31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Calibri;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,033,005
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;802,329
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;512,345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,931,762
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,521,274
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,122,720
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,964,767
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,323,603
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,635,065
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</glyc:DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="3">0.087</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
  <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="3">0.115</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
  <glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="3">0.090</glyc:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
  <glyc:IncreaseDecreaseDeferredRentCredit contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-103935</glyc:IncreaseDecreaseDeferredRentCredit>
  <glyc:IncreaseDecreaseDeferredRentCredit contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">146635</glyc:IncreaseDecreaseDeferredRentCredit>
  <glyc:IncreaseDecreaseDeferredRentCredit contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">578483</glyc:IncreaseDecreaseDeferredRentCredit>
  <glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">696531</glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses>
  <glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">63000</glyc:IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses>
  <glyc:NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement contextRef="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit14" decimals="INF">2</glyc:NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement>
  <glyc:NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement contextRef="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit14" decimals="INF">2</glyc:NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement>
  <glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="0">0</glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired>
  <glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="0">0</glyc:NumberOfLongLivedAssetsDeterminedToBeImpaired>
  <glyc:NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit14" decimals="INF">2</glyc:NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement>
  <glyc:NumberOfWarrantsExercised contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="INF">11908</glyc:NumberOfWarrantsExercised>
  <glyc:NumberOfWarrantsExercised contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="INF">23275</glyc:NumberOfWarrantsExercised>
  <glyc:PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit13" decimals="2">0.03</glyc:PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan>
  <glyc:PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan contextRef="As_Of_1_1_2017_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit13" decimals="2">0.03</glyc:PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan>
  <glyc:PotentialPaymentForAchievementOfSpecifiedMilestones contextRef="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">115000000</glyc:PotentialPaymentForAchievementOfSpecifiedMilestones>
  <glyc:PotentialPaymentForAchievementOfSpecifiedMilestones contextRef="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">135000000</glyc:PotentialPaymentForAchievementOfSpecifiedMilestones>
  <glyc:PotentialPaymentForAchievementOfSpecifiedMilestones contextRef="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementScenarioAxis_glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">70000000</glyc:PotentialPaymentForAchievementOfSpecifiedMilestones>
  <glyc:ProceedsFromPaymentsForContingentConsiderationOperatingActivities contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember" unitRef="Unit12" decimals="-5">-2000000</glyc:ProceedsFromPaymentsForContingentConsiderationOperatingActivities>
  <glyc:ResearchAndLicenseAgreementTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;10. Research and License Agreements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February 2004, the Company entered into a research services agreement (the Research Agreement) with the University of Basel (the University) for biological evaluation of selectin antagonists. Certain patents covering the rivipansel compound are subject to provisions of the Research Agreement. Under the terms of the Research Agreement, the Company will owe a 10% payment to the University for all future milestone and royalty payments received from Pfizer with respect to rivipansel. A milestone license fee of $2.0 million was recorded in the year ended December&amp;nbsp;31, 2015 for the payment due to the University of Basel representing 10% of the $20.0&amp;nbsp;million non-refundable milestone payment that the Company received from Pfizer in August 2015. The accrued license and milestone fee of $2.0 million was paid in February 2016.&amp;nbsp;&amp;nbsp;There were no payments recorded for the year ended December 31, 2016. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In October 2011, the Company and Pfizer entered into a licensing agreement (the Pfizer Agreement) that provides Pfizer an exclusive worldwide license to rivipansel for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. The Company was responsible for completion of the Phase 2 trial, after which Pfizer will assume all further development and commercialization responsibilities. Upon execution of the Pfizer Agreement, the Company received an up-front payment of $22.5 million. The Pfizer Agreement also provides for potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications; potential milestone payments of up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of the Company&amp;#x2019;s filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications; and potential milestone payments of up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. Pfizer has the right to terminate the Pfizer Agreement by giving prior written notice. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales-based milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. The Company is also eligible to receive royalties on future sales contingent upon annual net sales thresholds. In addition, the Company and Pfizer have formed a joint steering committee that will oversee and coordinate activities as set forth in the research program. The $22.5 million up-front payment was recognized over a period of 1.5 years. In May 2014, the Company received a non-refundable payment of $15.0 million from Pfizer as a partial milestone payment owed to the Company upon the dosing of the first patient in the Phase 3 clinical trial. The dosing of the first patient in a Phase 3 clinical trial of rivipansel in August 2015 triggered the remaining $20.0 million of the scheduled milestone payment under the Pfizer Agreement. During the years ended December&amp;nbsp;31, 2015 and 2014, the Company recorded revenue of $20.0 million and $15.0 million, respectively, pursuant to the Pfizer Agreement in the Company&amp;#x2019;s statement of operations. There was no revenue recognized under the Pfizer Agreement for the year ended December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In November 2014, the Company executed a worldwide license agreement with UniQuest Pty Limited (UniQuest) to secure the exclusive rights to two method-of-use patent applications relating to the use of E-selectin antagonists to reduce the risk of deadly infections in patients undergoing chemotherapy. Under the terms of the agreement, UniQuest received an upfront fee of $20,000 in 2014, and is eligible for a milestone payment of $2.0 million from the Company upon the Company&amp;#x2019;s receipt of marketing authorization from the FDA for a drug incorporating the licensed patents, as well as low single-digit royalties on any net sales for this indication. There were no expenses for this arrangement in 2016 and 2015. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</glyc:ResearchAndLicenseAgreementTextBlock>
  <glyc:RevenueRecognitionMilestoneMethodMilestonesAchieved contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit14" decimals="0">0</glyc:RevenueRecognitionMilestoneMethodMilestonesAchieved>
  <glyc:RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent contextRef="Duration_2_1_2004_To_2_29_2004_us-gaap_CounterpartyNameAxis_glyc_UniversityOfBaselMember_us-gaap_TypeOfArrangementAxis_glyc_ResearchServicesAgreementMember" unitRef="Unit13" decimals="2">0.10</glyc:RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent>
  <glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.60%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Calibri;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;ESTIMATED&amp;nbsp;USEFUL&amp;nbsp;LIVES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;7&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;3 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Shorter&amp;nbsp;of&amp;nbsp;lease&amp;nbsp;term&amp;nbsp;or&amp;nbsp;useful&amp;nbsp; life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</glyc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
  <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit14" decimals="INF">3</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments>
  <glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P90D</glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment>
  <glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">P60D</glyc:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment>
  <glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">20000000</glyc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions>
  <glyc:SharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">130601021</glyc:SharesAuthorized>
  <glyc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">54235</glyc:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
  <glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">72593</glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
  <glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">72539</glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
  <glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">54</glyc:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
  <glyc:UpfrontPaymentRecognitionPeriod contextRef="Duration_10_1_2011_To_3_31_2013_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember">P1Y6M</glyc:UpfrontPaymentRecognitionPeriod>
  <glyc:WarrantsExercisedWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="2">0.33</glyc:WarrantsExercisedWeightedAverageExercisePrice>
  <glyc:WarrantsExercisedWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="2">0.33</glyc:WarrantsExercisedWeightedAverageExercisePrice>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;6. Accrued Expenses &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following is a summary of the Company&amp;#x2019;s accrued expenses at December 31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,513,243
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,423,220
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued license and milestone fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,000,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued consulting and other professional fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;148,579
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;242,227
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;315,002
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;281,152
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued employee benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;290,547
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;195,442
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued franchise and other taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,590
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,267,371
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,145,631
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">564235</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">1565210</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">1037112</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedBonusesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">1432485</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">195442</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">290547</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">6145631</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">3267371</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">242227</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">148579</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">902099</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">1056561</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">127619078</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">154254193</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">1635065</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">1635065</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">2323603</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">2323603</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">2964767</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">2964767</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">1635065</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="0">1122720</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="0">512345</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">2323603</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="0">1521274</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="0">802329</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">2964767</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="0">1931762</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="0">1033005</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" unitRef="Unit1" decimals="INF">1806980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="INF">590595</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" unitRef="Unit1" decimals="INF">2235775</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="INF">578687</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" unitRef="Unit1" decimals="INF">2817674</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="INF">553868</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">48462279</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">42388327</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">47244370</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">40520144</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
  <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Basis of Accounting &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;2. Summary of Significant Accounting Policies &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Basis of Accounting &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Segment Information &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Use of Estimates &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Cash and Cash Equivalents &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Fair Value Measurements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December&amp;nbsp;31, 2016 and 2015, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="display:inline;"&gt;. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:24pt;"&gt;&lt;p style="width:24pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Level 1&amp;#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:24pt;"&gt;&lt;p style="width:24pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Level 2&amp;#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:24pt;"&gt;&lt;p style="width:24pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;"&gt;
				&lt;font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Level 3&amp;#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December&amp;nbsp;31, 2016 and 2015. The carrying value of cash held in money market funds of approximately $38.0 million and $45.5 million as of December&amp;nbsp;31, 2016 and 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Property and Equipment &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.60%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Calibri;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;ESTIMATED&amp;nbsp;USEFUL&amp;nbsp;LIVES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;7&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;3 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Shorter&amp;nbsp;of&amp;nbsp;lease&amp;nbsp;term&amp;nbsp;or&amp;nbsp;useful&amp;nbsp; life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Impairment of Long-Lived Assets &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Property, Plant, and Equipment&lt;/font&gt;&lt;font style="display:inline;"&gt;. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&amp;nbsp;31, 2016 and 2015, the Company determined that there were no impaired assets and had no assets held for sale. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Revenue Recognition &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has entered into a collaborative research and development agreement with Pfizer. The agreement is in the form of a license agreement. The agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the arrangement that contain material financial consequences to the Company. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The primary deliverable under this arrangement is an exclusive worldwide license to the Company&amp;#x2019;s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer&amp;#x2019;s behalf. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of ASC 605-25, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Revenue Recognition&amp;#x2014;Multiple-Element Arrangements&lt;/font&gt;&lt;font style="display:inline;"&gt;, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1)&amp;nbsp;the delivered item(s) has value to the customer on a stand-alone basis and (2)&amp;nbsp;if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i)&amp;nbsp;vendor-specific objective evidence (VSOE), if available; (ii)&amp;nbsp;third-party evidence (TPE) of selling price if VSOE is not available; or (iii)&amp;nbsp;an estimated selling price, if neither VSOE nor third-party evidence is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer collaboration agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company&amp;#x2019;s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Pursuant to ASC 605-25, each required deliverable under the Pfizer collaboration agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company&amp;#x2019;s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company&amp;#x2019;s technology and the related proprietary nature of the Company&amp;#x2019;s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the contract and will be combined with the research and development services (including participation on a joint steering committee). &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Pursuant to ASC 605-28, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Revenue Recognition&amp;#x2014;Milestone Method&lt;/font&gt;&lt;font style="display:inline;"&gt;, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&amp;nbsp;the consideration is commensurate with either (1)&amp;nbsp;the entity&amp;#x2019;s performance to achieve the milestone, or (2)&amp;nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&amp;#x2019;s performance to achieve the milestone, (b)&amp;nbsp;the consideration relates solely to past performance and (c)&amp;nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&amp;#x2019;s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment. There were no revenue milestones met in the year ending December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt; Accrued Liabilities &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&amp;#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company&amp;#x2019;s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i)&amp;nbsp;an evaluation by the project manager of the work that has been completed during the period; (ii)&amp;nbsp;measurement of progress prepared internally and/or provided by the third-party service provider; (iii)&amp;nbsp;analyses of data that justify the progress; and (iv)&amp;nbsp;the Company&amp;#x2019;s judgment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Research and Development Costs &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Stock-Based Compensation &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Compensation&amp;#x2014;Stock Compensation&lt;/font&gt;&lt;font style="display:inline;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A discussion of management&amp;#x2019;s methodology for developing some of the assumptions used in the valuation model follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Dividend Yield&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Volatility&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company&amp;#x2019;s initial public offering, there was not a market for the Company&amp;#x2019;s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&amp;#x2019;s historical volatility since its initial public offering to determine its expected volatility. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Risk-Free Interest Rate&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Term&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Forfeiture Rate&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Income Taxes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,&lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt; Income Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt;. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Comprehensive Loss &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&amp;nbsp;31, 2016, 2015 and 2014, the Company&amp;#x2019;s net loss equals comprehensive loss and, accordingly, no additional disclosure is presented. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Recently Issued Accounting Standards &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:inherit;"&gt;On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. The Company is evaluating the Pfizer collaboration agreement to determine the impact of the new revenue standard on the upfront and milestone payments within this specific collaboration agreement. The Company intends to select a transition method in the second quarter 2017 and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Georgia;color:#000000;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt; On August 27, 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern, which requires management to assess a company&amp;#x2019;s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Before this new standard, there was minimal guidance in U.S. GAAP specific to going concern. Under the new standard, disclosures are required when conditions give rise to substantial doubt about a company&amp;#x2019;s ability to continue as a going concern within one year from the financial statement issuance date. The Company adopted the standard for the reporting period ending December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).&amp;nbsp;&amp;nbsp;The final guidance will require lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. This standard is effective for annual reporting periods beginning after December&amp;nbsp;15, 2018. Early adoption will be permitted.&amp;nbsp;&amp;nbsp;The Company is currently evaluating the effect the new standard will have on the Company. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&amp;nbsp;&amp;nbsp;The ASU includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in financial statements including the income tax effects of share-based payments, minimum statutory withholding requirements and forfeitures. The new guidance will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It will also allow an employer to repurchase more of an employee&amp;#x2019;s shares than the current standard for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. This ASU is effective for annual reporting periods beginning after December&amp;nbsp;15, 2016, and interim periods within those annual periods. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. In evaluation of the new standard, the Company will elect a policy at adoption of the standard to account for forfeitures as they occur. &amp;nbsp;The Company has evaluated the standard and has determined the implementation will not have a material impact on the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;With the exception of the new standards discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">21292</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="0">2310603</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="0">55198923</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">46802560</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">40041641</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">52888320</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-8396363</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">-6760919</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Cash and Cash Equivalents &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring13october2016Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="INF">25.92</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring16january2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="INF">0.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring18july2018Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="INF">0.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring30january2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit15" decimals="INF">0.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring13october2016Member" unitRef="Unit1" decimals="INF">1544</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring16january2019Member" unitRef="Unit1" decimals="INF">301986</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring18july2018Member" unitRef="Unit1" decimals="INF">259907</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2015_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring30january2019Member" unitRef="Unit1" decimals="INF">15250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring16january2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">301986</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring18july2018Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">236632</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2016_us-gaap_ClassOfWarrantOrRightAxis_glyc_ClassOfWarrantExpiring30january2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">15250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2015" unitRef="Unit15" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit15" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">70258276</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">19050204</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">23250023</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">19050204</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">23250023</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">19049</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">23249</us-gaap:CommonStockValue>
  <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;11. &amp;nbsp;Employee Benefit Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has a defined contribution plan under the Internal Revenue Code Section&amp;nbsp;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis.&amp;nbsp;&amp;nbsp;For the year ended December 31, 2016, the Company made a discretionary match of 50% up to the first 3% of employee contributions. All matching contributions have been paid by the Company. The Company&amp;#x2019;s matching contributions vest in full at the employee&amp;#x2019;s third anniversary of employment and all employer contributions thereafter vest immediately. The total Company matching contributions were $79,000 for the year ended December&amp;nbsp;31, 2016.&amp;nbsp;&amp;nbsp;There were no Company matching contributions for the years ended December&amp;nbsp;31, 2015 and 2014.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Comprehensive Loss &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&amp;nbsp;31, 2016, 2015 and 2014, the Company&amp;#x2019;s net loss equals comprehensive loss and, accordingly, no additional disclosure is presented. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ContractualObligation contextRef="As_Of_11_30_2014_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">2000000</us-gaap:ContractualObligation>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">38805055</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Duration_1_1_2014_To_1_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="INF">9305359</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following is a summary of the Company&amp;#x2019;s prepaid expenses and other current assets at December&amp;nbsp;31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Prepaid expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;199,195
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;393,857
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other receivables&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;268,659
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38,683
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deposits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,649
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,270
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;478,503
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;441,810
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:DeferredRentCredit contextRef="As_Of_12_31_2015_us-gaap_StatementGeographicalAxis_glyc_RockvilleMember" unitRef="Unit12" decimals="0">243647</us-gaap:DeferredRentCredit>
  <us-gaap:DeferredRentCredit contextRef="As_Of_12_31_2016_us-gaap_StatementGeographicalAxis_glyc_RockvilleMember" unitRef="Unit12" decimals="0">822130</us-gaap:DeferredRentCredit>
  <us-gaap:DeferredRentCreditCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">68551</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">243647</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">753579</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueAdditions contextRef="Duration_10_1_2011_To_10_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">22500000</us-gaap:DeferredRevenueAdditions>
  <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="Duration_10_1_2011_To_12_31_2011_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">22500000</us-gaap:DeferredRevenueRevenueRecognized1>
  <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="Duration_1_1_2012_To_12_31_2012_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">22500000</us-gaap:DeferredRevenueRevenueRecognized1>
  <us-gaap:DeferredRevenueRevenueRecognized1 contextRef="Duration_1_1_2013_To_3_31_2013_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_UpFrontPaymentArrangementMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">22500000</us-gaap:DeferredRevenueRevenueRecognized1>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">39436788</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">54667237</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">10110590</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">14988522</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">24745536</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">34451814</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">52985</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">70511</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">1206920</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">2107964</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">96107</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">123744</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">39436788</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">54667237</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="Unit12" decimals="0">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="Unit12" decimals="0">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="Unit12" decimals="0">79000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit13" decimals="2">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_DefinedContributionPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="Unit13" decimals="2">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DepositsAssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">9270</us-gaap:DepositsAssetsCurrent>
  <us-gaap:DepositsAssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">10649</us-gaap:DepositsAssetsCurrent>
  <us-gaap:Depreciation contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">158708</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">191484</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">190540</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasic contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit15" decimals="2">-0.37</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit15" decimals="2">0.55</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit15" decimals="2">-0.38</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit15" decimals="2">-0.47</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit15" decimals="2">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit15" decimals="2">-0.67</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit15" decimals="2">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit15" decimals="2">-1.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit15" decimals="2">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit15" decimals="2">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit15" decimals="2">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit15" decimals="2">-0.37</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit15" decimals="2">0.51</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit15" decimals="2">-0.38</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit15" decimals="2">-0.47</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;3. Net Loss Per Share of Common Stock &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per share is computed by dividing net income by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method was used to determine the dilutive effect of the Company&amp;#x2019;s stock option grants, restricted stock units and warrants. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth the computation of basic and diluted earnings per share for the years ended December&amp;nbsp;31, 2016, 2015 and 2014: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,809,838)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,769,498)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,121,566)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.50)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.67)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.60)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted weighted average common shares outstanding &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,256,312
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,010,587
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,452,252
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following potentially dilutive securities outstanding at December&amp;nbsp;31, 2016, 2015 and 2014 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;553,868
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;578,687
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;590,595
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock options and restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,817,674
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,235,775
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,806,980
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="3">-0.558</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="3">-0.530</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="3">-0.479</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="3">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="3">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="3">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="3">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="3">0.046</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="3">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="3">0.046</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit13" decimals="3">0.074</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit13" decimals="3">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit13" decimals="3">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="0">60108</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="0">4308701</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">1382</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Fair Value Measurements &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December&amp;nbsp;31, 2016 and 2015, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="display:inline;"&gt;. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:24pt;"&gt;&lt;p style="width:24pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Level 1&amp;#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:24pt;"&gt;&lt;p style="width:24pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Level 2&amp;#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:24pt;"&gt;&lt;p style="width:24pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt; display: inline;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;"&gt;
				&lt;font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:1pt;"&gt;&lt;p style="width:1pt;width:1pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Level 3&amp;#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December&amp;nbsp;31, 2016 and 2015. The carrying value of cash held in money market funds of approximately $38.0 million and $45.5 million as of December&amp;nbsp;31, 2016 and 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-1424</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-8001</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">6595738</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">7805396</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">8650165</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Impairment of Long-Lived Assets &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Property, Plant, and Equipment&lt;/font&gt;&lt;font style="display:inline;"&gt;. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&amp;nbsp;31, 2016 and 2015, the Company determined that there were no impaired assets and had no assets held for sale. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;9. Income Taxes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The components of the gross deferred tax asset and related valuation allowance at December&amp;nbsp;31 were as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net operating loss carryforward&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,451,814
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,745,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Capitalized start-up costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,708,479
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,986,272
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Patent amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;216,203
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;238,378
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and orphan drug credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,988,522
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,110,590
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;123,744
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;96,107
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,107,964
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,206,920
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;70,511
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;52,985
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total gross deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;54,667,237
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39,436,788
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(54,667,237)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39,436,788)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Based on the Company&amp;#x2019;s operating history and management&amp;#x2019;s expectation regarding future profitability, management believes the realization of the Company&amp;#x2019;s deferred tax assets does not meet the more-likely-than-not criteria under ASC 740, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt;. Accordingly, a full valuation allowance has been established as of December&amp;nbsp;31, 2016 and 2015. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2016, the Company had $87,591,753 of U.S. Federal and state net operating losses, of which $250,359 will be recognized as a benefit through additional-paid-in-capital when realized, $7,394,601 of research and development tax credits and $7,593,921 of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&amp;#x2019;s ability to utilize its net operating losses and credits. As of December 31, 2016, the Company does not believe that an ownership change has occurred. Any future ownership changes may cause a limitation on the Company&amp;#x2019;s ability to utilize existing tax attributes. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and in the State of Maryland. The Company&amp;#x2019;s federal income tax returns for tax years 2003 and after remain subject to examination by the U.S. Internal Revenue Service. The Company&amp;#x2019;s Maryland income tax returns for the tax years 2006 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company did not have unrecognized tax benefits as of December&amp;nbsp;31, 2016 and 2015, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December&amp;nbsp;31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;U.S. Federal statutory tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;State taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Orphan drug credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.7)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.3)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(47.9)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(53.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(55.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Provision for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxesPaid contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">80000</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Income Taxes &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,&lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt; Income Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt;. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-270867</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-309792</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">1000975</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">4459292</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">1693238</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">-2504179</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDepositsOutstanding contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">52320</us-gaap:IncreaseDecreaseInDepositsOutstanding>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-1656823</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-474439</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">36693</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;7. Operating Leases &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;The Company leases office and research space in Rockville, Maryland under an operating lease with a term through October 31, 2023 (as amended to date, the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances.&amp;nbsp;&amp;nbsp;In connection with the Lease, the Company received rent abatement as a lease incentive. The annual rent increases and rent abatement have been recognized as deferred rent that is being adjusted on a straight-line basis over the term of the Lease.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space beginning on June 1, 2016. In addition to the other terms of the Lease, the Lease Amendment provided for a tenant improvement allowance reflected in the Company&amp;#x2019;s financial statements as an increase in capitalized leasehold improvements as incurred and an increase in deferred rent. In May 2016, the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company&amp;#x2019;s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company&amp;#x2019;s renewal option set forth in the Lease. The Company also has a one-time option to terminate the Lease effective as of October 31, 2020. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;Deferred rent related to the Lease was $822,130 and $243,647 at December 31, 2016 and December 31, 2015, respectively. Total rent expense under the Company&amp;#x2019;s leases was $784,739, &amp;nbsp;$595,497 &amp;nbsp;and $385,668 for the years ended December 31, 2016, 2015 and 2014, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents the future minimum lease payments as of December&amp;nbsp;31, 2016 under the Lease: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;YEAR&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AMOUNT&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;941,822
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;965,368
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;989,502
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,014,239
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,039,595
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;After 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,972,254
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,922,780
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">7990625</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">7087196</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">48462279</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">42388327</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">7746978</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">6333617</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LicenseCosts contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="0">20000</us-gaap:LicenseCosts>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">45500000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">38000000</us-gaap:MoneyMarketFundsAtCarryingValue>
  <us-gaap:NatureOfOperations contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;1. Description of the Business &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated on April&amp;nbsp;4, 2003 and commenced operations on May&amp;nbsp;21, 2003. The company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company has incurred significant losses in the development of its drug candidates. The losses in prior periods were primarily attributable to the research and development of the Company&amp;#x2019;s first drug candidate, rivipansel, as well as GMI-1271 and GMI-1359. The Company has not generated revenues from product sales. As a result, the Company has consistently reported negative cash flows from operating activities and net losses, had an accumulated deficit of $118,976,311 at December&amp;nbsp;31, 2016 and expects to continue incurring losses for the foreseeable future. The Company currently anticipates that its cash and cash equivalents will be sufficient to meet its anticipated cash requirements into the second quarter of 2018. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s operations are subject to certain risks and uncertainties. The risks include the need to manage growth, the need to retain key personnel, the need to protect intellectual property, the availability of additional capital financing on terms acceptable to the Company and reliance on its collaboration with Pfizer Inc. (Pfizer). The Company&amp;#x2019;s current operating assumptions and projections, which reflect management&amp;#x2019;s best estimate of future revenue and operating expenses, indicate that anticipated operating expenditures into the second quarter of 2018 can be met by available working capital; however, the Company&amp;#x2019;s ability to meet its projections is subject to uncertainties, and there can be no assurance that the Company&amp;#x2019;s current projections will be accurate. If the Company&amp;#x2019;s cash requirements are more than projected, the Company may require additional financing. The type, timing and terms of financing selected by the Company, if required, will be dependent upon the Company&amp;#x2019;s cash needs, the availability of financing sources and the prevailing conditions in the financial markets. There can be no assurance that such financing will be available to the Company at any given time or available on favorable terms. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Management believes that the Company has access to capital resources through private investments of equity from its existing stockholders. However, it has not secured any commitment for new financing as of the date of this report, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it will be required to curtail its operations, and if these measures fail, it may not be able to continue its business. Curtailment of operations would cause significant delays in the Company&amp;#x2019;s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">57382510</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">114121</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">23674548</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-212603</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-268594</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">-704202</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-4281587</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-8241890</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">-29731265</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-11121566</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-11121566</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="0">-7109129</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-12769498</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-12769498</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="0">10389405</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="0">-7168071</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-8881703</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="0">-7554978</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">-31809838</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-31809838</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="0">-8071570</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="0">-7854693</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">-8328597</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Recently Issued Accounting Standards &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:inherit;"&gt;On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. The Company is evaluating the Pfizer collaboration agreement to determine the impact of the new revenue standard on the upfront and milestone payments within this specific collaboration agreement. The Company intends to select a transition method in the second quarter 2017 and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Georgia;color:#000000;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt; On August 27, 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern, which requires management to assess a company&amp;#x2019;s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Before this new standard, there was minimal guidance in U.S. GAAP specific to going concern. Under the new standard, disclosures are required when conditions give rise to substantial doubt about a company&amp;#x2019;s ability to continue as a going concern within one year from the financial statement issuance date. The Company adopted the standard for the reporting period ending December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).&amp;nbsp;&amp;nbsp;The final guidance will require lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. This standard is effective for annual reporting periods beginning after December&amp;nbsp;15, 2018. Early adoption will be permitted.&amp;nbsp;&amp;nbsp;The Company is currently evaluating the effect the new standard will have on the Company. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&amp;nbsp;&amp;nbsp;The ASU includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in financial statements including the income tax effects of share-based payments, minimum statutory withholding requirements and forfeitures. The new guidance will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It will also allow an employer to repurchase more of an employee&amp;#x2019;s shares than the current standard for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. This ASU is effective for annual reporting periods beginning after December&amp;nbsp;15, 2016, and interim periods within those annual periods. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. In evaluation of the new standard, the Company will elect a policy at adoption of the standard to account for forfeitures as they occur. &amp;nbsp;The Company has evaluated the standard and has determined the implementation will not have a material impact on the financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;With the exception of the new standards discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit16" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">26166811</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">32855575</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">31931985</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">-11139807</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">-12784825</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">-31913485</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">6922780</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">941822</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">1039595</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">1014239</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">989502</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">965368</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">1972254</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">385668</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">595497</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">784739</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="As_Of_12_31_2016_us-gaap_IncomeTaxAuthorityAxis_glyc_FederalAndStateAuthoritiesMember" unitRef="Unit12" decimals="0">87591753</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">281152</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">315002</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherCurrentAssetsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;4. Prepaid Expenses and Other Current Assets &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following is a summary of the Company&amp;#x2019;s prepaid expenses and other current assets at December&amp;nbsp;31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Prepaid expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;199,195
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;393,857
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other receivables&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;268,659
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38,683
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deposits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,649
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,270
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Prepaid expenses and other current assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;478,503
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;441,810
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">18241</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">15327</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">103647</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherReceivablesNetCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">38683</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">268659</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">212603</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">268594</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">704202</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit15" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2015" unitRef="Unit15" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit15" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">60342745</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_10_20_2009_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">30726326</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2015" unitRef="Unit12" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2016" unitRef="Unit12" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">441810</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">478503</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">393857</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">199195</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">696531</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:PrepaidExpenseNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">759531</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">57248219</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">23601955</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">134291</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">114121</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">72593</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">133957</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">114124</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="0">27825</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">44771</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;5. Property and Equipment &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment, net consisted of the following at December&amp;nbsp;31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;262,135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230,987
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,130,180
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;965,586
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,610
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,723
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;169,423
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;181,053
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36,128
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36,128
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Construction in progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;508,417
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,112,893
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,423,477
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,056,561)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(902,099)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,056,332
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;521,378
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Depreciation of property and equipment totaled $190,540, &amp;nbsp;$191,484 and&amp;nbsp;$158,708 for the years ended December&amp;nbsp;31, 2016, 2015 and 2014, respectively.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">P3Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">P7Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">1423477</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember" unitRef="Unit12" decimals="0">965586</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="Unit12" decimals="0">181053</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="0">230987</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="0">36128</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" unitRef="Unit12" decimals="0">9723</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">2112893</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_glyc_LaboratoryEquipmentMember" unitRef="Unit12" decimals="0">1130180</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="Unit12" decimals="0">169423</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="Unit12" decimals="0">508417</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="Unit12" decimals="0">262135</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="Unit12" decimals="0">36128</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="As_Of_12_31_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" unitRef="Unit12" decimals="0">6610</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">521378</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">1056332</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Property and Equipment &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.60%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Calibri;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;ESTIMATED&amp;nbsp;USEFUL&amp;nbsp;LIVES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;7&amp;nbsp;years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;5 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer software&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;3 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Shorter&amp;nbsp;of&amp;nbsp;lease&amp;nbsp;term&amp;nbsp;or&amp;nbsp;useful&amp;nbsp; life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Property and equipment, net consisted of the following at December&amp;nbsp;31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;262,135
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;230,987
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,130,180
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;965,586
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Office equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,610
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,723
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Computer equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;169,423
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;181,053
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Leasehold improvements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36,128
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36,128
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Construction in progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;508,417
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Property and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,112,893
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,423,477
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Less accumulated depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,056,561)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(902,099)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Property and equipment, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,056,332
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;521,378
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;12. Quarterly Financial Information (Unaudited) &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Summarized quarterly financial information for each of the years ended December&amp;nbsp;31, 2016 and 2015 are as follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,328,597)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,854,693)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,071,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,554,978)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss per share&amp;#x2014;basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.36)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.34)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.41)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.40)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:50.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,035,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net (loss) income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,881,703)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,168,071)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,389,405
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,109,129)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;(Loss) income per share&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.47)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.38)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.37)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;(Loss) income per share&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.47)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.38)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.37)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">19571073</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">25050179</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">23281820</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_glyc_UniQuestPtyLimitedMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Research and Development Costs &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations. &lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">-87166473</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">-118976311</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">15000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Duration_5_1_2014_To_5_31_2014_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">15000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Duration_8_1_2015_To_8_31_2015_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_CounterpartyNameAxis_glyc_PfizerMember_us-gaap_TypeOfArrangementAxis_glyc_LicenseAgreementMember" unitRef="Unit12" decimals="-5">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Revenue Recognition &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has entered into a collaborative research and development agreement with Pfizer. The agreement is in the form of a license agreement. The agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the arrangement that contain material financial consequences to the Company. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The primary deliverable under this arrangement is an exclusive worldwide license to the Company&amp;#x2019;s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer&amp;#x2019;s behalf. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of ASC 605-25, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Revenue Recognition&amp;#x2014;Multiple-Element Arrangements&lt;/font&gt;&lt;font style="display:inline;"&gt;, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1)&amp;nbsp;the delivered item(s) has value to the customer on a stand-alone basis and (2)&amp;nbsp;if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i)&amp;nbsp;vendor-specific objective evidence (VSOE), if available; (ii)&amp;nbsp;third-party evidence (TPE) of selling price if VSOE is not available; or (iii)&amp;nbsp;an estimated selling price, if neither VSOE nor third-party evidence is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer collaboration agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company&amp;#x2019;s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Pursuant to ASC 605-25, each required deliverable under the Pfizer collaboration agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company&amp;#x2019;s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company&amp;#x2019;s technology and the related proprietary nature of the Company&amp;#x2019;s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the contract and will be combined with the research and development services (including participation on a joint steering committee). &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Pursuant to ASC 605-28, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Revenue Recognition&amp;#x2014;Milestone Method&lt;/font&gt;&lt;font style="display:inline;"&gt;, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&amp;nbsp;the consideration is commensurate with either (1)&amp;nbsp;the entity&amp;#x2019;s performance to achieve the milestone, or (2)&amp;nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&amp;#x2019;s performance to achieve the milestone, (b)&amp;nbsp;the consideration relates solely to past performance and (c)&amp;nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&amp;#x2019;s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment. There were no revenue milestones met in the year ending December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">15027004</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">20070750</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="0">20035375</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">35375</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">18500</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="0">18500</us-gaap:Revenues>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Duration_3_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember" unitRef="Unit12" decimals="-5">3900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Duration_6_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-5">19700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Duration_1_1_2017_To_1_1_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember" unitRef="Unit12" decimals="-5">2800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following is a summary of the Company&amp;#x2019;s accrued expenses at December 31: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,513,243
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,423,220
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued license and milestone fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,000,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued consulting and other professional fees&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;148,579
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;242,227
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;315,002
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;281,152
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued employee benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;290,547
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;195,442
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued franchise and other taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,590
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,267,371
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,145,631
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;553,868
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;578,687
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;590,595
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock options and restricted stock units&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,817,674
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,235,775
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,806,980
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net operating loss carryforward&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34,451,814
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;24,745,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Capitalized start-up costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,708,479
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,986,272
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Patent amortization&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;216,203
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;238,378
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and orphan drug credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,988,522
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,110,590
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred rent&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;123,744
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;96,107
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,107,964
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,206,920
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;70,511
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;52,985
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total gross deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;54,667,237
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;39,436,788
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(54,667,237)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(39,436,788)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth the computation of basic and diluted earnings per share for the years ended December&amp;nbsp;31, 2016, 2015 and 2014: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(31,809,838)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(12,769,498)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11,121,566)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted net loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.50)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.67)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.60)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted weighted average common shares outstanding &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;21,256,312
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,010,587
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,452,252
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;U.S. Federal statutory tax rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;34.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;State taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Orphan drug credit&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.7)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.3)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(47.9)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(53.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(55.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Provision for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Calibri;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,033,005
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;802,329
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;512,345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,931,762
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,521,274
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,122,720
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,964,767
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,323,603
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,635,065
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table presents the future minimum lease payments as of December&amp;nbsp;31, 2016 under the Lease: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;YEAR&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AMOUNT&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;941,822
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;965,368
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;989,502
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,014,239
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,039,595
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;After 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,972,254
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6,922,780
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following is a summary of RSU activity for the 2013 Plan for the year ended December&amp;nbsp;31, 2016: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;NUMBER&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;GRANT DATE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OF SHARES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;FAIR VALUE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Unvested at December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,833
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;14,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.61
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,417
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.62
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Unvested at December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,916
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.04
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:49.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,328,597)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,854,693)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,071,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,554,978)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss per share&amp;#x2014;basic and diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.36)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.34)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.41)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.40)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:50.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Quarter Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;35,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,035,375
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net (loss) income&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(8,881,703)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,168,071)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10,389,405
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,109,129)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;(Loss) income per share&amp;#x2014;basic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.47)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.38)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.37)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;(Loss) income per share&amp;#x2014;diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.47)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.38)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.51
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.37)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AGGREGATE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;REMAINING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;INTRINSIC&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXERCISE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;CONTRACTUAL&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;VALUE&amp;nbsp;(IN&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OPTIONS&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;PRICE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;TERM(YEARS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;THOUSANDS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,470,338
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;627,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.36
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,500)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.95
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(27,983)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.28
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,066,105
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;505
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested or expected to vest as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,057,409
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.9
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;500
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercisable as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;910,202
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WEIGHTED-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;REMAINING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AGGREGATE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;AVERAGE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;CONTRACTUAL TERM&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;INTRINSIC VALUE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;OPTIONS&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXERCISE PRICE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(YEARS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(IN THOUSANDS)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;758,187
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.27
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options exercised&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(28,368)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Options forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;729,819
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested or expected to vest as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;729,801
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.26
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,536
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercisable as of December&amp;nbsp;31,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;729,240
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.25
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,534
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected term &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;6.25 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;6.25 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;6.25 years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;68.98%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;80.76%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;90.27%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;1.70%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;1.70%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;2.14%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;0%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;12/31/2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;12/31/2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;NUMBER&amp;nbsp;OF&amp;nbsp;SHARES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;NUMBER&amp;nbsp;OF&amp;nbsp;SHARES&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXERCISE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;UNDERLYING&amp;nbsp;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;UNDERLYING&amp;nbsp;OUTSTANDING&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;PRICE&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;EXPIRATION&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WARRANTS&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;WARRANTS&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;PER&amp;nbsp;SHARE&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;DATE&lt;/font&gt;&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;236,632
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;259,907
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;July&amp;nbsp;18,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;301,986
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;301,986
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;January&amp;nbsp;16,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;15,250
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;January&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 33.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,544
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;25.92
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;October&amp;nbsp;13,&amp;nbsp;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:SecurityDeposit contextRef="As_Of_5_31_2016_us-gaap_StatementGeographicalAxis_glyc_RockvilleMember" unitRef="Unit12" decimals="0">52320</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">52320</us-gaap:SecurityDeposit>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Segment Information &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">1635065</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">2323603</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">2964767</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit13" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Unit13" decimals="INF">0.02083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit13" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Unit13" decimals="INF">0.02083</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="0">14500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">4.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="0">4833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="0">16916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">7.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="0">2417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">7.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="4">0.9027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="4">0.8076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="4">0.6898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="4">0.0214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="4">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit13" decimals="4">0.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="Duration_1_1_2017_To_1_1_2017_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">697500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_1_1_2017_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">2837201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="-3">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="-3">3534000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">910202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="INF">729240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">8.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit15" decimals="2">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">629232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">667258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="0">2275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">97707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">27983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">627250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">6.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">3.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="-3">505000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="-3">3536000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">1470338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="INF">758187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">2066105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="INF">729819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">8.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit15" decimals="2">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">7.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit15" decimals="2">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="-3">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="-3">3536000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">2057409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="INF">729801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">7.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit15" decimals="2">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">63865</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="0">2668712</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">50310</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit12" decimals="0">3053086</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit12" decimals="0">16024</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">7.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit15" decimals="2">1.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">6.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit15" decimals="2">5.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Stock-Based Compensation &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Compensation&amp;#x2014;Stock Compensation&lt;/font&gt;&lt;font style="display:inline;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A discussion of management&amp;#x2019;s methodology for developing some of the assumptions used in the valuation model follows: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Dividend Yield&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Volatility&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company&amp;#x2019;s initial public offering, there was not a market for the Company&amp;#x2019;s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&amp;#x2019;s historical volatility since its initial public offering to determine its expected volatility. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Risk-Free Interest Rate&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Term&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Expected Forfeiture Rate&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;#x2014;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_6_30_2016" unitRef="Unit15" decimals="2">6.10</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember" unitRef="Unit15" decimals="3">6.336</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_1_1_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember" unitRef="Unit15" decimals="3">6.228</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">30726326</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">1426593</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">18939838</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">19050204</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">23250023</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="0">2907419</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">30726</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">66150674</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">1428</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-63275409</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="0">50803428</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">125181463</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">18940</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-74396975</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">40471654</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">127619078</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">19049</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-87166473</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">35301131</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">154254193</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">23249</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="0">-118976311</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit13" decimals="1">0.1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">-30726326</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">9305359</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">4145584</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember" unitRef="Unit1" decimals="INF">668791</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_6_1_2016_To_6_30_2016" unitRef="Unit1" decimals="INF">3476793</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2017_To_1_1_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_glyc_AtMarketOfferingMember" unitRef="Unit1" decimals="INF">461989</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="INF">114836</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">157886</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="0">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="INF">99029</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">110366</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_EquityIncentivePlan2013Member" unitRef="Unit1" decimals="INF">3500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_glyc_StockIncentivePlan2003Member" unitRef="Unit1" decimals="INF">28368</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">-30726</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">21421</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">9305</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_10_20_2009_To_10_20_2009_us-gaap_StatementEquityComponentsAxis_glyc_SeriesA1ConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">38979412</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">57248219</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">57240169</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">8050</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">23601955</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">23597809</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">4146</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="0">134291</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">134134</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">157</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">114121</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="0">114012</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">109</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="As_Of_12_31_2016_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" unitRef="Unit12" decimals="0">7593921</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount contextRef="As_Of_12_31_2016_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" unitRef="Unit12" decimals="0">7394601</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Use of Estimates &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="INF">18452252</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="INF">19010587</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="INF">21256312</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>glyc-20161231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 8:17:09 AM-->
<!--Modified on: 3/1/2017 8:17:09 AM-->
<schema targetNamespace="http://glyc.com/20161231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:glyc="http://glyc.com/20161231" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://glyc.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>40401 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetail" id="DisclosurePropertyAndEquipmentDetail">
        <link:definition>40501 - Disclosure - Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" id="DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail">
        <link:definition>40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" id="DisclosureOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" id="DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail">
        <link:definition>40901 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" id="DisclosureNetLossPerShareOfCommonStock">
        <link:definition>10301 - Disclosure - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10401 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>10501 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10601 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>10701 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10801 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10901 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" id="DisclosureResearchAndLicenseAgreements">
        <link:definition>11001 - Disclosure - Research and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11101 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnaudited" id="DisclosureQuarterlyFinancialInformationUnaudited">
        <link:definition>11201 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" id="DisclosureNetLossPerShareOfCommonStockTables">
        <link:definition>30303 - Disclosure - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>30503 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30603 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>30703 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30803 - Disclosure - Stockholders Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30903 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedTables" id="DisclosureQuarterlyFinancialInformationUnauditedTables">
        <link:definition>31203 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" id="DisclosureDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>40101 - Disclosure - Description of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureNetLossIncomePerShareOfCommonStockDetail" id="DisclosureNetLossIncomePerShareOfCommonStockDetail">
        <link:definition>40301 - Disclosure - Net (Loss) Income Per Share of Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityPreferredAndCommonStockDetail" id="DisclosureStockholdersEquityPreferredAndCommonStockDetail">
        <link:definition>40801 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetail" id="DisclosureStockholdersEquityCommonStockWarrantsDetail">
        <link:definition>40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetail" id="DisclosureStockholdersEquityIncentivePlansDetail">
        <link:definition>40803 - Disclosure - Stockholders' Equity - Incentive Plans (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail" id="DisclosureStockholdersEquityCompanySStockOptionActivityDetail">
        <link:definition>40804 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" id="DisclosureStockholdersEquityWeightedAverageAssumptionsDetail">
        <link:definition>40805 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail" id="DisclosureStockholdersEquitySummaryOfRsuActivityDetail">
        <link:definition>40806 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" id="DisclosureStockholdersEquityStockBasedCompensationExpenseDetail">
        <link:definition>40807 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>40902 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" id="DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail">
        <link:definition>40903 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail" id="DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>41001 - Disclosure - Research and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>41101 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedDetail" id="DisclosureQuarterlyFinancialInformationUnauditedDetail">
        <link:definition>41201 - Disclosure - Quarterly Financial Information (Unaudited) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20161231_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20161231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20161231_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20161231_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <element id="glyc_AccruedFranchiseAndOtherTaxes" name="AccruedFranchiseAndOtherTaxes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="glyc_AccruedLiabilitiesPolicyTextBlock" name="AccruedLiabilitiesPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_AccruedLicenseAndMilestoneFees" name="AccruedLicenseAndMilestoneFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="glyc_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" name="DeferredTaxAssetRecordedToAdditionalPaidInCapital" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="DeferredTaxAssetsCapitalizedStartUpCosts" id="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element name="DeferredTaxAssetsPatentAmortization" id="glyc_DeferredTaxAssetsPatentAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" id="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <element name="LaboratoryEquipmentMember" id="glyc_LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element name="NumberOfWarrantsExercised" id="glyc_NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <element name="SeriesA1ConvertiblePreferredStockMember" id="glyc_SeriesA1ConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <element id="glyc_SharesAuthorized" name="SharesAuthorized" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="glyc_UpfrontPaymentRecognitionPeriod" name="UpfrontPaymentRecognitionPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="WarrantsExercisedWeightedAverageExercisePrice" id="glyc_WarrantsExercisedWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <element name="RockvilleMember" id="glyc_RockvilleMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element name="EmployeeStockOptionsAndRestrictedStockUnitsMember" id="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="glyc_IncreaseDecreaseDeferredRentCredit" name="IncreaseDecreaseDeferredRentCredit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glyc_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" name="DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" name="PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" name="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" name="ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="glyc_EquityIncentivePlan2013Member" name="EquityIncentivePlan2013Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_StockIncentivePlan2003Member" name="StockIncentivePlan2003Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_UniversityOfBaselMember" name="UniversityOfBaselMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_PfizerMember" name="PfizerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_UniQuestPtyLimitedMember" name="UniQuestPtyLimitedMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" name="AchievementOfSpecifiedDevelopmentMilestoneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" name="AchievementOfSpecifiedRegulatoryMilestoneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" name="AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ResearchServicesAgreementMember" name="ResearchServicesAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" name="RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ArrangementsAndNonarrangementTransactionsLineItems" name="ArrangementsAndNonarrangementTransactionsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" name="PotentialPaymentForAchievementOfSpecifiedMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" name="NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" name="ProceedsFromPaymentsForContingentConsiderationOperatingActivities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ClassOfWarrantExpiring18july2018Member" name="ClassOfWarrantExpiring18july2018Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ClassOfWarrantExpiring16january2019Member" name="ClassOfWarrantExpiring16january2019Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ClassOfWarrantExpiring30january2019Member" name="ClassOfWarrantExpiring30january2019Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ClassOfWarrantExpiring13october2016Member" name="ClassOfWarrantExpiring13october2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="glyc_ClassOfWarrantOrRightExpirationsInPeriod" name="ClassOfWarrantOrRightExpirationsInPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" name="NumberOfLongLivedAssetsDeterminedToBeImpaired" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" name="RevenueRecognitionMilestoneMethodMilestonesAchieved" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_ResearchAndLicenseAgreementTextBlock" name="ResearchAndLicenseAgreementTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_FederalAndStateAuthoritiesMember" name="FederalAndStateAuthoritiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" name="NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>glyc-20161231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 8:17:09 AM-->
<!--Modified on: 3/1/2017 8:17:09 AM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef roleURI="http://glyc.com/role/StatementBalanceSheetsParenthetical" xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementBalanceSheetsParenthetical" />
  <roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail" xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityCompanySStockOptionActivityDetail" />
  <roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" />
  <roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail" xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquitySummaryOfRsuActivityDetail" />
  <roleRef roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" />
  <roleRef roleURI="http://glyc.com/role/DisclosureDescriptionOfBusiness" xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementBalanceSheets" roleURI="http://glyc.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementStatementsOfCashFlows" roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePropertyAndEquipmentDetail" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureOperatingLeasesDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" />
  <calculationLink xlink:role="http://glyc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636239530283479428" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_636239530283479428" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239530283479428" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636239530283479428" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239530283479428" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239530283479428" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636239530283479428" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239530283479428" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636239530283479428" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636239530283479428" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_636239530283479428" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_SecurityDeposit_636239530283479428" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_636239530283479428" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent_636239530283479428" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636239530283635427" xlink:to="us-gaap_LiabilitiesCurrent_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636239530283635427" xlink:to="us-gaap_AccountsPayableCurrent_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636239530283635427" xlink:to="us-gaap_AccruedBonusesCurrent_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636239530283635427" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636239530283635427" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636239530283635427" xlink:to="us-gaap_DeferredRentCreditCurrent_636239530283635427" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636239530283635427" xlink:to="us-gaap_DeferredRentCreditNoncurrent_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239530283635427" xlink:to="us-gaap_PreferredStockValue_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239530283635427" xlink:to="us-gaap_CommonStockValue_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239530283635427" xlink:to="us-gaap_AdditionalPaidInCapital_636239530283635427" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636239530283635427" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636239530283635427" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636239530283635427" xlink:to="us-gaap_Revenues_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636239530283635427" xlink:to="us-gaap_OperatingExpenses_636239530283635427" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636239530283635427" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636239530283635427" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636239530283635427" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636239530283635427" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636239530283635427" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_NetIncomeLoss_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_Depreciation_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636239530283635427" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_ShareBasedCompensation_636239530283635427" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239530283635427" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_636239530283635427" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_636239530283635427" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636239530283635427" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_636239530283635427" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseDeferredRentCredit" xlink:label="glyc_IncreaseDecreaseDeferredRentCredit_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530283635427" xlink:to="glyc_IncreaseDecreaseDeferredRentCredit_636239530283635427" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239530283635427" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239530283635427" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239530283635427" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636239530283635427" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="extended" xlink:title="40401 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_636239530283635427" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentDetail" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239530283635427" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="glyc_AccruedResearchAndDevelopmentExpenseCurrent_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedLicenseAndMilestoneFees" xlink:label="glyc_AccruedLicenseAndMilestoneFees_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="glyc_AccruedLicenseAndMilestoneFees_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636239530283635427" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_636239530283635427" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_636239530283635427" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedFranchiseAndOtherTaxes" xlink:label="glyc_AccruedFranchiseAndOtherTaxes_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="glyc_AccruedFranchiseAndOtherTaxes_636239530283635427" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239530283635427" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239530283635427" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_636239530283635427" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_636239530283635427" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_636239530283635427" xlink:to="us-gaap_DeferredTaxAssetsGross_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239530283635427" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239530283635427" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239530283635427" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_636239530283635427" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239530283635427" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_636239530283635427" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239530283635427" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636239530283635427" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239530283635427" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_636239530283635427" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239530283635427" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_636239530283635427" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636239530283635427" xlink:to="us-gaap_DeferredTaxAssetsOther_636239530283635427" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636239530283635427" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_636239530283635427" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636239530283635427" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>glyc-20161231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 8:17:09 AM-->
<!--Modified on: 3/1/2017 8:17:09 AM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementStatementsOfCashFlows" roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityTables" roleURI="http://glyc.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureNetLossIncomePerShareOfCommonStockDetail" roleURI="http://glyc.com/role/DisclosureNetLossIncomePerShareOfCommonStockDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePropertyAndEquipmentDetail" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureOperatingLeasesDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityPreferredAndCommonStockDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityPreferredAndCommonStockDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityCommonStockWarrantsDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityIncentivePlansDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityCompanySStockOptionActivityDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquitySummaryOfRsuActivityDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureIncomeTaxesAdditionalInformationDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesAdditionalInformationDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail" roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <definitionLink xlink:role="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239530283791426" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_636239530283791426" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SeriesA1ConvertiblePreferredStockMember" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="glyc_SeriesA1ConvertiblePreferredStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SeriesA1ConvertiblePreferredStockMember" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="glyc_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseDeferredRentCredit" xlink:label="glyc_IncreaseDecreaseDeferredRentCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="glyc_IncreaseDecreaseDeferredRentCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30803 - Disclosure - Stockholders Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_636239530283947425" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_StockIncentivePlan2003Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530283947425" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PfizerMember" xlink:label="glyc_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="glyc_PfizerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530283947425" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LicenseAgreementMember" xlink:label="glyc_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="glyc_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_636239530283947425" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_636239530283947425" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:to="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RevenueRecognitionAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UpfrontPaymentRecognitionPeriod" xlink:label="glyc_UpfrontPaymentRecognitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="glyc_UpfrontPaymentRecognitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" xlink:label="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530283947425" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="glyc_LaboratoryEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureNetLossIncomePerShareOfCommonStockDetail" xlink:type="extended" xlink:title="40301 - Disclosure - Net (Loss) Income Per Share of Common Stock (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636239530283947425" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentDetail" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="glyc_LaboratoryEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_636239530283947425" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RockvilleMember" xlink:label="glyc_RockvilleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="glyc_RockvilleMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRentCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityPreferredAndCommonStockDetail" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SeriesA1ConvertiblePreferredStockMember" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="glyc_SeriesA1ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636239530283947425" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AtMarketOfferingMember" xlink:label="glyc_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="glyc_AtMarketOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_636239530283947425" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SharesAuthorized" xlink:label="glyc_SharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="glyc_SharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" xlink:label="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetail" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636239530283947425" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636239530283947425" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring18july2018Member" xlink:label="glyc_ClassOfWarrantExpiring18july2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="glyc_ClassOfWarrantExpiring18july2018Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring16january2019Member" xlink:label="glyc_ClassOfWarrantExpiring16january2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="glyc_ClassOfWarrantExpiring16january2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring30january2019Member" xlink:label="glyc_ClassOfWarrantExpiring30january2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="glyc_ClassOfWarrantExpiring30january2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring13october2016Member" xlink:label="glyc_ClassOfWarrantExpiring13october2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="glyc_ClassOfWarrantExpiring13october2016Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfWarrantsExercised" xlink:label="glyc_NumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="glyc_NumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_WarrantsExercisedWeightedAverageExercisePrice" xlink:label="glyc_WarrantsExercisedWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="glyc_WarrantsExercisedWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="glyc_ClassOfWarrantOrRightExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="glyc_ClassOfWarrantOrRightExpirationsInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetail" xlink:type="extended" xlink:title="40803 - Disclosure - Stockholders' Equity - Incentive Plans (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_StockIncentivePlan2003Member" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_636239530284103424" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_636239530284103424" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail" xlink:type="extended" xlink:title="40804 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_StockIncentivePlan2003Member" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" xlink:type="extended" xlink:title="40805 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail" xlink:type="extended" xlink:title="40806 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="glyc_EquityIncentivePlan2013Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239530284103424" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239530284103424" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" xlink:type="extended" xlink:title="40807 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636239530284103424" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_636239530284103424" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes - Additional Information (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_636239530284103424" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_636239530284103424" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="glyc_FederalAndStateAuthoritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_636239530284103424" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_636239530284103424" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_GeneralBusinessMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" xlink:label="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail" xlink:type="extended" xlink:title="41001 - Disclosure - Research and License Agreements - Additional Information (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UniversityOfBaselMember" xlink:label="glyc_UniversityOfBaselMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="glyc_UniversityOfBaselMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PfizerMember" xlink:label="glyc_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="glyc_PfizerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UniQuestPtyLimitedMember" xlink:label="glyc_UniQuestPtyLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="glyc_UniQuestPtyLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LicenseAgreementMember" xlink:label="glyc_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="glyc_LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ResearchServicesAgreementMember" xlink:label="glyc_ResearchServicesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="glyc_ResearchServicesAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636239530284103424" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636239530284103424" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" xlink:label="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" xlink:label="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" xlink:label="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" xlink:label="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedLicenseAndMilestoneFees" xlink:label="glyc_AccruedLicenseAndMilestoneFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_AccruedLicenseAndMilestoneFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueAdditions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:label="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" xlink:label="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UpfrontPaymentRecognitionPeriod" xlink:label="glyc_UpfrontPaymentRecognitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_UpfrontPaymentRecognitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" xlink:label="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_ContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_LicenseCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" xlink:label="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Employee Benefit Plan (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeAxis" xlink:label="us-gaap_DefinedContributionPlanTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="us-gaap_DefinedContributionPlanTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DefinedContributionPlanTypeAxis" xlink:to="us-gaap_DefinedContributionPlanTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="us-gaap_DefinedContributionPlanTypeDomain_636239530284259423" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DefinedContributionPlanTypeAxis" xlink:to="us-gaap_DefinedContributionPlanTypeDomain_636239530284259423" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DefinedContributionPlanTypeDomain" xlink:to="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>glyc-20161231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 8:17:09 AM-->
<!--Modified on: 3/1/2017 8:17:09 AM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities &amp; stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonuses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock; $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2016 and December 31, 2015</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock; $0.001 par value; 100,000,000 shares authorized, 23,250,023 shares issued and outstanding at December 31, 2016; 100,000,000 shares authorized, 19,050,204 shares issued and outstanding at December 31, 2015</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Convertible preferred shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Statements of Operations and Comprehensive (Loss) Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">GeneralAndAdministrativeExpense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Loss per share - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted weighted average common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted weighted average number of common shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">(Loss) income per share&#x2014;basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">(Loss) income per share&#x2014;diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SeriesA1ConvertiblePreferredStockMember" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_SeriesA1ConvertiblePreferredStockMember" xlink:to="glyc_SeriesA1ConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A-1 Convertible Preferred Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A-1 Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Aggregate amount of preferred stock issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock, shares</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of stock options and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Options And Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_lbl" xml:lang="en-US">Exercise of options and warrants</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl" xml:lang="en-US">Number of share options (or share units) and warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Options And Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_lbl" xml:lang="en-US">Exercise of options and warrants, shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:to="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Increase decrease in prepaid research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Increase Decrease In Prepaid Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl" xml:lang="en-US">Increase (Decrease) in Deposits Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_lbl" xml:lang="en-US">Deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and bonuses</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseDeferredRentCredit" xlink:label="glyc_IncreaseDecreaseDeferredRentCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_IncreaseDecreaseDeferredRentCredit" xlink:to="glyc_IncreaseDecreaseDeferredRentCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_IncreaseDecreaseDeferredRentCredit_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the deferred rent credit obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_IncreaseDecreaseDeferredRentCredit_lbl" xml:lang="en-US">Increase Decrease Deferred Rent Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_IncreaseDecreaseDeferredRentCredit_lbl" xml:lang="en-US">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Property asset acquisition included in accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Series A convertible preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Description of the Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Description of the Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">This note contains 1)the entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income and 2) the entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure Of Stockholders Equity And Compensation Related Costs Share Based Payments Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of stockholders' equity and share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US">Revenue Recognition [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ResearchAndLicenseAgreementTextBlock" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ResearchAndLicenseAgreementTextBlock" xlink:to="glyc_ResearchAndLicenseAgreementTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US">The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US">Research And License Agreement Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_lbl" xml:lang="en-US">Research and License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US">Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">Quarterly Financial Information (Unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedLiabilitiesPolicyTextBlock" xlink:label="glyc_AccruedLiabilitiesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AccruedLiabilitiesPolicyTextBlock" xlink:to="glyc_AccruedLiabilitiesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AccruedLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for accrued liabilities including identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AccruedLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Liabilities Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AccruedLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Computation of Basic and Diluted Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Potentially Dilutive Securities Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Summary of Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Summary of Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Lease Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_StockIncentivePlan2003Member" xlink:to="glyc_StockIncentivePlan2003Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_StockIncentivePlan2003Member_lbl" xml:lang="en-US">Pertains to the 2003 Stock Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_StockIncentivePlan2003Member_lbl" xml:lang="en-US">Stock Incentive Plan2003 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_StockIncentivePlan2003Member_lbl" xml:lang="en-US">2003 Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EquityIncentivePlan2013Member" xlink:to="glyc_EquityIncentivePlan2013Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US">Pertaining to the 2013 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US">Equity Incentive Plan2013 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EquityIncentivePlan2013Member_lbl" xml:lang="en-US">2013 Equity Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Company's Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Weighted-Average Fair Value of Options Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of RSU Activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Gross Deferred Tax Asset and Related Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate of Income Tax Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Summary of Quarterly Financial Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PfizerMember" xlink:label="glyc_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_PfizerMember" xlink:to="glyc_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_PfizerMember_lbl" xml:lang="en-US">Pertaining to Pfizer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_PfizerMember_lbl" xml:lang="en-US">Pfizer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US">Deferred Revenue Arrangement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US">Deferred Revenue [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US">Up Front Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xml:lang="en-US">Up-Front Payment Arrangement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number Of Operating Segments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets measured at fair value levels 2 or 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liabilities measured at fair value levels 2 or 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Carrying value of cash held in money market fund</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" xlink:to="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" xml:lang="en-US">Represents the number of long-lived assets determined to be impaired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" xml:lang="en-US">Number Of Long Lived Assets Determined To Be Impaired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_lbl" xml:lang="en-US">Number of long-lived assets determined to be impaired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_lbl" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_lbl" xml:lang="en-US">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Deferred Revenue, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Upfront payment revenue recognized</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UpfrontPaymentRecognitionPeriod" xlink:label="glyc_UpfrontPaymentRecognitionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_UpfrontPaymentRecognitionPeriod" xlink:to="glyc_UpfrontPaymentRecognitionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US">Period of time over which the up-front payment received was recognized as revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US">Upfront Payment Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US">Recognition period of up-front payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Milestone revenue</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" xlink:label="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" xlink:to="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved_lbl" xml:lang="en-US">Represents the number of milestones achieved during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved_lbl" xml:lang="en-US">Revenue Recognition Milestone Method Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved_lbl" xml:lang="en-US">Number of milestones met</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Share-based Compensation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US">Share-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LaboratoryEquipmentMember" xlink:to="glyc_LaboratoryEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer Software Intangible Asset [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer Software</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US">Property and Equipment Estimated useful lives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net (Loss) Income Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Earnings Per Share, Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Anti-dilutive securities excluded</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Accrued Research And Development Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedLicenseAndMilestoneFees" xlink:label="glyc_AccruedLicenseAndMilestoneFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AccruedLicenseAndMilestoneFees" xlink:to="glyc_AccruedLicenseAndMilestoneFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AccruedLicenseAndMilestoneFees_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for license and milestone fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AccruedLicenseAndMilestoneFees_lbl" xml:lang="en-US">Accrued License And Milestone Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AccruedLicenseAndMilestoneFees_lbl" xml:lang="en-US">Accrued license and milestone fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="glyc_AccruedLicenseAndMilestoneFees_lbl" xml:lang="en-US">Milestone license fee liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued consulting and other professional fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedFranchiseAndOtherTaxes" xlink:label="glyc_AccruedFranchiseAndOtherTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AccruedFranchiseAndOtherTaxes" xlink:to="glyc_AccruedFranchiseAndOtherTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AccruedFranchiseAndOtherTaxes_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for franchise and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AccruedFranchiseAndOtherTaxes_lbl" xml:lang="en-US">Accrued Franchise and Other Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AccruedFranchiseAndOtherTaxes_lbl" xml:lang="en-US">Accrued franchise and other taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RockvilleMember" xlink:label="glyc_RockvilleMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_RockvilleMember" xlink:to="glyc_RockvilleMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_RockvilleMember_lbl" xml:lang="en-US">Information pertaining to Rockville Md location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_RockvilleMember_lbl" xml:lang="en-US">Rockville [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_RockvilleMember_lbl" xml:lang="en-US">Rockville</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US">Deferred Rent Credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating leases, rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">After 2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AtMarketOfferingMember" xlink:label="glyc_AtMarketOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AtMarketOfferingMember" xlink:to="glyc_AtMarketOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AtMarketOfferingMember_lbl" xml:lang="en-US">Pertains to the sale of common stock under an at-the-market sales agreement under a shelf registration statement filed March 2015.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AtMarketOfferingMember_lbl" xml:lang="en-US">At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AtMarketOfferingMember_lbl" xml:lang="en-US">At The Market Equity Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SharesAuthorized" xlink:label="glyc_SharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_SharesAuthorized" xlink:to="glyc_SharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_SharesAuthorized_lbl" xml:lang="en-US">The maximum number of shares of stock, including common stock and Series A-1 Convertible Preferred Stock, the entity is permitted to issue under the Amended and Restated Certificate of Incorporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_SharesAuthorized_lbl" xml:lang="en-US">Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_SharesAuthorized_lbl" xml:lang="en-US">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" xlink:label="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" xlink:to="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount_lbl" xml:lang="en-US">Represents the amount of principal and accrued interest related to an earlier bridge financing included as a portion of the Series A-1 Preferred Stock Purchase Agreement financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount_lbl" xml:lang="en-US">Conversion Of Bridge Financing Principal And Accrued Interest Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount_lbl" xml:lang="en-US">Conversion of prior Bridge financing principal and accrued interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Aggregate number of common stock shares converted from convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Weighted average price per share issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate net proceeds from stock sale</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring18july2018Member" xlink:label="glyc_ClassOfWarrantExpiring18july2018Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ClassOfWarrantExpiring18july2018Member" xlink:to="glyc_ClassOfWarrantExpiring18july2018Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ClassOfWarrantExpiring18july2018Member_lbl" xml:lang="en-US">Pertaining to the class of warrants expiring on July 18, 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ClassOfWarrantExpiring18july2018Member_lbl" xml:lang="en-US">Class Of Warrant Expiring18july2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ClassOfWarrantExpiring18july2018Member_lbl" xml:lang="en-US">Warrants expiring July 18, 2018</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring16january2019Member" xlink:label="glyc_ClassOfWarrantExpiring16january2019Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ClassOfWarrantExpiring16january2019Member" xlink:to="glyc_ClassOfWarrantExpiring16january2019Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ClassOfWarrantExpiring16january2019Member_lbl" xml:lang="en-US">Pertaining to the class of warrants expiring on January 16, 2019.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ClassOfWarrantExpiring16january2019Member_lbl" xml:lang="en-US">Class Of Warrant Expiring16january2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ClassOfWarrantExpiring16january2019Member_lbl" xml:lang="en-US">Warrants expiring January 16, 2019</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring30january2019Member" xlink:label="glyc_ClassOfWarrantExpiring30january2019Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ClassOfWarrantExpiring30january2019Member" xlink:to="glyc_ClassOfWarrantExpiring30january2019Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ClassOfWarrantExpiring30january2019Member_lbl" xml:lang="en-US">Pertaining to the class of warrants expiring on January 30, 2019.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ClassOfWarrantExpiring30january2019Member_lbl" xml:lang="en-US">Class Of Warrant Expiring30january2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ClassOfWarrantExpiring30january2019Member_lbl" xml:lang="en-US">Warrants expiring January 30, 2019</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring13october2016Member" xlink:label="glyc_ClassOfWarrantExpiring13october2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ClassOfWarrantExpiring13october2016Member" xlink:to="glyc_ClassOfWarrantExpiring13october2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ClassOfWarrantExpiring13october2016Member_lbl" xml:lang="en-US">Pertaining to the class of warrants expiring on October 13, 2016.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ClassOfWarrantExpiring13october2016Member_lbl" xml:lang="en-US">Class Of Warrant Expiring13october2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ClassOfWarrantExpiring13october2016Member_lbl" xml:lang="en-US">Warrants expiring October 13, 2016</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares underlying outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per share</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfWarrantsExercised" xlink:label="glyc_NumberOfWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NumberOfWarrantsExercised" xlink:to="glyc_NumberOfWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NumberOfWarrantsExercised_lbl" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NumberOfWarrantsExercised_lbl" xml:lang="en-US">Number Of Warrants Exercised</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_WarrantsExercisedWeightedAverageExercisePrice" xlink:label="glyc_WarrantsExercisedWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_WarrantsExercisedWeightedAverageExercisePrice" xlink:to="glyc_WarrantsExercisedWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_WarrantsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants Exercised Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_WarrantsExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Warrants Exercised Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="glyc_ClassOfWarrantOrRightExpirationsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ClassOfWarrantOrRightExpirationsInPeriod" xlink:to="glyc_ClassOfWarrantOrRightExpirationsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ClassOfWarrantOrRightExpirationsInPeriod_lbl" xml:lang="en-US">The number of warrants that expired during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ClassOfWarrantOrRightExpirationsInPeriod_lbl" xml:lang="en-US">Class Of Warrant Or Right Expirations In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ClassOfWarrantOrRightExpirationsInPeriod_lbl" xml:lang="en-US">Number of warrants expired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US">Incentive plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Percent of shares subject to option grant that will vest</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US">Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period After Termination Of Employment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_lbl" xml:lang="en-US">Period from date of termination that any vested options shall expire</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Period for unrecognized compensation expense related to unvested options yet has not been recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Shares vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award options exercises in period total intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Cash proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Fair value of shares vested</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Authorized Shares Disclosure Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_lbl" xml:lang="en-US">Authorized shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Common stock authorized under 2013 plan</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" xml:lang="en-US">Total automatic increase in number of shares of common stock reserved for issuance under the Plan on January 1 of each year, as a percent of the total number of common stock outstanding at December 31 of the prior year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" xml:lang="en-US">Percentage Of Total Number Of Common Stock Outstanding On Last Business Day Of Prior Fiscal Year That May Automatically Increase Under Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_lbl" xml:lang="en-US">Automatic increase in number of shares reserved for issuance as a percentage of the total common stock outstanding at the end of the prior year</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Maximum Shares Issued Upon Exercise Of Incentive Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_lbl" xml:lang="en-US">Maximum number of shares that may be issued pursuant to exercise of incentive stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Increase in number of shares of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">OUTSTANDING OPTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">WEIGHTED-AVERAGE EXERCISE PRICE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US">VESTED AND EXPECTED TO VEST</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Outstanding options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">ADDITIONAL DISCLOSURES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Outstanding options exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average contractual term (years) exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value (in thousands) exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average contractual term outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value (in thousands) outstanding at end of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average fair value of the options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Weighted-average assumptions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSU [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Restricted Stock Units information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested service RSUs</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments_lbl" xml:lang="en-US">Number of equal annual vesting installments of RSUs with service conditions provided that the employee remains employed with the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting Period Number Of Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments_lbl" xml:lang="en-US">Number of vesting installments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">NUMBER OF SHARES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Unvested at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">WEIGHTED-AVERAGE GRANT DATE FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Unvested at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Unvested at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US">Deferred tax assets capitalized start up costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US">Capitalized start-up costs</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetsPatentAmortization" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US">Deferred tax assets patent amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US">Deferred Tax Assets Patent Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_lbl" xml:lang="en-US">Patent amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and orphan drug credits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research tax credit carryforward</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralBusinessMember" xlink:to="us-gaap_GeneralBusinessMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US">General Business [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralBusinessMember_lbl" xml:lang="en-US">Orphan drug credit carryforward</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" xlink:label="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" xlink:to="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital_lbl" xml:lang="en-US">Amount of net operating losses to be recognized through additional paid-in-capital when realized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital_lbl" xml:lang="en-US">Deferred Tax Asset Recorded To Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital_lbl" xml:lang="en-US">NOL to be recognized in APIC when realized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credits available to carry forward</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. Federal statutory tax rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research credit</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US">Orphan drug credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" xlink:label="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" xlink:to="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_lbl" xml:lang="en-US">Pertaining to the achievement of specified development milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_lbl" xml:lang="en-US">Achievement Of Specified Development Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_lbl" xml:lang="en-US">Achievement Of Specified Development Milestone</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" xlink:label="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" xlink:to="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_lbl" xml:lang="en-US">Pertaining to the achievement of specified regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_lbl" xml:lang="en-US">Achievement Of Specified Regulatory Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_lbl" xml:lang="en-US">Achievement Of Specified Regulatory Milestone</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" xlink:label="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" xlink:to="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_lbl" xml:lang="en-US">Pertaining to the achievement of specified levels of annual net sales of licensed products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_lbl" xml:lang="en-US">Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_lbl" xml:lang="en-US">Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LicenseAgreementMember" xlink:label="glyc_LicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_LicenseAgreementMember" xlink:to="glyc_LicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_LicenseAgreementMember_lbl" xml:lang="en-US">Licensing arrangement between two or more parties that provides exclusive use of a pharmaceutical product or patent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ResearchServicesAgreementMember" xlink:label="glyc_ResearchServicesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ResearchServicesAgreementMember" xlink:to="glyc_ResearchServicesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ResearchServicesAgreementMember_lbl" xml:lang="en-US">Research agreement defining service expectations, which may include a royalty provision under research and development arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ResearchServicesAgreementMember_lbl" xml:lang="en-US">Research Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ResearchServicesAgreementMember_lbl" xml:lang="en-US">Research Services Agreement</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UniversityOfBaselMember" xlink:label="glyc_UniversityOfBaselMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_UniversityOfBaselMember" xlink:to="glyc_UniversityOfBaselMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_UniversityOfBaselMember_lbl" xml:lang="en-US">Pertaining to the University of Basel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_UniversityOfBaselMember_lbl" xml:lang="en-US">University Of Basel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_UniversityOfBaselMember_lbl" xml:lang="en-US">University Of Basel</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UniQuestPtyLimitedMember" xlink:label="glyc_UniQuestPtyLimitedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_UniQuestPtyLimitedMember" xlink:to="glyc_UniQuestPtyLimitedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_UniQuestPtyLimitedMember_lbl" xml:lang="en-US">Pertaining to UniQuest Pty Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_UniQuestPtyLimitedMember_lbl" xml:lang="en-US">Uni Quest Pty Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_UniQuestPtyLimitedMember_lbl" xml:lang="en-US">Uni Quest Pty Limited</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:to="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" xml:lang="en-US">Research And License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_lbl" xml:lang="en-US">Research and License Agreements</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" xlink:label="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" xlink:to="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent_lbl" xml:lang="en-US">Represents the royalty commitment due as a percent of the milestone payments received under licensing arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent_lbl" xml:lang="en-US">Royalty Commitment Due Against License Fees Received As A Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent_lbl" xml:lang="en-US">Royalty payment due against license fees received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAdditions" xlink:to="us-gaap_DeferredRevenueAdditions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xml:lang="en-US">Deferred Revenue, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueAdditions_lbl" xml:lang="en-US">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:label="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:to="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" xml:lang="en-US">Represents the potential payment that may be received upon achievement of specified milestones per agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" xml:lang="en-US">Potential Payment For Achievement Of Specified Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones_lbl" xml:lang="en-US">Potential milestone payments</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" xlink:label="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" xlink:to="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US">The number of indications that trigger payment of milestones under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US">Number Of Indications Triggering Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US">Number of indications</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" xlink:label="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" xlink:to="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement_lbl" xml:lang="en-US">The number of method-of-use patent applications secured by exclusive rights under a worldwide license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement_lbl" xml:lang="en-US">Number Of Method Of Use Patent Applications Under Exclusive Rights Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement_lbl" xml:lang="en-US">Number of method-of-use patents under exclusive rights license agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Milestone payment obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="us-gaap_LicenseCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US">License Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseCosts_lbl" xml:lang="en-US">License upfront fees</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" xlink:label="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" xlink:to="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities_lbl" xml:lang="en-US">Amount of cash inflow (outflow) related to contingent consideration receivable or payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities_lbl" xml:lang="en-US">Proceeds From Payments For Contingent Consideration Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities_lbl" xml:lang="en-US">Payment of milestone liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Company matching contribution percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Percent of employee contributions the company contributes a matching contribution</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Employer match contribution</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US">Employee Stock Options And Restricted Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_lbl" xml:lang="en-US">Stock Options and Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Upon first anniversary of start date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Each month after the first anniversary</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_FederalAndStateAuthoritiesMember" xlink:to="glyc_FederalAndStateAuthoritiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US">Designated tax department of the U. S. government and the designated tax department of the state government entitled to levy and collect income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US">Federal And State Authorities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="glyc_FederalAndStateAuthoritiesMember_lbl" xml:lang="en-US">U.S. Federal And State</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeAxis" xlink:label="us-gaap_DefinedContributionPlanTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTypeAxis" xlink:to="us-gaap_DefinedContributionPlanTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTypeAxis_lbl" xml:lang="en-US">Defined Contribution Plan Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="us-gaap_DefinedContributionPlanTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTypeDomain" xlink:to="us-gaap_DefinedContributionPlanTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTypeDomain_lbl" xml:lang="en-US">Defined Contribution Plan Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanTypeDomain_lbl" xml:lang="en-US">Defined Contribution Plan Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_lbl" xml:lang="en-US">Other Postretirement Benefit Plans Defined Benefit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_lbl" xml:lang="en-US">Other Postretirement Benefit Plan [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>glyc-20161231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/1/2017 8:17:09 AM-->
<!--Modified on: 3/1/2017 8:17:09 AM-->
<linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://glyc.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementBalanceSheets" roleURI="http://glyc.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://glyc.com/role/StatementBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://glyc.com/role/StatementStatementsOfStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#StatementStatementsOfCashFlows" roleURI="http://glyc.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureDescriptionOfBusiness" roleURI="http://glyc.com/role/DisclosureDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureNetLossPerShareOfCommonStock" roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePropertyAndEquipment" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipment" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureAccruedExpenses" roleURI="http://glyc.com/role/DisclosureAccruedExpenses" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureOperatingLeases" roleURI="http://glyc.com/role/DisclosureOperatingLeases" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquity" roleURI="http://glyc.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureIncomeTaxes" roleURI="http://glyc.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureResearchAndLicenseAgreements" roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlan" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureQuarterlyFinancialInformationUnaudited" roleURI="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnaudited" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureNetLossPerShareOfCommonStockTables" roleURI="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureAccruedExpensesTables" roleURI="http://glyc.com/role/DisclosureAccruedExpensesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureOperatingLeasesTables" roleURI="http://glyc.com/role/DisclosureOperatingLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityTables" roleURI="http://glyc.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureIncomeTaxesTables" roleURI="http://glyc.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureQuarterlyFinancialInformationUnauditedTables" roleURI="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedTables" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureDescriptionOfBusinessAdditionalInformationDetail" roleURI="http://glyc.com/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail" roleURI="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureNetLossIncomePerShareOfCommonStockDetail" roleURI="http://glyc.com/role/DisclosureNetLossIncomePerShareOfCommonStockDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" roleURI="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosurePropertyAndEquipmentDetail" roleURI="http://glyc.com/role/DisclosurePropertyAndEquipmentDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" roleURI="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureOperatingLeasesDetails" roleURI="http://glyc.com/role/DisclosureOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityPreferredAndCommonStockDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityPreferredAndCommonStockDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityCommonStockWarrantsDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityIncentivePlansDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityCompanySStockOptionActivityDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquitySummaryOfRsuActivityDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" roleURI="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureIncomeTaxesAdditionalInformationDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesAdditionalInformationDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" roleURI="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail" roleURI="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetails" />
  <roleRef xlink:type="simple" xlink:href="glyc-20161231.xsd#DisclosureQuarterlyFinancialInformationUnauditedDetail" roleURI="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedDetail" />
  <presentationLink xlink:role="http://glyc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_636239530284259423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_636239530284259423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_636239530284259423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_636239530284259423" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_636239530284259423" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_636239530284259423" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_636239530284259423" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_636239530284259423" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_636239530284259423" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_636239530284259423" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers_636239530284259423" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_636239530284259423" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_636239530284259423" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat_636239530284259423" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_636239530284259423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239530284259423" xlink:to="us-gaap_AssetsCurrentAbstract_636239530284259423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239530284259423" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239530284259423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239530284259423" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239530284259423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636239530284259423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636239530284259423" xlink:to="us-gaap_AssetsCurrent_636239530284259423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239530284259423" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239530284259423" xlink:to="us-gaap_PrepaidExpenseNoncurrent_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239530284259423" xlink:to="us-gaap_SecurityDeposit_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636239530284259423" xlink:to="us-gaap_Assets_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_LiabilitiesCurrentAbstract_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239530284415422" xlink:to="us-gaap_AccountsPayableCurrent_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239530284415422" xlink:to="us-gaap_AccruedBonusesCurrent_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239530284415422" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239530284415422" xlink:to="us-gaap_DeferredRentCreditCurrent_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636239530284415422" xlink:to="us-gaap_LiabilitiesCurrent_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_DeferredRentCreditNoncurrent_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_Liabilities_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_StockholdersEquityAbstract_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_PreferredStockValue_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_CommonStockValue_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_AdditionalPaidInCapital_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_StockholdersEquity_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636239530284415422" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_636239530284415422" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_Revenues_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_636239530284415422" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_636239530284415422" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract_636239530284415422" xlink:to="us-gaap_OperatingExpenses_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_636239530284415422" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_636239530284415422" order="9" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementEquityComponentsAxis_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SeriesA1ConvertiblePreferredStockMember" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284415422" xlink:to="glyc_SeriesA1ConvertiblePreferredStockMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284415422" xlink:to="us-gaap_CommonStockMember_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284415422" xlink:to="us-gaap_AdditionalPaidInCapitalMember_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284415422" xlink:to="us-gaap_RetainedEarningsMember_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284415422" xlink:to="us-gaap_EquityComponentDomain_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementLineItems_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockholdersEquity_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_SharesOutstanding_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636239530284415422" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_636239530284415422" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_636239530284415422" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_636239530284415422" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_NetIncomeLoss_636239530284415422" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6362395302844154221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_StockholdersEquity_6362395302844154221" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6362395302844154221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_SharesOutstanding_6362395302844154221" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementEquityComponentsAxis_636239530284415422" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284415422" xlink:to="us-gaap_EquityComponentDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SeriesA1ConvertiblePreferredStockMember" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239530284415422" xlink:to="glyc_SeriesA1ConvertiblePreferredStockMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementLineItems_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_NetIncomeLoss_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239530284415422" xlink:to="us-gaap_Depreciation_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239530284415422" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239530284415422" xlink:to="us-gaap_ShareBasedCompensation_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636239530284415422" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses" xlink:label="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" xlink:to="glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositsOutstanding" xlink:label="us-gaap_IncreaseDecreaseInDepositsOutstanding_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" xlink:to="us-gaap_IncreaseDecreaseInDepositsOutstanding_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_IncreaseDecreaseDeferredRentCredit" xlink:label="glyc_IncreaseDecreaseDeferredRentCredit_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636239530284415422" xlink:to="glyc_IncreaseDecreaseDeferredRentCredit_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636239530284415422" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6362395302844154221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6362395302844154221" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636239530284415422" xlink:to="us-gaap_IncomeTaxesPaid_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636239530284415422" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636239530284415422" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636239530284415422" xlink:to="us-gaap_ConversionOfStockAmountConverted1_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of the Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_636239530284415422" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock" xlink:type="extended" xlink:title="10301 - Disclosure - Net Loss Per Share of Common Stock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10401 - Disclosure - Prepaid Expenses and Other Current Assets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="10501 - Disclosure - Property and Equipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Expenses">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="10701 - Disclosure - Operating Leases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10801 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10901 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureResearchAndLicenseAgreements" xlink:type="extended" xlink:title="11001 - Disclosure - Research and License Agreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ResearchAndLicenseAgreementTextBlock" xlink:label="glyc_ResearchAndLicenseAgreementTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="glyc_ResearchAndLicenseAgreementTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11101 - Disclosure - Employee Benefit Plan">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_636239530284415422" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnaudited" xlink:type="extended" xlink:title="11201 - Disclosure - Quarterly Financial Information (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_636239530284415422" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_636239530284415422" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedLiabilitiesPolicyTextBlock" xlink:label="glyc_AccruedLiabilitiesPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="glyc_AccruedLiabilitiesPolicyTextBlock_636239530284415422" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_636239530284415422" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636239530284415422" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_636239530284415422" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_636239530284415422" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636239530284415422" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables" xlink:type="extended" xlink:title="30303 - Disclosure - Net Loss Per Share of Common Stock (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_635949355900350934" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635949355900350934" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_635949355900350934" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property and Equipment (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Expenses (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Operating Leases (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30803 - Disclosure - Stockholders Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StatementTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_PlanNameAxis_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636239530284415422" xlink:to="us-gaap_PlanNameDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284415422" xlink:to="glyc_StockIncentivePlan2003Member_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284415422" xlink:to="glyc_EquityIncentivePlan2013Member_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementLineItems_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_636239530284415422" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedTables" xlink:type="extended" xlink:title="31203 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:type="extended" xlink:title="40101 - Disclosure - Description of the Business - Additional Information (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_CounterpartyNameAxis_636239530284415422" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239530284415422" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PfizerMember" xlink:label="glyc_PfizerMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284415422" xlink:to="glyc_PfizerMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_RangeAxis_636239530284415422" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239530284415422" xlink:to="us-gaap_RangeMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239530284415422" xlink:to="us-gaap_MaximumMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_TypeOfArrangementAxis_636239530284415422" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239530284415422" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LicenseAgreementMember" xlink:label="glyc_LicenseAgreementMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530284415422" xlink:to="glyc_LicenseAgreementMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_636239530284415422" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis_636239530284415422" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain_636239530284415422" xlink:to="us-gaap_UpFrontPaymentArrangementMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" xlink:to="us-gaap_NumberOfOperatingSegments_636239530284415422" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" xlink:to="us-gaap_AssetsFairValueDisclosure_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired" xlink:label="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_636239530284415422" xlink:to="glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract_636239530284415422" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" xlink:to="us-gaap_RevenueRecognitionAbstract_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_636239530284415422" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UpfrontPaymentRecognitionPeriod" xlink:label="glyc_UpfrontPaymentRecognitionPeriod_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_636239530284415422" xlink:to="glyc_UpfrontPaymentRecognitionPeriod_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_636239530284415422" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved" xlink:label="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_636239530284415422" xlink:to="glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636239530284415422" xlink:to="us-gaap_ShareBasedCompensationAbstract_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_636239530284415422" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract_636239530284415422" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" xlink:to="us-gaap_RangeAxis_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239530284415422" xlink:to="us-gaap_RangeMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239530284415422" xlink:to="us-gaap_MinimumMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239530284415422" xlink:to="us-gaap_MaximumMember_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239530284415422" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_FurnitureAndFixturesMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="glyc_LaboratoryEquipmentMember_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_OfficeEquipmentMember_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_ComputerEquipmentMember_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureNetLossIncomePerShareOfCommonStockDetail" xlink:type="extended" xlink:title="40301 - Disclosure - Net (Loss) Income Per Share of Common Stock (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636239530284415422" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636239530284415422" xlink:to="us-gaap_WarrantMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember" xlink:label="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636239530284415422" xlink:to="glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementLineItems_636239530284415422" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636239530284415422" xlink:to="us-gaap_NetIncomeLoss_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636239530284415422" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636239530284415422" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="extended" xlink:title="40401 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DepositsAssetsCurrent_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosurePropertyAndEquipmentDetail" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_FurnitureAndFixturesMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LaboratoryEquipmentMember" xlink:label="glyc_LaboratoryEquipmentMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="glyc_LaboratoryEquipmentMember_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_OfficeEquipmentMember_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_ComputerEquipmentMember_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_LeaseholdImprovementsMember_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636239530284415422" xlink:to="us-gaap_ConstructionInProgressMember_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_636239530284415422" xlink:to="us-gaap_Depreciation_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="glyc_AccruedResearchAndDevelopmentExpenseCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="glyc_AccruedResearchAndDevelopmentExpenseCurrent_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedLicenseAndMilestoneFees" xlink:label="glyc_AccruedLicenseAndMilestoneFees_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="glyc_AccruedLicenseAndMilestoneFees_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedFranchiseAndOtherTaxes" xlink:label="glyc_AccruedFranchiseAndOtherTaxes_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="glyc_AccruedFranchiseAndOtherTaxes_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Operating Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_635965757867839709" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_635965757867839709" xlink:to="us-gaap_StatementTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementGeographicalAxis_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis_636239530284415422" xlink:to="us-gaap_SegmentGeographicalDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RockvilleMember" xlink:label="glyc_RockvilleMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain_636239530284415422" xlink:to="glyc_RockvilleMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementLineItems_636239530284415422" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_DeferredRentCredit_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_SecurityDeposit_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636239530284415422" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636239530284415422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityPreferredAndCommonStockDetail" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_636123947846234333" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_636123947846234333" xlink:to="us-gaap_StatementTable_636239530284415422" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636239530284415422" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636239530284415422" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636239530284415422" xlink:to="us-gaap_IPOMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AtMarketOfferingMember" xlink:label="glyc_AtMarketOfferingMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636239530284415422" xlink:to="glyc_AtMarketOfferingMember_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_StatementEquityComponentsAxis_636239530284415422" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284415422" xlink:to="us-gaap_EquityComponentDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SeriesA1ConvertiblePreferredStockMember" xlink:label="glyc_SeriesA1ConvertiblePreferredStockMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239530284415422" xlink:to="glyc_SeriesA1ConvertiblePreferredStockMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239530284415422" xlink:to="us-gaap_CommonStockMember_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239530284415422" xlink:to="us-gaap_PreferredStockMember_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_SubsequentEventTypeAxis_636239530284415422" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636239530284415422" xlink:to="us-gaap_SubsequentEventTypeDomain_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636239530284415422" xlink:to="us-gaap_SubsequentEventMember_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284415422" xlink:to="us-gaap_ClassOfStockLineItems_636239530284415422" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SharesAuthorized" xlink:label="glyc_SharesAuthorized_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636239530284415422" xlink:to="glyc_SharesAuthorized_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636239530284415422" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_PreferredStockSharesIssued_636239530284415422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_636239530284415422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount" xlink:label="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount_636239530284415422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_CommonStockSharesAuthorized_636239530284415422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636239530284415422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636239530284415422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_PreferredStockSharesAuthorized_636239530284415422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636239530284571421" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284415422" xlink:to="us-gaap_ConversionOfStockSharesConverted1_636239530284571421" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636239530284415422" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharesIssuedPricePerShare_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetail" xlink:type="extended" xlink:title="40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_636239530284571421" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636239530284571421" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring18july2018Member" xlink:label="glyc_ClassOfWarrantExpiring18july2018Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636239530284571421" xlink:to="glyc_ClassOfWarrantExpiring18july2018Member_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring16january2019Member" xlink:label="glyc_ClassOfWarrantExpiring16january2019Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636239530284571421" xlink:to="glyc_ClassOfWarrantExpiring16january2019Member_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring30january2019Member" xlink:label="glyc_ClassOfWarrantExpiring30january2019Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636239530284571421" xlink:to="glyc_ClassOfWarrantExpiring30january2019Member_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantExpiring13october2016Member" xlink:label="glyc_ClassOfWarrantExpiring13october2016Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636239530284571421" xlink:to="glyc_ClassOfWarrantExpiring13october2016Member_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_636239530284571421" xlink:to="us-gaap_StatementEquityComponentsAxis_636239530284571421" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284571421" xlink:to="us-gaap_EquityComponentDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239530284571421" xlink:to="us-gaap_CommonStockMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_636239530284571421" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_636239530284571421" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_636239530284571421" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfWarrantsExercised" xlink:label="glyc_NumberOfWarrantsExercised_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_636239530284571421" xlink:to="glyc_NumberOfWarrantsExercised_636239530284571421" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_WarrantsExercisedWeightedAverageExercisePrice" xlink:label="glyc_WarrantsExercisedWeightedAverageExercisePrice_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_636239530284571421" xlink:to="glyc_WarrantsExercisedWeightedAverageExercisePrice_636239530284571421" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ClassOfWarrantOrRightExpirationsInPeriod" xlink:label="glyc_ClassOfWarrantOrRightExpirationsInPeriod_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_636239530284571421" xlink:to="glyc_ClassOfWarrantOrRightExpirationsInPeriod_636239530284571421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetail" xlink:type="extended" xlink:title="40803 - Disclosure - Stockholders' Equity - Incentive Plans (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_636123922648061023" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_636123922648061023" xlink:to="us-gaap_StatementTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_StatementEquityComponentsAxis_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636239530284571421" xlink:to="us-gaap_EquityComponentDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636239530284571421" xlink:to="us-gaap_CommonStockMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_PlanNameAxis_636239530284571421" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636239530284571421" xlink:to="us-gaap_PlanNameDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284571421" xlink:to="glyc_StockIncentivePlan2003Member_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284571421" xlink:to="glyc_EquityIncentivePlan2013Member_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_VestingAxis_636239530284571421" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_636239530284571421" xlink:to="us-gaap_VestingDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_RangeAxis_636239530284571421" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239530284571421" xlink:to="us-gaap_RangeMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239530284571421" xlink:to="us-gaap_MaximumMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment" xlink:label="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636239530284571421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_636239530284571421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_636239530284571421" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636239530284571421" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239530284571421" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6362395302845714211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6362395302845714211" order="10" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_636239530284571421" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_636239530284571421" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_636239530284571421" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan" xlink:label="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_636239530284571421" xlink:to="glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_636239530284571421" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail" xlink:type="extended" xlink:title="40804 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" xlink:to="us-gaap_PlanNameAxis_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636239530284571421" xlink:to="us-gaap_PlanNameDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_StockIncentivePlan2003Member" xlink:label="glyc_StockIncentivePlan2003Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284571421" xlink:to="glyc_StockIncentivePlan2003Member_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284571421" xlink:to="glyc_EquityIncentivePlan2013Member_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239530284571421" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6362395302845714211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6362395302845714211" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6362395302845714211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6362395302845714211" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636239530284571421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636239530284571421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail" xlink:type="extended" xlink:title="40805 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" xlink:to="us-gaap_PlanNameAxis_636239530284571421" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636239530284571421" xlink:to="us-gaap_PlanNameDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284571421" xlink:to="glyc_EquityIncentivePlan2013Member_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239530284571421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail" xlink:type="extended" xlink:title="40806 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" xlink:to="us-gaap_AwardTypeAxis_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636239530284571421" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" xlink:to="us-gaap_PlanNameAxis_636239530284571421" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636239530284571421" xlink:to="us-gaap_PlanNameDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EquityIncentivePlan2013Member" xlink:label="glyc_EquityIncentivePlan2013Member_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636239530284571421" xlink:to="glyc_EquityIncentivePlan2013Member_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments" xlink:label="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636239530284571421" xlink:to="glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6362395302845714211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6362395302845714211" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6362395302845714211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636239530284571421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6362395302845714211" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail" xlink:type="extended" xlink:title="40807 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239530284571421" xlink:to="us-gaap_IncomeStatementLocationAxis_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636239530284571421" xlink:to="us-gaap_IncomeStatementLocationDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636239530284571421" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636239530284571421" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636239530284571421" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636239530284571421" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail" xlink:type="extended" xlink:title="40901 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="glyc_DeferredTaxAssetsCapitalizedStartUpCosts_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetsPatentAmortization" xlink:label="glyc_DeferredTaxAssetsPatentAmortization_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="glyc_DeferredTaxAssetsPatentAmortization_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_636239530284571421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_636239530284571421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="us-gaap_DeferredTaxAssetsOther_636239530284571421" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="us-gaap_DeferredTaxAssetsGross_636239530284571421" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636239530284571421" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636239530284571421" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="extended" xlink:title="40902 - Disclosure - Income Taxes - Additional Information (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_IncomeTaxAuthorityAxis_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_636239530284571421" xlink:to="us-gaap_IncomeTaxAuthorityDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_FederalAndStateAuthoritiesMember" xlink:label="glyc_FederalAndStateAuthoritiesMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_636239530284571421" xlink:to="glyc_FederalAndStateAuthoritiesMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_TaxCreditCarryforwardAxis_636239530284571421" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_636239530284571421" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_636239530284571421" xlink:to="us-gaap_ResearchMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="us-gaap_GeneralBusinessMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_636239530284571421" xlink:to="us-gaap_GeneralBusinessMember_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636239530284571421" xlink:to="us-gaap_StatementLineItems_636239530284571421" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284571421" xlink:to="us-gaap_OperatingLossCarryforwards_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital" xlink:label="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284571421" xlink:to="glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284571421" xlink:to="us-gaap_TaxCreditCarryforwardAmount_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636239530284571421" xlink:to="us-gaap_UnrecognizedTaxBenefits_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail" xlink:type="extended" xlink:title="40903 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_636239530284571421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_636239530284571421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636239530284571421" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail" xlink:type="extended" xlink:title="41001 - Disclosure - Research and License Agreements - Additional Information (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract_636095289680996341" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_636095289680996341" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" xlink:to="us-gaap_StatementScenarioAxis_636239530284571421" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_636239530284571421" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedDevelopmentMilestoneMember" xlink:label="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636239530284571421" xlink:to="glyc_AchievementOfSpecifiedDevelopmentMilestoneMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedRegulatoryMilestoneMember" xlink:label="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636239530284571421" xlink:to="glyc_AchievementOfSpecifiedRegulatoryMilestoneMember_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember" xlink:label="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636239530284571421" xlink:to="glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" xlink:to="us-gaap_TypeOfArrangementAxis_636239530284571421" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636239530284571421" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_LicenseAgreementMember" xlink:label="glyc_LicenseAgreementMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530284571421" xlink:to="glyc_LicenseAgreementMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ResearchServicesAgreementMember" xlink:label="glyc_ResearchServicesAgreementMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636239530284571421" xlink:to="glyc_ResearchServicesAgreementMember_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" xlink:to="us-gaap_CounterpartyNameAxis_636239530284571421" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636239530284571421" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UniversityOfBaselMember" xlink:label="glyc_UniversityOfBaselMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284571421" xlink:to="glyc_UniversityOfBaselMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PfizerMember" xlink:label="glyc_PfizerMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284571421" xlink:to="glyc_PfizerMember_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UniQuestPtyLimitedMember" xlink:label="glyc_UniQuestPtyLimitedMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636239530284571421" xlink:to="glyc_UniQuestPtyLimitedMember_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_636239530284571421" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis_636239530284571421" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain_636239530284571421" xlink:to="us-gaap_UpFrontPaymentArrangementMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" xlink:to="us-gaap_RangeAxis_636239530284571421" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239530284571421" xlink:to="us-gaap_RangeMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239530284571421" xlink:to="us-gaap_MaximumMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ArrangementsAndNonarrangementTransactionsLineItems" xlink:label="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_636239530284571421" xlink:to="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent" xlink:label="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_AccruedLicenseAndMilestoneFees" xlink:label="glyc_AccruedLicenseAndMilestoneFees_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="glyc_AccruedLicenseAndMilestoneFees_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueAdditions" xlink:label="us-gaap_DeferredRevenueAdditions_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="us-gaap_DeferredRevenueAdditions_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_PotentialPaymentForAchievementOfSpecifiedMilestones" xlink:label="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="glyc_PotentialPaymentForAchievementOfSpecifiedMilestones_636239530284571421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement" xlink:label="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement_636239530284571421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_636239530284571421" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_UpfrontPaymentRecognitionPeriod" xlink:label="glyc_UpfrontPaymentRecognitionPeriod_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="glyc_UpfrontPaymentRecognitionPeriod_636239530284571421" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement" xlink:label="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement_636239530284571421" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="us-gaap_ContractualObligation_636239530284571421" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="us-gaap_LicenseCosts_636239530284571421" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636239530284571421" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="glyc-20161231.xsd#glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities" xlink:label="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_ArrangementsAndNonarrangementTransactionsLineItems_636239530284571421" xlink:to="glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities_636239530284571421" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Employee Benefit Plan (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_636229180097601086" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_636229180097601086" xlink:to="us-gaap_DefinedContributionPlanTable_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_636239530284571421" xlink:to="us-gaap_RangeAxis_636239530284571421" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636239530284571421" xlink:to="us-gaap_RangeMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636239530284571421" xlink:to="us-gaap_MaximumMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeAxis" xlink:label="us-gaap_DefinedContributionPlanTypeAxis_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_636239530284571421" xlink:to="us-gaap_DefinedContributionPlanTypeAxis_636239530284571421" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTypeDomain" xlink:label="us-gaap_DefinedContributionPlanTypeDomain_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTypeAxis_636239530284571421" xlink:to="us-gaap_DefinedContributionPlanTypeDomain_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTypeDomain_636239530284571421" xlink:to="us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_636239530284571421" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_636239530284571421" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_636239530284571421" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_636239530284571421" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_636239530284571421" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedDetail" xlink:type="extended" xlink:title="41201 - Disclosure - Quarterly Financial Information (Unaudited) (Detail)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_Revenues_636239530284571421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss_636239530284571421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636239530284571421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasic_636239530284571421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_636239530284571421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_636239530284571421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801333856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 27, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GLYCOMIMETICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,329,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801717840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,041,641<span></span>
</td>
<td class="nump">$ 46,802,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">478,503<span></span>
</td>
<td class="nump">441,810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">40,520,144<span></span>
</td>
<td class="nump">47,244,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,056,332<span></span>
</td>
<td class="nump">521,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid research and development expenses</a></td>
<td class="nump">759,531<span></span>
</td>
<td class="nump">696,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Deposits</a></td>
<td class="nump">52,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">42,388,327<span></span>
</td>
<td class="nump">48,462,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,565,210<span></span>
</td>
<td class="nump">564,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">1,432,485<span></span>
</td>
<td class="nump">1,037,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,267,371<span></span>
</td>
<td class="nump">6,145,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">68,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,333,617<span></span>
</td>
<td class="nump">7,746,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">753,579<span></span>
</td>
<td class="nump">243,647<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,087,196<span></span>
</td>
<td class="nump">7,990,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2016 and December 31, 2015</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.001 par value; 100,000,000 shares authorized, 23,250,023 shares issued and outstanding at December 31, 2016; 100,000,000 shares authorized, 19,050,204 shares issued and outstanding at December 31, 2015</a></td>
<td class="nump">23,249<span></span>
</td>
<td class="nump">19,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">154,254,193<span></span>
</td>
<td class="nump">127,619,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(118,976,311)<span></span>
</td>
<td class="num">(87,166,473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">35,301,131<span></span>
</td>
<td class="nump">40,471,654<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 42,388,327<span></span>
</td>
<td class="nump">$ 48,462,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801565664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">23,250,023<span></span>
</td>
<td class="nump">19,050,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">23,250,023<span></span>
</td>
<td class="nump">19,050,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6786216672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations and Comprehensive (Loss) Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="nump">$ 20,070,750<span></span>
</td>
<td class="nump">$ 15,027,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">23,281,820<span></span>
</td>
<td class="nump">25,050,179<span></span>
</td>
<td class="nump">19,571,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">8,650,165<span></span>
</td>
<td class="nump">7,805,396<span></span>
</td>
<td class="nump">6,595,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">31,931,985<span></span>
</td>
<td class="nump">32,855,575<span></span>
</td>
<td class="nump">26,166,811<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(31,913,485)<span></span>
</td>
<td class="num">(12,784,825)<span></span>
</td>
<td class="num">(11,139,807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">103,647<span></span>
</td>
<td class="nump">15,327<span></span>
</td>
<td class="nump">18,241<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (31,809,838)<span></span>
</td>
<td class="num">$ (12,769,498)<span></span>
</td>
<td class="num">$ (11,121,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common shares (in shares)</a></td>
<td class="nump">21,256,312<span></span>
</td>
<td class="nump">19,010,587<span></span>
</td>
<td class="nump">18,452,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807579536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Series A-1 Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 30,726<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">$ 66,150,674<span></span>
</td>
<td class="num">$ (63,275,409)<span></span>
</td>
<td class="nump">$ 2,907,419<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2013</a></td>
<td class="nump">30,726,326<span></span>
</td>
<td class="nump">1,426,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,050<span></span>
</td>
<td class="nump">57,240,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,248,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">134,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (30,726)<span></span>
</td>
<td class="nump">$ 9,305<span></span>
</td>
<td class="nump">21,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock, shares</a></td>
<td class="num">(30,726,326)<span></span>
</td>
<td class="nump">9,305,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,635,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,121,566)<span></span>
</td>
<td class="num">(11,121,566)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,940<span></span>
</td>
<td class="nump">125,181,463<span></span>
</td>
<td class="num">(74,396,975)<span></span>
</td>
<td class="nump">50,803,428<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,939,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">114,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,323,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,323,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,769,498)<span></span>
</td>
<td class="num">(12,769,498)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,049<span></span>
</td>
<td class="nump">127,619,078<span></span>
</td>
<td class="num">(87,166,473)<span></span>
</td>
<td class="nump">40,471,654<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,050,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,146<span></span>
</td>
<td class="nump">23,597,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,601,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,145,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Exercise of options and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">72,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Exercise of options and warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,964,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,964,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,809,838)<span></span>
</td>
<td class="num">(31,809,838)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,249<span></span>
</td>
<td class="nump">$ 154,254,193<span></span>
</td>
<td class="num">$ (118,976,311)<span></span>
</td>
<td class="nump">$ 35,301,131<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,250,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) and warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801627568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,809,838)<span></span>
</td>
<td class="num">$ (12,769,498)<span></span>
</td>
<td class="num">$ (11,121,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">190,540<span></span>
</td>
<td class="nump">191,484<span></span>
</td>
<td class="nump">158,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,964,767<span></span>
</td>
<td class="nump">2,323,603<span></span>
</td>
<td class="nump">1,635,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(36,693)<span></span>
</td>
<td class="nump">474,439<span></span>
</td>
<td class="nump">1,656,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="num">(63,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(696,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositsOutstanding', window );">Deposits</a></td>
<td class="num">(52,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,000,975<span></span>
</td>
<td class="num">(309,792)<span></span>
</td>
<td class="num">(270,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and bonuses</a></td>
<td class="num">(2,504,179)<span></span>
</td>
<td class="nump">1,693,238<span></span>
</td>
<td class="nump">4,459,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_IncreaseDecreaseDeferredRentCredit', window );">Deferred rent</a></td>
<td class="nump">578,483<span></span>
</td>
<td class="nump">146,635<span></span>
</td>
<td class="num">(103,935)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(29,731,265)<span></span>
</td>
<td class="num">(8,241,890)<span></span>
</td>
<td class="num">(4,281,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(704,202)<span></span>
</td>
<td class="num">(268,594)<span></span>
</td>
<td class="num">(212,603)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(704,202)<span></span>
</td>
<td class="num">(268,594)<span></span>
</td>
<td class="num">(212,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">23,601,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,248,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">72,593<span></span>
</td>
<td class="nump">114,121<span></span>
</td>
<td class="nump">134,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">23,674,548<span></span>
</td>
<td class="nump">114,121<span></span>
</td>
<td class="nump">57,382,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(6,760,919)<span></span>
</td>
<td class="num">(8,396,363)<span></span>
</td>
<td class="nump">52,888,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">46,802,560<span></span>
</td>
<td class="nump">55,198,923<span></span>
</td>
<td class="nump">2,310,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">40,041,641<span></span>
</td>
<td class="nump">$ 46,802,560<span></span>
</td>
<td class="nump">55,198,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property asset acquisition included in accrued expenses</a></td>
<td class="nump">$ 21,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series A convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,805,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_IncreaseDecreaseDeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the deferred rent credit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_IncreaseDecreaseDeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in prepaid research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in monies given as security or collateral for items acquired or borrowed on a temporary basis. Deposits may also be paid as initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797463616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text"><div> <div>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">1. Description of the Business </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated on April&nbsp;4, 2003 and commenced operations on May&nbsp;21, 2003. The company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company has incurred significant losses in the development of its drug candidates. The losses in prior periods were primarily attributable to the research and development of the Company&#x2019;s first drug candidate, rivipansel, as well as GMI-1271 and GMI-1359. The Company has not generated revenues from product sales. As a result, the Company has consistently reported negative cash flows from operating activities and net losses, had an accumulated deficit of $118,976,311 at December&nbsp;31, 2016 and expects to continue incurring losses for the foreseeable future. The Company currently anticipates that its cash and cash equivalents will be sufficient to meet its anticipated cash requirements into the second quarter of 2018. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s operations are subject to certain risks and uncertainties. The risks include the need to manage growth, the need to retain key personnel, the need to protect intellectual property, the availability of additional capital financing on terms acceptable to the Company and reliance on its collaboration with Pfizer Inc. (Pfizer). The Company&#x2019;s current operating assumptions and projections, which reflect management&#x2019;s best estimate of future revenue and operating expenses, indicate that anticipated operating expenditures into the second quarter of 2018 can be met by available working capital; however, the Company&#x2019;s ability to meet its projections is subject to uncertainties, and there can be no assurance that the Company&#x2019;s current projections will be accurate. If the Company&#x2019;s cash requirements are more than projected, the Company may require additional financing. The type, timing and terms of financing selected by the Company, if required, will be dependent upon the Company&#x2019;s cash needs, the availability of financing sources and the prevailing conditions in the financial markets. There can be no assurance that such financing will be available to the Company at any given time or available on favorable terms. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Management believes that the Company has access to capital resources through private investments of equity from its existing stockholders. However, it has not secured any commitment for new financing as of the date of this report, nor can it provide any assurance that new financing will be available on commercially acceptable terms, if at all. If the Company is unable to secure additional capital, it will be required to curtail its operations, and if these measures fail, it may not be able to continue its business. Curtailment of operations would cause significant delays in the Company&#x2019;s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6782742400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2. Summary of Significant Accounting Policies </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Basis of Accounting </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Segment Information </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Use of Estimates </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December&nbsp;31, 2016 and 2015, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, </font><font style="display:inline;font-style:italic;">Fair Value Measurements</font><font style="display:inline;">. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 2&#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December&nbsp;31, 2016 and 2015. The carrying value of cash held in money market funds of approximately $38.0 million and $45.5 million as of December&nbsp;31, 2016 and 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;font-style:italic;">Concentration of Credit Risk</font><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Property and Equipment </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.60%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">ESTIMATED&nbsp;USEFUL&nbsp;LIVES</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">7&nbsp;years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer software</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp; life</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Impairment of Long-Lived Assets </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="display:inline;font-style:italic;">Property, Plant, and Equipment</font><font style="display:inline;">. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&nbsp;31, 2016 and 2015, the Company determined that there were no impaired assets and had no assets held for sale. </font>
		</p>
		<p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Revenue Recognition </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has entered into a collaborative research and development agreement with Pfizer. The agreement is in the form of a license agreement. The agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the arrangement that contain material financial consequences to the Company. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The primary deliverable under this arrangement is an exclusive worldwide license to the Company&#x2019;s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer&#x2019;s behalf. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of ASC 605-25, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Multiple-Element Arrangements</font><font style="display:inline;">, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1)&nbsp;the delivered item(s) has value to the customer on a stand-alone basis and (2)&nbsp;if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i)&nbsp;vendor-specific objective evidence (VSOE), if available; (ii)&nbsp;third-party evidence (TPE) of selling price if VSOE is not available; or (iii)&nbsp;an estimated selling price, if neither VSOE nor third-party evidence is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer collaboration agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company&#x2019;s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to ASC 605-25, each required deliverable under the Pfizer collaboration agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company&#x2019;s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company&#x2019;s technology and the related proprietary nature of the Company&#x2019;s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the contract and will be combined with the research and development services (including participation on a joint steering committee). </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to ASC 605-28, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Milestone Method</font><font style="display:inline;">, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#x2019;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#x2019;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#x2019;s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment. There were no revenue milestones met in the year ending December 31, 2016.</font>
		</p>
		<p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;"> Accrued Liabilities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company&#x2019;s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i)&nbsp;an evaluation by the project manager of the work that has been completed during the period; (ii)&nbsp;measurement of progress prepared internally and/or provided by the third-party service provider; (iii)&nbsp;analyses of data that justify the progress; and (iv)&nbsp;the Company&#x2019;s judgment.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Costs </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Stock-Based Compensation </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&#x2014;Stock Compensation</font><font style="display:inline;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows: </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Dividend Yield</font><font style="display:inline;">&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Volatility</font><font style="display:inline;">&#x2014;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company&#x2019;s initial public offering, there was not a market for the Company&#x2019;s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#x2019;s historical volatility since its initial public offering to determine its expected volatility. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Risk-Free Interest Rate</font><font style="display:inline;">&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Term</font><font style="display:inline;">&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Forfeiture Rate</font><font style="display:inline;">&#x2014;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font><font style="display:inline;font-weight:bold;font-style:italic;">Income Taxes </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,</font><font style="display:inline;font-style:italic;"> Income Taxes</font><font style="display:inline;">. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Comprehensive Loss </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&nbsp;31, 2016, 2015 and 2014, the Company&#x2019;s net loss equals comprehensive loss and, accordingly, no additional disclosure is presented. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recently Issued Accounting Standards </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;">On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. The Company is evaluating the Pfizer collaboration agreement to determine the impact of the new revenue standard on the upfront and milestone payments within this specific collaboration agreement. The Company intends to select a transition method in the second quarter 2017 and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.</font>
		</p>
		<p style="margin:0pt;font-family:Georgia;color:#000000;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"> On August 27, 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern, which requires management to assess a company&#x2019;s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Before this new standard, there was minimal guidance in U.S. GAAP specific to going concern. Under the new standard, disclosures are required when conditions give rise to substantial doubt about a company&#x2019;s ability to continue as a going concern within one year from the financial statement issuance date. The Company adopted the standard for the reporting period ending December 31, 2016.</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).&nbsp;&nbsp;The final guidance will require lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. This standard is effective for annual reporting periods beginning after December&nbsp;15, 2018. Early adoption will be permitted.&nbsp;&nbsp;The Company is currently evaluating the effect the new standard will have on the Company. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In March 2016, the FASB issued ASU No. 2016-09, Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&nbsp;&nbsp;The ASU includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in financial statements including the income tax effects of share-based payments, minimum statutory withholding requirements and forfeitures. The new guidance will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It will also allow an employer to repurchase more of an employee&#x2019;s shares than the current standard for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. This ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. In evaluation of the new standard, the Company will elect a policy at adoption of the standard to account for forfeitures as they occur. &nbsp;The Company has evaluated the standard and has determined the implementation will not have a material impact on the financial statements.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With the exception of the new standards discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797505568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share of Common Stock</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">3. Net Loss Per Share of Common Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per share is computed by dividing net income by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method was used to determine the dilutive effect of the Company&#x2019;s stock option grants, restricted stock units and warrants. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth the computation of basic and diluted earnings per share for the years ended December&nbsp;31, 2016, 2015 and 2014: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,809,838)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769,498)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,121,566)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.50)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.67)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted weighted average common shares outstanding </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,256,312
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,587
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,452,252
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following potentially dilutive securities outstanding at December&nbsp;31, 2016, 2015 and 2014 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>553,868
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>578,687
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock options and restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,817,674
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,235,775
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,806,980
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6654843776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4. Prepaid Expenses and Other Current Assets </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of the Company&#x2019;s prepaid expenses and other current assets at December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>199,195
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>393,857
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other receivables</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>268,659
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,683
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deposits</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,649
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,270
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478,503
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>441,810
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797462816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">5. Property and Equipment </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment, net consisted of the following at December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>262,135
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,987
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,130,180
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,586
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,610
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,723
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,423
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,053
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Construction in progress</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>508,417
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,112,893
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,423,477
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Less accumulated depreciation</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,056,561)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(902,099)
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,056,332
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,378
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Depreciation of property and equipment totaled $190,540, &nbsp;$191,484 and&nbsp;$158,708 for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6783795728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">6. Accrued Expenses </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of the Company&#x2019;s accrued expenses at December 31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,513,243
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423,220
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued license and milestone fees</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,000,000
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued consulting and other professional fees</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148,579
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242,227
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315,002
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,152
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>290,547
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,442
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued franchise and other taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,590
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,267,371
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,145,631
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807226816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Operating Leases</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">7. Operating Leases </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The Company leases office and research space in Rockville, Maryland under an operating lease with a term through October 31, 2023 (as amended to date, the Lease) that is subject to annual rent increases. The Company has the right to sublease or assign all or a portion of the premises, subject to the conditions set forth in the Lease. The Lease may be terminated early by either the landlord or the Company in certain circumstances.&nbsp;&nbsp;In connection with the Lease, the Company received rent abatement as a lease incentive. The annual rent increases and rent abatement have been recognized as deferred rent that is being adjusted on a straight-line basis over the term of the Lease.</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In March 2016, the Company amended the Lease (the Lease Amendment) to lease additional space beginning on June 1, 2016. In addition to the other terms of the Lease, the Lease Amendment provided for a tenant improvement allowance reflected in the Company&#x2019;s financial statements as an increase in capitalized leasehold improvements as incurred and an increase in deferred rent. In May 2016, the Company also paid a security deposit of $52,320 to be held until the expiration or termination of the Company&#x2019;s obligations under the Lease. The term of the Lease Amendment for the additional space continues through October 31, 2023, the same date as for the premises originally leased under the Lease, subject to the Company&#x2019;s renewal option set forth in the Lease. The Company also has a one-time option to terminate the Lease effective as of October 31, 2020. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Deferred rent related to the Lease was $822,130 and $243,647 at December 31, 2016 and December 31, 2015, respectively. Total rent expense under the Company&#x2019;s leases was $784,739, &nbsp;$595,497 &nbsp;and $385,668 for the years ended December 31, 2016, 2015 and 2014, respectively.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents the future minimum lease payments as of December&nbsp;31, 2016 under the Lease: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AMOUNT</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>941,822
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,368
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>989,502
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,014,239
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2021</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,039,595
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">After 2021</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,972,254
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,922,780
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6781901280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of stockholders' equity and share-based compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">8. Stockholders&#x2019; Equity </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Convertible Preferred Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Series A-1 Convertible Preferred Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October&nbsp;20, 2009, the Company entered into a Series A-1 Preferred Stock Purchase Agreement with certain investors. In connection with the financing, the Company issued 30,726,326 shares of Series&nbsp;A-1 Convertible Preferred Stock for an aggregate amount of $38,979,412, which included the conversion of principal and accrued interest related to an earlier bridge financing of $16,099,770. In connection with the Series&nbsp;A-1 Preferred Stock financing, all then-outstanding shares of Series A and Series B Preferred Stock were converted into common stock, and all then outstanding warrants to purchase Series B Preferred Stock were converted into warrants to purchase common stock. Immediately prior to the Series A-1 Preferred Stock financing, the Company effected a 1-for-10 reverse stock split of the outstanding common stock. All prior-period applicable share amounts have been retroactively adjusted to reflect the reverse stock split. As of December&nbsp;31, 2013, the Company&#x2019;s Amended and Restated Certificate of Incorporation authorized the issuance of 130,601,021 shares of stock, of which 70,258,276 were designated as common stock with a par value of $0.001, and of which 60,342,745 were designated as Series A-1 Convertible Preferred Stock with a par value of $0.001. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Upon closing of the Company&#x2019;s initial public offering in January 2014, all outstanding shares of convertible preferred stock converted into an aggregate of 9,305,359 shares of common stock. In addition, immediately following the closing of the initial public offering, the Company&#x2019;s certificate of incorporation was amended to authorize 5,000,000 shares of undesignated preferred stock and 100,000,000 shares of common stock. Both the common stock and undesignated preferred stock have a par value of $0.001 per share. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Common Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 1, 2016, the Company entered into an at-the-market sales agreement with Cowen and Company, LLC to sell the Company&#x2019;s securities under a shelf registration statement filed in March 2015. As of December 31, 2016, the Company had issued and sold 668,791 shares of common stock under the at-the-market sales agreement. The shares were sold at a weighted average price per share of $6.336, for aggregate net proceeds of $3.9 million, after deducting commissions and offering expenses. Subsequent to December 31, 2016, the Company sold an additional 461,989 shares at a weighted average price per share of $6.228 under the at-the-market facility for an additional $2.8 million in net proceeds.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June 2016, the Company completed a public offering in which the Company sold 3,476,793 shares of its common stock at a price of $6.10 per share.&nbsp;The Company received net proceeds of $19.7 million from this offering, after deducting underwriting discounts, commissions and other offering expenses.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Warrants to Acquire Company Stock </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following common stock warrants were outstanding as of December&nbsp;31, 2016 and 2015: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">12/31/2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">12/31/2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER&nbsp;OF&nbsp;SHARES</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER&nbsp;OF&nbsp;SHARES</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">UNDERLYING&nbsp;OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">UNDERLYING&nbsp;OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PRICE</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXPIRATION</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WARRANTS</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WARRANTS</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PER&nbsp;SHARE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DATE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236,632
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259,907
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">July&nbsp;18,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>301,986
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>301,986
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">January&nbsp;16,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">January&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 33.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">-</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,544
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.92
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">October&nbsp;13,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For the year ended December&nbsp;31, 2016, a total of 23,275 warrants were exercised at a weighted average exercise price of $0.33 per share. For the year ended December&nbsp;31, 2015, a total of 11,908 warrants were exercised at a weighted average exercise price of $0.33 per share.&nbsp; For the year ended December 31, 2016, a total of 1,544 warrants expired. No warrants expired during the year ended December&nbsp;31, 2015. </font>
		</p>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">2003 Stock Incentive Plan </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The 2003 Stock Incentive Plan (the 2003 Plan) provided for the grant of incentives and nonqualified stock options and restricted stock awards. The exercise price for incentive stock options must be at least equal to the fair value of the common stock on the grant date. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 60&nbsp;days after the termination date. Stock options terminate 10 years from the date of grant. The 2003 Plan expired on May&nbsp;21, 2013. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2003 Plan for the year ended December&nbsp;31, 2016 is as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL TERM</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC VALUE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE PRICE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(YEARS)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(IN THOUSANDS)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>758,187
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.27
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,368)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.58
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,819
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,801
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercisable as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,240
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.25
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,534
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During 2016, 2015 and 2014 the Company issued 28,368, &nbsp;99,029 and 114,836 shares of common stock, respectively, in conjunction with exercises of stock options granted under the 2003 Plan. The Company received cash proceeds from the exercise of these stock options of approximately to $44,771, &nbsp;$114,124 and $133,957 during 2016, 2015 and 2014, respectively. Total intrinsic value of the options exercised during the years ended December&nbsp;31, 2016, 2015 and 2014 was $97,707, &nbsp;$667,258 and $629,232, respectively. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, there was $1,382 of total unrecognized compensation expense related to unvested options under the 2003 Plan that will be recognized over the first quarter of 2017. The total fair value of shares vested in the years ended December&nbsp;31, 2016, 2015 and 2014, was $16,024, &nbsp;$50,310 and $63,865, respectively. There were no options granted from this plan in 2016, 2015 or 2014.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">2013 Equity Incentive Plan </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan (the 2013 Plan) effective on January 9, 2014. The 2013 Plan provides for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Internal Revenue Code (the Code), to the Company&#x2019;s employees and its parent and subsidiary corporations&#x2019; employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company&#x2019;s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty-eighth of the option shares per month as of the first day of each month after the first anniversary. Upon termination of employment by reasons other than death, cause, or disability, any vested options shall terminate 90&nbsp;days after the termination date, unless otherwise set forth in a stock option agreement. Stock options generally terminate 10 years from the date of grant. </font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Authorized Shares </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The maximum number of shares of common stock that may be issued under the 2013 Plan was 1,000,000&nbsp;shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2015 and ending on January&nbsp;1, 2023, by 3% of the total number of shares of common stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#x2019;s board of directors. The maximum number of shares that may be issued pursuant to exercise of incentive stock options under the 2013 Plan is 20,000,000. As of January&nbsp;1, 2017, the number of shares of common stock that may be issued under the 2013 Plan was automatically increased by 697,500 shares, representing 3% of the total number of shares of common stock outstanding on January&nbsp;1, 2017, increasing the number of shares of common stock available for issuance under the 2013 Plan to 2,837,201 shares. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A summary of the Company&#x2019;s stock option activity under the 2013 Plan for the year ended December&nbsp;31, 2016 is as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">VALUE&nbsp;(IN</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PRICE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">TERM(YEARS)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">THOUSANDS)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,470,338
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.5
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,250
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.36
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,500)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.95
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,983)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.28
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,066,105
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.9
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,057,409
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.9
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>500
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercisable as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>910,202
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.4
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:9pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted-average fair value of the options granted during the year of December&nbsp;31, 2016, 2015 and 2014 was $3.39, &nbsp;$5.08 and $6.70 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected term </font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">68.98%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">80.76%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">90.27%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">1.70%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">1.70%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">2.14%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, there was $4,308,701 of total unrecognized compensation expense related to unvested options that will be recognized over a weighted-average period of approximately 2.0 years. The total fair value of shares vested in the years ended December 31, 2016 and December&nbsp;31, 2015 was $3,053,086 and $2,668,712, respectively. There were no shares vested as of December&nbsp;31, 2014 under the 2013 Plan.&nbsp;&nbsp;During 2016, the Company received cash of $27,825 and issued 3,500 shares of common stock in conjunction with exercises of stock options granted under the 2013 Plan.&nbsp;&nbsp;The intrinsic value of the options exercised during 2016 was $2,275.&nbsp;&nbsp;There were no option exercises under the 2013 Plan for the years ended December 31, 2015 and 2014.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">An RSU is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#x2019;s stock on the date of grant. The Company has granted RSUs with service conditions (service RSUs) that vest in three equal annual installments provided that the employee remains employed with the Company. As of December&nbsp;31, 2016, $60,108 of unrecognized compensation costs related to unvested service. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of RSU activity for the 2013 Plan for the year ended December&nbsp;31, 2016: </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">GRANT DATE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OF SHARES</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">FAIR VALUE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,833
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.61
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,417
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,916
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.04
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-based compensation expense was classified as follows on the statement of operations for the years ended December&nbsp;31: </font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,033,005
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>802,329
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>512,345
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,931,762
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,274
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,122,720
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964,767
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,603
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,635,065
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This note contains 1)the entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income and 2) the entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DisclosureOfStockholdersEquityAndCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6636469600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:13.5pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">9. Income Taxes </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The components of the gross deferred tax asset and related valuation allowance at December&nbsp;31 were as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net operating loss carryforward</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,451,814
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,745,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Capitalized start-up costs</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,708,479
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,986,272
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Patent amortization</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,203
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238,378
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and orphan drug credits</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,988,522
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,110,590
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123,744
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>96,107
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,107,964
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,206,920
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,511
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,985
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total gross deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,667,237
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,436,788
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(54,667,237)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,436,788)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Depreciation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Based on the Company&#x2019;s operating history and management&#x2019;s expectation regarding future profitability, management believes the realization of the Company&#x2019;s deferred tax assets does not meet the more-likely-than-not criteria under ASC 740, </font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;">. Accordingly, a full valuation allowance has been established as of December&nbsp;31, 2016 and 2015. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016, the Company had $87,591,753 of U.S. Federal and state net operating losses, of which $250,359 will be recognized as a benefit through additional-paid-in-capital when realized, $7,394,601 of research and development tax credits and $7,593,921 of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2026, the research and development tax credits in 2023 and the orphan drug tax credit in 2033. &nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s tax attributes, including net operating losses and credits, are subject to any ownership changes as defined under Internal Revenue Code Sections 382 and 383. A change in ownership could affect the Company&#x2019;s ability to utilize its net operating losses and credits. As of December 31, 2016, the Company does not believe that an ownership change has occurred. Any future ownership changes may cause a limitation on the Company&#x2019;s ability to utilize existing tax attributes. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company files income tax returns in the U.S. federal jurisdiction and in the State of Maryland. The Company&#x2019;s federal income tax returns for tax years 2003 and after remain subject to examination by the U.S. Internal Revenue Service. The Company&#x2019;s Maryland income tax returns for the tax years 2006 and thereafter remain subject to examination by the Comptroller of Maryland. In addition, all of the net operating losses, research and development tax credit and orphan drug credit carryforwards that may be used in future years are still subject to adjustment. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company did not have unrecognized tax benefits as of December&nbsp;31, 2016 and 2015, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows as of December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">U.S. Federal statutory tax rate</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">State taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.6
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.7
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.6
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research credit</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.6
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.4
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Orphan drug credit</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.5
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.7
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.7)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.8)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.3)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.4
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47.9)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53.0)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55.8)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6636398768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ResearchAndLicenseAgreementTextBlock', window );">Research and License Agreement</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">10. Research and License Agreements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2004, the Company entered into a research services agreement (the Research Agreement) with the University of Basel (the University) for biological evaluation of selectin antagonists. Certain patents covering the rivipansel compound are subject to provisions of the Research Agreement. Under the terms of the Research Agreement, the Company will owe a 10% payment to the University for all future milestone and royalty payments received from Pfizer with respect to rivipansel. A milestone license fee of $2.0 million was recorded in the year ended December&nbsp;31, 2015 for the payment due to the University of Basel representing 10% of the $20.0&nbsp;million non-refundable milestone payment that the Company received from Pfizer in August 2015. The accrued license and milestone fee of $2.0 million was paid in February 2016.&nbsp;&nbsp;There were no payments recorded for the year ended December 31, 2016. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In October 2011, the Company and Pfizer entered into a licensing agreement (the Pfizer Agreement) that provides Pfizer an exclusive worldwide license to rivipansel for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed. The Company was responsible for completion of the Phase 2 trial, after which Pfizer will assume all further development and commercialization responsibilities. Upon execution of the Pfizer Agreement, the Company received an up-front payment of $22.5 million. The Pfizer Agreement also provides for potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications; potential milestone payments of up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of the Company&#x2019;s filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications; and potential milestone payments of up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. Pfizer has the right to terminate the Pfizer Agreement by giving prior written notice. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales-based milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. The Company is also eligible to receive royalties on future sales contingent upon annual net sales thresholds. In addition, the Company and Pfizer have formed a joint steering committee that will oversee and coordinate activities as set forth in the research program. The $22.5 million up-front payment was recognized over a period of 1.5 years. In May 2014, the Company received a non-refundable payment of $15.0 million from Pfizer as a partial milestone payment owed to the Company upon the dosing of the first patient in the Phase 3 clinical trial. The dosing of the first patient in a Phase 3 clinical trial of rivipansel in August 2015 triggered the remaining $20.0 million of the scheduled milestone payment under the Pfizer Agreement. During the years ended December&nbsp;31, 2015 and 2014, the Company recorded revenue of $20.0 million and $15.0 million, respectively, pursuant to the Pfizer Agreement in the Company&#x2019;s statement of operations. There was no revenue recognized under the Pfizer Agreement for the year ended December 31, 2016.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In November 2014, the Company executed a worldwide license agreement with UniQuest Pty Limited (UniQuest) to secure the exclusive rights to two method-of-use patent applications relating to the use of E-selectin antagonists to reduce the risk of deadly infections in patients undergoing chemotherapy. Under the terms of the agreement, UniQuest received an upfront fee of $20,000 in 2014, and is eligible for a milestone payment of $2.0 million from the Company upon the Company&#x2019;s receipt of marketing authorization from the FDA for a drug incorporating the licensed patents, as well as low single-digit royalties on any net sales for this indication. There were no expenses for this arrangement in 2016 and 2015. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ResearchAndLicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research services and license agreements, including contracts and arrangements to be performed by or for others. Includes contingent payment receivables or liabilities for achievement of specific milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ResearchAndLicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6780605616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</a></td>
<td class="text"><div> <div>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">11. &nbsp;Employee Benefit Plan</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has a defined contribution plan under the Internal Revenue Code Section&nbsp;401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis.&nbsp;&nbsp;For the year ended December 31, 2016, the Company made a discretionary match of 50% up to the first 3% of employee contributions. All matching contributions have been paid by the Company. The Company&#x2019;s matching contributions vest in full at the employee&#x2019;s third anniversary of employment and all employer contributions thereafter vest immediately. The total Company matching contributions were $79,000 for the year ended December&nbsp;31, 2016.&nbsp;&nbsp;There were no Company matching contributions for the years ended December&nbsp;31, 2015 and 2014.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6789008352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">12. Quarterly Financial Information (Unaudited) </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Summarized quarterly financial information for each of the years ended December&nbsp;31, 2016 and 2015 are as follows: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,500
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,328,597)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,854,693)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,071,570)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,554,978)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss per share&#x2014;basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.36)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.41)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.40)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:50.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,375
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,035,375
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net (loss) income</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,881,703)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,168,071)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,389,405
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,109,129)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Loss) income per share&#x2014;basic</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.47)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.55
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.37)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Loss) income per share&#x2014;diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.47)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.51
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.37)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801330640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div> <div>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Basis of Accounting </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accompanying financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Segment Information </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of glycomimetic compounds.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Use of Estimates </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Cash and Cash Equivalents </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Cash and cash equivalents consist of investment in money market funds with commercial banks and financial institutions. The Company considers all investments in highly liquid financial instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Fair Value Measurements </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s financial instruments include cash and cash equivalents. The fair values of the financial instruments approximated their carrying values at December&nbsp;31, 2016 and 2015, due to their short-term maturities. The Company accounts for recurring and nonrecurring fair value measurements in accordance with ASC 820, </font><font style="display:inline;font-style:italic;">Fair Value Measurements</font><font style="display:inline;">. ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories: </font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 1&#x2014;Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:6pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 2&#x2014;Fair value is determined by using inputs, other than Level 1 quoted prices, that are directly and indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models that can be corroborated by observable market data. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:24pt;"><p style="width:24pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
				<font style="margin:4.5pt 0pt 0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:4.5pt 0pt 0pt;">
			<font style="display:inline;color:#000000;">Level 3&#x2014;Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity. In instances where the determination of the fair value measurement is based on inputs from different levels of fair value hierarchy, the fair value measurement will fall within the lowest level input that is significant to the fair value measurement in its entirety. </font></p></td></tr></table></div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company periodically evaluates financial assets and liabilities subject to fair value measurements to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of December&nbsp;31, 2016 and 2015. The carrying value of cash held in money market funds of approximately $38.0 million and $45.5 million as of December&nbsp;31, 2016 and 2015, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs).</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Concentration of Credit Risk</font><font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Property and Equipment </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment are recorded at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to seven years. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Expenditures for repairs and maintenance are charged to operations as incurred; major replacements that extend the useful life are capitalized. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.60%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">ESTIMATED&nbsp;USEFUL&nbsp;LIVES</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">7&nbsp;years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer software</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp; life</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Impairment of Long-Lived Assets </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company periodically assesses the recoverability of the carrying value of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="display:inline;font-style:italic;">Property, Plant, and Equipment</font><font style="display:inline;">. ASC 360 requires that long-lived assets and certain identifiable intangible assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of December&nbsp;31, 2016 and 2015, the Company determined that there were no impaired assets and had no assets held for sale. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div> <div>
		<p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Revenue Recognition </font>
		</p>
		<p style="margin:4pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">From time to time, the Company is awarded reimbursement contracts for services and development grant contracts with government and non-government entities and philanthropic organizations. Under these contracts, the Company typically is reimbursed for the costs in connection with specific development activities. The Company recognizes revenue to the extent of costs incurred in connection with performance under such grant arrangements. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has entered into a collaborative research and development agreement with Pfizer. The agreement is in the form of a license agreement. The agreement called for a nonrefundable up-front payment and milestone payments upon achieving significant milestone events. The agreement also contemplates royalty payments on future sales of an approved product. There are no performance, cancellation, termination, or refund provisions in the arrangement that contain material financial consequences to the Company. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The primary deliverable under this arrangement is an exclusive worldwide license to the Company&#x2019;s rivipansel compound, but the arrangement also includes deliverables related to research and preclinical development activities to be performed by the Company on Pfizer&#x2019;s behalf. </font>
		</p>
		<p style="margin:10pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Collaborative research and development agreements can provide for one or more of up-front license fees, research payments, and milestone payments. Agreements with multiple components (deliverables or items) are evaluated according to the provisions of ASC 605-25, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Multiple-Element Arrangements</font><font style="display:inline;">, to determine whether the deliverables can be separated into more than one unit of accounting. An item can generally be considered a separate unit of accounting if all of the following criteria are met: (1)&nbsp;the delivered item(s) has value to the customer on a stand-alone basis and (2)&nbsp;if the arrangement includes a general right of return relative to the delivered item(s) then delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on selling price hierarchy. The selling price hierarchy for each deliverable is based on (i)&nbsp;vendor-specific objective evidence (VSOE), if available; (ii)&nbsp;third-party evidence (TPE) of selling price if VSOE is not available; or (iii)&nbsp;an estimated selling price, if neither VSOE nor third-party evidence is available. Management was not able to establish VSOE or TPE for separate unit deliverables, as the Company does not have a history of entering such arrangements or selling the individual deliverables within such arrangements separately. In addition, there may be significant differentiation in these arrangements, which indicates that comparable third-party pricing may not be available. Management determined that the selling price for the deliverables within the Pfizer collaboration agreement should be determined using its best estimate of selling price. The process of determining the best estimate of selling price involved significant judgment on the Company&#x2019;s part and included consideration of multiple factors such as estimated direct expenses, other costs, and available clinical development data. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to ASC 605-25, each required deliverable under the Pfizer collaboration agreement is evaluated to determine whether it qualifies as a separate unit of accounting. Factors considered in this determination include the research capabilities of Pfizer, the proprietary nature of the license and know-how, and the availability of the Company&#x2019;s glycomimetics technology research expertise in the general marketplace. Based on all relevant facts and circumstances and, most significantly, on the proprietary nature of the Company&#x2019;s technology and the related proprietary nature of the Company&#x2019;s research services, management concluded that stand-alone value does not exist for the license, and therefore, the license is not a separate unit of accounting under the contract and will be combined with the research and development services (including participation on a joint steering committee). </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to ASC 605-28, </font><font style="display:inline;font-style:italic;">Revenue Recognition&#x2014;Milestone Method</font><font style="display:inline;">, at the inception of agreements that include milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#x2019;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#x2019;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. In making this assessment, the Company evaluates factors such as scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the agreement. </font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#x2019;s efforts during the period of substantial involvement are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligation, assuming all other revenue recognition criteria are met. In May 2014, the Company recognized $15.0 million in revenue as a result of the first non-refundable milestone payment received from Pfizer. In June 2015, the Company recognized $20.0 million in revenue as a result of Pfizer dosing the first patient in the Phase 3 clinical trial of rivipansel, which triggered the second non-refundable milestone payment. There were no revenue milestones met in the year ending December 31, 2016.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">.</font>
		</p>
		<p style="margin:16pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;"> Accrued Liabilities </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is required to estimate accrued liabilities as part of the process of preparing its financial statements. The estimation of accrued liabilities involves identifying services that have been performed on the Company&#x2019;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date. Accrued liabilities include professional service fees, such as for lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in conjunction with clinical trials, and fees to contract manufacturers in conjunction with the production of clinical materials. Pursuant to the Company&#x2019;s assessment of the services that have been performed, the Company recognizes these expenses as the services are provided. Such assessments include: (i)&nbsp;an evaluation by the project manager of the work that has been completed during the period; (ii)&nbsp;measurement of progress prepared internally and/or provided by the third-party service provider; (iii)&nbsp;analyses of data that justify the progress; and (iv)&nbsp;the Company&#x2019;s judgment.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div> <div>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Research and Development Costs </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Except for payments made in advance of services, research and development costs are expensed as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel, laboratory supplies and raw materials, sponsored research, depreciation of laboratory facilities and leasehold improvements, and utilities costs related to research space. Other research and development expenses include fees paid to consultants and outside service providers including clinical research organizations and clinical manufacturing organizations. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Stock-Based Compensation </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&#x2014;Stock Compensation</font><font style="display:inline;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes-Merton model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A discussion of management&#x2019;s methodology for developing some of the assumptions used in the valuation model follows: </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Dividend Yield</font><font style="display:inline;">&#x2014;The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Volatility</font><font style="display:inline;">&#x2014;Volatility is a measure of the amount by which a financial variable such as share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Prior to the Company&#x2019;s initial public offering, there was not a market for the Company&#x2019;s shares. The Company utilizes the historical volatilities of a peer group (e.g., several public entities of similar size, complexity, and stage of development), along with the Company&#x2019;s historical volatility since its initial public offering to determine its expected volatility. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Risk-Free Interest Rate</font><font style="display:inline;">&#x2014;This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Term</font><font style="display:inline;">&#x2014;This is a period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected life of the option term to be 6.25 years. The Company uses a simplified method to calculate the average expected term. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Expected Forfeiture Rate</font><font style="display:inline;">&#x2014;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:12pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Income Taxes </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for income taxes using the asset and liability method in accordance with ASC 740,</font><font style="display:inline;font-style:italic;"> Income Taxes</font><font style="display:inline;">. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and the financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for uncertain tax positions pursuant to ASC 740. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that tax position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Comprehensive Loss </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&nbsp;31, 2016, 2015 and 2014, the Company&#x2019;s net loss equals comprehensive loss and, accordingly, no additional disclosure is presented. </font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div> <div>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recently Issued Accounting Standards </font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;">On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2016 to December 15, 2017, with early adoption permitted but not earlier than the original effective date. Accordingly, the updated standard is effective for the Company in the first quarter of fiscal 2018. The Company is evaluating the Pfizer collaboration agreement to determine the impact of the new revenue standard on the upfront and milestone payments within this specific collaboration agreement. The Company intends to select a transition method in the second quarter 2017 and is currently evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.</font>
		</p>
		<p style="margin:0pt;font-family:Georgia;color:#000000;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"> On August 27, 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern, which requires management to assess a company&#x2019;s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. Before this new standard, there was minimal guidance in U.S. GAAP specific to going concern. Under the new standard, disclosures are required when conditions give rise to substantial doubt about a company&#x2019;s ability to continue as a going concern within one year from the financial statement issuance date. The Company adopted the standard for the reporting period ending December 31, 2016.</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).&nbsp;&nbsp;The final guidance will require lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. This standard is effective for annual reporting periods beginning after December&nbsp;15, 2018. Early adoption will be permitted.&nbsp;&nbsp;The Company is currently evaluating the effect the new standard will have on the Company. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In March 2016, the FASB issued ASU No. 2016-09, Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.&nbsp;&nbsp;The ASU includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in financial statements including the income tax effects of share-based payments, minimum statutory withholding requirements and forfeitures. The new guidance will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It will also allow an employer to repurchase more of an employee&#x2019;s shares than the current standard for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. This ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. In evaluation of the new standard, the Company will elect a policy at adoption of the standard to account for forfeitures as they occur. &nbsp;The Company has evaluated the standard and has determined the implementation will not have a material impact on the financial statements.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With the exception of the new standards discussed above, there have been no new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued liabilities including identifying services that have been performed on the Company&#8217;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795447904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule Of Property Plant And Equipment Useful Life</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 82.60%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">ESTIMATED&nbsp;USEFUL&nbsp;LIVES</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">7&nbsp;years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer software</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp; life</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772266480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share of Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div> <div>
		<p style="margin:9pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth the computation of basic and diluted earnings per share for the years ended December&nbsp;31, 2016, 2015 and 2014: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(31,809,838)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,769,498)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,121,566)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted net loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.50)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.67)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted weighted average common shares outstanding </font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21,256,312
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,010,587
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,452,252
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Outstanding</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>553,868
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>578,687
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>590,595
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock options and restricted stock units</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,817,674
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,235,775
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,806,980
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797421744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of the Company&#x2019;s prepaid expenses and other current assets at December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>199,195
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>393,857
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other receivables</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>268,659
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38,683
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deposits</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,649
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,270
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses and other current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>478,503
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>441,810
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772266480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><div> <div>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Property and equipment, net consisted of the following at December&nbsp;31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Furniture and fixtures</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>262,135
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>230,987
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Laboratory equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,130,180
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,586
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,610
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,723
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Computer equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>169,423
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>181,053
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Leasehold improvements</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36,128
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Construction in progress</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>508,417
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,112,893
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,423,477
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Less accumulated depreciation</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,056,561)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(902,099)
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Property and equipment, net</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,056,332
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>521,378
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6635200160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of the Company&#x2019;s accrued expenses at December 31: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,513,243
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423,220
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued license and milestone fees</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,000,000
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued consulting and other professional fees</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148,579
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>242,227
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>315,002
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,152
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>290,547
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>195,442
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued franchise and other taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,590
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,267,371
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,145,631
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797431232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div> <div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table presents the future minimum lease payments as of December&nbsp;31, 2016 under the Lease: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">YEAR</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AMOUNT</font><font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>941,822
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>965,368
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>989,502
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2020</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,014,239
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2021</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,039,595
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">After 2021</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,972,254
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:79.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,922,780
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6786268784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">12/31/2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">12/31/2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER&nbsp;OF&nbsp;SHARES</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER&nbsp;OF&nbsp;SHARES</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:27.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">UNDERLYING&nbsp;OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">UNDERLYING&nbsp;OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PRICE</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXPIRATION</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WARRANTS</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WARRANTS</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PER&nbsp;SHARE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">DATE</font><font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>236,632
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259,907
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">July&nbsp;18,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>301,986
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>301,986
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">January&nbsp;16,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,250
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.33
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">January&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:26.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 33.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">-</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:33.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,544
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25.92
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:26.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">October&nbsp;13,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,033,005
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>802,329
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>512,345
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,931,762
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,274
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,122,720
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total stock-based compensation expense</font></p>
				</td>
				<td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,964,767
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,323,603
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,635,065
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Company's Stock Option Activity</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL TERM</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC VALUE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE PRICE</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(YEARS)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(IN THOUSANDS)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>758,187
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.27
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(28,368)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.58
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,819
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,801
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.26
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:31.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercisable as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>729,240
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.25
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.2
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,534
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Company's Stock Option Activity</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AGGREGATE</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">REMAINING</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">INTRINSIC</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OUTSTANDING</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">EXERCISE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">CONTRACTUAL</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">VALUE&nbsp;(IN</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OPTIONS</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">PRICE</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">TERM(YEARS)</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">THOUSANDS)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,470,338
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.5
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>627,250
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.36
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options exercised</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,500)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.95
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Options forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,983)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.28
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,066,105
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.9
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested or expected to vest as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,057,409
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.41
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.9
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>500
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercisable as of December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>910,202
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.26
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.4
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Fair Value of Options Granted</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected term </font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">6.25 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">68.98%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">80.76%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">90.27%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">1.70%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">1.70%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">2.14%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">0%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div> <div>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is a summary of RSU activity for the 2013 Plan for the year ended December&nbsp;31, 2016: </font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">WEIGHTED-AVERAGE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">NUMBER</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">GRANT DATE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">OF SHARES</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">FAIR VALUE</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,833
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.61
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,417
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.62
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:64.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Unvested at December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,916
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.04
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797442400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Gross Deferred Tax Asset and Related Valuation Allowance</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net operating loss carryforward</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34,451,814
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,745,536
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Capitalized start-up costs</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,708,479
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,986,272
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Patent amortization</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>216,203
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>238,378
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and orphan drug credits</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,988,522
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,110,590
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred rent</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>123,744
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>96,107
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,107,964
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,206,920
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>70,511
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52,985
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total gross deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54,667,237
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,436,788
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(54,667,237)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(39,436,788)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 24pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Depreciation</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 42pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate of Income Tax Expense</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">U.S. Federal statutory tax rate</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>34.0
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">State taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.6
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.7
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.6
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research credit</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.6
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.4
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Orphan drug credit</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.0
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.5
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.7
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.7)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.8)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.3)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.4
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Change in valuation allowance</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47.9)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(53.0)
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55.8)
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:62.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.3pt 0pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807674240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Financial Information</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:49.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,500
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,328,597)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,854,693)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,071,570)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,554,978)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss per share&#x2014;basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.36)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.41)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.40)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:50.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Quarter Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,375
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,035,375
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3.6pt 0pt 0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net (loss) income</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,881,703)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,168,071)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10,389,405
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,109,129)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Loss) income per share&#x2014;basic</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.47)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.55
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.37)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Loss) income per share&#x2014;diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.47)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.38)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.51
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.37)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6805331792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (118,976,311)<span></span>
</td>
<td class="num">$ (87,166,473)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808371072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>segment </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number Of Operating Segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value levels 2 or 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value levels 2 or 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Carrying value of cash held in money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Impairment of Long-Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired', window );">Number of long-lived assets determined to be impaired | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=glyc_PfizerMember', window );">Pfizer | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone revenue</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved', window );">Number of milestones met | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=glyc_PfizerMember', window );">Pfizer | License Agreement | Up-Front Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Upfront payment revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_UpfrontPaymentRecognitionPeriod', window );">Recognition period of up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of long-lived assets determined to be impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NumberOfLongLivedAssetsDeterminedToBeImpaired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of milestones achieved during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_RevenueRecognitionMilestoneMethodMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time over which the up-front payment received was recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6390208&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=glyc_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=glyc_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801327440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment Estimated useful lives</a></td>
<td class="text">P7Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment Estimated useful lives</a></td>
<td class="text">P5Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment Estimated useful lives</a></td>
<td class="text">P5Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment Estimated useful lives</a></td>
<td class="text">P5Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment Estimated useful lives</a></td>
<td class="text">P3Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment Estimated useful lives</a></td>
<td class="text">P3Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment Estimated useful lives</a></td>
<td class="text">P7Y<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808140496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share of Common Stock (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,328,597)<span></span>
</td>
<td class="num">$ (7,854,693)<span></span>
</td>
<td class="num">$ (8,071,570)<span></span>
</td>
<td class="num">$ (7,554,978)<span></span>
</td>
<td class="num">$ (8,881,703)<span></span>
</td>
<td class="num">$ (7,168,071)<span></span>
</td>
<td class="nump">$ 10,389,405<span></span>
</td>
<td class="num">$ (7,109,129)<span></span>
</td>
<td class="num">$ (31,809,838)<span></span>
</td>
<td class="num">$ (12,769,498)<span></span>
</td>
<td class="num">$ (11,121,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,256,312<span></span>
</td>
<td class="nump">19,010,587<span></span>
</td>
<td class="nump">18,452,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive securities excluded</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553,868<span></span>
</td>
<td class="nump">578,687<span></span>
</td>
<td class="nump">590,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember', window );">Stock Options and Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive securities excluded</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,817,674<span></span>
</td>
<td class="nump">2,235,775<span></span>
</td>
<td class="nump">1,806,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=glyc_EmployeeStockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6638963552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 199,195<span></span>
</td>
<td class="nump">$ 393,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">268,659<span></span>
</td>
<td class="nump">38,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">10,649<span></span>
</td>
<td class="nump">9,270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 478,503<span></span>
</td>
<td class="nump">$ 441,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6801482816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,112,893<span></span>
</td>
<td class="nump">$ 1,423,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(1,056,561)<span></span>
</td>
<td class="num">(902,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,056,332<span></span>
</td>
<td class="nump">521,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">190,540<span></span>
</td>
<td class="nump">191,484<span></span>
</td>
<td class="nump">$ 158,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">262,135<span></span>
</td>
<td class="nump">230,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,130,180<span></span>
</td>
<td class="nump">965,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">6,610<span></span>
</td>
<td class="nump">9,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">169,423<span></span>
</td>
<td class="nump">181,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">36,128<span></span>
</td>
<td class="nump">$ 36,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 508,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=glyc_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795887776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 2,513,243<span></span>
</td>
<td class="nump">$ 3,423,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccruedLicenseAndMilestoneFees', window );">Accrued license and milestone fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued consulting and other professional fees</a></td>
<td class="nump">148,579<span></span>
</td>
<td class="nump">242,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">315,002<span></span>
</td>
<td class="nump">281,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">290,547<span></span>
</td>
<td class="nump">195,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccruedFranchiseAndOtherTaxes', window );">Accrued franchise and other taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 3,267,371<span></span>
</td>
<td class="nump">$ 6,145,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AccruedFranchiseAndOtherTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for franchise and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AccruedFranchiseAndOtherTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AccruedLicenseAndMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for license and milestone fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AccruedLicenseAndMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795867616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating leases, rent expense</a></td>
<td class="nump">$ 784,739<span></span>
</td>
<td class="nump">$ 595,497<span></span>
</td>
<td class="nump">$ 385,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit paid</a></td>
<td class="nump">52,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">941,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">965,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">989,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">1,014,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">1,039,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">After 2021</a></td>
<td class="nump">1,972,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">6,922,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=glyc_RockvilleMember', window );">Rockville</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred Rent Credit</a></td>
<td class="nump">$ 822,130<span></span>
</td>
<td class="nump">$ 243,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=glyc_RockvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=glyc_RockvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6809609232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Preferred and Common Stock (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 20, 2009 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_SharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,601,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate amount of preferred stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,601,955<span></span>
</td>
<td class="nump">$ 57,248,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount', window );">Conversion of prior Bridge financing principal and accrued interest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,099,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,476,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Weighted average price per share issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock sale | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,726,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate amount of preferred stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,979,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,342,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate amount of preferred stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,146<span></span>
</td>
<td class="nump">$ 8,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,258,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,145,584<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Aggregate number of common stock shares converted from convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,305,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOfferingMember', window );">At The Market Equity Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="nump">461,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Weighted average price per share issued | $ / shares</a></td>
<td class="nump">$ 6.228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock sale | $</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOfferingMember', window );">At The Market Equity Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Weighted average price per share issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.336<span></span>
</td>
<td class="nump">$ 6.336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock sale | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of principal and accrued interest related to an earlier bridge financing included as a portion of the Series A-1 Preferred Stock Purchase Agreement financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ConversionOfBridgeFinancingPrincipalAndAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares of stock, including common stock and Series A-1 Convertible Preferred Stock, the entity is permitted to issue under the Amended and Restated Certificate of Incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=glyc_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=glyc_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6809680096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Warrants (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NumberOfWarrantsExercised', window );">Number Of Warrants Exercised</a></td>
<td class="nump">23,275<span></span>
</td>
<td class="nump">11,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_WarrantsExercisedWeightedAverageExercisePrice', window );">Warrants Exercised Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ClassOfWarrantOrRightExpirationsInPeriod', window );">Number of warrants expired</a></td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring18july2018Member', window );">Warrants expiring July 18, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring18july2018Member', window );">Warrants expiring July 18, 2018 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying outstanding warrants</a></td>
<td class="nump">236,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring16january2019Member', window );">Warrants expiring January 16, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring16january2019Member', window );">Warrants expiring January 16, 2019 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying outstanding warrants</a></td>
<td class="nump">301,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring30january2019Member', window );">Warrants expiring January 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring30january2019Member', window );">Warrants expiring January 30, 2019 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying outstanding warrants</a></td>
<td class="nump">15,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring13october2016Member', window );">Warrants expiring October 13, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring13october2016Member', window );">Warrants expiring October 13, 2016 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 25.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ClassOfWarrantOrRightExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants that expired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ClassOfWarrantOrRightExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_WarrantsExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_WarrantsExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring18july2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring18july2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring16january2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring16january2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring30january2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring30january2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring13october2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=glyc_ClassOfWarrantExpiring13october2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808500176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Incentive Plans (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment', window );">Period from date of termination that any vested options shall expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,707<span></span>
</td>
<td class="nump">$ 667,258<span></span>
</td>
<td class="nump">$ 629,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,771<span></span>
</td>
<td class="nump">$ 114,124<span></span>
</td>
<td class="nump">$ 133,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,368<span></span>
</td>
<td class="nump">99,029<span></span>
</td>
<td class="nump">114,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,368<span></span>
</td>
<td class="nump">99,029<span></span>
</td>
<td class="nump">114,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,024<span></span>
</td>
<td class="nump">$ 50,310<span></span>
</td>
<td class="nump">$ 63,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan | Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan | Each month after the first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.083%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment', window );">Period from date of termination that any vested options shall expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,308,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for unrecognized compensation expense related to unvested options yet has not been recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,053,086<span></span>
</td>
<td class="nump">$ 2,668,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan | Upon first anniversary of start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan | Each month after the first anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percent of shares subject to option grant that will vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.083%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Incentive plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,366<span></span>
</td>
<td class="nump">157,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,366<span></span>
</td>
<td class="nump">157,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract', window );"><strong>Authorized shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized under 2013 plan</a></td>
<td class="nump">2,837,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan', window );">Automatic increase in number of shares reserved for issuance as a percentage of the total common stock outstanding at the end of the prior year</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions', window );">Maximum number of shares that may be issued pursuant to exercise of incentive stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares of common stock</a></td>
<td class="nump">697,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2013 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract', window );"><strong>Authorized shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized under 2013 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total automatic increase in number of shares of common stock reserved for issuance under the Plan on January 1 of each year, as a percent of the total number of common stock outstanding at December 31 of the prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_PercentageOfTotalNumberOfCommonStockOutstandingOnLastBusinessDayOfPriorFiscalYearThatMayAutomaticallyIncreaseUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedSharesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of maximum shares issued upon exercise of incentive stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfMaximumSharesIssuedUponExerciseOfIncentiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from date of termination of employment by reasons other than death, cause, or disability that any vested options shall expire, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriodAfterTerminationOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807644752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Company's Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">758,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(28,368)<span></span>
</td>
<td class="num">(99,029)<span></span>
</td>
<td class="num">(114,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">729,819<span></span>
</td>
<td class="nump">758,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED-AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>VESTED AND EXPECTED TO VEST</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding options</a></td>
<td class="nump">729,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (in thousands)</a></td>
<td class="nump">$ 3,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>ADDITIONAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding options exercisable at end of period</a></td>
<td class="nump">729,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price exercisable at end of period</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average contractual term (years) exercisable at end of period</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value (in thousands) exercisable at end of period</a></td>
<td class="nump">$ 3,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average contractual term outstanding</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value (in thousands) outstanding at end of period</a></td>
<td class="nump">$ 3,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>OUTSTANDING OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period</a></td>
<td class="nump">1,470,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">627,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(3,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="num">(27,983)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period</a></td>
<td class="nump">2,066,105<span></span>
</td>
<td class="nump">1,470,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>WEIGHTED-AVERAGE EXERCISE PRICE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period</a></td>
<td class="nump">$ 8.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">5.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">7.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">6.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period</a></td>
<td class="nump">$ 7.41<span></span>
</td>
<td class="nump">$ 8.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>VESTED AND EXPECTED TO VEST</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding options</a></td>
<td class="nump">2,057,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 7.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value (in thousands)</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>ADDITIONAL DISCLOSURES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Outstanding options exercisable at end of period</a></td>
<td class="nump">910,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price exercisable at end of period</a></td>
<td class="nump">$ 8.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average contractual term (years) exercisable at end of period</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value (in thousands) exercisable at end of period</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average contractual term outstanding</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value (in thousands) outstanding at end of period</a></td>
<td class="nump">$ 505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_StockIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790354672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Weighted-Average assumptions (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of the options granted</a></td>
<td class="nump">$ 3.39<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
<td class="nump">$ 6.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.98%<span></span>
</td>
<td class="nump">80.76%<span></span>
</td>
<td class="nump">90.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790352848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of RSU Activity (Detail) - 2013 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>NUMBER OF SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period | shares</a></td>
<td class="nump">4,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">14,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="nump">2,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period | shares</a></td>
<td class="nump">16,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>WEIGHTED-AVERAGE GRANT DATE FAIR VALUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period | $ / shares</a></td>
<td class="nump">$ 7.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">4.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">7.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period | $ / shares</a></td>
<td class="nump">$ 5.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Units information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested service RSUs | $</a></td>
<td class="nump">$ 60,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments', window );">Number of vesting installments | item</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual vesting installments of RSUs with service conditions provided that the employee remains employed with the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingPeriodNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=glyc_EquityIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790358192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,964,767<span></span>
</td>
<td class="nump">$ 2,323,603<span></span>
</td>
<td class="nump">$ 1,635,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,033,005<span></span>
</td>
<td class="nump">802,329<span></span>
</td>
<td class="nump">512,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,931,762<span></span>
</td>
<td class="nump">$ 1,521,274<span></span>
</td>
<td class="nump">$ 1,122,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795540272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 34,451,814<span></span>
</td>
<td class="nump">$ 24,745,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">2,708,479<span></span>
</td>
<td class="nump">2,986,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetsPatentAmortization', window );">Patent amortization</a></td>
<td class="nump">216,203<span></span>
</td>
<td class="nump">238,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and orphan drug credits</a></td>
<td class="nump">14,988,522<span></span>
</td>
<td class="nump">10,110,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">123,744<span></span>
</td>
<td class="nump">96,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Deferred compensation</a></td>
<td class="nump">2,107,964<span></span>
</td>
<td class="nump">1,206,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">70,511<span></span>
</td>
<td class="nump">52,985<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">54,667,237<span></span>
</td>
<td class="nump">39,436,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (54,667,237)<span></span>
</td>
<td class="num">$ (39,436,788)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized start up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetsPatentAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets patent amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetsPatentAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6767917792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital', window );">NOL to be recognized in APIC when realized</a></td>
<td class="nump">$ 250,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits available to carry forward</a></td>
<td class="nump">7,394,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">Orphan drug credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits available to carry forward</a></td>
<td class="nump">7,593,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember', window );">U.S. Federal And State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 87,591,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating losses to be recognized through additional paid-in-capital when realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DeferredTaxAssetRecordedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Carryforwards<br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=glyc_FederalAndStateAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6777534592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research credit</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent', window );">Orphan drug credit</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">8.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(47.90%)<span></span>
</td>
<td class="num">(53.00%)<span></span>
</td>
<td class="num">(55.80%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6810203280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and License Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>May 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2011 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th"><div>Feb. 29, 2004</div></th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccruedLicenseAndMilestoneFees', window );">Milestone license fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,281,820<span></span>
</td>
<td class="nump">25,050,179<span></span>
</td>
<td class="nump">$ 19,571,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember', window );">License Agreement | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember', window );">License Agreement | Pfizer | Up-Front Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueAdditions', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Upfront payment revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_UpfrontPaymentRecognitionPeriod', window );">Recognition period of up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember', window );">License Agreement | Uni Quest Pty Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement', window );">Number of method-of-use patents under exclusive rights license agreement | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Milestone payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=glyc_ResearchServicesAgreementMember', window );">Research Services Agreement | University Of Basel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent', window );">Royalty payment due against license fees received (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_AccruedLicenseAndMilestoneFees', window );">Milestone license fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities', window );">Payment of milestone liability</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedDevelopmentMilestoneMember', window );">Achievement Of Specified Development Milestone | License Agreement | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement', window );">Number of indications | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedDevelopmentMilestoneMember', window );">Achievement Of Specified Development Milestone | License Agreement | Pfizer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_PotentialPaymentForAchievementOfSpecifiedMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedRegulatoryMilestoneMember', window );">Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement', window );">Number of indications | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedRegulatoryMilestoneMember', window );">Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_PotentialPaymentForAchievementOfSpecifiedMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember', window );">Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products | License Agreement | Pfizer | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems', window );"><strong>Research and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_PotentialPaymentForAchievementOfSpecifiedMilestones', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_AccruedLicenseAndMilestoneFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for license and milestone fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_AccruedLicenseAndMilestoneFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ArrangementsAndNonarrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ArrangementsAndNonarrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of indications that trigger payment of milestones under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of method-of-use patent applications secured by exclusive rights under a worldwide license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_PotentialPaymentForAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the potential payment that may be received upon achievement of specified milestones per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_PotentialPaymentForAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) related to contingent consideration receivable or payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty commitment due as a percent of the milestone payments received under licensing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time over which the up-front payment received was recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=glyc_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=glyc_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=glyc_UniQuestPtyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=glyc_UniQuestPtyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=glyc_ResearchServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=glyc_ResearchServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=glyc_UniversityOfBaselMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=glyc_UniversityOfBaselMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795617264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - Other Postretirement Benefit Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company matching contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer match contribution</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percent of employee contributions the company contributes a matching contribution</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808551056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,035,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="nump">$ 20,070,750<span></span>
</td>
<td class="nump">$ 15,027,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (8,328,597)<span></span>
</td>
<td class="num">$ (7,854,693)<span></span>
</td>
<td class="num">$ (8,071,570)<span></span>
</td>
<td class="num">$ (7,554,978)<span></span>
</td>
<td class="num">$ (8,881,703)<span></span>
</td>
<td class="num">$ (7,168,071)<span></span>
</td>
<td class="nump">$ 10,389,405<span></span>
</td>
<td class="num">$ (7,109,129)<span></span>
</td>
<td class="num">$ (31,809,838)<span></span>
</td>
<td class="num">$ (12,769,498)<span></span>
</td>
<td class="num">$ (11,121,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share - basic and diluted</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (0.67)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">(Loss) income per share&#8212;basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">(Loss) income per share&#8212;diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M8Z ,HA; U#PQ'J>^@PM@AA$FG[\+:%?B4OT3NW2 G9)3=FMJ',=Z;)=<V4'
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MKN?VK,CI59"JP7OF\6M=(_9WBPGM-G[@?TR\5)=2J E0Y"VZX)]8_&KW3([
M&.54U;CA%6T\AL\;_U.PW@50&;3BM<(=G_0]5<J!TC<U^';:^% 188*/0H5
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M!P2?A>HN99_UMT@_$+0=;D@P7M/%/U!+ P04    "  $3&%*'D@^;!4#
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MZ/\#Q+L!I@\P$:7DTJRN^^NLR9;SJCQ/JLL".F7M.H4[$^9WTS[LIK/[+DQ
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M7X 9YIPY,PS%I,VS[0$<>I5"V1+WS@T'0FS=@V3V2@^@_$VKC63.FZ8C=C#
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M@RV&@L;'X]MPMM.838;'?OY!;/G&Y4]02P,$%     @ !$QA2@%3!TRW 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL;5/;;MLP#/T501]0
M)8[79H%MH.DP=, &!!W6/BLV;0O5Q97DN/O[4;+KNIU?))'B.3RDJ&PP]MFU
M )Z\*JE=3EOONP-CKFQ!<7=E.M!X4QNKN$?3-LQU%G@504JR9+.Y9HH+38LL
M^DZVR$SOI=!PLL3U2G'[]PC2##G=TC?'@VA:'QRLR#K>P&_P?[J318O-+)50
MH)TPFEBH<WJ[/1S3$!\#'@4,;G$FH9*S,<_!^%'E=!,$@832!P:.VP7N0,I
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MG+2;(D!J.DV;M$E1IZV?'3C JLU1VX3NW\\VA-*4?<%WQ[UW[\[G=$#S;!L
M1UZU:FU&&^>Z/6.V:$ +>X,=M/Y/A48+YUU3,]L9$&4$:<5XDMPQ+61+\S3&
MCB9/L7=*MG TQ/9:"_/W  J'C&[H)? HZ\:% ,O33M3P"]SO[FB\QV:64FIH
MK<26&*@R>K_9'W8A/R;\D3#8A4U")R?$Y^!\+S.:!$&@H'"!0?CC# ^@5"#R
M,EXF3CJ7#,"E?6'_&GOWO9R$A0=43[)T348_4U)")7KE'G'X!E,_MY1,S?^
M,RB?'I3X&@4J&[^DZ*U#/;%X*5J\CJ=LXSE,_!?8.H!/ 'X%8&.AJ/R+<")/
M#0[$C+/O1+CBS9[[V10A&$<1_WGQUD?/^>8V2=DY$$TYAS&'+W/F#.;9YQ)\
MK<2!?X#S=?AV5>$VPK?O%/ZG_FZ58!<)=N\(^%6+:SG;JR)L,5,-IH[;9$F!
M?1LW>1&=%_:>QSMY2Q^W_:<PM6PM.:'S-QOG7R$Z\%*2&[]"C7]@LZ.@<L'\
MY&TSKMGH..RF%\3F9YS_ U!+ P04    "  $3&%*8[_5JK0!  #2 P  &0
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M$"B>T<%Y36) D;@Z")3.Z.#T)R"W\X<2AT#YC ZN  2D=UZX.@@T]S_ 18"
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M<JN4!9=*<N=RZ=T4KP:'UOKM>[?7\UN>#:N&94S)^J^H?@-02P,$%     @
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M4]MNW" 0_17$!X1=>Y-L5K:E;*JJE5IIE:K-,VN/;11@7,#KY.\#V'&=U"_
M#.><N3!D YIGVP(X\J*DMCEMG>L.C-FR!<7M%7:@_4V-1G'G3=,PVQG@520I
MR9+-YH8I+C0MLN@[F2+#WDFAX62([97BYO4($H><;NF[XU$TK0L.5F0=;^ 7
MN-_=R7B+S2J54*"M0$T,U#F]WQZ.NX"/@#\"!KLXDU#)&?$Y&-^KG&Y"0B"A
M=$&!^^T"#R!E$/)I_)TTZ1PR$)?G=_6OL79?RYE;>$#Y)"K7YG1/204U[Z5[
MQ.$;3/5<4S(5_P,N(#T\9.)CE"AM7$G96X=J4O&I*/XR[D+'?1AOTKN)MDY(
M)D(R$_8Q#AL#Q<R_<,>+S.! S-C[CH<GWAX2WYLR.&,KXIU/WGKOI=C>W63L
M$H0FS''$)$O,C&!>?0Z1K(4X)O_1DW5ZNIIA&NGI,GIZO2ZP6Q7818'=AQ)O
M/Y6XAME_"L(6/55@FCA-EI38ZSC)"^\\L/=)?)-_\'':?W+3"&W)&9U_V=C_
M&M&!3V5SY4>H]1]L-B34+AQO_=F,8S8:#KOI!['Y&Q=O4$L#!!0    (  1,
M84HCEGS3M@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;&U3
MVV[<(!#]%<0'!"^[;38KVU(V4=1*K;1*U>29M<<7!1@7\#KY^P!V'"OU"S##
M.6<N#.F YL4V (Z\*JEM1AOGN@-CMFA "7N%'6A_4Z%1PGG3U,QV!D0924HR
MGB3?F1*MIGD:?2>3I]@[V6HX&6)[I81Y.X+$(:,;^N%X;.O&!0?+TT[4\ ?<
MW^YDO,5FE;)5H&V+FABH,GJ[.1QW 1\!3RT,=G$FH9(SXDLP?I8934)"(*%P
M04'X[0)W(&40\FG\FS3I'#(0E^</]8=8NZ_E+"S<H7QN2]=D=$])"97HI7O$
MX0=,]7RC9"K^%UQ >GC(Q,<H4-JXDJ*W#M6DXE-1XG7<6QWW8;SA^XFV3N 3
M@<^$?8S#QD Q\WOA1)X:'(@9>]^)\,2; _>]*8(SMB+>^>2M]U[RS<U-RBY!
M:,(<1PQ?8F8$\^IS"+X6XLC_H_-U^G8UPVVD;Y?1M]?K KM5@5T4V"WC)\F7
M$M<P7XMDBYXJ,'6<)DL*['6<Y(5W'MA;'M_D$SY.^V]AZE9;<D;G7S;VOT)T
MX%-)KOP(-?Z#S8:$RH7CM3^;<<Q&PV$W_2 V?^/\'5!+ P04    "  $3&%*
M>)[N9+8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QM4]MN
MG# 0_17+'Q"SAK3I"I"RJ:I6:J55JK;/7AC BHVI;9;T[SLVA-*$%]LS/N?,
MQ>-\,O;)=0">/&O5NX)VW@]'QES5@1;NQ@S0XTUCK!8>3=LR-U@0=21IQ7B2
MO&-:R)Z6>?2=;9F;T2O9P]D2-VHM[)\3*#,5]$!?'(^R[7QPL#(?1 O?P?\8
MSA8MMJK44D/OI.F)A::@]X?C*0OX"/@I87*;,PF57(QY"L:7NJ!)2 @45#XH
M"-RN\ !*!2%,X_>B2=>0@;@]OZA_BK5C+1?AX,&H7[+V74'O**FA$:/RCV;Z
M#$L]MY0LQ7^%*RB$ATPP1F64BRNI1N>-7E0P%2V>YUWV<9_FFXPOM'T"7PA\
M)=S%.&P.%#/_*+PH<VLF8N?>#R(\\>'(L3=5<,96Q#M,WJ'W6O*$Y^P:A!;,
M:<;P#>:P(ABJKR'X7H@3?T/G^_1T-\,TTM-M]/3#OD"V*Y!%@>R_$M-7)>YA
MLE=!V*:G&FP;I\F1RHQ]G.2-=QW8^_B([!]\GO9OPK:R=^1B/+YL[']CC =,
M);G!$>KP@ZV&@L:'XWL\VWG,9L.;8?E!;/W&Y5]02P,$%     @ !$QA2K"E
M@,P" @  $ 8  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULC57M;IPP
M$'P5BP>(@?N .P%2+E'52JUT2M7TMP_V#A0;4]MWI&]?VQ!*R5;*'VRO9V?&
MAEVR7JH770,8\BIXJ_.@-J;;4ZK+&@33=[*#UNZ<I1+,V*6Z4-TI8)5/$IS&
M8;BE@C5M4&0^=E1%)J^&-RT<%=%7(9CZ?0 N^SR(@K? 4W.IC0O0(NO8!;Z#
M^=$=E5W1B:5J!+2ZD2U1<,Z#^VA_B$*7X!'/#?1Z-B?N*"<I7]SB2Y4'H7,$
M'$KC*)@=;O  G#LFZ^/72!I,FBYQ/G]C_^0/;P]S8AH>)/_95*;.@S0@%9S9
ME9LGV7^&\4";@(RG_PHWX!;NG%B-4G+MGZ2\:B/%R&*M"/8ZC$WKQW[829(Q
M#4^(QX1X2DB]#AV$O/-'9EB1*=D3-5Q^Q]P[CO:QO9O2!?U5^#UK7MOHK8C#
M349OCFC$' 9,/,-$$X):]DDBQB0.\;OT&$]?H0Y7/GW]C\/MPB&&27"1-2JR
M1@C2A0B&V>$B&U1D\YX@"G&"+4JP10BBA4L,\Y_[3E"1!"%8X00I2I!^P"6&
M6>,B.U1DAQ LOUL,L\5%;&-!JR-$*))E>6"@=*%#9P4I0%U\*]*DE-?6]\%9
M=&IW][$OZ+_PH5=^8^K2M)J<I+%MP1?O64H#UDMX9[^QVK;G:<'A;-PTL7,U
M]*AA860W]E\Z_02*/U!+ P04    "  $3&%*/_9@/\$!   W!   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6QU5&%OVR 0_2N('U!LXFQ=9%MJ.DV;
MU$I1IVV?B7VV4<%X@./VWP^PXUD9^Q*X\[OWW@&7?%+ZU70 %KU)T9L"=]8.
M!T),U8%DYDX-T+LOC=*261?JEIA! ZM#D12$)LD'(AGO<9F'W$F7N1JMX#V<
M-#*CE$R_'T&HJ< IOB9>>-M9GR!E/K 6OH/],9RTB\C*4G,)O>&J1QJ: C^D
MA^/>XP/@)X?);/;(=W)6ZM4'W^H")]X0"*BL9V!NN< C".&)G(W?"R=>)7WA
M=G]E_Q)Z=[V<F8%')7[QVG8%OL>HAH:-PKZHZ2LL_>PQ6II_@@L(!_=.G$:E
MA F_J!J-57)A<58D>YM7WH=U6OBO9?$"NA30FP(R"P7GGYEE9:[5A/1\]@/S
M5YP>J#N;RB?#481OSKQQV4M)TT\YN7BB!7.<,72#25<$<>RK!(U)'.D_Y31>
MOHLZW(7RW58]R^($690@"P395I\F-RW&,/]I<A\5V4<(Z(U(#+.[$2&;BY.@
MV_!D#:K4V(=QV637J7B@X>+_PN>1>F:ZY;U!9V7=\PF7W"AEP5E)[IR7SDWQ
M&@AHK-]^='L]O^4YL&I8QI2L_Q7E'U!+ P04    "  $3&%*C>*W*;<!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6QM4]MNW" 0_17$!X1=
MUIM&*]M2-E642(VT2M7VF;7'%P48!_ Z^?L"=APW]0LPPSEG+@SI@.;%-@".
MO"FI;48;Y[H#8[9H0 E[A1UH?U.A4<)YT]3,=@9$&4E*,K[97#,E6DWS-/I.
M)D^Q=[+5<#+$]DH)\WX$B4-&M_3#\=S6C0L.EJ>=J.$GN%_=R7B+S2IEJT#;
M%C4Q4&7T=GLX)@$? ;];&.SB3$(E9\278#R6&=V$A$!"X8*"\-L%[D#*(.33
M>)TTZ1PR$)?G#_7[6+NOY2PLW*'\TY:NR>@-)254HI?N&8<'F.K94S(5_P,N
M(#T\9.)C%"AM7$G16X=J4O&I*/$V[JV.^S#>['<3;9W )P*?"3<Q#AL#Q<R_
M"R?RU.! S-C[3H0GWAZX[TT1G+$5\<XG;[WWDG.>I.P2A";,<<3P!68[(YA7
MGT/PM1!'_A^=K]-WJQGN(GVWC+Y/U@6258$D"B3_E+C_4N(:YOI+$+;HJ0)3
MQVFRI,!>QTE>>.>!O>7Q33[AX[0_"5.WVI(S.O^RL?\5H@.?RN;*CU#C/]AL
M2*A<.'[S9S..V6@X[*8?Q.9OG/\%4$L#!!0    (  1,84K+3_A)O0$  -P#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;'U386^;,!#]*\C?5V,[
MA2P"I"73M$JM%'7J]MF!(Z#:F-E.:/_];$,1R]"^X+OS>\_O#CL;E'XU#8"-
MWJ3H3(X::_L=QJ9L0')SIWKHW$ZMM.36I?J,3:^!5X$D!:9QG&#)VPX56:@=
M=9&IBQ5M!T<=F8N47+_O0:@A1P1]%)[;<V-] 1=9S\_P ^Q+?]0NP[-*U4KH
M3*NZ2$.=HR]D=V >'P _6QC,(HY\)R>E7GWR4.4H]H9 0&F] G?+%0X@A!=R
M-GY/FF@^TA.7\8?ZM]"[Z^7$#1R4^-56MLG1%D45U/PB[+,:OL/4SSV*IN8?
MX0K"P;T3=T:IA G?J+P8J^2DXJQ(_C:N;1?68=Q)Z41;)]")0&<"V?R7P"8"
MNR'@T5EH]2NWO,BT&B(]_JR>^SM!=LP-L_3%,+NPY[HUKGHM*$TS?/5"$V8_
M8N@2\S?B\"^"Q3,$.P.S"[KJ@@8^6_ )3=8%V*H "P*;A<#]C<?]"$D#I N0
M3X1L/Z<)(^2FG17H-B5)LDG9C2F\F+._]T]<G]O.1"=EW2\+@ZV5LN!4XSMW
MF1KWU.9$0&U]F+I8CQ=N3*SJI[>$YP==_ %02P,$%     @ !$QA2O-P^5IN
M P  =@\  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULE5?M<J(P%'T5
MA@<H)!! 1YVIMK9V=F<ZW=G=WU2C,@7B0M3NVV\(*37AQK+]44@XYWZ0>X_<
MR9E5;_6>4NZ\%WE93]T]YX>QY]7K/2W2^H8=:"F>;%E5I%PLJYU7'RJ:;B2I
MR#WL^Y%7I%GISB9R[[F:3=B1YUE)GRNG/A9%6OV=TYR=IRYR/S9>LMV>-QO>
M;')(=_0'Y3\/SY58>9V535;0LLY8Z51T.W5OT?@)!PU!(GYE]%Q?W#M-*J^,
MO36+U6;J^DU$-*=KWIA(Q>5$%S3/&TLBCC_*J-OY;(B7]Q_6ES)YD<QK6M,%
MRW]G&[Z?NHGK;.@V/>;\A9T?J4J(N([*_AL]T5S FTB$CS7+:_G?61]KS@IE
M1812I._M-2OE]=P^B9"BP02L"+@CX.N$0!&"3X)_E1 J0CC4 U$$,I00*4+4
M$0)\E1 K0OSI@5PE)(J0# UII BCH03D?YR<WU%0)*NJ/7)90W<I3V>3BIV=
MJFV#0]IT&QJCIDS7S:ZL2OE0U%$M=D\SC).)=VHL*<R\Q6 -,](Q=P F\'7,
MLH]!.N()LO*)\40J73X8S&>. 0M8][* ,(&1#X0)=<P]A"%&SA FTC$/$";6
M,8\0QCBG%80QSND)P(0^_(8#N&(":2&X/,6(P!9"V$(H+81:#$8E+%L,D9C2
MJ!7-!X%]$,"'40?+%A-?^# J]N$:0HLB@J.(@"B,2EM&O4S-**XAM"AB.(H8
MB,*HY67<RS1(?/EG!-,'AH3H0"VF!(XIZ5=1;+$P@BV,@*S,[AM]^6ZO(;0H
M&J4%!=0'XHA,Y?._++6K$#T2FY2CWCO%86RQ <OG+<) -HF9#00:61Q95 0%
M?1O$EK!%1U#X'PE;= )!0M%+&  1BQXABQ0@0 L(MMBP-#**@:ZQV; T'DJ
M. Q-FBO093%B'Y*#!8!$!$(N 62O!X:Z?1SB5G\=%A5!@(P04QS18)7 %I7
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MB4-/9DA%01-:"7KR=X0B%.D$!7[Z272'6OS\D\4<M1AH2BUN$X)Y8#E!@9N
M)'>HQ6U TCEJ,=!J(@_N%H)8(9WX+A'<"V0U7RW%S4##&6I1T(1:BCN&(F:(
M)]12W R4WJ$6-P/%[H(/:C'0^T]Q,+H?*Y 7UQDH+Q?7VK4EH]6A^]A1=[_^
M@W>MRW<F+V6MO*/0YI9V=^E9" VFEO#!6*(PW=(PX7#6=IB:L>Q:AFZB1=.W
M0\'0DV5_ 5!+ P04    "  %3&%*V+*CAV8#  "D#0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6R-EUUOFS 4AO\*XG[%-OBK2B(U;;>US:1JT[9K
MFC@)&N ,G&;[][,-31-SVG$3L/.\KX^/#V!/#KKYU6Z5,M&?JJS;:;PU9G>9
M).URJZJ\O= [5=M_UKJI<F.;S29I=XW*5UY4E0E!B"557M3Q;.+['IO91.]-
M6=3JL8G:?57ES=^Y*O5A&N/XI>-KL=D:UY',)KM\H[XI\WWWV-A6<G19%96J
MVT+74:/6T_@*7RXP<0)/_"C4H3VYC]Q4GK3^Y1IWJVF,7$2J5$OC+')[>5;7
MJBR=DXWC=V\:'\=TPM/[%_>/?O)V,D]YJZYU^;-8F>TT%G&T4NM\7YJO^O!9
M]1.B<=3/?J&>56EQ%XD=8ZG+UO]&RWUK=-6[V%"J_$]W+6I_/73_,-[+8 'I
M!>0HL&._)TA[0?HJR-X59+T@&RN@O8".%;!>P,8*>"_@8P6B%XBQ MD+Y%@!
M1B\KAUXE['W)<;'QZ%%>EAN30))TA>4K]28W^6S2Z$/4= _;+G?/-+ZT*FON
M>GWM^S]MM;:V]WE&.)XDS\ZI9^8=0TZ9%)TS]T/FU26Q(1SC(& <<S(<XWR$
M:X#@ 7,S9+)SXA9R2<^9CT,FG.XGR"88ZC/$T'/F#F)8D-K_IN;A_P$OA@AC
M\ *E<*&DWB ]BY3##AGLD'F'[,1!!IF?=PCW2.V1#R(E@DH>% , <D$S%CK>
M0(Z(8\J#!-U"CI1FDHN@.B!'(3!'P="?($?,W.A!H0Q!C%(A,Q16"^B()"8R
M*!D 3+% 4J3!;!X $ML2E)D,R 5$8DPP?:N0*%P&=% &8<7/.T2>#H4NTH"Z
MAJG@*;P!J2Q8@EN8"K(*0/@B6*,'T(D%];N *3B/#,XC&^21A+5ZWS'T9!B"
M"64I#M\@0Q!+A!$58>  *#)*""5P\!P.G@/!2]A!P YB^#X2"':0L(,<QB""
MNKB7@^E2F@H6/D4 QBT5)@_ )**2PF&['03XR49 X&^D'[_UV<?CTX?A3_85
M)B,2V$-G)6A?EBS\6CY ($DI#S^9"P"TKS8F!^$G)YN@2C4;O]UOHZ7>U\9-
M_:3W>*2X\B>*H'^.+^\PT'_OCB!^T_5JWYU?ON3-IJC;Z$D;NWGS^ZNUUD;9
M^-&%C7QKCTS'1JG6QMUR>]]TYX:N8?2N/Q,EQX/9[!]02P,$%     @ !4QA
M2O7!*B$# @  ?04  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL?53;
MCILP%/P5Q >L 7.-"%)#5;52*T5;=?OLP"&@-9C:3MC^?6U#$ ML7["/F9DS
M8XS3@?%740-(ZZVEG3C:M93] 2%1U- 2\<1ZZ-2;BO&62%7R*Q(]!U(:4DN1
MYS@A:DG3V5EJULX\2]E-TJ:#,[?$K6T)_WL"RH:C[=J/A>?F6DN]@+*T)U?X
M"?)7?^:J0K-*V;30B89U%H?J:']R#WFH\0;PTL @%G-+)[DP]JJ+;^71=K0A
MH%!(K4#4<(<<*-5"RL:?2=.>6VKB<OY0_V*RJRP7(B!G]'=3ROIHQ[950D5N
M5#ZSX2M,>0+;FL)_ASM0!==.5(^"46&>5G$3DK63BK+2DK=Q;#HS#I/^@[9/
M\":"-Q-<_[\$/!'PBH!&9R;J9R))EG(V6'S\6#W19\(]8+69A5XT>V?>J;1"
MK=XS+\8INFNA"7,:,=X2\QZ1;Q'8F2%(&9A=>+LN/,/'"[Z+\;X WA7 1L!_
M%\-?Q1@QD<%T8Y,D<9-@E64+PPF.@VC?CK]KQ]^QL^IS&C'!HH\7QF&0K.QL
M83@.XP\V)]AU$VS<X&AE)MAT<9W07WO9HA(O^N!#A[M6PJV5]6D+-_OO1W'@
MK&#Y#LQW8W?M!BU^!'TQ_2#\VG3"NC"I_BES\BO&)"A)YTDEJ]5=.!<4*JFG
MD9KS\488"\GZZ;)#\XV;_0-02P,$%     @ !4QA2N:-@E<T P  ^PP  !D
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MR*W61EF:Z,[2W-LOD7Z1JZUQM[&]K]IQO%T8?>@^-:+^>V?Q'U!+ P04
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MI8 V'JWB 4K]"9 W ;()\ <;R+$Q:5*KZ2<- 0AB1U=M=0A#!.$=1]@+A#U
MV"DT:<@:*+8_?R'B+40\A8CCG&P* 9R1-'=XMC*((81W7D3BQ4D\.(F#DVSJ
M($#BV-U46QG, "#0CY-Z<5(/3NK@I-LZ>4RP(ZNV,I 3C._@9%Z<S(.3.76R
M[>J0_,Z6R+U5\DT5['[2^7:/PR1%*7!@MKH$8)(@X/!$J_/&G/\_J+@TO0P.
M7.FCRQXP9\X5TSGC!^VMUE?.TFG969EFJMMB.GBGCN+#?*=$R\56_@-02P,$
M%     @ !4QA2C/^)][- @  RPD  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&ULC59M;YLP$/XKB!]0\!O@*(E4TDZ;M$E5IVZ?W<1)4 $SVTFZ?S_;
M4$K M/L2L'F>>^XNOO,M+T*^J"/G.GBMREJMPJ/6S2**U/;(*Z9N1,-K\V4O
M9,6T6<I#I!K)V<Z1JC*"<9Q$%2OJ<+UT>P]RO10G718U?Y"!.E45DW]S7HK+
M*@3AV\9C<3AJNQ&MEPT[\)]</S4/TJRBWLJNJ'BM"E$'DN]7X2U8W -B"0[Q
MJ^ 7-7@/;"C/0KS8Q;?=*HRM1[SD6VU-,/,X\PTO2VO)^/&G,QKVFI8X?'^S
M_L4%;X)Y9HIO1/F[V.GC*LS"8,?W[%3J1W'YRKN 2!ATT7_G9UX:N/7$:&Q%
MJ=QOL#TI+:K.BG&E8J_MLZC=\])^26E'\Q-@1X ] 20?$E!'0.\$_"$!=P3\
MOP32$<@[ ;GTMK&[9-XQS=9+*2Z!;,]#P^RQ PMB_JZMW73_COMF\JG,[GD-
M*5U&9VNHP^0M!@XPH$=$QGHO 7T2.9S0X;7 9HI \37D;@I)DFO(O<]*['<4
M>7.!G %\90",<M%B4H>I'2;-<(I&*=M,88023--15%,8RDB29'ZOL==K[/%Z
ME."\Q9"A.Q#!F>00KPQQ)M"5#/(;2+P&DHD/, :CA.13$,4@@] OE'J%4I]0
M-A*:@FA"T%SF,Z]0YA,:%\\41#-*XIF(J%>(>H3@J$+R*0C$ ,/!T;Q2 K&_
M'\0^K7$5>% @1M2<\1FQF>;3=9_X$S4P5:,IA 3/J'G[T"V DTK)T%@*3J02
M"F&:S=0*\'<2X&LE<][ZRQKXZIJ,W<63!F**!8R[Y\:#@Q@E.)UQR=\" /F\
MU=QWH/237A,-+JB*RX.;%E2P%:=:VR8^V.TGDEMH+[C1?@X6=^U<\6ZF'7-^
M,'DH:A4\"VVN3W?)[870W'@9WQ@OCV:RZA<EWVO[FIIWV8X7[4*+IAN=HGY^
M6_\#4$L#!!0    (  5,84J:H?HC?P0  #P7   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;)58VV[C-A#]%4,?$(D<4J0"VT#CK"] "P1;M'U6;#HV
M5K)<28FW?U]=&*]$#FTF#]'%9RX<SCFD.+T4Y8_JH%0]^9EGIVH6'.KZ_!B&
MU?:@\K1Z*,[JU/RR+\H\K9O'\BVLSJ5*=YU1GH4TBN(P3X^G8#[MWKV4\VGQ
M7F?'DWHI)]5[GJ?E?T\J*RZS@ 2?+[X?WPYU^R*<3\_IF_I3U7^=7\KF*;QZ
MV1US=:J.Q6E2JOTL^(T\;EC<&G2(OX_J4@WN)^U07HOB1_NPV<V"J,U(96I;
MMR[2YO*A%BK+6D]-'O]JI\$U9FLXO/_TONP&WPSF-:W4HLC^.>[JPRR0P62G
M]NE[5G\O+FNE!\2#B1[][^I#90V\S:2)L2VRJOL_V;Y7=9%K+TTJ>?JSOQY/
MW?6B_7^:X094&]"K 8B;!J -X&I ;QLP;<!\(W!MP']%N#V&6!O$OA&$-A"^
M!E(;2%^#1!LDOPRZ,83]_'4-\9S6Z7Q:%I=)V??T.6VI0QZ3IN6V[<NNP[K?
MFIZHFK<?<XCB:?C1.M*8IQY#1Q@QQBPPC!QCGC%,,L9\0S D&F.6&(:,,2L/
MS!K#T#%F@V'@B@F;VEX+3-$"T\X!C!PPW &@#J!SP$8.N#&2'L,[S*G#D&8:
M(Q)1@H=B:"B&Y!KC#CCJ@".Y&IVRY%:NQORN[B(VMQ"C-&,TS1A)TVC658\1
M@Q 4FHHFW*R]#>2",DE)@J<DT)0$DI+!C86P(I$X2A(A'(.7:"1I18J-IE]*
MNYTB_6=4R1NY\4&.LD_0[!.[3M34AQXCA]WQ$$6F0GBA-O=0HY1)A&ML9"7-
MI:EID54?CE;<%[CQ (Z3=RP0!*DX,;,G7B7W@VWNPL9YX[I+;.&5KI'CPDL0
MY:4&59Z)+;W 1"P2QR)!<.4E#(D%9JP>E QBQ0^NJN "31"%ILR,PVVA2<2M
MUL%EEM@Z*QRB2'!5),)_12*XW!%;[ZPU:4%L=6JV.#0&Z@J&JQ-!Y,E<618:
M-"POR$0D;+#Y&&\L<%FA]V5E36T1B"-@5##NB(6K /50@37]$F^I8[_DSUN*
M\Y9BO#56[94&$3)*UI4J3EIJD]:9*DY'ROW[F^(DHSZ;&6IO4AAAL3E_-DI&
MW#4BG+'4WLB8VXNUQ@R;4D242RI<0\>I3:5_J^!\I=AV@IK%2ZQTF^)Q+IDY
M+AO8UL\IFX#S&FQ>.W4(<+H"\>\KP'D(].Y$;C3F"YLZ<'SC8)0U1/H;V$MM
M A$'[EA3 &<M8$NM=+C :0M?H"W@M 6;MJ9X;S3&>P<'."4!^;:@KIKA3 -_
MI@'.-/!@VA,@3(M)(AW),IP_#../L9=ZTJ#A6A4_4%<?,)QF#%L5F1F)V%^2
M\L8L,IR/S.8C@,L%SC(&WK/(' <$&'?,KT<-&NTY8BD2UU$$SC&&[53!#,61
M600P%K;57=@X(9RQ#%EHS<E>,GL)A02;['!P0->>*_^1EF_'4S5Y+>JZR+L3
MN7U1U*IQ&CTTZ1]4NKL^9&I?M[>BN2_[\]S^H2[.^JPZO!Z8S_\'4$L#!!0
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M6RWO-@5^CNW#W'>+[MFY>[9:;5>O&QK3573MC ;-MM>0B88\*HJY(D:C)+(
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ML>H/OWYB9#L<[-'X[V+S#U!+ P04    "  %3&%*^&-ES0@"  #R!0  &0
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M#9A-CXDFF'!$(*T^;A%!6VRB&=W98#M'Q,$]9#>'I"EL(@;CC"T_GL: ,2R
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M?[5[KBPTJAQK"HVH6>-P*-;N\V*U6VJ\ ;S5T(F;O:,K.3#VKHUOQ[7KZ82
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MJIML[EO!F 25HO>D#J)2(WLT"!12;Q.UY_W@Z@W)VF$FH_''D/T#4$L#!!0
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M2FEIG#?AV-;>7&K:22*WNAQR,\[KHWT]T>K0W%J<]NHT_0]02P,$%     @
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MDR(+@&+6 > %])SPXJ?9EVQ>TD=V@2&4EF6==ZTOOBX#O'F>/N3SO,FS$(*
M(,@$ZF29KM.'>7!1X'FU N1Y*(M59%GF<?>R9QDL C=<!,#P8:M6N7$4@FM2
MSNR'=,'*(C[ZAE$)V9_*^10NUW_0N37K #YP8#)WC:__E+P8#H;#$8"K2@#7
M5ME/R4E_.!SB_R4UWYMTU3R55?[/;/I34I3FUQP)R)01SUVL)&T2N '9X@%0
MT? S>JG]:_MN(,=^62_32?:??UHB/E5?LC_])0F0@&]VY^I'O/;X^F'BH_[A
M"3P]//J.?6P=?731'\+HA\/C;Q\]H!7CZ31'1(!3QSMV ,+%)%WF@ 41K%TM
M5G.BBM-LED_R#MRL(RBR%<]H\;M\V:*0>S<IXO-3UN3 O_:!8KY(?A2X;/YT
M"]+VW7EO?3,XI%V_X(/;]>VRF[5HA-VP<O^UK<N.OAY?<_35#0M&QIXA\:Z1
M*GU<(KM%B9;P  :#R_D$Q#'_DB7ORGI'3GC\.V;9PVGV05":E*&X=0O,IHB!
MLVYX+$/* U)XNX5G!8)=5F0HL.'KZ721%R0%-KC"CB^$(01+:;]'8)Q5Y2(I
M+1S:[WPDYIY'8? !&,@<QR#1P8,=_AQ>MAJ$'-IU/E\AT2C, $L4( 1?$%&2
M/: ZTW(^3RM^2+\&)QV.^)SECT_X1_H%=O28)<6*B!WR.35^31/PG\&H/HKX
M[.V**% W[MV!9 ^CCP]&@$P%K*')01I(W/VEX3JN2O29(L<W2(ZO"Y!2MY+C
MUQO(<1<19.9@K\Y1QWN.2FQY'T5]&E@!GXF!2!ZY>8%0]7=^WN\@\5=?LVJ2
MUS1,N8SB>.25KM'X4&O48>'EI4^6DZ;T5OJ[/NY: 2')P4-:9WSGX,*E,;G-
M7,X=3SL@E%M.N^O]]GN!>+%EW.#]R.'0C7].*]2%=SE,[_TNN':L/]#ZMZP_
M>-^G)J1I@9[WO(%_"5-"<6T"9#XJ=(^GOZWJAH<%Q*FR25E,0#%U)!5^Q;])
MHULAL@#!*R,C!_P)5"08+H\B%7$,P-!I7H,>!22)\#BFMNV*MET\[/(I+1Y1
MMBA$*Z/A-Z@A;16*WN]0MS[L IB 'L'EK;>\<[,"QI[B[#L#)EA+OL,\;_("
MD'#+6JIRDF53X?#Y[R/&_F"9NF-,O#HHJ]T<P.)+/D4%>)W,=E@\?4@HD)#^
ML:-]HM.0T4\>LL>\*'!6/!HRP'W#UQDJ4EW?W:V6RSG=<;@1<#4F< %7%8,:
M1YK!?8=M6/-G=%ZR9\ K29-^C<"C+ YH+(4=L*1=0.G,*GB/X$785TTB!8IU
M\]64T2[=8H+PF9>1<P!;G)3SC>SP=59/JIP0!X<$03-YM:KS(@N85EQ''PV2
M#4/TWL[7D_)]OD ]$$X0Q/A!LH=OH)2?%NO]?I+" //T&07.25DM2Y:!DZ<L
MG?YCE59-5C%L;F'U7_+Y'*C^^[1: P, I?LYK4DNYN_@1?ARO*SR>7*,G&!X
M9,1B0(P)/G:Z!KSY/ETGAR-^<9#</V5$%6%9<!%A79,YR/D34IU1BGW(RR:;
M/!7EO'Q<VS=G:#_FB7%?B'DE',8ZT"P - 4\F2>/"),%PR295JM'XA/I= I
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M8AMN5Z"'YVK'>P!A,T&!<X'$%';,F&?NHJ:?,)>1'9%RHQ"!7 'Q3Z-0ZVV
MWXILR)OQ"&D*XB@***!"R#D 0)_+ZC,.)N#_*7DJGV%M53]*I,S1:?Q6 $&6
MKI#10[T^[16MH9E93%$2="LZ/=IH;$[K7U/SF"N'U .)VR"YCE/5\,*QZ%31
MA(49%)U &J\6Z=I\I7'4XB8C3[-> HF&LS7LFM$53]DB,5!N&A^A[G'O?&9F
M0%E8]C/-\$AQMZNE2*71'9%L&;]2:NH2M&FAO"PK9/@NG799\*8L1Y3/8)/
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M,SR+(;T/:D<)B%8T3HV\A+/-F^0VKS_WY&_THR#FLZ%%/,OX6V"C9+V&7%-
M\BB^+,<XHA69"=**, #M8N))8:4;97L,*K)DP]J7629-'T&^$)GJ350(IH4L
M2_3<L5$0Q#7D2ZT+.-&;9=^YVJ'1IIR_TR!&7$S_ _6R1?H;W(NX(F9DOD]%
MWE!@L'7;UF1(ISPE5N1H0+0VDMURBD";LH5]FBT(<0IV %09>@DQV DN*I*3
M!6J\  1?TK?:K'/,D,56/(X8L(/DYH%#'4&X\E*SKDPH6R^>L46L&2,2JRE+
MHJB8B55$0@L9E5,,]4@Q8/N XB8>V.SV!>Z5T<*1'&6S%2:&((<&.?O1QJ*P
M>$H&7S3)KV'/&/:Q)$K=B,.$+$H4K9B;F\ 4AUFD"Y(W(1B^0]>%0LJN%B6&
MG\C\F=.9^!36*E[F$=V-2&[IMOAD0!SL9(CP[,&#Y$I[Q5@36P)#,+8IU&@+
M#E1%Y\936CWRG=-6+!=#\).@( PR3R>9NE79UR834XL%\4Q&97,Y*M488J5A
M4$R-PNV @O:L56,YAX3PJ',U%L\OF?%D&PTC?LPO>U=W]]?OQ_=7KY-/=U=O
M/KU+WEW_?'77>[.J"H*,V#>^$I1Z9WSVO7?L-BVKM4/&WHD\_(C.[2SRX)*7
M7VUZ5)>S!L/$>D=F*@S;0><*AB%5L#,V%]RAELU>RWE&1@U4N '^"L2]ZP4>
MJ#$-OBN+QX-W.6(59V=V"TULU13Y R\8YC@X!;.)<D D(G.<8TYS"+N-Z.H2
MCO.%C*]L_0;!XN@4M/<;ZP2_ 8K0]'TR($H\O*DEI+2)3$M455S\QFHJ$D*#
M5YOD>'Z52!T::3,.B\P=U$ B*C*B$E_89%U)K"C;1?,*;K"1OWU'M <B-BR*
MP9N#(Y5'Q\(7U;G;*+#;^\-;;L4H4@[(70#TUPG\D=F)CM#W*.*RJP4H/D;S
M(7^=NCANCE'AJ!&^];!0%R C-G8:R[K(6AB1?>4X7KJEJP7.[\WEYO$]RO"W
MDU(%!96@*MN H;)JOI:X US%&+US[NAXR0A;$!71:-<"&:V?(0/_$HE]"]AJ
M;U..I(3+X]<'<M%D,<P=,O;(5-KPW%C-J.H\OLHST9"!DWD*\25T58ZW2HP:
MSDKA-1@+:R()'81XAJ1_GWSYGF1=$M=!9AGT)$V-$/BQ(!;8>T/,2T+W\/\'
M88T8$CNEB*M\\0 R''-2]&UBS091!T"XSXW+1;L['JE$@7N9B,LC7I_"UK,H
MRN) _42:L_$F+)]R)#)/0'/RB1=!B-P=$4S4=SM%"U/72Z&7Y**6'4QM'!4?
M#SM0"@[(X#6BV([JB[<;%P'FBU 6A6L;"R-"+C%6SJR6F22<+S*E\D[QW6'!
MBT%("2N/(B"W5+J:/71LXBZ)TMBHH2\;@O>LR*T#BWAG[E'NHBI0BL=[ 9QK
M@MX6]U;[(P2Y0#EE>S&*K43<5\L#$)@P!"9=6Q0 A0JN*MH=Y=>:)=H4781?
MR%FIU$GW-M/\]NQDNT*$R!;+.:E/5;E.YT"K[>@8H,'$E4(&#=U?$ON>&L^Y
M"1M)^<*I Y*@6@ SA]@JRP 9=7G#FH4*$-4YBID,UHD<T#B)E(* &@;P4/8F
M^0$H W$.YN3%GF;(>#C:9"67 F^NF@O_B?DU('923N9S6<VGSQB=80[3G\ Z
M.%S0IO55@DJQ:H+=:(MAK9=46W&:(N\4,J(P:6+;X_=,R+) /H@\PG-DM%5!
M:D_I?(8Z[[?= 39[FI 5Q%PR@U<<7X6<T2"N =@L$],$CVQPJ]^!T4#\W5RL
M$*)RL)QGVN.^YP$.11W XGJ?4-#8R:8BKI& 77;(:J?#DX-#X"<1HB_&U?<R
M_<$5YZLD8T5CDKYO2 ,Q2XSBF7^V8N8UP0!"@UQ0&H)@57 @K(M60%F MD;?
MN\ &,ABS%Q*WZ6(,PB$H L@&H"L] B-;\"IQ=%S6O$SV1OMZX;A(F'H/P(K$
MT[I%B"&LX-06R.-9)86S/$CGI55(\6SW#O<E$LB_8@;W4[,AN#R@][#[!XA-
MP1<!\5%F"Q<DHA7]O$XX2MMR!258M;_+:PTX0(<':P?W8_:9\315:2%GXW:N
M$=6L\5Y$WVG.N5ITK-YQU$;A>R )A5":W0'\U#LMBOA6EM@!ID33<HTY=9*1
M\)S7-I2#U$NC1/HS6PL8BE42_3)1-F]F"1T/.1P%+;V:<&HS^UZ^G\"UF9;5
M@14$2FO2S1 B>!Y[/]]]O-KG6#3CL_H)/L[Q'/-J>H#6L+5Z__[F:I_RY+R%
MP><X$*Z [#!N*%@GC ;#(>VVLJSW-<U>9#D!GH8I2+:)3*]#<@:)BD=\EAA
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M7&W1]]P&.IAR3\0H,5844!Y^JETALB6)J60;L^=+LOI#QE6W1(E>>Z&:UO[
MJ-(;4S+9JC;5 2.%9#@&E*VF,\KRMI73:C0GN @MFY6L$^,<OV6(L.L7(T6-
M<OV:G)9PR7_-,01*KE(;>SAN<)I-YL1(B4OD4_%X8I0U1U35%/L!PB#GEI0)
MQ3F(TSDHP^06\7.)E@8R?LL"U"]4V$]XN]UO*]8M56+X%^ ,-(VUW3RQF$*>
M390MYU@GC\YDCUUM1-R^V"GW"3_\B$'[4;)G?]9?B%"2VD28&ZH<UB&B<86V
M>;+D#B8E^M7(]<OZK_4RVMAX,52WQ^%BNOX5)&XCLEL2VY_X+7"I<*A4)P V
M-7@<]"DDO'+KL@%F2#8ECZ6&L?LBC7W-,;B5/.=4;Y$<7Y9;8:5(C/5TM+R]
M_"CT889"RG)T@,EW IE2A:TC :DJKS\?O,%@]VO)9TYN\0 MCN>U*45 12/N
M*T(R3$MMG#OQ.<L^6TU'J",'FBDY%/52K&WVA7& PI?9_H=:%.6+SME1LWB0
M$H1NS11 WB+?]FK<XU"M%:>:YE- HO&(MFAS8$=CXPGH1J84+2#JQ]8WXH1>
MI%_SQ6HAH=BS9#0TJ0(:V5QQA"U;$IB0*>]T<'@2&VQ%*@9BVG+.";<2 D\%
M?N832B\0?QF7J7=[@]$5U$".G64<\NX?.9VK>43GG+?C7P&VF!4C^-R&J,GN
M:UDG952FC1SP)DXV_-]B114&T%?Q0*XEYFLD(*R0GR,O;[-2'[3M9;L:*:NJ
M("&"=!&Z:K-5)3Y<;=R5"DP2O(.Y?.:$,/BO7(NZ^OPD?@&S<[+,&&;?X[8.
MR3U6V_6$#"\-GAL?<$U>)3=)*5V5L[8V1]R1!7]V/.PG>LX$4RND7*XW2\OR
M:*XO//2C QV;)PPDFJ5*43QDS3.JF^;;!U.6>D,A#[:>&?[C<B)-"0Y,&T'J
M@1,>(*^UAY=A@C$B$<PT3Y]-\Y:T69&.@3]S!=<4]9:)KJ]EA!1;498D5K63
M]MTWA4K2KR)'(? &R5@)"1A.])Q* (RK(D#.@P*$ +2 H8^6* D53YJ:L\"E
MIC8^7/'HUD7AXDF(29W(8^O'T: F!:GVTN($-W0"G#6_>39=8G1Z'/C'YXPR
MC%HKX]\1#QGN'(?62J:VOG.2*0_F^6<@[ <8OG> #!MSJVK2 NEJI8T_-4N'
M]:K&W>%]EV0#[Z4%M>,A.=$.Q[KW \C_LWQ+-H HVX2[\K[P)98''I\H81D7
MGC^5S$2LU,JE6LE4CPH,&4?A3)NY"GZ6T0G!N>%-L^X,\C:51*SY4^F^JT)M
M0:U7G$MP-^8F$=]3! ,*,Z",([_/3>LGRB9#H05K,]6NW+]SVJE4&*D-ISQ1
M$E5 (K[YEJTEAOMC9#F^$EBEN3V#25LXCA=8M.O!\KOS.M(5A@,Q;#0K1F 4
MI=::5#6AG&Q>F)R*]^PV0W8&3.::]1Q5N>L. R32:EKW/HJCX[RO5OEF?/?*
M:$?CNT_)AW) 3P^&%RZ,@&!RZ9M9+R4TM$[V[BD=X71XNM\7VSN[;L3M;+HP
M$!9HLN'*%C%3(A784!,3[$QCS#6U!S95S]B."/BR0 DG>2R13NK<"ZI=)TMD
MU%TMIQPP*! QBBS%S+ 49RL$QEQ'CZN<.1>@#PF35%:*R&;>6"TV(Q)L8AN6
M2%4D?UCT9(D@8'M 4Y76EXM2!>=74EBED'+<K2$:R$7)1S1>/:+3V7F).H[Q
MY #/>:=C?"D\-[5^^"N[D]=4L)@/R'&#ITQM5A>OPG*&!H 6V#-58]DU'&#?
MH[U0N!W* (+3:_]XUI<(C+1"X^[46#$(PI3CM6HX[@=>R$W%$I)R3 $F?[GD
MP'!7K8FA2*X/M*6AN?J:Z%1355EGW!Z4BOQZ1%/%I0BMWA(6%U1OP"RG2;,1
MT&+86BTY/K\CH<1&46! CHD@Z5A&:Q.89CLU65R(HVF(I08VK9*U>(SL;ZE5
M4>863 SF&X4G?F])A;%U@8NZG.?\6F?I-,.65#FC 1)%<YG.=J*+B(VOO:IN
MGW0M7"F0!)AWY<?<C%U]W4M3"9/\M6]+W#@5):@*5W<X6JR.'2\F>S)>O7?B
MC?Y82E%8')TEV=+F==C:^F79P,W)O$I/Z+P2&<T+%QPDKUB_(=Q!%#0'HTT;
M)L,^3C0MQL%BO!6J-+;6T%X1JDH5*24"K*K>/E*&2\XY/#J.85JN'AIS/M\+
M0;DW>)?(46U#K")HYQK',+GQI&&D7\:-KFDD\P6_Y,H&=S@P@S?90[5"D9U%
MD0W8>WHP/.PG[[A-A;#M\^-#*9@](QII#TRX(U=*QNQ-41X=*T_GQ#0QX&+.
M8S+MR:N6NYCC$BCKO9P=K&JM)::2#FZU10G@ZR;!HFL'!0VWLA6@QE<^\S!!
MFY:)!/1Z.Y7R$=4G3HI;T%&])^_++N=TX;L_V+HQ^BF).$#D(,]&Y_LODVOE
MF<+3NA*]GSLNB^OF1F)0QBI@&O>-2[#1DEZV7L.2+]XHMMRLR09;8D'!FL4U
M)?5C$5(R6V[W"$GB&PNRI+C':WH:7Q8Q0:L7R"FP\3(R89_IT&JA%&Z\P:AO
ML9BGRX<74V6"$:$1SS9^);@J9&PEE"-<1U2X0B_?D0FB8"07\X=H*:):>)71
MS%#JD^I4E%A(2CQ)V'R\%5],6S#29.FY-[*6/=E)1Z8(NT^%8$<:4# R9H*S
MW( $5 *!\)FS\Z@H:>$T5/\I!<5WGD_6[* B_;PT[])L"NJBVZZ3$NN_"RT@
MO/S#R,"I5*^FM)N%:_QA)**20OAI<%LJ=1O=()N""$<XJ%N?]?!Q-5 <Q/6G
MD_8"K-*+4.=UXV+.0N(DL1L\4UD$*0(JVD+)A!Y#]OUV1F*3$T'MUVS*!)(8
M//B60VHY(ETJAQ[0.)"\/!^2::5%F(.MRI2RJ<!&]FU7M5<Q6;U?C/4B^ZJB
MV=MPJ8U3#@'_ .322"XN;*8HZ0NOHG19E*O"JQ1#[^OZ913<;:LRM1YU.(JB
M.XEU?:,6@S> R$3+J7+5ANZH1X-D^T<][A/;W6TV*#1(_D"$A_U&XFI,?]F#
M;?UE==?M(,ZG;RE,D.@T40W3_+)4KU737*&NMC.NA/%S&9[V^N7EW7?0GMO;
MC!'?7)T\M%:(PXD_%>T()63RX08*'G7K5?I_1_2S;BTH/FX*"0*R/&%="9]+
M7FKA6GRR25;5,64OJM02E;O#X+)P?PA:"0,E0@*E^@_;O7^+G>QE#W_$_YS@
M?XY[IC%K[P7]SS=T1>[\(NAZW(F++<CHTFKV4+B)%KM+MW2F;^U5D1;?U!@!
M>.?:PT7W+2FV@1"H[1R8%0<@_D40@2-VO#:P<?2)]%NGN( KW4R40YHN19+@
M&C+M#X_17[[CMZVS(']H[9H4Q&[$4L;VFIR*V5?&-NX=[[0TA&Y:8Q!.F7 M
M#->FO(C>:ZE %[S?.2<.U-U\4E>,:K]U,DCB+W94F..FI::KEPT9<K#LWGU'
M"3&$0;1\6% V+%(NK*,8&&:[4RM#"6 WT90]<>)V; Z&J^O.,G2;($*[>-V*
M](MWH06:W*1S"OJ_&/9/T#D)?XWZQ^?'].*+T<EY_VQX_ETDSZ^!&7!Y$U%M
M+DC[^:D+NC:O?,=5:?<SW8 38^O2V1*M2 !V >$N$=;9'C&.T1ZP>57B&8W*
M8 HHJ^!Q^HPO87OA=A2CY%CWDGTRPS8[3[DL1DI9DV.[O1*]D^Z^TVP\:3\_
MPQ +_Q7/]VG,(WQCA-BJH- DWDE5 MQ3W869K26L39@@%.Z"]''2E [U#H^2
M/;2[+*SFSFT'$2%HA?LVSD&5$;9*%5?PJ&C=H8!/1BJJYL$V-EX4EV\'D9=S
M<"I2,RHMA,/]0W\-!?+;.9D#6OM=S;%0S9/1EVFUO ;ZTY0M,%G<+)!@N92U
M=JX@ .=E1=$:+:M]AUWS.JQ"9></(J,Y>8=I_(/1Y,G0Q<#(J>XJO"3UF&*
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MVC/=VWXX?7K4/9L1BD9&*'*.H=(9BRXXV\BP%'G9"%#U!@&J=?%4/=Q%EIK
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MOTG'<;;EV7%]KJ,MH^C#.SSKGQ^>2"$;#DM4 E,@L?P!)MN1-ME^JQV40$U
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M:]$0O#CXI!RU5(*(X$([\:$.+YT>3VUP*CH,!0KA59+O.RO.<\B.<Q_G*$H
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MMAGLYZI9/G#L9@:04-H"SJ U1$&!E#XA?J,G]>+:^(L+-./EMM"$F41;;[:
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MWW?R#5!+ 0(4 Q0    (  1,84H?(\\#P    !,"   +              "
M 0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  1,84IF\PM@@@   +$    0
M              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M!$QA2MNF/P'M    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ !$QA2IE<G",0!@  G"<  !,
M ( !M0(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  $3&%*7;J&
M.)L"  ">"0  &               @ 'V"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ !$QA2HL\3W:1 P  Y@X  !@
M ( !QPL  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  1,
M84IA<LBW0 (  +('   8              "  8X/  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  $3&%*'D@^;!4#    "P  &
M        @ $$$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ !$QA2G>?DN%T!    10  !@              ( !3Q4  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  1,84JAEIN(I@0  +D4   8
M              "  ?D9  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  $3&%*49E-3[0!  #2 P  &               @ '5'@  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ !$QA2JGC2%JW 0
MT@,  !@              ( !OR   'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    (  1,84H;A!HDLP$  -(#   8              "  :PB
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  $3&%*LC@4
M_[,!  #2 P  &0              @ &5)   >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    (  1,84H:+)OXM $  -(#   9
M  "  7\F  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M!$QA2G]SB;NS 0  T@,  !D              ( !:B@  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  $3&%*)4 2@;0!  #2 P  &0
M            @ %4*@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    (  1,84IR5DZEM0$  -(#   9              "  3\L  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ !$QA2I+![;VR 0
MT@,  !D              ( !*RX  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  $3&%* 5,'3+<!  #2 P  &0              @ $4
M,   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  1,84J0
MH#AFL@$  -(#   9              "  0(R  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ !$QA2F._U:JT 0  T@,  !D
M     ( !ZS,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  1,84K\*3.]MP$  -(#   9              "
M 5P^  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ !$QA
M2B.6?-.V 0  T@,  !D              ( !2D   'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  $3&%*>)[N9+8!  #2 P  &0
M        @ $W0@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   (  1,84JPI8#, @(  ! &   9              "  21$  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ !$QA2C_V8#_! 0  -P0
M !D              ( !748  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  $3&%*C>*W*;<!  #2 P  &0              @ %52
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  1,84K+3_A)
MO0$  -P#   9              "  4-*  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ !$QA2O-P^5IN P  =@\  !D
M ( !-TP  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  $
M3&%*7$?QS64"  "?"0  &0              @ '<3P  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  5,84K8LJ.'9@,  *0-   9
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M970S-BYX;6Q02P$"% ,4    "  %3&%*FJ'Z(W\$   \%P  &0
M    @ $X80  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M  5,84H2\NAK)P,  #$.   9              "  >YE  !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ !4QA2B@;Q\QB!   \Q8  !D
M             ( !3&D  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  %3&%*W&_SFZ0$  !U%P  &0              @ 'E;0  >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  5,84K?Y;&+<0(
M ,@(   9              "  <!R  !X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ !4QA2M9+=IQT @  1 @  !D              ( !
M:'4  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  %3&%*
M_B/\$%\"  !@!P  &0              @ $3>   >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    (  5,84H%\<4DA0(  &D(   9
M      "  :EZ  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ !4QA2OAC9<T( @  \@4  !D              ( !97T  'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  %3&%*M'Z=$&H"  "E"
M&0              @ &D?P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    (  5,84HRW 1I2 0    6   9              "  46"  !X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ !4QA2@D&>U8;
M @  ) 8  !D              ( !Q(8  'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  %3&%*J?)F&$D#  !&#0  &0
M@ $6B0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  5,
M84H68$^2=6P  .J7 0 4              "  9:,  !X;"]S:&%R9613=')I
M;F=S+GAM;%!+ 0(4 Q0    (  5,84HZHR+W:0(  %X-   -
M  "  3WY  !X;"]S='EL97,N>&UL4$L! A0#%     @ !4QA2B<F<)0 !
M/R    \              ( !T?L  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   (  5,84J<X3!XU $   @>   :              "  ?[_  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  5,84IBCXVUQ $  /\=
M   3              "  0H" 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   Z #H R \  /\# 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>144</ContextCount>
  <ElementCount>242</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock</Role>
      <ShortName>Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Research and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureResearchAndLicenseAgreements</Role>
      <ShortName>Research and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables</Role>
      <ShortName>Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Stockholders Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Net (Loss) Income Per Share of Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureNetLossIncomePerShareOfCommonStockDetail</Role>
      <ShortName>Net (Loss) Income Per Share of Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureNetLossPerShareOfCommonStockTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosurePropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureAccruedExpensesSummaryOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureOperatingLeasesDetails</Role>
      <ShortName>Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders' Equity - Preferred and Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityPreferredAndCommonStockDetail</Role>
      <ShortName>Stockholders' Equity - Preferred and Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Stockholders' Equity - Common Stock Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetail</Role>
      <ShortName>Stockholders' Equity - Common Stock Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Stockholders' Equity - Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityIncentivePlansDetail</Role>
      <ShortName>Stockholders' Equity - Incentive Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Stockholders' Equity - Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityCompanySStockOptionActivityDetail</Role>
      <ShortName>Stockholders' Equity - Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Stockholders' Equity - Weighted-Average assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityWeightedAverageAssumptionsDetail</Role>
      <ShortName>Stockholders' Equity - Weighted-Average assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40806 - Disclosure - Stockholders' Equity - Summary of RSU Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquitySummaryOfRsuActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of RSU Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40807 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' Equity - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesScheduleOfGrossDeferredTaxAssetAndRelatedValuationAllowanceDetail</Role>
      <ShortName>Income Taxes - Schedule of Gross Deferred Tax Asset and Related Valuation Allowance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryFederalIncomeTaxRateAndEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate and Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Research and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureResearchAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Research and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="glyc-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Quarterly Financial Information (Unaudited) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedDetail</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://glyc.com/role/DisclosureQuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>glyc-20161231.xml</File>
    <File>glyc-20161231.xsd</File>
    <File>glyc-20161231_cal.xml</File>
    <File>glyc-20161231_def.xml</File>
    <File>glyc-20161231_lab.xml</File>
    <File>glyc-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001558370-17-001198-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-17-001198-xbrl.zip
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M5J^YJ$HKS $$?<1_^4&.A ++">(6H-F0V.TU-U$P+:LD&N;2C@)<#3I">?%
M7$O2S.@:00UDCAD=(Q]7- PG/9=B!]8@?R=X2%^F@HS'(/2<1_@Y)7)./#@)
M'@@+C@([><4.02> @F,LL%W<DQ;BQ5S[3^ _FX*HPFHQE..+P!$" "],OF7\
MJ\>1:POMYX3QO6%CZ.C :,:83(T[FA2CI(Y@Q51K<"ED$S34R.XX%*HOCR:J
MD&-BA+-;1A2"#]4PR#"BR8RI1@ P80GQF$KE$@H8E1J8"#V,/<;<#_'<_Q7:
M-IW=];A/  IPPN\]4#O.P3!#C<9B&01JQ),CD$28,)%8+E56LYN(E4#![(
M-PLRZB(F)HG?.*\&N%Z.)TC>GR#04V0V1O C+NZIB\EM2N)DYI"2#LP:P)#
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MB'FMJ&@UH-7 &NAM'9>1=V[H/3]P=N$/@W#,54)E>>=R0E&I <686!4S@#_
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M%!AX"O]>N#)\;QD,(;"U'\M9DRO@AA.'*&K92U+PW !Y?."!P8GO1V Y(C1
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M'J_>4WIH2NCN3ZC^Y<.Q@[,[XI.QNZ&\#C\IHTS'G^>&-7/A[B=H_E/ W4G
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M!JE<+\'.[P=P^ K@!LH&X/*9JP-S=QP.-N'P&& .B@RZ)"I6[70=R-P@T9;
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M-'U?L@]1N^+_4P,G)#;VL2R<(L4K=24:V![BQJ.XX1IZQ1D@O@[ZZ<&-:/X
MO(HVE#ZHYE0PE72R1&4=.[+*)-Z>AX, 7-'^!.MG>:54&\/,%CH;--(T=KD=
M R[7O4M=0?;H'6+UP26/\#8-3.4$!O:F#SHX!!N=JG/XU:;)^A25MAO:R31U
MX3"BAB=C#*+2KEA3/+FE]HG/9@5-/Z=NZ%UA2S$ ]W7E_BZN#PV0S-BC_J6-
ME!.Z4>XSKIB=N@/T?70@DCBASC$>^^$3,)1/8F;#8)]4>A1*:!D&YLW>4R'&
M_>5L+/!D5Q(A>;()<1C51LD4YR_-E<\CEYT(P'GNPD2+CB1?!@Q%0H^MCT%Q
M#>\6MHZ!'&;I(XLHH_ SS, G[@]M0%M46A0XPCP18!D\]G@OE4D,&(?*<C3X
MQC0NP1PM=C:;.M?AVNT+2T>_'H@$V/2(#1X1S\/)MC9GBP@O!$]2T@7@J$,!
M/@=#:9FQRNX(M<BI=V$A!5=HI.ZC"!=4:9HJ^BX[S#]1-I"^-HAX&NU)WQQA
MF DQ(+$,\3;[PBCAP.>C8IBQR'T(-C6FB=!;4U)L/7'IQO(BV$%!?@1@9?>]
MUJ3H,)JW(I[PL%UV0RVVTO8WC)\]9'BU<,JPX40AC1^SVJ]94)_?+[<!:=8L
M(E?I'Z_2:+^"]WU^Y6%A=HM]>;6[%E0:UGUOONDMS+>QU[:YL5ZFI;86[VCZ
M;E7>-VMH"G2?"MVJVE-K+9)R7N@6PD0(D^ZB6PB3TU*WL",K0G?AC+Z]5KUH
MPM=8K7M.74RJ;RT$* -7'C97N]B@?[3>2/3^.G:;(=&0KX7[)ACT3#;Z2,WY
MNF+<-';?:NP#UD3+M>E]1MXM'=U$5^>A%]O1^*(=X:%NH[?V<%"WT2N$@Q .
M[46O$ [=C@VW%KV=L*AWQ'&:)B7E5V=/841_)K&$2;86O;+E84H4S1T<!R$6
MU^J@/=UPVF^'8MR5N&D'E7(F8+&3RLG(_9?J";IV+;H']D[6XT;ORWU#E4WU
MK%J2'8F^A0P1,N0,98C6EX=]0S;T09N-\8:;'9TPN2MS>&HRQM]:,WK][;^T
M=ZT5QI?)C%W3Z: =WEKOM!W:M3I>:(K>/7*CRJ:&PAJMFN6A8LK]X4@((F'W
M"\DD)%.#)-/(',C:4&NSS]!:$ZD3WD0[?(8;*\:"!=84JZ[]E]Y5[J"ST'!Z
M;X?B%>JU@>JUT4I4!16JZ.<D.(0)+R2)D"352Q+=E/6AV69CO.$F2"=,[K8'
M\+,^IEA#* AGV%C!"9-[R69M13MHF;?61VV'IA7!LE;IX'8&R]2^/#)-V= .
MBI9U1Q())T"()B&:FB&:%%F%_QDCI<V^0VN-I$YX%>WP';+KK.&JVM;M=Q0:
M3NGMT+E"LS90LS9:?VJZ/.R+['LA280D$9+D$$DR&LBJ,FRS%=YP"Z03MG;;
M(_B9%8X- X@?=36AIK4>:3NTJXB-M4KOMC,VIJ%"ED>#5EOW(FK?4GP+R20D
MT]JH@ZPI WFDB:"]<"0Z';3_@NWN.N@>-)S":U.UNU4Z%AKU-!IUMUUILN(<
M*K*AJN<D.<[6:A>B1(B28XH2 Z_ &FTVP!MNA'3"S*X^7M_73FF ?P]BRUO;
MRU<DW#>(7UJB:46 K%TZN)T1,J,O#P9#6=,/.E'OCBP2;H 03D(X-40XZ2.Y
MKP_DH=GJ"[NM-90ZX5BTPWWXM^4E-,5'LCPO>+1\FW3096@XO;?CX%PHV 8>
MC^^K1:O6F"]R>_[E.4F*LS7;A>@0HJ,BT9%;VP>)CI89?,*H/L-H_8J6K1TT
MMUOK>+9#FXH86*OT;/>V2RKL%_[UKR=-4?M'V+L.23+A*)PGKPC1UJKM.IUH
MZXPI+1R9UCB+NWHHGFO=N9X;NR2ZZJ!V;SBAMT-E=](0JEVS=A*KK6/XMF!5
M2  A 5J!U=JMWH:K_$[8MNTO@3,+B>V*RC<-8XYV:,/NQ41$"*M5VR6B\R(Z
MWW!\-X97A&AKU7:)Z'SCC;1.>##M2"9B5W^=-0'[#NK[AI-^.Y1X6V5_IU5U
M6S?E?'P-X5$T *N-H7LAC!JX*>?C'33<$.J$#U"O![8C_1>NZ*1O'E-$U:Z-
M6^L>UZ:6:RJST0X[J,EU,CJ)\ X)D+;@6T@4(5$ZC/#:;?+6FB2=L-8;FT__
MF<1G4I>SX61>BY[4X'<G2.X\TOE"U[\T/Q)V1KLA O/MMF:$'!)RJ N[(6+R
M#3%_%JQ\]M$"$LQV@)=C2G\]#LP''*YE8,\V@4G)W?4=XL=76K]GG SR-U8$
M5G[@2_&$2&^#Z<SRYSG9CUY%4C CH14#G4@3-XJ#<"Y9OB,!%-8]F0*\Y:?)
MTXS8,:O/&9)[*T0*D\9)G(1$FH7!V(U9OL]<+HPAW1'/)0^P1@0C), V_V5C
M!./UD*UP4D!(P2!^$$M3 FX,OCH-0G+IN3^)-[^,)Y9_B;_:H1L#]BP)G%\2
M2M??WDK#OB)+2UR^\00#?[J"17FNS3#ZT;>#*9&^6T\K,IHV;4=/NK;M@"+-
M PQ9@#G/0S&R6/)4FE@18(WX$HF0*=QH HB [P!A[XA-IG<DS*E25V4)D#:@
M6P=_&#UI#T)5M44!70?%7F]8HUPD&$"3(_UB#F5CI,I#0\=7?_2^]:0/!/;=
M\BA" ($QD7R@EYS6O0#H*9+Q^<>):T^D7S1#D75C)#VZL"-W2*5V<._#*BC:
M+?C*)T#=,'L8)/<3"84K[IGE7<XLUP%<7=K6#"D%1B0^IW+BR-(O0UD?]>6!
MHN)T(8F(%<*,")H#3.$%,\HC2.4VD+L+9(Z__8*KTN611E\+PAD0M^2$R7WY
MR0?+]5!J2G$@V58(_#L.PD=@3* U:1:$139;Q@%[A;\1I8L':L#A@-E=8&OX
MH"D:1_Q6X+,W=/H,OK0:>/:8KO>D@^1K,\CV^SHI1H57'(?N71(CQ;F^[254
M:JZB2(HRCD:0#X#]*+G[&T0N[@<2?/#HDS":N#/)!I3>XQM44@(@#I=V'WV0
M?4"7TE?8'C]!N!PB?8-!@!0B23<U.HMNZD@B;!C<B\+00>(!V8_'=.)U*^."
M'B%+8A>)7<+-W[0LF+3$XM)JSLXD/=<=\*,5PSA+&*"B,K#M!'4%# [O<GVT
MC*NI-0>*3R("#.VY4Y=KLN?TXXI5DB?0E+BX\MZV6.@6J%<:NQY!%J9J#E<8
M$L"F3[D:L43EZYC+U[^3T(T<UV;:"S:9/_2-RES8Y4]6./?@AYZTED/2L59,
M"8*)?IZ#S(F 2!0F4ZPQ4#@\-+5@N@*#D"= E,_V]&Z>0[O$$=](^.#:Y!F@
M4KC70C4A9<@&J;0#P;\]>#AW' :>!R^4L/71SS2,C&;!>A&.0F4+J4Q_*@IB
M_G59 5 F0RX!#9B@Z0@KX-S$5DI%4HQJHBB8G+^3*,8)]^*!4=-8P'$=*GHF
M%LB=Q"^8 HA/;@E$VYMC,MN75*)9?NS:[@PY) :CFVIN)LHB<"?=L6O#$Q[(
M^@<2\DU_BB55 UO7CR=1B6J9RLX@A/T"V@.;D<XX(T#TF'HO6;8=)LP3P)>>
M79,%\G\Z U<2$ ;K*S  6O]^!&SS%=[V;9"&%M,I=R1^1&,5@45S*Z&.Q"K&
MQD6G9@&A"L9]($M/K)Q6<BEXXP"-Y.>P?[4/$3;4FRQ4+.:A'T7YE8^#00AJ
M^MG$\[BW_\>%<D$_1S/+3C_S,(5-D#BR, 4/']B 3VL6D:OTCU=L(LE4>C@7
MPP^+42PO=M=SN8'6TVJ-BDP(^P'6-HN/%B,ISX*,/ :BO9JX#DBV OWL&L(Z
M=5J=UC-J3<=N^FY5'&0W:TZT/C-T]WN:H&Y!W1U%MZ!N0=W=1;?64VL]Y>\,
MNJO(MJO=JE^1ZVB!$WJ*,U!S;Q,^>[/3)GQ56U-(&6".[$ER!NB[CXP+[P+/
M6=JPY_^J?CN/H&8.3N.N;S_W8K[B=J[@1@S='6'CZC;'&K5O@@\%'V[!AX;@
M0\&'@@]KY\/^4>S2>AVXSN_;GFS757_PP(K/PYZV<#PM7;+O3I:Z7,ILRX]9
MTU/3\_ =:[W"N/_I[A&5W6IU=>H-V0/#:B%RQF>DMP0J;^BK]WM*QTS&O>NF
MZH5DFY,QQ:]U&H."/P1_"/X0_%$??S30U6FZ&?7K^?DL+?9,6+IWO/).5/N]
MD,8R2=L":SMAO<D*H=\;M-E>:NO=;4'O=1E O:&@=T'O9T/O!\KWNNW]=E5^
M:*>UWLD3AJ_I/4)V.;"#MGP+7>%.:X%V!H14$2\5EE(#MJO)/&*TVT<6/")X
MY.@\,NSUV^QG-,V8.B\/I,5^QI>E.B0==#6$0R'"2F5Q/VJWVR ,'T'ON[G)
M:L\0!"\(_FP(WCSLG*QN>UY8[2WRF9IDSW^+ _OGY1TM-HW%XX@?T<IP';3J
MF^;SGKLZJ#[P4[52>*'TAB_;; :)4*C@B&HY0NV9@B,$1]2_70WB"/T@CJC;
M=6B:671>3D6+78<O6#*]@WZ"\ 9:@/7&J-_3=26KVW1JZPX)MFG@I@BV:?H.
M=9IMFGP4H;4[M4AX#2WRV9KD3[S-^IFM:*O803^C:8YW!W7"P?4 FQ9LZ@][
M(Q%_%7:2X(F<)PR]IPB>$#PA>*+ $\:!YW1U>Q%-,X[.R[]HL1=Q$P8/;H2^
M S9[S7M1BOI&W784#JB%AXV<G2#!?IS;JH"V*F81=EV_0S75CQ3\(?A#\(?@
M#\$?C7) &FM:'51?E7W$UN.++F/Z:U5K*RUMP[H*WG#ZVAH#,EO#K.@0_[:X
M&*GXX???DNCRWK)F5Q^I-_#=>GKG1K871$E(O@,KO?$"^^?K?_Y#DGY?>I)$
M-Y:+5R-\9+JO9/S'Q;LDI(<3MRK\@^1_^SVX5;5;G7VZD!+?94_^@#]4[4)R
MB.U.+2_"ENZO3100*V!B,ZT!XP:DDSW/@'T6GD$)GL'%:XZF##$;=ES5*A7T
MV^S]<C\4?/;*C4%$V&PLA@J)(DIZAB;6K6I)?G('5>OWC%.LDS[X?4*DM\%T
M9OESR;+M(/'C:,E/E9((!(\4P[-6%)%8LGQ'\ESKSO7<>"Y-23P)'#PFPQ%"
M!T_'I$<WGDC7W]Y*P[XB+PF(C:RWA&VIB.Y=QJ-O]Z1W9$S"D#CEA5DAD4)B
M!_<^(-"A"\=58AL4(.B(_"<AL)@(US9.8N!.:4ZL,)*"L>2X8QB1_7Q'XD="
M_.Q=O+U$'Z+HBDKX<@G[C,^.71^0Y5H> #$+PABQ;$W9)EBQ1"Q[0B>\)/ "
MNQ(5^!+Q+3N&/W$FSWIDPRWW<('O9S/ '\I6*0[HA#,@F<"AZWF<N# Z?EE<
M"2*$/,T(FR"0+/C)CG%,.@Q#7D^Z7G4B*KF11"*4Y6XT@=<?)X 2G\"PD85P
M!;!*)X'GG'0O$%2.(@X@6WT)A#O<(B $V*#>/GQ6DA[-8[0$,!?&%NP(8F,6
M1"YB-9)F21@E%@P**.!\U),^9 2#^TVFL(R4?NE>(,F5QH$//V$78)X%E++O
MD6<9P1"@;A]WT"$Q":< =X'B+&D:A.32<W\2;WX93RS_T@\ LDE(H@F(2)P7
MOHW+4]\1I.<HB7!UN'D?QQF'9 ]-"=W]B1OEP\GTL3OBD[$;9R20<2D\.B46
MZDH'J"=G.O[\Q'I(I=4$A#A0I$0!=R=!0"%E<*4T)24S "/Q8E"(,9& &&./
M(9:*,#XZY<P$Y%P($J\G%7<S@PS9"G"'$\(.APF,'1+/XCA/_,(2"O R]IT!
M4WM4-KA,C,S61@V?98*]#9 %?;ZD]0%=$7E'V'\_^M><A&^L.14,%9HCE]I0
M,0?#$HS/SUXEL$8)6&,CL+HR&HZTFH!=-*PV *N"G3<:&M4"BW3^5T&W54@)
M_;XQTC8B=P& BD'>D1[4P4C7=+-6D'>DBDO-4/KJ<%0MS.\(%?'1ER0&^>^C
MYUHET(:F:\IS$*^8?Q/(-V"$@<.36HKOG_#N.;GV'7JOY)K9*54*.G5@#$Q-
M?VX9V\!T]'7M*A/[PWY??Y:>&K&L'4E.'P!O5[NHO_#%Z,OX+S"1"5D1 SBN
M6VW6ZE;3-X<]Z0LX)19U?1@Z]K'QZS+M%[(FM@\4M6$A12/7(]RE';O@P*'%
M&J;UO:.99=,DV:] L ^NYQ%9^@0.GX=/);",$)Z7@FR7Z5#,N ;? WP--/R#
MY'XB?;'CX X>UU59TA1-EUZ >6^!+>XP$]H!6YKY!I127C*? ]R!*+G[F[JI
MX+#Z?D+]:5BJRUDT*AOL$^XTT$ KOA-AI!R! DL;W%'WGCJU])-$W7+F63&S
MG$Q=&%$NSHD_ *,ZW'/#" D8[; ^;LM3:!D,]$]I:LVI#T8=+>H@ "H]^&XN
M$1>%!7T-$>@%H2/QJ$0*/XR:NHRV&]K)%!4<>-F]59W?/OH(&GCA=!692T/A
MD$O#@GM"W ?JM #NK+O4O\0]X)L&"(5OX"&VF)6XYL11&@)<,O3GP.$L^$!6
ME <"Z//I;C+_S'+^!L\Q]3^C.+1PNRZ16M$QA>>"!XXH2D1\@QBN6\YYG1$A
M0'V?J)! !54FMXRO,ZYXD?]YC3\BZ;Q$_F+$A\<?2,08_* BYX[ <GVD%2"1
M_Y< 75"YH0YZ$LR;/IXR:,#X"D@E*M%*0:#DTS+WV^$A0113/H9BW"E^S]DB
M"WN%9.RQT KG=[[$_#QJ]"HJQ/JRT$U$><O/>(=RMC6C84_D$+IN&E\I3$Q?
M@C<2RCC(; LCE)B*HN(3B)L5&^!%@80&"[(7@?$PENLPLQDQ](NAR6!D\_C+
MA'@HS6/7HX.0IYG+K!$JG;@@*PC*E3@([CSWWF)2DFF&!?&XQ,F%+4F#LTMT
M@#:2ZR<D6JM(V,(C(#FJ0Q"#Z6BI0(=EN$!.L*M<V3F+$"Z)_)5+!*231P M
MF%%L/*<+2ALQH6(V\,EE#,R8OHXSI4JB@!1"H[(@AW$E@*Z%]2I[Q4F;)#<Z
M(P#?E31<(1R8;^8C[.$OIJ;)JJY0?OY%Z^ORH#_$(P#P+L@TWUIU0)]8_-:0
MT1R;,9KP,#X9Q*EB)LP-*5#S2KKE!AX%9FCVY:$^D@MGZ[\8(T/NCX:%KRBH
MNFG(@X&9L1,['F&2?0EV!BM= ?K'"T"W.K0_#E =T+@SC=K-T#SV8V9H\J,C
M8&-WFDRY.IM9\TR< PNGR,KQF^WX@ARZVI>Y3X.-G5BWD#S.LBQ41?GU598]
MSG!I$\_CR0_HB-//*/G3SSQK TU3$F99&SR;PH:-L6: M?2/5VPB6)K2P\D8
M@EC.QO)J=TV4'HYZ9JU9(A/F8:NPMOQV<.4Y(^59T! ? _E?35P'V*] 0+OF
MDVR?=U%-3H_:&]1ZZ[OIN[7U)0.![N:A&QPAO=9+&^>%;M GAD!W%>A>2!%L
MC"(^^%*>E<3!*?(XS7W4[G+*&XZ5#?5_[Z^_[I['51JBTZJ\JNTNI%(SB[8I
M!+ JNKSRKWWV%E &)CULKG:Q0:D->Z.JKRG4P]>-W>CK3U]^?/Y>':\?D^OK
MUKF=)X8]=Z^I*KS55[ZWB+YHBCH\#^7:CLOW KU'(O1?JJ?RVOWE=C8>'?55
MV=2TCFGQ=HB73JC9QLH84*9F!Y5IPVE:(+&QA4YJUY"-UH,#0]8'9IOU8,,E
M0R>T7=-LC>WTX*B#>K!I.]$Q#=DT])Z[[FRI=VF.9$,1WJ70MZVR:;;2JIK2
M0:W:<)H62!0:LHW>I2ICQK2FC]JL"1LN&SJA[YIF;6RG"=4.:L*F[43'=&33
MT'ONVK.=_B7H51T\S)'19KW:-%8X+XW;6'%S/8Y)*'54NS:<LFM#XF[)K(VE
MW;:IRMW0WFR-.!IJLF8<U/.S;HW8<.G0";W7-*MC"ZE"[\5W4!DV;2N:K2;W
M:(_0- 1O0>LMR)"M=".:K%,'\DC3Y*&IM%FG-HT']M6V[..YMIS86'-RH43E
MFJ*SU]'ME_$.14&'HY$RT JUA]?6DMURQHWU.H>*.51'@]UFO/:=;S$@ :MN
MD3!Z_Y\$JV(=LO"^V1]H6K&\[J;IJ@-N(X[ZFFZ:NC:L +BW6) ,J/L@(AGV
M!Z.AN1(:/OXA\V]$QT#7]8&Z&AN;YO]@N>&_+2\IL-1!N%!60K%BEJH@VHB=
MO2&RL0#5VR!:6X^W5#]9O=45]HF/</L62Y*3<&:%\?RS-2773VYT>^_-[5N
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MXVO?>9^N]9T;V5X0)2'Y#K3SQ@OLGZ__^0])^GWCF^^CV)WBF<./B(P3[R^
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MVZ%Y&TNX78PO[!M%J+Q5E"GKFBD;HZ'H*B<$@!  YR< AK)I].7!2!<"0 B
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MV6),#3Y&YD9+XS2Z39U1\I^$^"@2."?P76\Y[;*(Q!RHT0,*#1EA<#&$LK*
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MP/5=#L>+[A6@>P7M1$WJ0@V[2<2!(3PR"3))^4QB=W6[<U"_9,G"00RY&UC
MOR0)\6+_CG?)C.+IG3?1AO'L5O-C,E2S1::T.:H<GA:+95+Y8#F+9::C][I=
MW;4.JI:IPT28!" U(37!H"9#-TW665_J%I[2!DE*9!5RY Z+[:PQH;2C7J(
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MH%":DQT #X24R '$9F [ZG]AB\[\EU52E'!O+&UZ+,PM"VJS(4<<!+E/AI*
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M5(0E]](BS!HDRMD@Y1/'=][DEFC!A($_X[,0FA>&T8,W\;%%$F8@>\CCX'Z
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M"ZBCF0]9QB-'D*,<W'04R=2C>%M'+T-O&BT7VA8,N:%'34=-;P;TJ.FHZ<V
M'G96I0S<F%5A5B6#:*HRE"VDE=_CF-[])@XV9%;/(>KHV@\UNH>L1'43A<-7
MK+!\V0J-(P[>(::6H-E:-#10^>2&!MH005,#==% Y9,;&FA#!,WV351@H)C3
MUV>@NTA/U1(!](Y%BW.QO<E0&Y)[$D;3,54HC?Q@6S6JZ"L%L%H@1^L$:4,0
MM> 5NY ,&KQ;<,P_*R 1T0O,Y#R5U]0-V]8-XZ"SZY!@D&"08)!@GCPFT+!T
MV^HAO2"]2 (OTHM$].*:E%Z<@Z(7@ 4@.>A%B0H-6([Y3"8D]D)>AO&&XV 2
M)"GK='%/%*[$ -=X.>(514 L/2K9;3X%+#%4NN"G@BAD-]@A!QNFWK--O=.V
MD!V0'9 =D!W6V,&U3-WJ''06$;(#L@.R@Y+L8%J6WK$,F4L5P-E!B8($M'+0
M%JPRB%(OI%^(_.]O;UA;3\TO]/54N%P!35:*%3*4A[?4,&6/IMK0 %9CZJ54
M04".:2R]UW;T3KN#)(,D(PW 2#*2D8QMV7K;L)%DD&2D 1A)1BJ2,?6V[>I&
M&Q>2 *C;9&^;>>1*N0>E/'<>RZ=9.HO)EV 2C&?C2S))O?#">V2[?))/47P^
M)6RAR>3V#T)OG:P>\5+JV2OK<C09X1C3PIE-^:&8EM-R:Y/QX(YHHXB"_$ Q
MT+(#8*8Q21@\6LH^Y/!IXPP_+60P:=,<0,U+M&BD?20^&=^0>*DPMJEK#!6-
M&BB)^84XP.^T%U1)$HV?OU/N,)U.K]7%KMP+!=JKDTVMA^FTRS[I6BEIE5\@
M1KAK@]MLMVQLZEV?=HMNKJ@,W&7,RU;AB,4TV #2EN&OD_[EA@?>RI77U4)0
MK&]I4E\.D8US.JU>V>LML''.BJ#[7\Z_G@W*L_4JK5ZTSU5>&01VXQ&>2T,K
MD&Y1?;$,L],,YRI'J1KAE6<V3'B^+.=<6,\Q]:YUT!XG@%Y<#GI1PLV"Y1CJ
M3+L*.E/@.HT@@MVR(]Q#@O:#;5>WVUV9_2!P9E#"VT&+-;;S@ST%_2 T22CF
M(:'!VW3?*6EVV>WIKH'9)?I;J6*:K;RJ92CH58'K-(*('E+&[-+4#=/1+?N@
MSKBB/2%P;E#"WT&+-K;SA*:"GA":)!3SD=#@;;KWE#._9 =:T RS=^!./LPP
MF^MQP=)-?Y226%/4NP+7;&$@8N=!(:Y2I<Z#O8ZE6^Y!?4E%>T3@[*"$WX,6
M=6S!*KSSH(+.$)HH8+M)[!<#Q'$VIE],6^^Q;K[= [OY8I99AK?-WC:R7\P!
MC5R>ZPUS%DWN29*2X27];QSX]-45Z^S[=1*D2=]/@_L@?=R_)\QU?L?KB]";
MG'ECTO\1)->WX:-_??*?&;WTZ81MF KN"?L"_87]A?=14:*73)!HGI;,QO01
M'UF3F,NKKYJ70TJ_EC6%86/6V. 7?WDD7JP1^O3#%]K*[-5&!@9(];>8$=I3
MINVT+*%MJ^MI++!H):#)V$:F 4U_=A)0Z;TUND*[["N/L&D)/L= >811AVNH
M$W3145;<4@H]7=4Z;"%+""RK"X^V9>L;56^/)V@S'G6)IOHBN^CP!%0KG<KA
M%AYO-PMNU.ZZ9^S$1N(J,[7P(%QE<(7'WZ"(0K&.<AC;8VP/4#08_:@5_6!L
MC]HM-=S;=V/NMAPE6!MLM/3GR>GGWP<G']_VOYU<]C^?5.)Y,>+%B!>X<#'B
M54DT&!/(#"[&MU5[C+.O7SZ<;!ZW@F8AV"PP, 9C(I\O^V<#[6-_@"$Q&#/!
MB!4C5A3-3D<BU7^ EMURQ?8<4-XUG7_2KG[O7YY<80 'Q3,)6[70Z#,C*V[B
M4;HS0AY;$=^G_NFE]JW_QU<,L<$0F:HA-O1N"E_S7<Z:ESZ]J7;YQC),MQG!
MMQS;_Z4-K*#;1*7N'6"-68)&(X[>M6TT [ L W!=]'[P:EQ_5WM!%/6X-A*J
MILT15%<+F7LZK?9!Y[0 S CDH!XE<H)=^6?^K^74&?)\CCV:H0\5#.\!X*]8
M1(]Q.Q[BLM9:U]%=X\ >@$W4:<6"<%E#;=G*^<KPAM-JFS)'UL!90XGXN;S,
M7DQD_2F*1R10,[8&+1O%HFYH6;QHORHZ'E>OXJBM+=KZQP_+,)TJUMNI8TL5
M24NQQ$ ]6U$Z95!/7/51F^B4!%J8T*QD!4#8NX4U?.,K?A3,1P# KUC6@;D%
MGJ.W5K2S=,?L-$FG,<;'XK^DD3QD'I%]60W&T\W+9K;@D]T6U+<5C,*A"4VQ
MD!P:O*)]+-R) ,C>UVSK/;.-=H !?G.KPDJ'_G+2DMLR')F3 FC.&<\27G_^
M5\\2/MO]X-_GSA#^?S,O3DD</GX*)M[$#[SP=#**XC$_&'C_LX-?/0.XE+-A
M<SO+MNX+/BK68<4"]4\/6[W+XBPQZ<Z-M5I&V:UXE))6Z9&A@<91&]RFT3(;
M<%8D%+B%E[,:!S>2"9*)HG CF2"9J LW(Q.,NY%,E(4;R:16,K$1[OJTVVBY
M"'<9<)>Q\$5XO1%6%T_!<VG"ZXF@.N*6>MZ':;[25MWIJ=([&FP[XGR62#N9
M#"O9E2':LX 28*WLAJX(71%0:<!S1:\>\&$*KFZ @KX*1_3*<N4*K$ET!064
M2-&:E+*F*S)-U\W)0'-2UYR@+3Q4RYS^/9L0M*1&6)*-CJE*2_KBQ?Y=?3$>
MEA^P_ ! ?-"%A>6'^N4C\KC2"O(OK*NO^+GF;*]62VYHH T1-!JHG'*#8Z!B
MNW0I+V@T4#GE!L9 2Z_DH('68:!8LL&23;GB@]ZAZ)+<D\F,-*-B(T='"CDV
M!4"#=PM=K^)D6=';&-5K3E1GRWIPX3@RE+KP(D-)U(_+[!YZLB>R"[)+(]A%
MC2@?XQ]Y98<,)0.\PAA*['9N9*C]30A@/58.AE*BG J6ILY(JH51DBA8-06N
MUW)X7K"*JV)]8=\J0MD5@S==W;:ZNMOK_"1S4(X$("V(2 !B":"C=UU';_=L
M)  D@&81@-"8%0P!='6C8^INQT "0 )H% &(+;&!(8".[M((H-?I'D0 HJM>
MP E B=H6M,KB%LSQ1Y0DVI3$6G+GQ:18^;WQDL#7O,E0&P;A+*VDF9OHPA@T
M@2GF+Z'!V]!<NOS%.J7[6!ILM*6.KZ&I.C(),DE3F<1!)D$FD07>AI;WI& 2
MQT0F02:1!=Z&U@GE8)+#9@]$%P^AJ7IC#P*?OROE3.S\ KGLZS\$VVK $4&+
M0X$T//=:?@$I%L$HC[#P-$=YA(4G.4U &%D"64)JA)$ED"5D1]@4G80KCS"R
M!+*$[ @++X<JC[#P8JC,"*_50^6LW.$A&I#*=-#;FU9XG+1KE&\)V!,8CY,&
M9#W5L1NZ(G1%0*4!SQ7AB9VB'1$>)XW6U$SH\3AI]61:MSFY&!?@<=)*BA./
MDU;*DO X:5"FA.4'+#]@^4&(?/ P3"BBK.BL/1=#0_GDA@;:$$&C@<HI-S &
M6GK)!0T4#50!N8$Q4#Q.6DH#Q9(-EFS*%1_TKA%XG'1=PE!LM3\T>+?0=>RU
M!.6P5MO5[8ZK6"B-[*(NO,@N>!0B,A0R%%QXA3$4N(Q9@OC',G0#8R!D&*G@
M%<8P4'M08@PD83U5#H92HAP*EJ;8<=!OV'G0/VG!Q(_&*I8_@2NX'"X8K :K
M6&S8-V"OX%3(;M?4.P8>"XL$@ 300 +HZ&:;'PV+!( $T"@"$)NN02[9F89N
M=WNZ8TA=LD-.D!;$AI;?( 4%1D\WK9[4I[T )P EZE[0JHY;,,>;/PK5L!?.
MC%:P4 9-6HHY2VCP-C2WEN,DM8[4"3<T54<F029I*)/876029!)9X&UHN4_.
MM7L4-:E+@-"4'[E%36Z!NFH/4I1R6+X#E[^!,XD254:P=+)%+7$8A+.TDC,?
M1%<3@6N^'#X4K&JKF,\#\H>2U__0]J4%$6U?M.U+7K%#VY<6Q(96WX#7V$QD
M V2#)K$!+K-3HRH&W/;7:E_96^\F).N2F']:S3-O8V?/M!)<//:TJ%H_KS^_
M5GSSZ\^SY.VMYTW?7?EW9#@+R?DH/WXT?/P43+R)'WCAZ604Q6,O#:+)@$$R
MH,K](8S\[^___C=-^W7S$E>LL/7!2\CP.!I/R23AO[U*Z4_.I^QETO?3X#Y(
M'U>OI_ET+/3-)1G]=O1Q%O.?79OT'\LPV]>#Z-JTKNW\77[;ZXO0FYQY8]+_
M$237M^&C?WWRGQF]].F$]7@,[@G[ OV%_86?OG7T/H=F <::8 L&.2<AXU^_
M+"R2*X7FDS#,-?JW(^.(OT^FGC]_GYMBUF5R88JYB?A1&'K3A+R;O_@ENQ%5
M!J/%;I:I5&:(F_JQ<TG6;;E"W3[ T\-?-K,"F<]_J?3I4@ %5'K0)O9T0^41
M9L<CH Y7K,/($E4CW#40X2H1[K9ZJ,/($C(C;%JM'K($ZK#D"*.GJQ;A7JN-
M&4>E"!LM1VA%4V:$U\J=<M:5!!X%N]?A/<\>RJ1>10G6*;V*%9.@'X>D6&6I
M67 K0QW2P"TV$F\8W*(+4 V#&\FD5E<INC0%"NXJ#MC\\^3T\^^#DX]O,6:7
MW%;0\=8+M^AZ6,/@%ET< P5WQ6=J[^(*L/"&A3=%18.%-[5\"!;>,%>6&FXZ
MBF3J4;RMHU>WF700>LR;%1 >UIBDMY7^MY/+_N<3M!3XEK*]AS%;#H:NE5K-
MY\^7)Y_[@RKL!HLI6$P!+UPLIJ@DFGJ]DP6O+:7<@4$S]!H,W)CI@W'EF+U(
M8S68YPNUE,N3+_W3L].SSV@K\&T%,WTP=G-Z-K@\/;LZ/<9,7S[A8::/F;["
M_@J\=\),OV*"._\ZN!KTSSYB7*=87(>5@XHMY^1_3BZ/3Z^P=""!V6#I0*BI
M')_3'*A_//C:_P.M!;ZU8/$ C.5\Z__Q]60IP3>G9UA%D$^*6$7 *H+"CDNX
M:%Y^M8_@A%8HDB@,AMH_#/Y_R)[G%X/3\[,K-$#Y1 ?$1BNHA:"-K@CZXO+T
M&"LA$@JN4@NMO>R"5KDBW,')Y9<W?YWT+Z]^0MN43WQ O&<%11ZTTU4[_?W\
MZU7_[&,E9HK5':SNU"G<X^.3DT^?X)[[=SY+D]2;L(?3O$2+1MI'XO.SMI:"
MM$U]^<8R3+<9[E.HZ-1OO@'=,BJ-]@%VY\CEL0? M1VA:^I.Q]!MNXM,8SP%
M+U#J =>J;S^\-:[4FI']6Q7Z6S!3!6?U0FRM*P$A=5M6&[D(DFW(5J-KA)&X
M:"/HKY7!6S +06S&BTY#JHJC')4-)4J"NYK$_%_+J;4*.$V#:))HM[$W2<E0
MP?H> #DH5M+#PIT(U"$'^FVKHUNNT2":P)"^$O)M1%PHNN(&F4G<EBUU74U)
M&A%>_E(25=15='G2H"JZ]*0FJJ(K1%@'DJ@*)[A"1'Z0V \2)6M$H&6D6/4(
M6E6ZZ76E\J>6R\X)W]BZ:Q@_(<'($]B(#L(EFZE4_[1T"5:K=%H]7*XB#\<(
M+THU#&_4;_2A2N,MNL35-+Q%%[^@):+-*HL!**SL4/P:1?&(!+A "DM<<,OJ
MBA6R+/KY,)K=A&3K!@E@"E961^]U;:DK5FK&'*)C:JP^58\QY!I3NV5)O859
M25807DE2$E745?1@TJ JNO:C)JJB*SQ8QVE>%6V;HLX>G:_:"A9^H(E.L2H0
M-'BQ/B3GN@1+-]IMW31P<8)$H8_H,%VR!5""N4EXS4I.9NJT'!-)J2E&(KQ,
M)JN1]-!&T'$WEY.J:%HINEXG)Q6YA^40HLMYT!+J9A7ZP!8MOI$D)4,MBC7R
M8TI\]CJ-M'OZUT97]X#;A!PU/+!*KWBE#K(7M73#[>B.(758C\$[ %3!A.A*
MU]8@<XGL%314>(!U,M@*CVX3W:8B+*)B90LR>;C&02UF1=>O@&?D2E2IH-4(
MMV"1DZRQEL?RXR87K*")3K%2%C1X14?IZO7=JL,%]TQ#MPP+>0:C^^;.:"M=
M+I.3E_ \QB89B? 2FYQ&TFDY:"/HN)O+22H6[.2DHH-FO407\J"ETON6^+*W
MK/"T+I[YI]4\\P'AP^*QIT5]^WG]^;7BFU]_GB5O;SUO^N[*OR/#64C.1U=W
M7DP^> D9'D?C*9DD'FOT=95&_O>\YU??3X/[('T<,'P&5/T_A/3#]W__FZ;]
M6M[U-)\.C+ZY)*/?CC[.8OZS:Y/^PZI\UX/HVK2N[?Q=?MOKB]";G'ECTO\1
M)->WX:-_S6]T.O')A-Z$L,\MP["_\"KBT?L<I@4P:T(N6&P>7AG4[RQ,EBN(
MYI,PS+7[MR/CB+]/IIX_?Y\;+'L">LOY]7)#HE82>M.$O)N_^"6[$54,H\5N
MEJE79JZ;NK)K%=HV6QVAGO..9!_0L2WYM'12B.Y)3"GVX9UV%PR'9%*PN%V]
M8\$#S']9:9)KM8PV"JC"X)%F2!8B7&EXCCJL>@*D/,*4)6S4860)F1$VN^CI
M4(<E1Q@]7=4L80M>?J$\PL*K<C(CO%:8D[/J\419U)NE41U%T>[>]8[%+Y6N
M=Y0EFL(T0%;I SES)KSXT2RX4;L;/R^L,-S":R3-@AO)I%[M%ET]:1;<J-WH
M*M6%6WB1I5EP"Z^X@()[KQ+ 0U8SNHG"88DU :SF8#5'!M'(07-8S<$056JX
MZ2B2J4?QMHY>T72G92+TJ.EJPHVEAJK#U3]/3C__/CCY^+;_[>2R__D$0Q_)
M30;K%UB_4!=NK%]@_0*^<+%^ 58T<M <UB\PJY,:;JQ?@''HBPP/O0)\N\%J
MB%!;N3SYTC\].SW[C+8"WU9V\3$]S-&KM)O^Y\^7)Y_[@RK*AYCQ8\8/7KB8
M\8,5#1A_A1F_4)H[_SJX&O3//F)T)X6U8 4!C.7@U+ T5H/U Z&6<GQ^-KCL
M'P^^]O_0!B>77]!DX)L,EA' F,\IM9[3LZO38^U;_X^O6$R04(183,!B GJM
MDAN1;QC>NL!>?E6Z.*LH5B11& RW/NP;E#PKJ59<#$[/SZ[0%-$4A59"T"Q7
MS/+D?TXNCT^O3K2+R]-CK(B@==9?<4&+7+'(-W^=]"^O?D)31%,46LE!LUPU
MR],S;?#[^=>K_MG'2JP3*SE8R:E3N- //CZ?I4GJ3=C#;7TDN-L,KPE==+*5
M:DJ2QQX UW?LI=O5S6X'#<%X"ER(D]L0]SWCT9<R=$:5@([,EH5<!,HV9*L:
M-<!(G):%-H+^&O&6IE&)RGA#+%!)>>*TG!6D7>.:^;^64VO1*#MG6B,_2.P'
M"1DJ6!#"LH\(U/<-%,L."M]87=UN=W]JD@;+X1]%QW^8>0(LST#.+\V6VT4:
M 48CPFLE2J**NHHN3Q94A1<VE$15>/D"BQ02E8@$ER]&43PB0:ID^0):&4]\
MA@)O1;7D<YG:V@K<?_RP#--IR#9 I><@1 ><ZMF*TM47]<2%U*8HM0FO^S0,
M;]1O=-TJXRV\BM0PO(77EZ#EU<VJ/(&M7>RSC:JM8#@)5D R%9<L^ODPFMV$
M9.OJ$N0)\([5T[MFKTEJ+8<O%1TKREH=4+J8 YE)3,JS#:*19BB\Z(H,9(6W
MY=Z;A&X3 *I@6*2*?<&BRR^@R4-W[8/<I>A:"U94FE?/VH)'OI$D)4,MBC7R
M8TI\]CJ-M'OZUT:77B24I.)%&3GWP_-RC6&B*6!$VMP%($J7>.3D)=F+/V@D
M4I6%Y#02R0M&Z+@EQ1L,)ZE89)*4BF0O/T%+J)M5F );M#C)FMYXK!+0Y'H3
M6 $I7E6"S/FL=F0Y1I/4&@/-"E %$TXJ70>"S"1FRW(;1"/-4'C1-1W("B]Y
MY0;=)@!4P;"(BE48T.2AN[8C<ZU%KHI*]I95 -8%,?^TFF<^P($O'GM:U*R?
MUY]?*[[Y]>=9\O;6\Z;OKOP[,IR%Y'QT=>?%Y(.7D.%Q-)Z22>*Q7CI7:>1_
MS]OJ]/TTN _2QP'#9T 5_4-(/WS_][]IVJ\O7>_">QR32=I_\.)A\7K?O'#&
M;])/DMDX^]OJM36?#I*^N22CWXX^SF+^[6N3_L-*+]>#Z-JTKNW\7?X(UQ>A
M-SGSQJ3_(TBN;\-'__KD/S/ZV*<3=IY:<$_8%^@O["^\MG/T/L=L@=*:Q N&
MFA.605W'PE*YMF@^"<-<U7\[,H[X^V3J^?/WN8UF)[HM;#2W'3\*0V^:D'?S
M%[]D-]*Z1HO=*U.US$ W]6;7 J#;;IF.2$JXR\Z9,^G8EBQ:.D%$]R2FQ/KP
M3KL+AD,R*5C?KIZOP/OS7U893=/@I/1CFV474.F;NQU$N.( &W48=5AJA%&'
M48<!(US&9+#P6+"L4Y/W2,'V.B.YE".1Y6 ?4 =:U]'OIW0JPB/@5ZREHN42
M:"=H)ZK9214'L:.=H)VH9B?.3G:B:L0,?3?HR6(W+XG'6C.H#;I,*ET.(CJM
MKV2W2:G.9@L)M5N6JST2+T[08F!*"&T(NH30AJ!+"&T(NH3VM"$E@FVPX=LB
MI+Z/0B\-PB!]5)#AP,*O-&O)P4T9H>;%D)RINJU>]U]H!^C/&RV')RRC:[0Z
M;;0,M(QFR^$)R^@9+:NSFV4H$=E*6+*\#)+O;T<Q(5K -(:UA8R]E"C(:A(*
M1VEVDSV/?X+W>!<0-!UPHD)C@BXA-"9I1(7&!%U"3QB3Q2+CY@7D8".[1:EY
M&-P'0S(9:H\!"8<*TAU8$2A-8=(2E9(N7PYIH%7 D -:!21IH%7 D,/A5K$6
MT69O&]Z69/\V(L^V*&%7N8M"JG%)UB/D+$K)GUX<>Y,T.8\OF18F>W4C@=Q5
MA-ZI@K8B5KME"VWC!' O[\OFL_RE6<N&4JME"^UY!E! Y>[YH2;@(,*5MF1
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M@KUN.V)( *^5XQ'@L@&NR.6  W@?YGGI=@,2C\U:N.']1?LO^TL)1/KJ<$#
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MW<' U>,<-REZ7D#6YL=3:'\%)!SNS,=%>E\W] EA5$C#I)#ZI"'3]*D7#*G
MLCMF1]'S+T;:E 4DS+J'$17(PK2HM22$<&O++.)P516.^+(A]$%H+R_#/(E'
M-=Q+&&7,-7G,(@#MYC'W-IXV"B8T  @HK=U[E'L8ILF,?9)H"0L;.=,2+I!1
M.&-3!>QIWU"62"/Z"?O=XI8_<=ZB7#X?%)7<XD?:F\6?B[\8SF)F;EY.:BV-
MQJ_T*O27Z5)Q5JTVH*$V>^#I[(;B2(<V(NP:.OL%?> 'KCLI&[P7?R<IM^QG
M+\8'F:PZB1E[N/^2A/_JJ9$&A$='[*&I+M_&T6Q*A]>Z;>G4J[-P?/%P++">
M?ST)J'IYL<;41Z<!]G@:DA\4!)VK?,)/<*9?RTF(L=5/]*,PHO LPK,GQ_"D
M,.AM6& 7I,\"Q@V+4,\QIJK$O_B$A.0U+=8\^2WKGJS-VR=KK'_R@606\""2
MB>)KZXJJ3<P-[)$%>F2A:0^$?&>B)!ZUI#QBX<Y\KN[L2X_$BW7FPS/]9W+(
MG/<XHH_JAU%"J']F5#>F5IG=<R&@,!B1LF-!X1S(YB!+$8]7C);IDV>X+K%:
M!(<\+RK25<RG1FE:3_)TFC+2^=IO>-C%V(6W2,X$1V]D&ERD:UPRCZ]>E5^N
M !&+!]LMRWWJ8C3X8(.C1#*E%PCH=;((AOV,6K\_"YD6<J+/B@*%L=&K*Z B
MR^I3&<;,+79^/6[!N6TOH^+IXJAX)JYU]<G"^U6/=[.X:A;>^"S!#MEKFG&S
M_TUFE(MI8DI_=T-8,)-E$3R/G+&T+SNB]24]6G_L+,UE2C2+)SS7I$FME[F-
MT2SF.<<\Y\DBUMN )@AS-TMCL229JR.ARA4]$L(#KX>[:+QB. _,Q<Y3JQ?4
M*2\#:3_/W_Q<+!#-W[Q6''NQ1O5$D2LYY;D2KX%=D)C_[8F%4.UKV\A*5Z_6
M3C?F8)^ZQ?Y/\D0-<L]^W\O?SVZHG ,O?KSR0G(^XM]9%C3[Z1<>%IWG4< 6
ME4R; 6%OE#)+1F*]7SH;!_G/C '!<MG!XW2U1?W:Y_6@8&W4TK=%H; <YR4]
ML+?4@VQ2ACX[2?KF,3O6.4X#&B=<Q(2.B&96N[2"MXV.U;8WUNX5G[F&(3VK
MVEMT +#:;F^]JUI)C^]4__C=GMWK;G0P*.GYW>J?OV>XAK5Q@GE)SW\P,[Z^
M/MZV7,.P=M ?=O&[**3>-,F>Y47]?W7Q5,_H."O[XS>N?]#]:Z"4S<4VG14Z
M$3*@^;>6I[9<> $-)8Z]*0LNM^WL:KI&N^- &<RKZKVQ2L=9\5E"'_Z2I#2]
M(L,3+V;K3Y/M1O"6^J:.N[J#I=1A.*\OQNL:=H4X[NIC#M)HTW+-KNFT;2BC
MV5VEN[V5\QN$/OV>.MUQ[!X[GZJJ8;BO/8%C.!VS[59&;+O&'0?J=*=-PY!.
M919:>A2U,8*>X51&<+L^_9XZW:4*U78ZE1'+1KZ^$7:XMF&:MEG9 ]2JTZYC
MN30NK [.JG6:!M;5Z?2N3[^G3IO4V73:MGF03IU%*>%_O9J&09K%UFQR^I)5
MN?9;REU=++]RQ*7)>O.^./:7Q_8$,EG!Y".?"<F6LF7IUO*GYZ/"(U\1GWZ5
M3Z+MLTR[QC+*VR?J* <-&#AX^V?</;89PUVGACIP.B,/_"-8>'1Y&]7UD/;5
M,90^[OW(9O]Q.Z;CNMWU$+3&<=N5C+O<*O1FR_EVM]-;Y^0:06L70'MV*F6S
MR.QTVIV-8*9^'7_ZZ&( LPV;UD%3FNZV)+D/8/S#M5T5+Y^24L-F*&-U*]3.
MSP]D_ =U$S%-IVMO&T; 0:&R"0:WT^W"A:.B/=;2&$7UQ]5D06//L+9E0S@@
M5&83IF&WX=I$7<?OV.[683-D$ XR#(OZBO7"9_D@\,W8LN7H&^6<IR8F]QTK
M;-A*J4%:IF.]GFFH!-?.14Y6RZ@=H==2'9:3T?\9/8[%\IV E0#=7J?GK+2&
MV69<Y4'QI%*\.N';L9RNM;$F0_!3UVGY# 'JL^1&8&=C9H4XP2->WUW]ZAQ+
MVS![[I845-=3U^JC;+?7Z6ZL#I$+@9TUU3&=+>.8/49\<$G@U;E-V[&V*&$^
M_S UCJ76.5_;H?]3$I?=5T2X':! K.7ZKP[$I/$/5&4_K&YQF+*;-,+8,C"4
M#)?=E7U;_[4%$ /OQS$-TH/TV(OCQU$4LQXR_6SK[U8+*IZ^0'%\G[,>%1]8
MTP"2;+F6HN/V[%[1$%YXT-I'=$D2XL7^W99#L7M.V]AG*%\GR_8@]$<?*) C
MMO?VD*5\A9#UF<L?_ ROQJ$[/T-"SD<GBUUM5?8;,KNU;V'<HO'0UZSUR!*"
M/39GUC*@1;^6:4RF7KY_D#[YLG5 ,N=$MM><B9(U2&'+M_@&Q,_]_D76]X:U
M6ESVXF#["\?>=U+8V\@VPA>[;?#]E=YH1/PT[YXSC6*^;Y=;5K8+/TE(FOTT
M#+R;^?Y\]IYU 0FC>0.$Y[Z8KG0!XMLKGQH9^]USS\#;K<SRN[+-H!.V4[>P
MV3O[T;*/3]+2^F%Z%\UN[[2L 7/>38A9 NL*,PS87''6M(5^+RF@I!<Q'$8D
M:W=P0\* /D4&&6_AD%V"3'SZC66K&8^UBO'",O=NKIKRJIFO=2E;Z4E9V%_S
MP4L"OS\9?@S"67I8JO'$]BK'M2RW$&CL]U"5#^R5L/*I?5>FX18/<04ZL%=*
M&IL3&J;EMFVS)(G]W[=O/T512HV$:%>42>B#O7U+/_KUYQ\W<?C^_P-02P,$
M%     @ !4QA2D#:+HVJ#P  O9@  !$   !G;'EC+3(P,38Q,C,Q+GAS9.U=
M;6_C-A+^?L#]!YZ_= N<XSC)OB1(6CC)I@C@K%,G:7N?"D:B;+:RY))4$O?7
MWY"B9,FBJ!=OUCF<4*#KB#/#&3[D<#BDJ-,?7Q8^>B*,TS XZPWW]GN(!$[H
MTF!VUHMX'W.'TMZ//_SS'Z?_ZO=_.Y^.D1LZT8($ CF,8$%<]$S%'-T0QJCO
MHW-&W1E!Z,/>T=[[_;U]U.]KYG/,@3@,D))RL#=,2RZTH# X08>#X>!@?_@1
M?3H9?CS9/T:CFY3N!O3R:!4A=^9D@9' ;$;$%[P@?(D=<M:;"[$\&0QF_LK9
M<\*%9/XP/#@<]A 6@M''2)"KD"TNB8<C7X#UP5\1]E6%T"@^D3;G"#+%T(H!
M3ZMX?G[>>S[<"]D,*MD?#GZ[&=\II33A"0V>"!<I_<LC\_<X<?9FX=,@+I/:
M'?;WAWVI7\PDJ=P-)EW%^T%<F) &81!$BYP^*;DKV$"LEF0 1'V@(HPZ"9]/
M@S_-7%#)X4 6/P**:368.MQLA2J21@SS1M10*Z_22T$GW;+#X^/C@2I-2#EU
MS,I @4$5EU S.11(\J,\.1=+5B(>2@SR)0VUM"8-N,"!D[:F[)BV7AI3D1=G
M;E9#EBCRO!HPB&<8+U,>#_-'I80N,+-(*+B11Y48F)PP"@1;F773A2:VB#'P
M.&5\NC3+"&,<H5,<!*'  MR6^EL^62YIX(7Z3W@@^\8)"WUR#RHC^>-A>EUL
M85DPN -9:H2?8U^"<C<G1/ >HNY9KZ0LK2BIRB4>#:A2"4;]/K@^E++";\V-
M8O;3P2;/IK@(W.4D^$']7C+"08JR=PP/-+<FL7$ZV'<BOP7C6K-R/OTT:>,M
MFS[]P2?>9$F84IJ/ O<B7$ #S$G Z1,9AWP3EP:,=M ."J"M1:/00VOA" <N
MRHE'4GZ'JA75"\SG5W[X; -P36/'ZJ@"*RD'*4$=* DHEY0[?L@C1FX966+J
M?GY90N\E<JQ,Q)RP"^5OQ8AS<%%WT6*!V6KBU2&^) )3/\;U]:NQ=8TCZ!I#
MZ YK+> /+1LEPM7X5>*1EH_B"F0_BA62G:@^V[M8L^^[SF;J;"$X3K$"1#__
M%=&E'*-E_:64T@[Y>Q/DL2R%62JM \H"U,AQ6$32$9B.S(WG9NR:,=OA_%"$
M4XM9#\7<0"V4=C"7PZS#F& V)CA%A&_B64)E!^YC$;A4#HH%)=#P#AL#-M<!
M/"3W^ 5&D#,G;N23B?<3@]CRDG@$IAP7RM2< SYR2GR9./D%^Y&R;N1#O",7
M&>81^E5EV_O!<;$?Q+4C5;T<O%H#.7J5#BA10I+$TZIRW5H1E&J"4E6Z45[L
M23H[E_PK9]) 4+&ZAK4Q6RC5=;^H0VF/P0%FB7*2$,S\5'.NDH8RXCJ8[/F&
M6RQ#RCD1%"RP)1_RA%69B/?63 1ZEY/6C27[&O9.A,Z?\]!W">,RJA0KRV+6
M0&P'Z[!B59L5^!V*17: %:?12\(=1I>RSHEW'G$:$%Z(<,Q$-H"&,)H*$UM&
MC(0(!A)*A'70%*%)%P9W=!90#WP.S#V.RA!#D'@;^M2AI(!532X[> =%\#)K
MB(QDM!:-$MD=ED4LOQ ATYZWA-W-81*9>!?A8A$&RDMM(FBEM>-V6,0-I*F,
M*P)Y2 E423\E,O:2'5[MTGYM<G@5^&V3D.M@K)=0JY-*JX"I=A*MPZ0R=U:1
M':M HD;^J\.@,K%5D=&JP*!&*JO#P!#>E:R/K!1V)#X9PK9N'=0TG6C)!E:T
M?T4RKVOW8KM/P4C,G#G,OF/J2(<]FC$2K^,W@;#26I$9[A>12:2I&5O+0VN!
M'5A%L#XOEGZX(N2<!%"YN/5QL(F1B<0.C2%1D A!6@J28CI BH#\'&$F"/-7
M5S3 @4.QGTDB/P0X<JF0QR[S&-7DLL-F2!&D<E$J.)O41N]2V5WNM'6^9[N\
M3ZW\S\$^_-<^_X/>);\ZF%O#?(\?_;8@:UX;Q(< \>$V$,=U=  WS/698:W!
M80?SL AF==ZO W'+!* 9S :<=E"/BJ V.&;78=LH*UB&92FE';OW)NS,Q^PZ
MH.JF"LT8F8GL\'PHPE,\&-<!4S=_: ;&3&0'YF,1F.*QN Z8!DG%DD"RC,X.
MSR=#T)B1I/.+'4+U$HUF:(H$=DR.BYCD3A!V8&R;/S'CU(C7"N'0L!9KD$OI
M$&YZOFGDNDJ+'&3FH\"-^6U('S4\%27#DK2J//S=>=XM$RPEA_F;,=O!WNH4
M57?Z_ROD2FN_3[6UO*J>L$T^M7M%JWT6+@Z%C)DU<T^HS6='O.0DWCLI^_LD
M0+.DYCID&ZQQ;IE^(R9^E=T.<%-V.\XUCUS$N3O]VHY^);Y#NQW:&8A^Q8R!
MURQYT;():Q7*1?]M1CF':U)'!W C@,$[@MGTB<AM_]K8&KFJ8+6F,S*PIL+5
M480.T,8C=HF#U9TJF:BESLB!UH2B!B.W0D05U$?U1["LZ3NN!W%<&4IJZZ!O
M!/VOA,[F J;6)\+PC(PXCQ:J06N/ZTH)5<"_KPE\4E%?UX3PNJH.]4:HI\NI
M*8^:CG0+;Q72'VHBG5E[3>\>NJ'=$F3Y1%U6*%TF";@R1.^?U4:[AI JV#_6
MA5T^UM<K9FM+]OPZ_.OM6S1(G];DLB-\7(R^-^Y(Z+*DV^ Y)4X8.-2G2O-S
M(IX)">3KU)$(V>J*P#"2H&GZ*19$)L \CTB_27(%E;W@Z]=5U7?LNV/R''A6
M(Z150JE.2"N5X4.R^C@7EVA6*.WZ7KM#_PV<2ULQUA[3XE6!S@&UZ02&-P5*
M]F0LE'8HZ[Y:T.VU;+]);AZBC7CM8&[WPL'_TU"4_Y/73T^)A]3%SR?R+N*S
M'J?0^>4URNK9G!'OK"=![R=W)_\.YNZ]+/R$1%#A ]]MIA&05(K_&V$_I9):
M6*YO5KUILQVU>HD(<*X%*87KJT&(V@6CA \2$WMH\-6,!\0,QE^L<6QI^T9/
M>(NF0Y\SF'Z9]L26EN>[\ELTW,>/!L/'^)'X+6WV)>_KF'LZR%[=#7_EK_8^
M!6M#)E!0N,K?=J=Z_!6 <>@H0186^5<_X>O+1_WA0?]PN/?"W43')BJL[6NF
M0L*WG0KFV_WK:)+E_!(S2E6.I2K##UNITDZ-ECJ8OXM0$XN$0=;ZOD%]99\.
M**G6R"-_]-?,[?K?<3Q: S+#Z@W).G;[C.6X&C>Y]9,"MB8P,@Z(+WCRI+\6
ME=-%?X]#A672]?VNS[E?,1C&<\I)\GZ*?O5=*GW6JR*BOB^/')[U!)#U4.QM
MU7<<3A9A ($66UT+LI"Q"1@6/7)PK)$TZR<61LN$% *S!;A']1N\'@W=>R4H
M=C(B*7J,;^$[ZSF,0#!7:=J8XD=8SHOD=<?5/7D1Y[ZZ:2EGGI70:&+\O9 3
MD=!M8:0;,7W'9*4Y\=(V<&^H3[B ]KTB!:C*J=XT5IDE_"5Y(GZH#C;I?*Q^
MI6G#TIHL;]/LRXW[8V7RB;GP=[C.(-QBZEX'%WA)A;S<,C:^#>-NFL ECX86
M,%O!M;+T;^+>@3[B87D1\N3F!V.+E;-L91^&4H8=<=;SL"^#DLW6,UMI:99Z
M#7 +$TD@1@N8,.C?VB&4VVZB_I\PVW)U[DBKD+6[%GG6<'A&@UD+LV,KS5;7
M<M>Q@=>!_,B7W+&*_[T.]*N:5F^5[>>M)7Q3_!/_UKB!8$D5 D'(5NGQU1NR
M>"0LTP06FMSTZX8+3(/=@0U1/R@U\9+C79]?"',@2G(SMEAH<OU6GO[D7QNN
M!K;< 2GAH^%%&#S)A2?(2@\JJOW2 DJU.=X(9FO%95L7MII'$I]9?'/T:DUR
MBU?* SUCYB;GRT"E*+ZO6,7"<QS$9X/X+Q!PR6/B2IT$>4F/?5_?9*1;>Z<J
M6.(!&@@R(^PUXMDM+4]LN<$O=!$M[N(!PSE$@@]+>5(@'E?26'U$+W-$+.M@
M=Z;!MQWO91-QOAWX*!+SD,D@*M<W\\\M'::A(2WT?%AZ+ R$1D+&N[,XEQCW
M\43M:C*+%4FG?;U^7_#_&\?9DN>WC,IL7&I]0S[M:\'1+O4K"SN<4Z;0^Y]
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M(5*'R$LF@:)U6VTI8T>^O"I;:GBQ1W[N.^_3JXAV[-J5(]C0;G_#A J:'5L
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M7T(3;YDO9'SJ2+5>D,"__A]02P,$%     @ !4QA2O""_3<0*   :=L" !4
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M#6 35F$PI4)_("$QD<SFO7%ES'18J8\.?J$21;7"9,;.N&U^E)_;%$(<I+*
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M_;1%A^ZOO2?5B>.K]W>V$5]L7^,GOME^5+S9GHPYB@<=L5&3:^NDEWOKYXQ
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M7;6*B)0"M4*O/Q\P.)X,@O[Y_U!+ P04    "  %3&%*.R.)$VEB   SG@4
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M=40S7'H>+^KA!+>.[UV&I\[69WM150A9!8UT :)GOG;](0>=__)#QT<S!%]
M$P G?D@R!*2+C[[<0\;I">/>E7,_G[[?T=3Q0^J=.S$\<DZ6KKO;[ )H[GM&
M5[ZK3/,V0<2Q G.1J@;1CC6[;9BRU%"T')'DF.3;"B[)D+_#L9G>4E5%\ 2D
M36$!XV.>/6$ L^._!<?^X<=]O+H;QM)DA<(P:VA8P6MK_-"82Q%&M#8Y6)K[
MW!XS5:"A1\*UXG3)MK<NR[Y3=CUZ3+V+"(U .Q?$+HNI!Y*8.[^)>3E&CY^-
M;VG,B\P:1:'4R#:$(]M$4T<H59C(04L]6^UQ3(9/HI@("B(P ]WO1%5AM%>]
M8PB8" &+8(TMUB7J-2^+.([1+#21;+ FE2AJ*SK$0+8>.3OM5I/5W"X1;;"4
MSL)D%M*(+-IE*2)*W&$&<@1[+*0N0IMU"&@K+*/*BK%58(;U.PMQ&H4O-$Y]
M.,EN2\NHAM/MN-WK]$'JEBT7 ]>JU:TTC+'LL6]%,PU#%"LLO;WYA,K<T5II
MC"5.W5BB\?IHC')3W?$P9H2)?I_=Y1AF@(9YZ]WQ?%*_"+?P]#58-'O.78T.
M.ZV'+BT&NM68'+<TX)A68G@VD78VPCYE]1;#OO-50Q3MX4H);8DEJ(]5"E!\
M"V@YBS2UWYHL*7/^[3I\=&CB9X9BB?*WG#FL:-]GSHRA+:"?-?I+8N$IXS)T
MHPTM^FZU/+I00N,81 OS55M0@,YN!EH^))D7&5P"C\=NMC1V(+--7!\RI=K&
M=$W#Q'^AY-NK*$F^(X(^9J+;"PUWRD=EY9^QDM;J[-53T\3?$!+0J@-+TLS$
MG['RR$R8PU.XS"C"Y],H2>%2/JL$W-:"SP /1T6-!:KJ;BO2[$IMR%%#H0H\
MPA%%QD?>, /[,5E?H4I1\JHFB"_*[K+2UXS]L[+P=2:)T@MH<;"<N8$@=0^O
M04!P^ZW<2-QMI6QY!2LW$:PU8J DD@+L>/;QB8;,R@,FS-+;^*$/EIVR+9;>
M0EJQ<&S$4)BJE;2@S&XG1OPT]*L%"\=0!HG"+<6IX>$;2[$BYBMAV\I9PB%O
MKPX9EFZG<B"\[5.= \UVZ1RURILIOUFEH,9^R (-%D=G.$:WR5B%1-;B)M-2
M/2[!\#3YD >-+@O0+*:!K-"M;,.?"'P>$A4!&D1UAGZ"UU$8U?G7;U[:D)"4
MW$B4FKYK,>97?0-VFE; &T)6L0ISR!"17A0.D,9'CDI>T[35NQ_ X*B\E-&J
MAM< 9E=HR>B-+\Y@ZOY[SJ>"K4IL*D' _HRS\'3A4#2;KMT#3,:X0;:J*>O?
M!EPOL+U"_C0ZSVGZZ"2^"S$,/]BERHR(5BP<SV$H3-67M*#,[EV,^&DH5/'X
MODB:6Q".*6)D A?'V?03J&3>$W"\>"0W]RVTBL[NDH$@^=8/B1<%@1.+/_+?
M3K,_,+#_?O)>Y9()D4[(T^$$X+F(7ZC_O&8<+)GTSC.]WD']G)L5EZYR[6_F
M.?H2PW$HPT2O^IE^E&9W/T/8-##BUXP\<03]FB%KLT'F,M^Y)R#D _"RN+6I
M *<F?FQX,N3-01>_9]5&P'CYMV/1[[K46[2\*UC/CD)BRUNN=O_RNZ],__[P
MUR>9%'C*WFT';-G.M\..UY:=;O<=KE7[6CW[+:J/OL<KDNS84M>]"K41+E8E
MJ@Z"U8M3&2 BU*LRYJHED5)6T,H"_1.,0%IG% *KRZ^^*EC9@H.L;SI!I'HF
M0\#3+S4W3=<LBJ&5L.0+0#?2TV9<RNO,GT4;QP]5?EP.B[2,ZQBO+>(RP/F7
M<#47K5I"O@API"S&25@WT?#G8.]RO?WP0Z:U\)O_NJ<QU-/Z4*G#4'_/_9F7
M+3Z0IAOJO#K=1RQ0\2YXDVB\%[D[<('\%GO A*N688Y-EB<?2+7HQD%9@7>3
MF(7,F$<422L1^2)HS&SPLWTQ*Y[V2;V$!@[]$5_3_I5 F,_UM/I1?:.'I.5#
M6+:N KY6B5MPK*J&KU9N+8(ME?&U&G18'_^RJ(^/; (C"'-RJ2SVCU<N7VL5
M*F [RN*K[4 .B5[^7JLLS9+WN K?B7E)<7[$J(]A(0)KJ@\8E1S KS-@^B1_
MKG("9L7K#9G.ZL'G)010:]B/P_+,K21$[9*S7<P8ON6"\JI6U_25_T4=;C7"
M16PX82I8HP=%&R).6PHSKN2=*K)J.41@$X%>-!QC) 0 TGOZ(>+!'\&8JBD3
MHJ1(UE[8SP'X QNL/)(A(BZ?GV/ZS)9HXFRB7<BEJM1DY=\7NYR00C[A$7NZ
MD@:R5;Y$(9J!,SG M,6;2-GJY$[R_8.E_L1,P(X.9=)]1W_'8B;K=9%MEJ69
M)5%@GQ/A3I+_[6;+7Y*=?Z6QZR?*9)P>=*QR+>T"FVY9I$1L<3AM'/;9R@B0
MC!XI"%KEASK+G?\=##7:(C^FU#J<$:Q42\@J,S40V7@W8+6AMK(HCR2</#D,
M@M^3TS#AUZ=D&<<,CJ>4D*<]J<+=.GO^Z^6K$S.#SD9:%$:<0,]5P="XYOR3
MF)B0[[';&^J-,3^Y@Z)6.BA;Y1FZ'1KH<^V.UXBKZ(0Q>K.J7$O?4Y=!0G^U
M'HN4 4VK/'*WB3#=1+42M,5/=^&VS^:J) U64<U]**E;Y<@&34A=VL. 2QK5
M3H?6^03A\49V"L9$K?(*':?">,]V-'ZA$[N](CY'YQF&34DGUS!DVZ#*#C4\
M6"Y#[Q<'=MRI\C0V CV,/-(1)J!,+AU #"GC=##'#946378@$EBY3R!.0AS"
M1-@%//29KFFQQ2]AL^TQ?]CZF@TW=[[J^!.B=GM90Z)ZJ(E1)CEIK+C35%,A
M.0O5/O;TGJUY?AOHVDP)VN/;NDU!FW,SHV:5=^O"<MM-1Z'&WT9YC8U=Z*?)
M=S6]+L,9Q!,. !P@VQM K28BDD+L<'2#YD;CZ;)64\?EZ@9-1INOPP\"+;W_
MWB4I?[CY$"FR6_D4\+!J-?IZ1_^Q\Q,_91O<^,5WJ9BN.^I&SR&GPA<)Q49Z
M^F&Q<K7GF<YZNO>T8R)DC,\AD"1/NQ@63EV'.>A^D;:](*H;B04I." 9"[GS
MJS"!E;J.,JO<<V93Y5:(6O <G!W3G61]$42O;;U,]"CHQ0>48BAJ#C3@,4L-
M*)AIJ3  6(2CH18]!39NX^C%]ZCW<?_(E/PR+ H;+]W4?^&1G],H9+_8L=^5
M+:9:5&XLXFAE5D><FH/ZK"-0QBCL.AK;TI*?W"!R\G ;_BV,P%:M[TA9]KL<
MA4=9LW&J?<^P&P!-.D_E1#@%&4NVWK":AJX?T%J)UX?(<#):G,DT0UFPQ1YY
MVI3;ZI'&P=U*CRI$V_:Y&(PTZU6S/W=T5U/[)8-D$+RIC(NI+.K4LM_"SR[,
MXDY,'(DDW@VQ"]H9W3+&?5E@3@Z"XTYD;%;=0/7OLYMO<_"&KE1!<)9L&Y@T
ML-^.;(J[6+"I="\:Z;!#,&^@AM@XS?%#\#,WX;T3T)O5;<;?+9."%]7B_"GD
M-T5&:J/62;1:-S4CS/F;JG5@J]F0C"'GBR53Q3,_V4:)GZME3HIP6N1<I9AS
M);(.$I47)V=R>5Q&)[#1[O+BL_6PF"JTH0!&?%2N9+WQLKP!B?.\7,&&<68X
M4G90)]85<5'\CH-L/QM3QM<9%?^M[&"S,'%[$WMC FA][3N*>-#JWA![=NOI
MREKSP6)&@'R;DX#"PI4S65&'!SE0-%C2TS6\'>'O0)PDH5F[Q,!WGOP .3+4
ME.TVIEO']\ZRW,"L)=@R]'C[KR7GWWBBS(C98IE=1-=;J0DE"RS6G$U3Z\TH
MYAU,N:*+OG&"&M;&<539<R'SAJ=<RHA+F2?9.%)I!R28*06XTS7L/K348:00
MDLH&BEVDD_6D@Y-(-HA9M:5Z&3FPTVVFPG%+Z_:Y$V(G$CTG!^7]<NO-*?*\
ML K-B;HOM_NJ"2;@UO0SV[0#.:,\!&%04,T0UY;]A48P_79"@FC![D')E>EF
M(2<P7>&V(1L$<_%R2)N,:.FZ4',IN77VT*O56.H&GBW&HQ!(;S@'2!88C90C
M4X/)D4F&;<MYV$RH@ONMG'MD<XEWS$.49_(NPC=0+3(:A5BM=G. 9X?I2)GJ
M8#V 3Z[4@1=$ S(3+9>A=O1\BL)=SSV<X6DS/R7?L3WC*?NO?QB0-<:RX RI
M%D9Y7&RBV'$R5/'5T)N'-1S[<K/P"K.HO ]B1X4HYH%7\4((3 9^[^6OA'E@
MP^6CD.@I\)\YF\@'1.,9:)X%<U0"N$0@([P&ZBW16?7#'&MNLL)%#B5ZC+G(
MLJ5Y&,4CRSV>/.=X&NN.4B?0+?>334IK3IYU3N$R?*')5 \6.A.WRDGTG!H#
M9]&1LBU.HQ?;79U',<CQ/E@89Y[*B;#!?60U%>'YH/N/G1_36J+7,O3:4A"[
M$,!Q ]U%K)JZ.?;LYMR5M>:E14: /XT5)(I$Q(7(1%SP<R]Z.N)P41E3:P?.
M\1;F(@[S-Y,XL>-<L\=?JX]LC9Y\;;9J8S]\4FH;>]^JE5DA\X4?.J$[T<:^
M,W&KG$3/J3%P%ATIV^(T>K'=U7D4@QSOQGZ<>2HGP@;WP61T*?62"V8Y><<2
MJ&%9M'M5[;3:\9"V\:8"U7;O;4CS;]K-.)(D& D\ K-"JCUH=*UYYS&K<63R
MDT&-NK!-2Q05>PP]&E^R7S#W\0))KO(')'!L21A8L(-LEVHELDY3/-J8-IGT
MR!/9[@Y&&M 25S*J-!W<4%8)< <#DV)D?L16-OO@PR](P4"]CJ!-SFS.6546
MT#W6P\@DN['C/'R,?^@XLL/&Y(<,JR(4PR>%1RBVE4E9677, *&9'X3_0 CV
MQ0D@3"NJ"1[F6RBFKAL)'*/O(V;5Q+O@SV[0W9EK/KP$+86EGO]0H;+(:V5*
M4@5Q+'4$:;E=\J>F$#9T<]GY#[2DB5C<8+?=!KRPHA/DM1@OPU44;[B_::N,
M:8J-5/Z@FW"U>@AFJ/,72.C"5[/L0 6[+*))*@0L*+4UHHB>G[A!E.QB$2H
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MJFME Q(^8I;"P,<D1>'O<C.)T(\'9_;RHEJ'7I.K;J50655G+2@G8)S%H<5
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MQ,2SK@O'CW]V@AW]3!T(A/"[Q@Y[K@[X.%;66<"JI1DCSVYM'3EKJ"+@$TZ
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MY#))(%!2F8'[E.V#G=CK9:Z*..^]NZ;>+J#0O5IQ-_N8T-4NN/)7E%<BT$:
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M)7K<KO@E^3:[)(\S>6*E/ ,VPME@V85\QASLN$2I$MFBW(J"L-DU%*/8WK;
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MG7P36!WTN!V@6B*4#6#.QEOQ?QVFMY@#+Y^#O4\#Q/ @%^J!C;+\ZJNZS!_
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MP/KBVF6L^.:HB^\8G,ZXQ/*[5R>!%(G-EH8)#ZDN7YW8@\IU[IK>*+HM]J*
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MDU+ P;EY8-0P"0PBVP8],E-*! %SST I;9[PZW<+>F2NE"CX^HT"=](A(R#
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MCI>.'>\_W/-7L'H!P9XP:\MK*U>&D/8OPD7)4RKD8TE"3I:,/;*.&5)F5C!
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M3HK/=/1Z8S+@]SJVL,U\W]#@$O\VDDJ_J>N"4&O:S *"KWS()-<X!_O/BP7
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MGC'*E0\#&+R$=W-F-RE5B;:0$3EGB)-[*&E+=!"ON'3*$N:G5*_3A4YI*W3
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MZBWOD8I>6T&P6207!K3]E4 +VJ"DO?C+4&K+![U.B90, 24BKZTUC"R7Y$7
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M,C,Q7V-A;"YX;6Q02P$"% ,4    "  %3&%*\(+]-Q H  !IVP( %0
M        @ $V- $ 9VQY8RTR,#$V,3(S,5]D968N>&UL4$L! A0#%     @
M!4QA2CLCB1-I8@  ,YX% !4              ( !>5P! &=L>6,M,C Q-C$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    (  5,84J[%U^((#X  /'3!  5
M      "  16_ 0!G;'EC+3(P,38Q,C,Q7W!R92YX;6Q02P4&      8 !@"*
) 0  :/T!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
